
<html lang="en"     class="pb-page"  data-request-id="52673a6b-8ade-4ba8-9f39-a1e15e6537aa"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.1c00040;website:website:acspubs;issue:issue:10.1021/jmcmar.2021.64.issue-12;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of a Biased Allosteric Modulator for Cannabinoid 1 Receptor: Preclinical Anti-Glaucoma Efficacy" /></meta><meta name="dc.Creator" content="Sumanta  Garai" /></meta><meta name="dc.Creator" content="Luciana M.  Leo" /></meta><meta name="dc.Creator" content="Anna-Maria  Szczesniak" /></meta><meta name="dc.Creator" content="Dow P.  Hurst" /></meta><meta name="dc.Creator" content="Peter C.  Schaffer" /></meta><meta name="dc.Creator" content="Ayat  Zagzoog" /></meta><meta name="dc.Creator" content="Tallan  Black" /></meta><meta name="dc.Creator" content="Jeffrey R.  Deschamps" /></meta><meta name="dc.Creator" content="Elke  Miess" /></meta><meta name="dc.Creator" content="Stefan  Schulz" /></meta><meta name="dc.Creator" content="David R.  Janero" /></meta><meta name="dc.Creator" content="Alex  Straiker" /></meta><meta name="dc.Creator" content="Roger G.  Pertwee" /></meta><meta name="dc.Creator" content="Mary E.  Abood" /></meta><meta name="dc.Creator" content="Melanie E. M.  Kelly" /></meta><meta name="dc.Creator" content="Patricia H.  Reggio" /></meta><meta name="dc.Creator" content="Robert B.  Laprairie" /></meta><meta name="dc.Creator" content="Ganesh A.  Thakur" /></meta><meta name="dc.Description" content="We apply the magic methyl effect to improve the potency/efficacy of GAT211, the prototypic 2-phenylindole-based cannabinoid type-1 receptor (CB1R) agonist-positive allosteric modulator (ago-PAM). I..." /></meta><meta name="Description" content="We apply the magic methyl effect to improve the potency/efficacy of GAT211, the prototypic 2-phenylindole-based cannabinoid type-1 receptor (CB1R) agonist-positive allosteric modulator (ago-PAM). I..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 7, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00040" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00040" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00040" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00040" /></link>
        
    
    

<title>Discovery of a Biased Allosteric Modulator for Cannabinoid 1 Receptor: Preclinical Anti-Glaucoma Efficacy | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00040" /></meta><meta property="og:title" content="Discovery of a Biased Allosteric Modulator for Cannabinoid 1 Receptor: Preclinical Anti-Glaucoma Efficacy" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0019.jpeg" /></meta><meta property="og:description" content="We apply the magic methyl effect to improve the potency/efficacy of GAT211, the prototypic 2-phenylindole-based cannabinoid type-1 receptor (CB1R) agonist-positive allosteric modulator (ago-PAM). Introducing a methyl group at the α-position of nitro group generated two diastereomers, the greater potency and efficacy of erythro, (±)-9 vs threo, (±)-10 constitutes the first demonstration of diastereoselective CB1R-allosteric modulator interaction. Of the (±)-9 enantiomers, (−)-(S,R)-13 evidenced improved potency over GAT211 as a CB1R ago-PAM, whereas (+)-(R,S)-14 was a CB1R allosteric agonist biased toward G protein- vs β-arrestin1/2-dependent signaling. (−)-(S,R)-13 and (+)-(R,S)-14 were devoid of undesirable side effects (triad test), and (+)-(R,S)-14 reduced intraocular pressure with an unprecedentedly long duration of action in a murine glaucoma model. (−)-(S,R)-13 docked into both a CB1R extracellular PAM and intracellular allosteric-agonist site(s), whereas (+)-(R,S)-14 preferentially engaged only the latter. Exploiting G-protein biased CB1R-allosteric modulation can offer safer therapeutic candidates for glaucoma and, potentially, other diseases." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00040"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00040">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00040&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00040&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00040&amp;href=/doi/10.1021/acs.jmedchem.1c00040" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 12</span><span class="cit-fg-pageRange">, 8104-8126</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/12" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.1c00843" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Featured Article</span><a href="/doi/10.1021/acs.jmedchem.0c01961" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of a Biased Allosteric Modulator for Cannabinoid 1 Receptor: Preclinical Anti-Glaucoma Efficacy</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Sumanta Garai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sumanta Garai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sumanta++Garai">Sumanta Garai</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Luciana M. Leo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Luciana M. Leo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania 19140, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Luciana+M.++Leo">Luciana M. Leo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anna-Maria Szczesniak</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anna-Maria Szczesniak</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacology and Department of Ophthalmology and Visual Sciences, Dalhousie University, Halifax, Nova Scotia B3H 4R2, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anna-Maria++Szczesniak">Anna-Maria Szczesniak</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dow P. Hurst</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dow P. Hurst</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Drug Discovery, University of North Carolina Greensboro, Greensboro, North Carolina 27402, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dow+P.++Hurst">Dow P. Hurst</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Peter C. Schaffer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peter C. Schaffer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peter+C.++Schaffer">Peter C. Schaffer</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ayat Zagzoog</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ayat Zagzoog</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">College of Pharmacy and Nutrition, University of Saskatchewan, 104 Clinic Pl, Saskatoon, Saskatchewan S7N2Z4, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ayat++Zagzoog">Ayat Zagzoog</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tallan Black</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tallan Black</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">College of Pharmacy and Nutrition, University of Saskatchewan, 104 Clinic Pl, Saskatoon, Saskatchewan S7N2Z4, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tallan++Black">Tallan Black</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jeffrey R. Deschamps</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jeffrey R. Deschamps</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Naval Research Laboratory, Code 6930, 4555 Overlook Avenue, Washington, District of Columbia 20375, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey+R.++Deschamps">Jeffrey R. Deschamps</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Elke Miess</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Elke Miess</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacology and Toxicology, Jena University Hospital—Friedrich Schiller University Jena, D-07747 Jena, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Elke++Miess">Elke Miess</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stefan Schulz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stefan Schulz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacology and Toxicology, Jena University Hospital—Friedrich Schiller University Jena, D-07747 Jena, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stefan++Schulz">Stefan Schulz</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David R. Janero</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David R. Janero</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts 02115, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+R.++Janero">David R. Janero</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-4633-1038" title="Orcid link">https://orcid.org/0000-0002-4633-1038</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alex Straiker</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alex Straiker</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">The Gill Center and the Department of Psychological & Brain Sciences, Indiana University, 1101 E. 10th St, Bloomington, Indiana 47405, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alex++Straiker">Alex Straiker</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Roger G. Pertwee</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Roger G. Pertwee</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Medicine, Medical Sciences and Nutrition, Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, Scotland, U.K</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Roger+G.++Pertwee">Roger G. Pertwee</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mary E. Abood</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mary E. Abood</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania 19140, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mary+E.++Abood">Mary E. Abood</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-1744-2820" title="Orcid link">https://orcid.org/0000-0002-1744-2820</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Melanie E. M. Kelly</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Melanie E. M. Kelly</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacology and Department of Ophthalmology and Visual Sciences, Dalhousie University, Halifax, Nova Scotia B3H 4R2, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Melanie+E.+M.++Kelly">Melanie E. M. Kelly</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Patricia H. Reggio</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Patricia H. Reggio</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Drug Discovery, University of North Carolina Greensboro, Greensboro, North Carolina 27402, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Patricia+H.++Reggio">Patricia H. Reggio</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Robert B. Laprairie</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Robert B. Laprairie</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacology and Department of Ophthalmology and Visual Sciences, Dalhousie University, Halifax, Nova Scotia B3H 4R2, Canada</div><div class="loa-info-affiliations-info">College of Pharmacy and Nutrition, University of Saskatchewan, 104 Clinic Pl, Saskatoon, Saskatchewan S7N2Z4, Canada</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#22504d404750560c4e435250434b504b476257514351490c4143"><span class="__cf_email__" data-cfemail="fa8895989f888ed4969b8a889b9388939fba8f899b8991d4999b">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Robert+B.++Laprairie">Robert B. Laprairie</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Ganesh A. Thakur</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ganesh A. Thakur</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts 02115, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#32551c465a53594740725c5d40465a5753414657405c1c575647"><span class="__cf_email__" data-cfemail="ea8dc49e828b819f98aa8485989e828f8b999e8f9884c48f8e9f">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ganesh+A.++Thakur">Ganesh A. Thakur</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-7468-8819" title="Orcid link">https://orcid.org/0000-0002-7468-8819</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00040&amp;href=/doi/10.1021%2Facs.jmedchem.1c00040" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 12</span><span class="cit-pageRange">, 8104–8126</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 7, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>9 January 2021</li><li><span class="item_label"><b>Published</b> online</span>7 April 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 June 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00040" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00040</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8104%26pageCount%3D23%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DSumanta%2BGarai%252C%2BLuciana%2BM.%2BLeo%252C%2BAnna-Maria%2BSzczesniak%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D12%26contentID%3Dacs.jmedchem.1c00040%26title%3DDiscovery%2Bof%2Ba%2BBiased%2BAllosteric%2BModulator%2Bfor%2BCannabinoid%2B1%2BReceptor%253A%2BPreclinical%2BAnti-Glaucoma%2BEfficacy%26numPages%3D23%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8126%26publicationDate%3DJune%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00040"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1055</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">1</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00040" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of a Biased Allosteric Modulator for Cannabinoid 1 Receptor: Preclinical Anti-Glaucoma Efficacy&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Sumanta&quot;,&quot;last_name&quot;:&quot;Garai&quot;},{&quot;first_name&quot;:&quot;Luciana&quot;,&quot;last_name&quot;:&quot;M. Leo&quot;},{&quot;first_name&quot;:&quot;Anna-Maria&quot;,&quot;last_name&quot;:&quot;Szczesniak&quot;},{&quot;first_name&quot;:&quot;Dow&quot;,&quot;last_name&quot;:&quot;P. Hurst&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;C. Schaffer&quot;},{&quot;first_name&quot;:&quot;Ayat&quot;,&quot;last_name&quot;:&quot;Zagzoog&quot;},{&quot;first_name&quot;:&quot;Tallan&quot;,&quot;last_name&quot;:&quot;Black&quot;},{&quot;first_name&quot;:&quot;Jeffrey&quot;,&quot;last_name&quot;:&quot;R. Deschamps&quot;},{&quot;first_name&quot;:&quot;Elke&quot;,&quot;last_name&quot;:&quot;Miess&quot;},{&quot;first_name&quot;:&quot;Stefan&quot;,&quot;last_name&quot;:&quot;Schulz&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;R. Janero&quot;},{&quot;first_name&quot;:&quot;Alex&quot;,&quot;last_name&quot;:&quot;Straiker&quot;},{&quot;first_name&quot;:&quot;Roger&quot;,&quot;last_name&quot;:&quot;G. Pertwee&quot;},{&quot;first_name&quot;:&quot;Mary&quot;,&quot;last_name&quot;:&quot;E. Abood&quot;},{&quot;first_name&quot;:&quot;Melanie&quot;,&quot;last_name&quot;:&quot;E. M. Kelly&quot;},{&quot;first_name&quot;:&quot;Patricia&quot;,&quot;last_name&quot;:&quot;H. Reggio&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;B. Laprairie&quot;},{&quot;first_name&quot;:&quot;Ganesh&quot;,&quot;last_name&quot;:&quot;A. Thakur&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;07&quot;,&quot;issue&quot;:&quot;12&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;8104-8126&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00040&quot;},&quot;abstract&quot;:&quot;We apply the magic methyl effect to improve the potency/efficacy of GAT211, the prototypic 2-phenylindole-based cannabinoid type-1 receptor (CB1R) agonist-positive allosteric modulator (ago-PAM). Introducing a methyl group at the α-position of nitro group generated two diastereomers, the greater potency and efficacy of erythro, (±)-9 vs threo, (±)-10 constitutes the first demonstration of diastereoselective CB1R-allosteric modulator interaction. Of the (±)-9 enantiomers, (−)-(S,R)-13 evidenced improved potency over GAT211 as a CB1R ago-PAM, whereas (+)-(R,S)-14 was a CB1R allosteric agonist biased toward G protein- vs β-arrestin1/2-dependent signaling. (−)-(S,R)-13 and (+)-(R,S)-14 were devoid of undesirable side effects (triad test), and (+)-(R,S)-14 reduced intraocular pressure with an unprecedentedly long duration of action in a murine glaucoma model. (−)-(S,R)-13 docked into both a CB1R extracellular PAM and intracellular allosteric-agonist site(s), whereas (+)-(R,S)-14 preferentially engaged only the lat&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00040&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00040" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00040&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00040" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00040&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00040" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00040&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00040&amp;href=/doi/10.1021/acs.jmedchem.1c00040" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00040" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00040" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00040%26sid%3Dliteratum%253Aachs%26pmid%3D33826336%26genre%3Darticle%26aulast%3DGarai%26date%3D2021%26atitle%3DDiscovery%2Bof%2Ba%2BBiased%2BAllosteric%2BModulator%2Bfor%2BCannabinoid%2B1%2BReceptor%253A%2BPreclinical%2BAnti-Glaucoma%2BEfficacy%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D12%26spage%3D8104%26epage%3D8126%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291713" title="Polyacrylamide">Polyacrylamide</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292444" title="Molecular structure">Molecular structure</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/12" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00040&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">We apply the magic methyl effect to improve the potency/efficacy of GAT211, the prototypic 2-phenylindole-based cannabinoid type-1 receptor (CB1R) agonist-positive allosteric modulator (ago-PAM). Introducing a methyl group at the α-position of nitro group generated two diastereomers, the greater potency and efficacy of <i>erythro</i>, (±)-<b>9</b> vs <i>threo</i>, (±)-<b>10</b> constitutes the first demonstration of diastereoselective CB1R-allosteric modulator interaction. Of the (±)-<b>9</b> enantiomers, (−)-(<i>S</i>,<i>R</i>)-<b>13</b> evidenced improved potency over GAT211 as a CB1R ago-PAM, whereas (+)-(<i>R</i>,<i>S</i>)-<b>14</b> was a CB1R allosteric agonist biased toward G protein- vs β-arrestin1/2-dependent signaling. (−)-(<i>S</i>,<i>R</i>)-<b>13</b> and (+)-(<i>R</i>,<i>S</i>)-<b>14</b> were devoid of undesirable side effects (triad test), and (+)-(<i>R</i>,<i>S</i>)-<b>14</b> reduced intraocular pressure with an unprecedentedly long duration of action in a murine glaucoma model. (−)-(<i>S</i>,<i>R</i>)-<b>13</b> docked into both a CB1R extracellular PAM and intracellular allosteric-agonist site(s), whereas (+)-(<i>R</i>,<i>S</i>)-<b>14</b> preferentially engaged only the latter. Exploiting G-protein biased CB1R-allosteric modulation can offer safer therapeutic candidates for glaucoma and, potentially, other diseases.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01702" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01702" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">A member of the G protein-coupled receptor (GPCR) superfamily, cannabinoid type-1 receptor (CB1R), helps regulate diverse physiological processes in the central nervous system and periphery. Pharmacological CB1R modulation is therapeutically attractive as a potential means to address a variety of disease states and pathological conditions that represent important unsolved medical problems, including pain, cardiometabolic syndromes, substance-use disorders, and ocular conditions predisposing to vision loss.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4 ref5 ref6 ref7">(1−7)</a> Although the past several decades have witnessed the synthesis and pharmacological profiling of myriad designer CB1R orthosteric agonists and antagonists/inverse agonists with diverse chemical structures and biological profiles, their clinical application has been stymied by attendant psychiatric and behavioral side effects and the disrepute of some synthetic CB1R orthosteric agonists as notorious drugs of abuse.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a></div><div class="NLM_p">Consequently, allosteric CB1R potentiation is gaining traction for translationally exploiting CB1R as a therapeutic target.<a onclick="showRef(event, 'ref10 ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12 ref13">(10−13)</a> An allosteric modulator engages (a) site(s) on CB1R topologically distinct from the orthosteric site, where endogenous ligands bind and potentiates [positive allosteric modulator (PAM)] or attenuates [negative allosteric modulator (NAM)] orthosteric-ligand affinity/efficacy. In addition, allosteric modulators termed “allosteric agonists” exhibit intrinsic efficacy by virtue of which they directly regulate signaling pathways independent of orthosteric ligand by engaging (a) site(s) on the GPCR distinct from the orthosteric site. For realizing therapeutic gain through CB1R activation, application of the principles of allostery to design and synthesize small-molecule CB1R allosteric modulators leverages several potential advantages over typical CB1R orthosteric agonists that may translate into improved safety, efficacy, and overall pharmacological profile.<a onclick="showRef(event, 'ref11 ref13 ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref11 ref13 ref14 ref15 ref16">(11,13−16)</a></div><div class="NLM_p">Along with allosterism, “biased agonism” or “functional selectivity” is another molecular-pharmacology feature that may be designed into GPCR ligands for optimizing their safety and/or efficacy as candidate drugs.<a onclick="showRef(event, 'ref17 ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19 ref20">(17−20)</a> Compared to a “balanced” agonist, biased agonists acting at the same GPCR can elicit distinct cellular signaling profiles by preferentially stabilizing different active conformational states of the target receptor. Typically, CB1R exerts its biological effects by coupling to G proteins in G<sub>i/o</sub> subfamily. Yet CB1R may signal through a variety of G protein-dependent and -independent pathways, with β-arrestin signaling paradigms being prominent among the latter.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The variety of ligand-dependent signaling effects exhibited by CB1R invites dedicated discovery of biased ligands that may direct CB1R-dependent information output preferentially along beneficial/therapeutic signaling pathways and away from others with more of an adverse-event risk.<a onclick="showRef(event, 'ref22 ref23 ref24 ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24 ref25 ref26 ref27">(22−27)</a> This proposition has very recently met translational success upon the United States Food and Drug Administration (FDA) regulatory approval of the first GPCR biased agonist, the μ-opioid receptor agonist oliceridine {(<i>R</i>)-TRV130} (Trevena, Inc.; Chesterbrook, PA), as an analgesic.<a onclick="showRef(event, 'ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref30">(28−30)</a> Several other examples of biased ligands with preclinical safety and therapeutic efficacy attest to their therapeutic potential.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Although the concept of biased agonism was first introduced for orthosteric GPCR ligands, subsequent medicinal chemistry efforts have produced functionally selective allosteric ligands for pharmacotherapeutic exploitation.<a onclick="showRef(event, 'ref32 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref34">(32−34)</a></div><div class="NLM_p">Our drug-discovery efforts on the design, synthesis, and profiling of novel CB1R allosteric modulators as potential therapeutics led to the identification of enantiomers of the prototype CB1R ago-PAM, GAT211 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), exhibiting enantiospecific allosteric CB1R modulation. As an ago-PAM, the resolved <i>R</i>-(+)-enantiomer (GAT228, <b>7</b>) is a partial allosteric agonist able to directly activate CB1R, whereas the <i>S</i>-(−)-enantiomer (GAT229, <b>8</b>) is a potent CB1R PAM and lacks GAT228’s intrinsic agonist activity (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The distinct molecular pharmacology of each GAT211 enantiomer demonstrates that the absolute stereochemistry of the benzylic center has a profound effect on ligand engagement and functional activity.<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35,36)</a> Both GAT228 and GAT229 showed signs of bias for G protein-dependent over β-arrestin2 signaling,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> as they have two recently profiled ago-PAMs from this laboratory [GAT591 (<b>5</b>) and GAT593(<b>6</b>)].<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Both racemic GAT211 and its enantiomers demonstrated preclinical analgesic efficacy and therapeutic activities against glaucoma and Huntington’s disease, all without apparent liabilities (i.e., tolerance, dependence, substance-abuse) associated with conventional CB1R orthosteric agonists.<a onclick="showRef(event, 'ref38 ref39 ref40 ref41 ref42 ref43 ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref38 ref39 ref40 ref41 ref42 ref43 ref44 ref45">(38−45)</a> The enantiospecific allosteric modulation of CB1R by GAT211(<b>4</b>) enantiomers and the attractive <i>in vivo</i> therapeutic profiles of these leads invites expansion of the structure–activity relationship (SAR) around this focused library of 2-phenylindole CB1R activators as detailed herein for optimizing their biological and physicochemical properties and defining the extent to which their pharmacological characteristics are tunable.<a onclick="showRef(event, 'ref37 ref46'); return false;" href="javascript:void(0);" class="ref ref37 ref46">(37,46)</a> In this work, we have exploited the “magic methyl effect” involving tactical replacement of a hydrogen atom by a methyl group in the right place of the molecule, a frequently used strategy for improving potency/efficacy.<a onclick="showRef(event, 'ref47 ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref47 ref48 ref49">(47−49)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of representative CB1R allosteric modulators.<a onclick="showRef(event, 'ref27 ref35 ref37'); return false;" href="javascript:void(0);" class="ref ref27 ref35 ref37">(27,35,37)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00040&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02768" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02768" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Ligand Design</h3><div class="NLM_p">Our previous SAR studies demonstrated that the nitro functionality is a pharmacophore key to the CB1R PAM activity of the GAT211 scaffold. We further established that a chiral center on GAT211 has profound effects on activity and selectivity such that the two enantiomers generated (GAT228 and GAT229) display distinct molecular-pharmacology phenotypes and enantiospecific molecular-interaction profiles at CB1R.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Accordingly, we hypothesized that strategic installation of a methyl group at the α-position of the critical nitro functional group might be beneficial in terms of activity and functional selectivity, since this substitution creates an additional chiral center<a onclick="showRef(event, 'ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref50 ref51">(50,51)</a> and two diastereomers. The resultant family of four distinct enantiomers would allow interrogation of possible diastereomeric/enantiomeric interaction of these ligands with CB1R and the effect of the additional chiral center on (ago-)PAM activity (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Ligand design using magic methyl effect strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00040&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Chemistry</h3><div class="NLM_p">To introduce a methyl group at the α-position of the −NO<sub>2</sub> moiety, base-mediated enolization followed by quenching with methyl iodide was not successful. We next tried a classical Michael-addition approach. Treating 2-phenyl indole (<b>11</b>) with (<i>E</i>)-(2-nitroprop-1-en-1-yl)benzene (1<b>2</b>) in the presence of CF<sub>3</sub>CO<sub>2</sub>NH<sub>4</sub> under reflux yielded two Michael adducts, erythro stereoisomer, (±)-<b>9</b> as the major product and threo isomer (±)-<b>10</b> as the minor product (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> The reaction was readily scaled up to provide multigram quantities, and both diastereomers were separated by column chromatography followed by fractional crystallization. The structure of each diastereomer was characterized by <sup>1</sup>H, <sup>13</sup>C NMR, and high-resolution mass spectroscopy. In the <sup>1</sup>H NMR of both diastereomers, the chemical shift (δ) value of the methyl group at the α-position to the nitro group of erythro-diastereomer, (±)-<b>9</b>, was at δ = 1.52 (doublet), whereas δ = 1.42 (doublet) for threo-diastereomer, (±)-<b>10</b>. The enantiomers of each diastereomer were separated by chiral superfluid column chromatography [(−)-<b>13</b>, (+)-<b>14</b>, (+)-<b>15</b>, (−)-<b>16</b>] at greater than 99% optical purity (see the <a href="/doi/suppl/10.1021/acs.jmedchem.1c00040/suppl_file/jm1c00040_si_001.pdf" class="ext-link">Supporting Information</a>). The absolute stereochemistry of each enantiomer was determined by single-crystal X-ray diffraction (XRD). The absolute stereochemistry of (−)-<b>13</b> is <i>S</i>,<i>R</i>; for (+)-<b>14</b>, <i>R</i>,<i>S</i>; for (+)-<b>15</b>, <i>S</i>,<i>S</i>; and for (−)-<b>16</b>, <i>R</i>,<i>R</i> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<named-content content-type="anchor" rid="sch1" type="simple"></named-content></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. ORTEP diagram of (−)-<b>13</b> (a, CCDC no. 1861405), (+)-<b>14</b> (b, CCDC no. 1861417), (+)-<b>15</b> (c, CCDC no. 1861406), and (−)-<b>16</b> (d, CCDC no. 1861407) and determination of absolute stereochemistry.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00040&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0017.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Reagents and Conditions: (a) NH<sub>4</sub>CF<sub>3</sub>CO<sub>2</sub>, 10% aq EtOH, Reflux, 36 h, <b>9</b>:<b>10</b> (9:1), 85%; (b) Chiral High-Performance Liquid Chromatography (HPLC), MeOH, and Super Fluid</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00040&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Structure–Activity Relationship (SAR) Studies</h3><div class="NLM_p">The influence of methylation and chirality on GAT211’s biological activity as a PAM was indexed <i>in vitro</i> as CB1R-dependent inhibition of cyclic adenosine monophosphate (cAMP) formation and β-arrestin2 recruitment in Chinese hamster ovary (CHO-K1) cells stably expressing human CB1R (hCB1R) with CP55,940 as orthosteric agonist (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Cellular cAMP formation reflects G-protein-dependent adenylyl cyclase modulation, whereas β-arrestin2 recruitment reflects G protein-independent information pathways,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> the two principal classes of signaling pathways for GPCRs, including CB1R.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. hCB1R-Positive Allosteric Modulator (PAM) Activities<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_0018.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">PAM activity was quantified for cAMP inhibition using the DiscoveRx HitHunter assay in cells (CHO hCB1R) treated with EC<sub>20</sub> (10 nM) CP55,940 + ligand for 30 min, and for β-arrestin2 recruitment using the DiscoveRx PathHunter assay in cells (CHO hCB1R) treated with EC<sub>20</sub> (10 nM) CP55,940 + ligand for 90 min. Data were fit to a variable-slope (four-parameter) nonlinear regression model in GraphPad (v. 8.0.1). Data are mean with 95% confidence interval (CI) (EC<sub>50</sub> values) or mean ± standard error of the mean (SEM; <i>E</i><sub>max</sub> values) for <i>n</i> = 2–3 independent experiments performed in duplicate. Statistical analyses were by nonoverlapping CI or two-way analysis of variance (ANOVA) followed by Tukey’s post hoc test. *<i>p</i> < 0.05 relative to GAT211 within assay; <sup>#</sup><i>p</i> < 0.05 relative to (±)-<b>9</b> within assay; <sup>@</sup><i>p</i> < 0.05 relative to (±)-<b>10</b> within assay; <sup>∧</sup><i>p</i> < 0.05 relative to cAMP assay within compound. Concentration–response curves are in Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00040/suppl_file/jm1c00040_si_001.pdf" class="ext-link">Figure S1</a>.</p></div></div><div></div></div><div class="NLM_p last">The comprehensive <i>in vitro</i> SAR for the GAT211 congeners in these cell-based assays as derived from the concentration–response data in Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00040/suppl_file/jm1c00040_si_001.pdf" class="ext-link">Figure S1</a> is given in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. Compared to parent compound GAT211 (cAMP, EC<sub>50</sub> = 230 nM, <i>E</i><sub>max</sub> = 110%; β-arrestin2, EC<sub>50</sub> = 940 nM, <i>E</i><sub>max</sub> = 46%), methyl-substituted erythro diastereomer (±)-<b>9</b> displayed greater potency as a PAM of cAMP inhibition and a trend toward greater efficacy as a PAM of β-arrestin2 recruitment (cAMP, EC<sub>50</sub> = 15 nM, <i>E</i><sub>max</sub> = 110%; β-arrestin2, EC<sub>50</sub> = 520 nM, <i>E</i><sub>max</sub> = 64%). (−)-(<i>S</i>,<i>R</i>)-<b>13</b>, one of the enantiomers of racemic (±)-<b>9</b>, was an equally potent but less efficacious PAM of CB1R-dependent cAMP inhibition (EC<sub>50</sub> = 31 nM, <i>E</i><sub>max</sub> = 79%) with greater efficacy in the β-arrestin2 recruitment compared to the racemic (±)-<b>9</b> (EC<sub>50</sub> = 980 nM, <i>E</i><sub>max</sub> = 88%). The other enantiomer, (+)-(<i>R</i>,<i>S</i>)-<b>14</b> was more efficacious than (±)-<b>9</b> as a CB1R PAM of cAMP formation (cAMP, EC<sub>50</sub> = 132 nM, <i>E</i><sub>max</sub> = 130%) and was inactive in the β-arrestin2 recruitment assay (EC<sub>50</sub> = >10 000 nM, <i>E</i><sub>max</sub> = 0%). The other threo diastereomer (±)-<b>10</b>, was not significantly different from GAT211 in the cAMP inhibition assay (cAMP, EC<sub>50</sub> = 120 nM, <i>E</i><sub>max</sub> = 94%), but less efficacious than GAT211 in the β-arrestin2 recruitment assay (EC<sub>50</sub> = 2000 nM, <i>E</i><sub>max</sub> = 25%). The enantiomer (+)-(<i>S</i>,<i>S</i>)-<b>15</b> obtained from diastereomer (±)-<b>10</b> showed a trend toward improved potency with reduced efficacy as a CB1R PAM of cAMP inhibition (EC<sub>50</sub> = 110 nM, <i>E</i><sub>max</sub> = 69%) with a slight difference in potency or efficacy for β-arrestin2 recruitment (EC<sub>50</sub> = 790 nM, <i>E</i><sub>max</sub> = 30%) relative to the diastereomer (±)-<b>10</b>. The opposite enantiomer, (−)-(<i>R</i>,<i>R</i>)-<b>16</b>, displayed a trend toward reduced potency with reduced efficacy in the cAMP inhibition assay (EC<sub>50</sub> = 610 nM, <i>E</i><sub>max</sub> = 67%) and was inactive in the β-arrestin2 recruitment assay (EC<sub>50</sub> = 10 000 nM, <i>E</i><sub>max</sub> = 0%) relative to the diastereomer (±)-<b>10</b>. Similar to the parent compound GAT211, both diastereomers and all enantiomers did not exhibit any activity at CB2R in both cAMP and β-arrestin2 assays (data not shown). These data demonstrate that methyl substitution at the α-position of the −NO<sub>2</sub> moiety has discrete influences on the signaling and molecular-pharmacology profiles of the prototypic 2-phenylindole ago-PAM, GAT211. The racemic diastereomers (±)-<b>9</b> and (±)-<b>10</b> display unique properties not specifically dependent upon one enantiomer or another, perhaps the result of combinatorial effects that are absent when only when enantiomer is tested. However, benzylic <i>R</i>-enantiomers (+)-(<i>R</i>,<i>S</i>)-<b>14</b> and (−)-(<i>R</i>,<i>R</i>)-<b>16</b> were devoid of β-arrestin2 activity, suggesting the stereochemistry at benzylic carbon is important for β-arrestin2 recruitment. Biological activity is maintained or enhanced, and ligand bias toward G protein-dependent vs -independent signaling can be augmented.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> <i>In Vitro</i> Biochemical Characterization: Orthosteric Radioligand Binding and G-Protein Activation</h3><div class="NLM_p">By virtue of its PAM property, GAT211 increases the specific binding of orthosteric agonist [<sup>3</sup>H]CP55,940 to hCB1R in membranes isolated from CHO cells stably expressing this GPCR.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Compound (±)-<b>9</b>, its enantiomers (−)-(<i>S</i>,<i>R</i>)-<b>13</b> and (+)-(<i>R</i>,<i>S</i>)-<b>14</b>, as well as (+)-(<i>S</i>,<i>S</i>)-<b>15</b> increased [<sup>3</sup>H]CP55,940 binding to hCB1R, whereas (±)-<b>10</b> and its enantiomer (−)-(<i>R</i>,<i>R</i>)-<b>16</b> marginally influenced [<sup>3</sup>H]CP55,940 binding at higher concentrations (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>a,b, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effect of test compounds on (a, b) the binding of 0.7 nM [<sup>3</sup>H]CP55,940 to membranes obtained from CHO cells stably expressing hCB1R or on (c–f) the binding of [<sup>35</sup>S]GTPγS to G protein in membranes obtained from CHO cells stably expressing hCB1R and treated with either (c, d) test compounds alone or (e, f) CP55,940 + 1 μM test compound. Data were fit to a variable-slope (four-parameter) nonlinear regression model in GraphPad (v. 8.0.1) and are given as mean ± SEM for <i>n</i> = 4–6 independent experiments performed in duplicate. <i>K<sub>i</sub></i>, EC<sub>50</sub>, and <i>E</i><sub>max</sub> values derived from these plots are presented in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00040&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Effect of GAT Compounds on [<sup>3</sup>H]CP55,940 Binding to hCB1R<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center"><i>K<sub>i</sub></i> (nM)</th><th class="colsep0 rowsep0" align="center" char="±"><i>E</i><sub>max</sub> (% CP55,940)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(±)-<b>9</b></td><td class="colsep0 rowsep0" align="left">150 (88–250)</td><td class="colsep0 rowsep0" align="char" char="±">74 ± 4.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(−)-(<i>S</i>,<i>R</i>)-<b>13</b></td><td class="colsep0 rowsep0" align="left">26 (7.3–91)</td><td class="colsep0 rowsep0" align="char" char="±">55 ± 4.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(+)-(<i>R</i>,<i>S</i>)-<b>14</b></td><td class="colsep0 rowsep0" align="left">100 (30–260)</td><td class="colsep0 rowsep0" align="char" char="±">39 ± 3.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(±)-<b>10</b></td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="char" char="±">–19 ± 1.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(+)-(<i>S</i>,<i>S</i>)-<b>15</b></td><td class="colsep0 rowsep0" align="left">120 (34–330)</td><td class="colsep0 rowsep0" align="char" char="±">36 ± 3.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(−)-(<i>R</i>,<i>R</i>)-<b>16</b></td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="char" char="±">–34 ± 3.6</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Effect of test compounds on [<sup>3</sup>H]CP55,940 binding was assessed in CHO cells stably expressing hCB1R. Data were fit to a variable slope (four-parameter) nonlinear regression model in GraphPad (v. 8.0.1). Data are mean with 95% confidence interval (CI) (<i>K<sub>i</sub></i> values) or mean ± SEM (<i>E</i><sub>max</sub> values) for <i>n</i> = 4–6 independent experiments performed in duplicate. Data were normalized to % CP55,940 bound without compound (0%). Radioligand binding curves are in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>.</p></div></div></div><div class="NLM_p">The extent of G-protein activation following hCB1R agonist engagement (i.e., ligand efficacy) was quantified as binding of the nonhydrolyzable GTP analog, GTPγS, to the cognate G<sub>i/o</sub>.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> All compounds tested enhanced GTPγS binding in the absence of CP55,940, indicating that they possess intrinsic allosteric agonist activity (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>c,d, <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). These compounds are termed as allosteric agonists as they have intrinsic agonist activity and at the same time, they do not compete with the orthosteric agonist binding. Among the compounds profiled, (±)-<b>9</b> and its enantiomers, (−)-(<i>S</i>,<i>R</i>)-<b>13</b> and (+)-(<i>R</i>,<i>S</i>)-<b>14</b>, displayed greater efficacy than (±)-<b>10</b> and its enantiomers. Compound (−)-(<i>S</i>,<i>R</i>)-<b>13</b> was the most potent compound in the series with regard to GTPγS binding (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>c,d, <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Among all six compounds, (±)-<b>9</b> and (−)-(<i>R</i>,<i>R</i>)-<b>16</b> enhanced CP55,940-dependent GTPγS binding to the greatest extent, with (±)-<b>9</b> doing so independently of CP55,940 concentration (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>e,f, <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). The remaining four compounds, (−)-(<i>S</i>,<i>R</i>)-<b>13</b> and (+)-(<i>R</i>,<i>S</i>)-<b>14</b>, (±)-<b>10</b>, (+)-(<i>S</i>,<i>S</i>)-<b>15</b>, and (−)-(<i>R</i>,<i>R</i>)-<b>16</b>, enhanced GTPγS binding at 1 μM in combination with 0.1 or 1 nM CP55,940, but did not augment GTPγS binding in a CP55,940 concentration-dependent manner (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>e,f). Collectively, these data support an SAR-driven correlation between CB1R-agonist and PAM activity/potency and modulation of orthosteric ligand binding, with (±)-<b>9</b> and its enantiomers, (−)-(<i>S</i>,<i>R</i>)-<b>13</b> and (+)-(<i>R</i>,<i>S</i>)-<b>14</b>, displaying superior potency and efficacy. Similar to our observations in the preliminary DiscoveRx screen, these data support the conclusion that racemic (±)-<b>9</b> displays pharmacological properties that are not intrinsically associated with its individual enantiomers. Rather the biological activity of (±)-<b>9</b> appears in the assay examined to reflect the overall enantiomeric mixture, perhaps as a consequence of some functional influence between the two enantiomers therein.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Effect of Test Compounds on [<sup>35</sup>S]GTPγS Binding in the Absence or Presence of CP55,940<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="(" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="(">compound alone</th><th class="rowsep1 colsep0" colspan="2" align="center">CP55,940 + 1 μM compound</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char="(">EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char="±"><i>E</i><sub>max</sub> (% CP55,940)</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center"><i>E</i><sub>max</sub> (% CP55,940)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CP55,940</td><td class="colsep0 rowsep0" align="char" char="(">1.6 (0.93–2.6)</td><td class="colsep0 rowsep0" align="char" char="±">37 ± 1.4</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(±)-<b>9</b></td><td class="colsep0 rowsep0" align="char" char="(">140 (85–230)</td><td class="colsep0 rowsep0" align="char" char="±">69 ± 2.4</td><td class="colsep0 rowsep0" align="left">n.c.</td><td class="colsep0 rowsep0" align="left">69 ± 8.5***</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(−)-(<i>S</i>,<i>R</i>)-<b>13</b></td><td class="colsep0 rowsep0" align="char" char="(">25 (11–56)</td><td class="colsep0 rowsep0" align="char" char="±">78 ± 3.5</td><td class="colsep0 rowsep0" align="left">n.c.</td><td class="colsep0 rowsep0" align="left">38 ± 2.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(+)-(<i>R</i>,<i>S</i>)-<b>14</b></td><td class="colsep0 rowsep0" align="char" char="(">170 (98–320)</td><td class="colsep0 rowsep0" align="char" char="±">77 ± 3.1</td><td class="colsep0 rowsep0" align="left">n.c.</td><td class="colsep0 rowsep0" align="left">34 ± 6.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(±)-<b>10</b></td><td class="colsep0 rowsep0" align="char" char="(">63 (24–150)</td><td class="colsep0 rowsep0" align="char" char="±">38 ± 2.3</td><td class="colsep0 rowsep0" align="left">n.c.</td><td class="colsep0 rowsep0" align="left">39 ± 5.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(+)-(<i>S</i>,<i>S</i>)-<b>15</b></td><td class="colsep0 rowsep0" align="char" char="(">140 (63–290)</td><td class="colsep0 rowsep0" align="char" char="±">45 ± 2.9</td><td class="colsep0 rowsep0" align="left">n.c.</td><td class="colsep0 rowsep0" align="left">26 ± 2.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(−)-(<i>R</i>,<i>R</i>)-<b>16</b></td><td class="colsep0 rowsep0" align="char" char="(">75 (16–260)</td><td class="colsep0 rowsep0" align="char" char="±">28 ± 3.1</td><td class="colsep0 rowsep0" align="left">1.3 (0.10–9.7)</td><td class="colsep0 rowsep0" align="left">69 ± 4.6***</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Effect of test compounds on [<sup>35</sup>S]GTPγS binding was assessed in CHO cells stably expressing hCB1R. Data were fit to a variable-slope (four-parameter) nonlinear regression model in GraphPad (v. 8.0.1). Data are means with 95% confidence interval (CI) (EC<sub>50</sub> values) or mean ± SEM (<i>E</i><sub>max</sub> values) for <i>n</i> = 4–6 independent experiments performed in duplicate. Data were normalized to % stimulation over baseline. Concentration–response curves are in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>. ***<i>p</i> < 0.001 Student’s two-tailed <i>t</i>-test, test compound vs CP55,940. n.c., not converged refers to concentration–response relationships in which EC<sub>50</sub> could not be accurately calculated from data due to their shape.</p></div></div></div><div class="NLM_p last">The diastereoselective nature of the interaction of (±)-<b>9</b> vs (±)-<b>10</b> with hCB1R, whereby (±)-<b>9</b> was some eightfold more potent in the cAMP assay and fourfold more potent in the β-arrestin2 recruitment assay (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) prompted extended biochemical and electrophysiological characterization of (±)-<b>9</b> and its enantiomers, (−)-(<i>S</i>,<i>R</i>)-<b>13</b> and (+)-(<i>R</i>,<i>S</i>)-<b>14</b>. Further profiling was also deemed compelling from the fact that (±)-<b>9</b>, (−)-(<i>S</i>,<i>R</i>)-<b>13</b>, and (+)-(<i>R</i>,<i>S</i>)-<b>14</b> were all more potent and efficacious than the racemic parent, GAT211, with superior activity in biochemical assays of cAMP inhibition, β-arrestin2 recruitment and [<sup>3</sup>H]CP55,940 and GTPγS binding (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>).</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> <i>In Vitro</i> Cell-Based Characterization: Agonism, Signaling Bias, and Positive Allosteric Modulation</h3><div class="NLM_p">To assess their potency, efficacy, and ligand bias as agonists and PAMs in G-protein-dependent (cAMP formation) and -independent (β-arrestin1 and β-arrestin2 recruitment) signal-transduction pathways, we evaluated (±)-<b>9</b>, (−)-(<i>S</i>,<i>R</i>)-<b>13</b>, and (+)-(<i>R</i>,<i>S</i>)-<b>14</b> in another cell line (HEK293 cells) expressing CB1R. All three compounds produced a maximal response for inhibition of cAMP formation, acting as full allosteric agonists relative to the reference agonist, CP55,940 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>a). In the cellular cAMP assay, (±)-<b>9</b>, (−)-(<i>S</i>,<i>R</i>)-<b>13</b>, and (+)-(<i>R</i>,<i>S</i>)-<b>14</b> were all more potent agonists than parent compound, GAT211 (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).<a onclick="showRef(event, 'ref35 ref37'); return false;" href="javascript:void(0);" class="ref ref35 ref37">(35,37)</a> Both (±)-<b>9</b> and (−)-(<i>S</i>,<i>R</i>)-<b>13</b> were weak partial agonists of β-arrestin1 and β-arrestin2 recruitment and did not differ significantly from the GAT211 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>b,c, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>) with more apparent efficacy at β-arrestin2 than β-arrestin1 recruitment (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>c, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Notably, (+)-(<i>R</i>,<i>S</i>)-<b>14</b> had no significant effect on β-arrestin1 and β-arrestin2 recruitment (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>b,c).</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effect of test compounds on forskolin (FSK)-stimulated cAMP production (a, d), recruitment of β-arrestin1 (b, e), and recruitment of β-arrestin2 (c, f) in HEK293 cells expressing CB1R. (a, d) HEK293 cells stably expressing CB1R were treated with 5 μM FSK and 0.01 nM–10 μM CP55,940 or test compound alone (a) or with 10 nM CP55,940 + 0.01 nM–10 μM test compound (d) for 30 min, and cAMP inhibition was then quantified in the LANCE Ultra cAMP assay. (b, e) HEK293 cells stably expressing β-arrestin1 and transiently expressing rat CB1R (CB1R) were treated with 0.01 nM–10 μM CP55,940 or test compound alone (b) or with 100 nM CP55,940 + 0.01 nM–10 μM test compound (e) for 90 min, and β-arrestin1 recruitment was then quantified in the β-arrestin recruitment enzyme complementation assay. (c, f) HEK293 cells stably expressing β-arrestin2 and transiently expressing CB1R were treated with 0.01 nM–30 μM CP55,940 or test compound alone (c) or with 100 nM CP55,940 + 0.01 nM–10 μM test compound (f) for 90 min, and β-arrestin2 recruitment was then quantified in the β-arrestin recruitment enzyme complementation assay. Data are expressed as % CP55,940 response and were fit to a nonlinear regression (four-parameter) model (GraphPad v. 8.0.1) (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). (g–l) Data were fit to the Black–Leff operational model to estimate bias (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>) with CP55,940 as the reference agonist. Data are mean ± SEM for <i>n</i> = 3–4 independent experiments performed in triplicate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00040&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Allosteric Agonist and PAM Activity of Lead Compounds<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="(" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="5" align="center">inhibition of FSK-stimulated cAMP</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="(">agonist mode</th><th class="rowsep1 colsep0" colspan="2" align="center">PAM mode</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char="(">EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char="±"><i>E</i><sub>max</sub> (% CP55,940)</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center"><i>E</i><sub>max</sub> (% CP55,940)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CP55, 940</td><td class="colsep0 rowsep0" align="char" char="(">25 (17–36)</td><td class="colsep0 rowsep0" align="char" char="±">100 ± 3.6</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(±)-<b>9</b></td><td class="colsep0 rowsep0" align="char" char="(">46 (31–67)</td><td class="colsep0 rowsep0" align="char" char="±">90 ± 3.4</td><td class="colsep0 rowsep0" align="left">64 (34–120)</td><td class="colsep0 rowsep0" align="left">84 ± 3.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(−)-(<i>S</i>,<i>R</i>)-<b>13</b></td><td class="colsep0 rowsep0" align="char" char="(">24 (14–40)</td><td class="colsep0 rowsep0" align="char" char="±">93 ± 3.4</td><td class="colsep0 rowsep0" align="left">61 (18–81)</td><td class="colsep0 rowsep0" align="left">90 ± 7.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(+)-(<i>R</i>,<i>S</i>)-<b>14</b></td><td class="colsep0 rowsep0" align="char" char="(">140 (88–210)</td><td class="colsep0 rowsep0" align="char" char="±">91 ± 4.5</td><td class="colsep0 rowsep0" align="left">210 (110–410)</td><td class="colsep0 rowsep0" align="left">85 ± 5.8</td></tr></tbody></table><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="5" align="center">β-arrestin1 recruitment</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">agonist mode</th><th class="rowsep1 colsep0" colspan="2" align="center">PAM mode</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char="±"><i>E</i><sub>max</sub> (% CP55,940)</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center"><i>E</i><sub>max</sub> (% CP55,940)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CP55,940</td><td class="colsep0 rowsep0" align="left">820 (520–1300)</td><td class="colsep0 rowsep0" align="char" char="±">100 ± 6.8</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(±)-<b>9</b></td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="char" char="±">24 ± 4.1</td><td class="colsep0 rowsep0" align="left">4300 (2600–7400)</td><td class="colsep0 rowsep0" align="left">110 ± 7.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(−)-(<i>S</i>,<i>R</i>)-<b>13</b></td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="char" char="±">54 ± 2.1</td><td class="colsep0 rowsep0" align="left">2000 (1100–3300)</td><td class="colsep0 rowsep0" align="left">130 ± 7.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(+)-(<i>R</i>,<i>S</i>)-<b>14</b></td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="char" char="±">7.6 ± 1.2</td><td class="colsep0 rowsep0" align="left">4800 (2100–6700)</td><td class="colsep0 rowsep0" align="left">52 ± 5.6</td></tr></tbody></table><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="5" align="center">β-arrestin2 recruitment</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">agonist mode</th><th class="rowsep1 colsep0" colspan="2" align="center">PAM mode</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char="±"><i>E</i><sub>max</sub> (% CP55,940)</th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center"><i>E</i><sub>max</sub> (% CP55,940)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CP55,940</td><td class="colsep0 rowsep0" align="left">480 (270–850)</td><td class="colsep0 rowsep0" align="char" char="±">100 ± 8.1</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(±)-<b>9</b></td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="char" char="±">37 ± 3.5</td><td class="colsep0 rowsep0" align="left">2300 (930–3600)</td><td class="colsep0 rowsep0" align="left">95 ± 12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(−)-(<i>S</i>,<i>R</i>)-<b>13</b></td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="char" char="±">78 ± 1.3</td><td class="colsep0 rowsep0" align="left">1300 (670–3900)</td><td class="colsep0 rowsep0" align="left">100 ± 11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(+)-(<i>R</i>,<i>S</i>)-<b>14</b></td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="char" char="±">17 ± 4.4</td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">54 ± 6.1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Compound activity was quantified for cAMP inhibition, β-arrestin1 recruitment, and β-arrestin2 recruitment in HEK293 cells treated with test compound alone or with 10 nM CP55,940 + test compound for 30 min (cAMP assay) or 100 nM CP55,940 + test compound for 90 min (β-arrestin assays). Data were fit to a variable-slope (four-parameter) nonlinear regression model in GraphPad (v. 8.0.1). Data are mean with 95% confidence interval (CI) (EC<sub>50</sub> values) or mean ± SEM (<i>E</i><sub>max</sub> values) for <i>n</i> = 3–4 independent experiments performed in triplicate. Data were normalized to % CP55,940. Concentration–response curves are in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>.</p></div></div></div><div class="NLM_p">To estimate the ligand bias of our compounds as allosteric agonists, the quantitative agonist profiling data were fit to the operational model of Black and Leff (1983). We observed that (±)-<b>9</b> was biased toward cAMP inhibition (i.e., G protein-dependent signaling) relative to β-arrestin1, but not β-arrestin2 recruitment, favoring recruitment of β-arrestin2 over β-arrestin1 (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). (−)-(<i>S</i>,<i>R</i>)-<b>13</b> did not display bias between cAMP inhibition relative to β-arrestin1 or β-arrestin2 recruitment (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). (+)-(<i>R</i>,<i>S</i>)-<b>14</b> displayed consistent bias toward cAMP inhibition compared to both β-arrestin1 and β-arrestin2 recruitment (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). These data demonstrate that the ligand bias of our mixed agonist-PAMs was dependent upon their stereochemistry, implying that each ligand has unique interactions with CB1R upon receptor engagement, stabilizing specific active CB1R conformations that elicit a characteristic pharmacological profile. Notably with respect to the compounds’ allosteric agonist activity, (−)-(<i>S</i>,<i>R</i>)-<b>13</b> was not biased toward either G protein-dependent (i.e., cAMP production) or -independent (i.e., β-arrestin recruitment). However, (+)-(<i>R</i>,<i>S</i>)-<b>14</b>, which exhibited moderate potency as an allosteric agonist (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>a), exhibited the greatest bias for G-protein-dependent vs -independent signaling.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Estimation of Bias for (±)-<b>9</b>, (−)-(<i>S</i>,<i>R</i>)-<b>13</b>, and (+)-(<i>R</i>,<i>S</i>)-<b>14</b><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="(" /></col><col align="char" char="(" /></col><col align="char" char="(" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char="(">ΔΔLog<i> R</i></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">agonism</th><th class="colsep0 rowsep0" align="center" char="(">cAMP−β-arr1</th><th class="colsep0 rowsep0" align="center" char="(">cAMP−β-arr2</th><th class="colsep0 rowsep0" align="center" char="(">β-arr1−β-arr2</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(±)-<b>9</b></td><td class="colsep0 rowsep0" align="char" char="(">1.2 (0.10–1.9)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="(">–0.20 (−1.0–1.6)</td><td class="colsep0 rowsep0" align="char" char="(">–1.4 (−3.7 to −0.24)<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(−)-(<i>S</i>,<i>R</i>)-<b>13</b></td><td class="colsep0 rowsep0" align="char" char="(">0.51 (−0.16–0.89)</td><td class="colsep0 rowsep0" align="char" char="(">0.67 (−0.03–1.2)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="(">–0.01 (−1.5–1.5)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(+)-(<i>R</i>,<i>S</i>)-<b>14</b></td><td class="colsep0 rowsep0" align="char" char="(">0.89 (0.45–1.2)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="(">1.3 (0.61–2.3)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="(">–0.7 (−1.6–0.2)</td></tr></tbody></table><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="(" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">ΔΔLog <i>R</i></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">+ CP55,940</th><th class="colsep0 rowsep0" align="center">cAMP−β-arr1</th><th class="colsep0 rowsep0" align="center">cAMP−β-arr2</th><th class="colsep0 rowsep0" align="center" char="(">β-arr1−β-arr2</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(±)-<b>9</b></td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="char" char="(">–0.64 (−1.0 to −0.41)<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(−)-(<i>S</i>,<i>R</i>)-<b>13</b></td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="char" char="(">0.89 (0.13–2.3)<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(+)-(<i>R</i>,<i>S</i>)-<b>14</b></td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="char" char="(">–0.54 (−1.1–0.44)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">All values estimated using the Black–Leff operational model for agonism for the data presented in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>. Data are mean values with 95% confidence interval (CI) from <i>n</i> = 3–4 independent experiments.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Bias indicated for cAMP inhibition.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">Bias indicated for β-arrestin1 (βarr1) recruitment.</p></div><div class="footnote" id="t5fn4"><sup><sup>d</sup></sup><p class="last">Bias indicated for β-arrestin2 (βarr2) recruitment. n.d., not determined, since 10 nM CP55,940 was used in cAMP inhibition experiments, compared to 100 nM in β-arrestin1 and β-arrestin2 experiments.</p></div></div></div><div class="NLM_p">We next assessed (±)-<b>9</b>, (−)-(<i>S</i>,<i>R</i>)-<b>13</b>, and (+)-(<i>R</i>,<i>S</i>)-<b>14</b> as PAMs in the presence of a single concentration of CP55,940 orthosteric agonist. We used 10 nM CP55,940 in our cAMP experiments and 100 nM CP55,940 in our β-arrestin experiments since, at these concentrations in each respective test system, CP55,940 alone was able to elicit a submaximal response to allow potential augmentation by positive allosteric modulation of CB1R within a reliable dynamic range. (−)-(<i>S</i>,<i>R</i>)-<b>13</b> was the most potent inhibitor of G protein-dependent signaling (i.e., cAMP inhibition), followed by (±)-<b>9</b> and (+)-(<i>R</i>,<i>S</i>)-<b>14</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>d, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). This pattern was consistent with the relative potencies observed for agonist activity of (±)-<b>9</b>, (−)-(<i>S</i>,<i>R</i>)-<b>13</b>, and (+)-(<i>R</i>,<i>S</i>)-<b>14</b> in the cAMP inhibition assay, demonstrating that these compounds display similar rank-order potency.</div><div class="NLM_p">Similarly, in both β-arrestin1 and β-arrestin2 assays, (−)-(<i>S</i>,<i>R</i>)-<b>13</b> was the most potent and efficacious PAM, followed by (±)-<b>9</b> and (+)-(<i>R</i>,<i>S</i>)-<b>14</b> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>e,f, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Since different concentrations of probe orthosteric agonist were used in the cAMP (10 nM) and β-arrestin assays (100 nM), bias between G-protein-dependent and -independent signaling could not be estimated.</div><div class="NLM_p">Nonetheless, these PAM data could be fit to the Black and Leff operational model to assess potential β-arrestin1 vs β-arrestin2 bias. As a PAM in the presence of 100 nM CP55,940, (±)-<b>9</b> displayed bias toward β-arrestin2 over β-arrestin1, whereas (−)-(<i>S</i>,<i>R</i>)-<b>13</b> displayed bias toward β-arrestin1 over β-arrestin2 (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). To our best knowledge, these experiments constitute the first analyses of bias for a CB1R PAM among cAMP inhibition, β-arrestin1 recruitment, and β-arrestin2 recruitment.</div><div class="NLM_p">Compared to the activity of parent compound GAT211, (±)-<b>9</b> and its enantiomers displayed superior potency and efficacy as agonists and PAMs for inhibiting cAMP production and recruiting β-arrestins 1 and 2.<a onclick="showRef(event, 'ref35 ref37'); return false;" href="javascript:void(0);" class="ref ref35 ref37">(35,37)</a> Given their notable activity, (±)-<b>9</b> and its enantiomers were further characterized to estimate allosteric parameters of potency co-operativity (α), efficacy co-operativity (β), allosteric affinity (p<i>K</i><sub>B</sub>), and allosteric modulator intrinsic efficacy (τ<sub>B</sub>), with log(αβ) calculated to represent the total allosteric co-operativity factor for each PAM within each signaling pathway.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> For this purpose, HEK293 cells expressing CB1R were treated with 1 nM–10 μM CP55,940 and 10 nM–300 nM (±)-<b>9</b>, (−)-(<i>S</i>,<i>R</i>)-<b>13</b>, or (+)-(<i>R</i>,<i>S</i>)-<b>14</b>, and cAMP inhibition, β-arrestin1 recruitment, and β-arrestin2 recruitment were quantified. Data were then fit to the allosteric binding model combined with the Black–Leff operational model, as previously detailed.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> In all assays, the estimated affinities of all three compounds were in the low nanomolar range (0.89–35 nM [p<i>K</i><sub>B</sub> 9.05–7.45]) and within the same concentration range as their potencies in other signaling assays, with no statistically significant difference among them (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). In the cAMP assay, all compounds displayed α values > 1, consistent with a PAM, but β values < 1 due to a small downward shift in <i>E</i><sub>max</sub> with increasing PAM concentrations (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>a,d,g). Mean log(αβ) values for (±)-<b>9</b> and (−)-(<i>S</i>,<i>R</i>)-<b>13</b> were > 0, consistent with a PAM, whereas the mean log(αβ) value (+)-(<i>R</i>,<i>S</i>)-<b>14</b> was < 0, consistent with its categorization as an allosteric agonist. All three compounds displayed log(τ<sub>B</sub>) values > 0, consistent with their having intrinsic agonist activity, as had been observed in biochemical assays (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>a,d,g, <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Consistent with PAMs, (±)-<b>9</b> and its enantiomers displayed α values > 1 in the β-arrestin1 recruitment assay, and these α values were smaller than those in the cAMP assay. The β values for (±)-<b>9</b> and its enantiomers were > 1, as indicated by the increase in <i>E</i><sub>max</sub> for these compounds with increasing PAM concentration (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>b,e,h). (±)-<b>9</b> and (<i>S</i>,<i>R</i>)-<b>13</b> displayed log(αβ) values that were > 0, consistent with a PAM. However, (<i>R</i>,<i>S</i>)-<b>14</b> displayed a log(αβ) value ≈ 0 due to the relatively small changes in α and β observed with this compound (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>b,e,h, <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). These collective data allow conclusion that (±)-<b>9</b> and its enantiomers all have intrinsic agonist activity with log(τ<sub>B</sub>) values > 0, consistent with prior assays (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>), although the log(τ<sub>B</sub>) for (<i>R</i>,<i>S</i>)-<b>14</b> hovered around 0, given its minimal intrinsic efficacy. For β-arrestin2 recruitment, all three compounds displayed α and β values > 1, consistent with PAMs (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>c,f,i). All log(αβ) values were also > 0, consistent with PAMs, although (+)-(<i>R</i>,<i>S</i>)-<b>14</b> displayed a log(αβ) value ≈ 0 because of the comparatively small changes in α and β observed with this compound (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>c,f,i, <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>).</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effect of test compounds on inhibition of forskolin (FSK)-stimulated cAMP production (a, d, g), β-arrestin1 recruitment (b, e, h), or β-arrestin2 recruitment (c, f, i) in HEK293 cells stably expressing hCB1R. (a, d, g) HEK293 cells stably expressing CB1R were treated with 5 μM FSK and 0.01 nM–10 μM CP55,940 ± 10–300 nM (±)-<b>9</b> (a), (−)-(<i>S</i>,<i>R</i>)-<b>13</b> (d), or (+)-(<i>R</i>,<i>S</i>)-<b>14</b> (g) for 30 min, and cAMP inhibition was then quantified. (b, e, h) HEK293 cells stably expressing β-arrestin1 and transiently expressing CB1R were treated with 0.01 nM–10 μM CP55,940 ± 10–300 nM (±)-<b>9</b> (b), (−)-(<i>S</i>,<i>R</i>)-<b>13</b> (e), or (+)-(<i>R</i>,<i>S</i>)-<b>14</b> (h) for 90 min, and β-arrestin1 recruitment was then quantified. (c, f, i) HEK293 cells stably expressing β-arrestin2 and transiently expressing CB1R were treated with 0.01 nM–10 μM CP55,940 ± 10–300 nM (±)-<b>9</b> (c), (−)-(<i>S</i>,<i>R</i>)-<b>13</b> (f), or (+)-(<i>R</i>,<i>S</i>)-<b>14</b> (i) for 90 min, and β-arrestin2 recruitment was then quantified. Data are expressed as % CP55,940 response and were analyzed with the combined allosteric binding model and Black–Leff operational model for agonism to estimate cooperativity factors (α, β) with CP55,940 as the reference agonist (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Data are mean ± SEM for <i>n</i> = 3–4 independent experiments performed in triplicate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00040&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Cooperativity Profiles for (±)-<b>9</b>, (−)-(<i>S</i>,<i>R</i>)-<b>13</b>, and (+)-(<i>R</i>,<i>S</i>)-<b>14</b><a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" rowspan="2" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char="±">cAMP</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char="±">(±)-<b>9</b></th><th class="colsep0 rowsep0" align="center" char="±">(−)-(<i>S</i>,<i>R</i>)-<b>13</b></th><th class="colsep0 rowsep0" align="center" char="±">(+)-(<i>R</i>,<i>S</i>)-<b>14</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">p<i>K</i><sub>B</sub></td><td class="colsep0 rowsep0" align="char" char="±">7.67 ± 0.25</td><td class="colsep0 rowsep0" align="char" char="±">8.78 ± 0.33</td><td class="colsep0 rowsep0" align="char" char="±">8.29 ± 0.39</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">α</td><td class="colsep0 rowsep0" align="char" char="±">20 ± 3.7</td><td class="colsep0 rowsep0" align="char" char="±">38 ± 6.1</td><td class="colsep0 rowsep0" align="char" char="±">51 ± 2.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">β</td><td class="colsep0 rowsep0" align="char" char="±">0.07 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">0.05 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">0.03 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">log(αβ)</td><td class="colsep0 rowsep0" align="char" char="±">0.09 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">0.14 ± 0.06</td><td class="colsep0 rowsep0" align="char" char="±">–0.27 ± 0.08</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">log(τ<sub>B</sub>)</td><td class="colsep0 rowsep0" align="char" char="±">4.4 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">1.5 ± 0.09</td><td class="colsep0 rowsep0" align="char" char="±">0.18 ± 0.09</td></tr></tbody></table><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" rowspan="2" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char="±">β-arr1</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char="±">(±)-<b>9</b></th><th class="colsep0 rowsep0" align="center" char="±">(−)-(<i>S</i>,<i>R</i>)-<b>13</b></th><th class="colsep0 rowsep0" align="center" char="±">(+)-(<i>R</i>,<i>S</i>)-<b>14</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">p<i>K</i><sub>B</sub></td><td class="colsep0 rowsep0" align="char" char="±">8.20 ± 0.81</td><td class="colsep0 rowsep0" align="char" char="±">8.27 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">9.01 ± 0.24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">α</td><td class="colsep0 rowsep0" align="char" char="±">2.2 ± 0.57</td><td class="colsep0 rowsep0" align="char" char="±">1.4 ± 0.06</td><td class="colsep0 rowsep0" align="char" char="±">2.5 ± 0.73</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">β</td><td class="colsep0 rowsep0" align="char" char="±">14 ± 1.9</td><td class="colsep0 rowsep0" align="char" char="±">12 ± 1.7</td><td class="colsep0 rowsep0" align="char" char="±">1.5 ± 0.40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">log(αβ)</td><td class="colsep0 rowsep0" align="char" char="±">1.4 ± 0.08</td><td class="colsep0 rowsep0" align="char" char="±">0.77 ± 0.05</td><td class="colsep0 rowsep0" align="char" char="±">–0.04 ± 0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">log(τ<sub>B</sub>)</td><td class="colsep0 rowsep0" align="char" char="±">1.2 ± 0.16</td><td class="colsep0 rowsep0" align="char" char="±">2.0 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">0.06 ± 0.03</td></tr></tbody></table><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" rowspan="2" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char="±">β-arr2</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char="±">(±)-<b>9</b></th><th class="colsep0 rowsep0" align="center" char="±">(−)-(<i>S</i>,<i>R</i>)-<b>13</b></th><th class="colsep0 rowsep0" align="center" char="±">(+)-(<i>R</i>,<i>S</i>)-<b>14</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">p<i>K</i><sub>B</sub></td><td class="colsep0 rowsep0" align="char" char="±">7.45 ± 0.32</td><td class="colsep0 rowsep0" align="char" char="±">8.19 ± 0.34</td><td class="colsep0 rowsep0" align="char" char="±">9.05 ± 0.24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">α</td><td class="colsep0 rowsep0" align="char" char="±">4.7 ± 0.35</td><td class="colsep0 rowsep0" align="char" char="±">3.7 ± 0.16</td><td class="colsep0 rowsep0" align="char" char="±">2.6 ± 1.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">β</td><td class="colsep0 rowsep0" align="char" char="±">21 ± 6.9</td><td class="colsep0 rowsep0" align="char" char="±">21 ± 4.3</td><td class="colsep0 rowsep0" align="char" char="±">2.3 ± 0.90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">log(αβ)</td><td class="colsep0 rowsep0" align="char" char="±">1.7 ± 0.23</td><td class="colsep0 rowsep0" align="char" char="±">1.8 ± 0.20</td><td class="colsep0 rowsep0" align="char" char="±">0.54 ± 0.30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">log(τ<sub>B</sub>)</td><td class="colsep0 rowsep0" align="char" char="±">1.1 ± 0.03</td><td class="colsep0 rowsep0" align="char" char="±">2.6 ± 0.15</td><td class="colsep0 rowsep0" align="char" char="±">1.1 ± 0.09</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">All values estimated using the allosteric binding model combined with the Black–Leff operational model for agonism for the data presented in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>. Data are means with 95% CI of <i>n</i> = 3–4 independent experiments.</p></div></div></div><div class="NLM_p last">Based on the collective <i>in vitro</i> profiling data reported herein, ligand biases, agonist signaling, and PAM signaling reflect the pharmacological mode of action as well as the unique stereochemistry of each compound, supporting the proposition that unique ligand–receptor interactions may facilitate bias. Following this characterization of allosteric-agonist/PAM and signaling, we next profiled these ligands <i>in silico</i> and then for potential physiological, therapeutic, and adverse effects in living systems.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> <i>In Silico</i> Determination of Ligand Binding</h3><div class="NLM_p last">Similar to all Class A GPCRs, CB1 has charged residues at the intracellular end of TMH3 R3.50 and TMH6 D6.30 that form a salt bridge (called the “ionic lock”), which keeps CB1 in its inactive state, unable to couple to G protein. When the ionic lock is broken, either by ligand binding tripping the binding pocket F3.36/W6.48 toggle switch or as a consequence of a mutation, CB1 moves into the activated state conformation (R*). Many years ago, we reported a missense mutation F4.46(238)L in the rat Cnr1 gene, that encodes for CB1, and is a gain of function mutant that results in an adolescent-like phenotype.<a onclick="showRef(event, 'cit54a'); return false;" href="javascript:void(0);" class="ref cit54a">(54a)</a> Cell-based assays showed that the F4.46L mutant was highly constitutively active and consistent with these results, molecular dynamics calculations revealed the binding pocket toggle switch, F3.36/W6.48, and the ionic lock were more frequently broken in the F4.46L mutant compared to WT. We have also reported previously that when GAT228 binds in the intracellular TMH1–2–4 allosteric-agonist exosite, it forms an extended aromatic cluster, interacting directly with F4.46 (holding the F4.46 in its activated state χ1 = trans conformation). At the same time, GAT228 can interact with H2.41 and W4.50. In the inactive state, F4.46 is in a χ1 = g+ and does not face lipid, but points into an intracellular TMH2–3–4 pocket. Recently, an important crystal structure of CB1/CP55,940/ORG27569 revealed ORG27569, a known negative allosteric modulator of CB1, bound at the intracellular TMH1–2–4 exosite such that F4.46 is restricted to the χ1 g+ conformation (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6KQI">6KQI</a>).<a onclick="showRef(event, 'cit54b'); return false;" href="javascript:void(0);" class="ref cit54b">(54b)</a> When CB1R activates, F4.46 undergoes a χ1 g+ → trans change and F4.46 leaves this pocket and faces toward the TMH1–2–4 allosteric-agonist exosite. In this latter case, TMH2 and TMH3 (on the intracellular end) can move toward TMH4 and away from TMH6, stretching the R3.50/D6.30 ionic lock until it breaks and activates the CB1 G-protein signaling pathway. Therefore, when binding at the allosteric-agonist exosite, GAT228 binding promotes the F4.46 χ1 g+ → trans rotameric change that may trigger the activation sequence of CB1, making GAT228 a “nonorthosteric” agonist. Based on this information, we hypothesized that (+)-(<i>R</i>,<i>S</i>)-<b>14</b> would act similarly upon F4.46 to promote G-protein signaling and we sought to understand how (−)-(<i>S</i>,<i>R</i>)-<b>13</b> could also be acting at the allosteric-agonist exosite. To do this, we first looked at conformational effects of the magic methyl addition in the (−)-(<i>S</i>,<i>R</i>)-<b>13</b> series.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Conformational Search Results</h3><div class="NLM_p">Conformational searches of each compound in the <b>13</b>–<b>16</b> series were performed to identify the global minimum conformer and minima up to 7.0 kcal/mol. Two important results became apparent from the global minima output. First, the addition of the methyl adjacent to the nitro group controls the direction of that nitro group, with (−)-(<i>S</i>,<i>R</i>)-<b>13</b> and (+)-(<i>R</i>,<i>S</i>)-<b>14</b> having the nitro group near the indole (see <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). (+)-(<i>S</i>,<i>S</i>)-<b>15</b> and (−)-(<i>R</i>,<i>R</i>)-<b>16</b> have the nitro group pointing up away from the indole. These results are consistent with the X-ray diffraction results for (−)-(<i>S</i>,<i>R</i>)-<b>13</b>–(+)-(<i>R</i>,<i>S</i>)-<b>14</b> vs (+)-(<i>S</i>,<i>S</i>)-<b>15</b>–(−)-(<i>R</i>,<i>R</i>)-<b>16</b> shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>. Second, the methyl sterically restricts the orientation of the phenyl ring attached to the central stereocenter. Comparison of the orientation of that phenyl in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, shows that (−)-(<i>S</i>,<i>R</i>)-<b>13</b> and (+)-(<i>S</i>,<i>S</i>)-<b>15</b> have this phenyl oriented down, while (+)-(<i>R</i>,<i>S</i>)-<b>14</b> and (−)-(<i>R</i>,<i>R</i>)-<b>16</b> have the phenyl ring oriented up. Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00040/suppl_file/jm1c00040_si_001.pdf" class="ext-link">Figure S4</a> shows that GAT228 shows the same rotational difference as (+)-(<i>R</i>,<i>S</i>)-<b>14</b>. The identical shift is apparent between GAT229 and (−)-(<i>S</i>,<i>R</i>)-<b>13</b>.</div><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Global minimum conformers of compounds <b>13</b>–<b>16</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00040&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The allosteric-agonist exosite has a requirement, based on our previous work with GAT228 and results on (−)-(<i>S</i>,<i>R</i>)-<b>13</b> presented here, that the nitro group be positioned near R(148), while the aromatic rings within the GAT compounds be near F4.46 and W4.50. The conformational cost of the nearest minima to fit this binding pocket requirement for each compound is shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>. A striking difference is quickly revealed between the compounds based on the high cost of redirecting the nitro group from the global minima conformation in (+)-(<i>S</i>,<i>S</i>)-<b>15</b> and (−)-(<i>R</i>,<i>R</i>)-<b>16</b> to point down toward the indole, compared to (+)-(<i>R</i>,<i>S</i>)-<b>14</b> or (−)-(<i>S</i>,<i>R</i>)-<b>13</b>. Also, the low cost of rotating the nitro group from the back face of the indole to the front face is revealed in the 0.24 kcal/mol conformational cost from the global minima for (−)-(<i>S</i>,<i>R</i>)-<b>13</b>. The relative conformational energy expense of these two changes explains why (+)-(<i>S</i>,<i>S</i>)-<b>15</b> and (−)-(<i>R</i>,<i>R</i>)-<b>16</b> do not perform as well as (−)-(<i>S</i>,<i>R</i>)-<b>13</b> or (+)-(<i>R</i>,<i>S</i>)-<b>14</b> in the experimental results. It is likely that (−)-(<i>S</i>,<i>R</i>)-<b>13</b> does not pay a high conformational price to occupy the allosteric-agonist site and neither would (+)-(<i>R</i>,<i>S</i>)-<b>14</b>. (+)-(<i>S</i>,<i>S</i>)-<b>15</b> and (−)-(<i>R</i>,<i>R</i>)-<b>16</b> clearly pay a high conformational cost to access the allosteric-agonist site by reorientation of the nitro group (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). It may be possible that (+)-(<i>S</i>,<i>S</i>)-<b>15</b> and (−)-(<i>R</i>,<i>R</i>)-<b>16</b> do not reorient the nitro group and lose a large majority of interaction with R(148).</div><figure id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Lowest energy minima that have the nitro group in a generally similar position relative to the indole ring seen in the binding conformation of (−)-(<i>S</i>,<i>R</i>)-<b>13</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00040&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Molecular Dynamics</h3><div class="NLM_p">(−)-(<i>S</i>,<i>R</i>)-<b>13</b> was superimposed in the CB1 R* allosteric-agonist site using our previously published data on GAT228. The nearest minima of (−)-(<i>S</i>,<i>R</i>)-<b>13</b> to the allosteric-agonist site binding conformation of GAT228 was used for this purpose (see <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). After manual adjustment to relieve steric contacts and subsequent minimization, the (−)-(<i>S</i>,<i>R</i>)-<b>13</b> CB1 R* complex was prepared for molecular dynamics (MD) simulations in a fully hydrated 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) bilayer. After initial equilibration of 1 μs, four 1 μs production runs were collected for the (−)-(<i>S</i>,<i>R</i>)-<b>13</b> CB1 R* complex. (−)-(<i>S</i>,<i>R</i>)-<b>13</b> was stable in the allosteric-agonist pocket, maintaining significant interactions with R(148), F4.46, and W4.50 as shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B. The initially modeled direct hydrogen-bonding interactions between the (−)-(<i>S</i>,<i>R</i>)-<b>13</b> nitro group and R(148) changed as R(148) preferred direct hydrogen bonds with the terminal exposed carbonyl of TMH1 residue L1.58(142). The nitro group maintained strong VdW and coulombic interactions with R(148) over all four simulations with an average distance of 4 Å between the nitro oxygens and the R(148) guanine nitrogen atoms as shown in Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00040/suppl_file/jm1c00040_si_001.pdf" class="ext-link">Figure S2</a>. Water was unable to interrupt the interaction between the (−)-(<i>S</i>,<i>R</i>)-<b>13</b> nitro group and the R(148) guanine during all four production runs (data not shown).</div><figure id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) Separate PAM and allosteric-agonist sites occupied by (−)-(<i>S</i>,<i>R</i>)-<b>13</b> (ligand carbons in green CPK style). (B) Closeup view of (−)-(<i>S</i>,<i>R</i>)-<b>13</b> is shown at the allosteric-agonist site with F4.46 in red; source target for the model is PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6N4B">6N4B</a>. Other closely interacting residues are shown in cyan. (C) A slightly pulled back, but similar, viewpoint of the allosteric-agonist site compared to (B) is rendered as a Connolly surface in gray. Of the four molecular dynamics production trajectories, the coordinates for images (B) and (C) are taken from the end of the third molecular dynamics production trajectory at 991 ns as a representative orientation of (−)-(<i>S</i>,<i>R</i>)-<b>13</b> at the allosteric-agonist site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00040&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Aromatic interactions did not change significantly over the course of the simulation between (−)-(<i>S</i>,<i>R</i>)-<b>13</b>, F4.46, and W4.50. Pairwise interaction energies for all residues within 5 Å of (−)-(<i>S</i>,<i>R</i>)-<b>13</b> were calculated for the representative snapshot of the allosteric-agonist site used in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B,C and the data are provided in Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00040/suppl_file/jm1c00040_si_001.pdf" class="ext-link">Table S30</a>. <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B shows a closeup view of the allosteric-agonist site with all residues within 5 Å that have pairwise interaction energies deeper than −1.0 kcal/mol shown. The χ1 dihedral of F4.46 remained in trans in the production runs, promoting the CB1 active state, as shown in Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00040/suppl_file/jm1c00040_si_001.pdf" class="ext-link">Figure S3</a>. In <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>C, the deep crevice of the allosteric-agonist exosite in the surface of CB1 occupied by (−)-(<i>S</i>,<i>R</i>)-<b>13</b> is revealed. Neither water nor the POPC lipids near this site were able to displace (−)-(<i>S</i>,<i>R</i>)-<b>13</b>. The root-mean-square deviation (RMSD) of the CB1 TMH regions in the (−)-(<i>S</i>,<i>R</i>)-<b>13</b>/ CB1 R* equilibration is given in Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00040/suppl_file/jm1c00040_si_001.pdf" class="ext-link">Figure S5</a>, while the RMSD of the (−)-(<i>S</i>,<i>R</i>)-<b>13</b>/ CB1 R* TMH regions during the production runs is shown in Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00040/suppl_file/jm1c00040_si_001.pdf" class="ext-link">Figure S6</a>.</div><div class="NLM_p">(−)-(<i>S</i>,<i>R</i>)-<b>13</b> vs (+)-(<i>R</i>,<i>S</i>)-<b>14:</b> (−)-(<i>S</i>,<i>R</i>)-<b>13</b> is an effective PAM because, similar to GAT229, the stereochemistry allows optimized fit to the PAM site while the “magic methyl” restricts conformational flexibility. It is also an effective allosteric-agonist compound due to the magic methyl effect, low conformational cost of binding to the allosteric-agonist site, and ability to stabilize F4.46 in the active state conformation. Availability to both sites opens the possibility of (−)-(<i>S</i>,<i>R</i>)-<b>13</b> binding to both sites simultaneously (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A). To understand why (+)-(<i>R</i>,<i>S</i>)-<b>14</b> has negligible PAM effects in functional assays, we attempted to dock the ligand at the PAM site. Using manual docking techniques in the CB1 R* model, steric conflicts between the receptor and ligand were unable to be relieved while attempting to keep Y2.57 interaction with the nitro group (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>B). Rotation of Y2.57 away from the PAM site, χ1 trans → g<sup>+</sup>, may destabilize ligand binding by loss of significant van der Waals interaction and complete loss of any interaction for the nitro group.</div><figure id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. (A) (−)-(<i>S</i>,<i>R</i>)-<b>13</b> (green carbons) complexed at both the allosteric-agonist and PAM CB1 sites. CB1 residues (light tan carbons) in close contact with each (−)-(<i>S</i>,<i>R</i>)-<b>13</b> molecule are displayed; source target for the model is PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6N4B">6N4B</a>. The PAM site is located underneath the EC1 loop at the extracellular ends of TMH2/3. The allosteric-agonist site is located at the intracellular ends of TMH1/2/4; (B) (+)-(<i>R</i>,<i>S</i>)-<b>14</b> (pink carbons) has steric clashes with Y2.57 (light tan carbons) inhibiting access to the PAM site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00040&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Electrophysiological Characterization of (±)-<b>9</b> and (+)-(<i>R</i>,<i>S</i>)-<b>14</b> in Autaptic Hippocampal Neurons</h3><div class="NLM_p">We have previously shown that autaptic hippocampal neurons elicit a depolarization-induced suppression of excitation (DSE), a form of retrograde inhibition that is mediated by the endogenous cannabinoid agonist 2-arachidonoylglycerol (2-AG) acting at the CB1R orthosteric site.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> A CB1R PAM would not be expected to directly inhibit synaptic transmission, but it has the potential to enhance 2-AG-mediated DSE. We observed that (±)-<b>9</b> and (+)-(<i>R</i>,<i>S</i>)-<b>14</b> inhibited excitatory postsynaptic currents (EPSCs) independent of endocannabinoid production in autaptic neurons (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>a,b,d,e). The relative EPSC charge after (±)-<b>9</b> (1 μM) treatment was 0.78 ± 0.07, <i>n</i> = 4 and after (+)-(<i>R</i>,<i>S</i>)-<b>14</b> (1 μM) treatment was 0.73 ± 0.06, <i>n</i> = 5 [means ± SEM, <i>p</i> < 0.05, <i>t</i>-test vs 1.0 (1 = no effect)]. The inhibition of EPSCs by (±)-<b>9</b> and (+)-(<i>R</i>,<i>S</i>)-<b>14</b> is consistent with their action as agonists. In the case of (±)-<b>9</b>, EPSC inhibition substantially occluded DSE (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>c). In contrast, (+)-(<i>R</i>,<i>S</i>)-<b>14</b> partially occluded DSE, but it was still evident that (+)-(<i>R</i>,<i>S</i>)-<b>14</b> delayed DSE recovery (e.g., <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>f), an observation consistent with (+)-(<i>R</i>,<i>S</i>)-<b>14</b>’s acting as an allosteric agonist in this experimental system.</div><figure id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Ago-PAM properties of (+)-(<i>R</i>,<i>S</i>)-<b>14</b> and (±)-<b>9</b> in autaptic hippocampal neurons. (a) Sample time course showing inhibition of EPSCs upon treatment with (±)-<b>9</b>. (b) Averaged direct inhibition of EPSCs upon 1 μM (±)-<b>9</b> application. (c) Sample DSE time course before and after (±)-<b>9</b> showing that (±)-<b>9</b> agonist effects occlude DSE responses. (d) Sample time course showing inhibition of EPSCs upon treatment with (+)-(<i>R</i>,<i>S</i>)-<b>14</b>. (e) Averaged direct inhibition of EPSCs upon 1 μM (+)-(<i>R</i>,<i>S</i>)-<b>14</b> application. (f) Sample DSE time course from a cell showing a slowed DSE recovery after (+)-(<i>R</i>,<i>S</i>)-<b>14</b> treatment. * <i>p</i> < 0.05 by <i>t</i>-test vs 1.0 (no effect).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00040&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Anti-Glaucoma Efficacy of (±)-<b>9</b>, (−)-(<i>S</i>,<i>R</i>)-<b>13</b>, and (+)-(<i>R</i>,<i>S</i>)-14 on Intraocular Pressure (IOP)</h3><div class="NLM_p">Glaucoma is a neurodegenerative disease and one of the leading causes of irreversible worldwide blindness. The reduction of intraocular pressure (IOP) strategy has been found to be most effective to reduce the risk of developing glaucoma and the progression of existing diseases. Several IOP-lowering eye-drops are available with a different mode of action and efficacy including β-blocker, carbonic anhydrase, prostaglandin analogs, α-2 adrenergic agonists, etc.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Laser treatment and surgery have also been less commonly used for the treatment of glaucoma. However, the short duration of action, drug-penetration of existed eye drops, and practicability of laser and surgery treatment limited their uses for the effective treatment of glaucoma. From the last few decades ligands, targeting cannabinoid receptors have been evaluated for their IOP-lowering effect.<a onclick="showRef(event, 'ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref57 ref58">(57,58)</a> Although CB1R orthosteric agonists can decrease IOP in humans and animals, their general therapeutic use is effectively precluded by a short duration of action (due to CB1R desensitization) and the possibility of psychotropic side effects.<a onclick="showRef(event, 'ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref57 ref58">(57,58)</a> Alternatively, CB1R ago-PAM does not exhibit these adverse properties, suggesting that CB1R ago-PAMs administered alone or with a subthreshold concentration of CB1R orthosteric agonist may constitute a potentially safer and longer-lasting therapeutic approach for reducing IOP and obviating the risk of glaucoma-associated vision loss.</div><div class="NLM_p">This background prompted us to determine the effects of topical administration of (±)-<b>9</b>, (−)-(<i>S</i>,<i>R</i>)-<b>13</b>, and (+)-(<i>R</i>,<i>S</i>)-<b>14</b> on IOP in mice. In ocular normotensive C57Bl/6 mice, 0.2% (±)-<b>9</b> or 0.25% orthosteric agonist WIN55,212 administered alone had no significant effect on IOP. However, 0.2% (±)-<b>9</b> administered with a subthreshold concentration of WIN55,212 (0.25%) significantly decreased IOP at 1, 6, and 12 h following topical application [−1.00 ± 0.23 (<i>p</i> ≤ 0.05), −0.78 ± 0.22 (<i>p</i> ≤ 0.001), and 50.05 ± 0.23 (<i>p</i> ≤ 0.01) mmHg from baseline, respectively, <i>n</i> = 6–13] (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>). This IOP-lowering effect was evident 12 h post-drug administration, making it remarkably long-lasting compared to the reported 1–2 h duration of the IOP-lowering effect of orthosteric CB1R agonists.<a onclick="showRef(event, 'cit57a ref58 ref59'); return false;" href="javascript:void(0);" class="ref cit57a ref58 ref59">(57a,58,59)</a></div><figure id="fig12" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. IOP-lowering effect of subthreshold WIN55,212-2 (WIN; 0.25%) is potentiated by the PAM (±)-<b>9</b> (0.2%) in ocular normotensive C57Bl/6 mice (<i>n</i> = 6–13). Values are represented as a change in IOP (mean ± SEM) from baseline (time-0). *<i>p</i> < 0.05, **<i>p</i> < 0.01, ***<i>p</i> < 0.001 (one-way ANOVA, followed by Dunnett’s multiple comparisons test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00040&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The effects of topical administration of (−)-(<i>S</i>,<i>R</i>)-<b>13</b> and (+)-(<i>R</i>,<i>S</i>)-<b>14</b> were also tested in ocular hypertensive <i>nee</i> mice, where the endocannabinoid tone was expected to be elevated.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> The <i>nee</i> mice carry a spontaneous mutation in the <i>Sh3pxd2b</i> gene, which results in numerous structural and functional abnormalities in those animals. The <i>nee</i> mice develop early-onset glaucoma, presumably due to iridocorneal adhesions, which consequently results in a blockade to aqueous humor outflow and a corresponding increase in IOP.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> This therefore provides a useful model for testing of our compounds.</div><div class="NLM_p">The topical administration of 0.2% (−)-(<i>S</i>,<i>R</i>)-<b>13</b> had no significant effect on IOP (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a> and <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a>). At a higher dose (1.0%), however, topical (−)-(<i>S</i>,<i>R</i>)-<b>13</b> significantly reduced IOP in <i>nee</i> mice at 1, 6, and 12 h post-administration [(−2.49 ± 0.99 (<i>p</i> ≤ 0.01), −1.89 ± 0.81 (<i>p</i> ≤ 0.05), and −1.57 ± 1.85 (<i>p</i> ≤ 0.01) mmHg from baseline, respectively; <i>n</i> = 11–18]) (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>). (±)-<b>9</b>, (−)-(<i>S</i>,<i>R</i>)-<b>13</b>, and (+)-(<i>R</i>,<i>S</i>)-<b>14</b> were also tested in ocular hypertensive <i>nee</i> mice that evidence a drastic elevation in IOP and an expected heightened endocannabinoid tone. In this glaucoma model, topical 0.2% (+)-(<i>R</i>,<i>S</i>)-<b>14</b> alone significantly decreased IOP at 1, 6, and 12 h post-administration [−2.20 ± 0.80 (<i>p</i> ≤ 0.05), −2.62 ± 1.11 (<i>p</i> ≤ 0.0), and 2.51 ± 1.22 (<i>p</i> ≤ 0.01) mmHg from baseline, respectively; <i>n</i> = 7–18] (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>). This therapeutic effect suggests that a CB1R ago-PAM may be useful in controlling IOP under pathological conditions, particularly where endocannabinoid levels are increased. The IOP-lowering effects of (±)-<b>9</b>, (−)-(<i>S</i>,<i>R</i>)-<b>13</b>, and (+)-(<i>R</i>,<i>S</i>)-<b>14</b> reported in this study are consistent with our previous reports where allosteric agonists or ago-PAMs in combination with subthreshold concentrations of orthosteric ligands were effective for therapeutic IOP modulation.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div><figure id="fig13" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Effects of PAM (−)-(<i>S</i>,<i>R</i>)-<b>13</b> on IOP in hypertensive <i>nee</i> mice at 1, 6, and 12 h after topical administration (<i>n</i> = 11–18). IOP was significantly lower in eyes receiving 1.0% (−)-(<i>S</i>,<i>R</i>)-<b>13</b> compared to vehicle at all times examined. Values are represented as a change in IOP (mean ± SEM) from the baseline (time-0). *<i>p</i> < 0.05, **<i>p</i> < 0.01 (one-way ANOVA, followed by Dunnett’s multiple comparisons test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00040&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig14" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Effects of PAMs (±)-<b>9</b>, (−)-(<i>S</i>,<i>R</i>)-<b>13</b>, and (+)-(<i>R</i>,<i>S</i>)-<b>14</b> on IOP in ocular hypertensive <i>nee</i> mice at 1, 6, and 12 h after topical administration (<i>n</i> = 7–18). IOP was significantly lower in eyes receiving 0.2% (+)-(<i>R</i>,<i>S</i>)-<b>14</b>, compared to vehicle at each time point examined. Values are represented as a change in IOP (mean ± SEM) from the baseline (time 0). *<i>p</i> < 0.05, **<i>p</i> < 0.01 (one-way ANOVA, followed by Dunnett’s multiple comparisons test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00040&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">From a translational perspective, therapeutic application of CB1R PAMs to treat glaucoma has several unique and clinically attractive advantages that are in marked contrast to both typical CB1R orthosteric agonists and current standards of care. Use of CB1Rs PAMs alone or with subthreshold doses of orthosteric ligands would minimize, if not eliminate, psychotropic side effects and inherent pharmacological responses (tolerance, dependence) associated with orthosteric CB1R agonists.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Current treatments for glaucoma involve chronic repetitive administration of IOP-lowering agents having short durations of action that undermine patient compliance.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Our demonstration that the IOP-lowering effect of (±)-<b>9</b> and (+)-(<i>R</i>,<i>S</i>)-<b>14</b> is sustained at least to 12 h post-drug administration (i.e., several-fold longer than the 1–2 h duration of the IOP-lowering effect of orthosteric CB1R agonists reported in the literature)<a onclick="showRef(event, 'cit57a ref58 ref59'); return false;" href="javascript:void(0);" class="ref cit57a ref58 ref59">(57a,58,59)</a> would eliminate the now prevalent need for frequent administration of IOP-lowering drugs. This observed long duration of action could be potentially due to the intrinsic pharmacokinetic properties of the biased compound that need more extensive investigation. These considerations constitute a compelling rationale for advancing CB1R biased allosteric agonists or ago-PAMs, either alone or with a subthreshold concentration of orthosteric ligand, as a potential therapeutic approach for IOP in patients with ocular hypertension.</div></div><div id="sec2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> <i>In Vivo</i> Catalepsy, Thermoregulation, and Nociception Tests</h3><div class="NLM_p">To determine whether (±)-<b>9</b>, (−)-(<i>S</i>,<i>R</i>)-<b>13</b>, and (+)-(<i>R</i>,<i>S</i>)-<b>14</b> had cannabinergic activity <i>in vivo</i>, we employed the classical triad assay consisting of tests for catalepsy (ring holding), thermoregulation (body temperature), and nociception (warm-water tail withdrawal) to male C57Bl/6 mice treated with 0.1, 1.0, 3.0, or 10 mg/kg of each test ligand and evaluated the specified endpoints at 5, 15, and 20 min thereafter compared to vehicle-treated animals and the positive control, Δ<sup>9</sup>-tetrahydrocannabinol (THC). At 1.0, 3.0, and 10 mg/kg, (±)-<b>9</b> and (−)-(<i>S</i>,<i>R</i>)-<b>13</b>, and (+)-(<i>R</i>,<i>S</i>)-<b>14</b> were without cataleptic effect (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>a). (±)-<b>9</b> elicited a dose-dependent decrease in body temperature to a lesser degree than did vehicle at 3.0 and 10 mg/kg, whereas (−)-(<i>S</i>,<i>R</i>)-<b>13</b> and (+)-(<i>R</i>,<i>S</i>)-<b>14</b> did not elicit hypothermia at these doses (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>b). (±)-<b>9</b> displayed no statistically significant anti-nociceptive activity at all doses tested similar to (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>c) (−)-(<i>S</i>,<i>R</i>)-<b>13</b> and (+)-(<i>R</i>,<i>S</i>)-<b>14</b> at 10 mg/kg (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>c). These data support the conclusion that (±)-<b>9</b>, (−)-(<i>S</i>,<i>R</i>)-<b>13</b>, and (+)-(<i>R</i>,<i>S</i>)-<b>14</b> did not elicit acute cannabinoid-like activity <i>in vivo</i> to the extent of a CB1R orthosteric partial agonist, such as THC (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>). Similar to our <i>in vitro</i> screen, these data suggest the racemic (±)-<b>9</b> displays unique properties not specifically dependent upon one enantiomer or another, but rather indicative of the mixture of enantiomers.</div><figure id="fig15" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Male C57Bl/6 mice were treated with 0.1–10 mg/kg ip test compound or vehicle (1:1:18 ethanol/cremaphor/saline). Physiological assessments of (a) catalepsy (5 min, % maximum possible effect (MPE) 60 s), (b) body temperature (15 min), and (c) nociception in the tail flick assay (52 °C) (20 min, % MPE 20 s) were then made. Data are mean ± SD, <i>n</i> = 6–13 animals/treatment. <sup>***</sup><i>p</i> < 0.001 relative to vehicle (two-way ANOVA followed by Bonferroni’s post hoc test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00040&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51835" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51835" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Strategic application of the magic methyl effect to the CB1R ago-PAM, GAT211, generated a diastereomer, <b>GAT562</b>, (±)-<b>9</b>, with 15-fold greater potency than parent compound. As supported by computational free-energy calculations, (±)-<b>9</b> was also more potent than the other GAT211-derived diastereomer, (±)-<b>10</b>, providing initial demonstration of the diastereoselective interaction of allosteric modulators with CB1R. Extensive pharmacological characterization of both enantiomers of the most potent diastereomer, (±)-<b>9</b>, in cAMP, β-arrestin1/2, GTPγS, and radioligand binding assays showed that the <b>GAT1600</b>, (−)-(<i>S</i>,<i>R</i>)-<b>13</b> enantiomer acts as a CB1R ago-PAM, whereas the opposite enantiomer, <b>GAT1601</b>, (+)-(<i>R</i>,<i>S</i>)-<b>14</b>, behaves as a CB1R biased allosteric agonist in both biochemical/cellular assays and a functional electrophysiology evaluation, a molecular pharmacology distinction supported by docking studies. Most importantly, (+)-(<i>R</i>,<i>S</i>)-<b>14</b> showed significant bias for G-protein-dependent vs -independent signaling. To the best of our knowledge, (+)-(<i>R</i>,<i>S</i>)-<b>14</b> represents the initial disclosure of G-protein biased CB1R allosteric agonists. Our initial demonstration of the preclinical efficacy and unprecedently long duration of action of (+)-(<i>R</i>,<i>S</i>)-<b>14</b> as a biased allosteric agonist for lowering IOP and its lack of cannabimimetic effect suggest its potential therapeutic value in treating glaucoma.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64210" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64210" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Materials and Methods</h3><div class="NLM_p last">All commercial chemicals and solvents were purchased from Sigma-Aldrich, Inc. (St. Louis, MO), Alfa Aesar, and Combi-blocks as reagent grade and unless otherwise specified were used without further purification. Biotage Initiator microwave system was used for the synthesis of select intermediates. Reaction progress was monitored by thin-layer chromatography (TLC) using commercially prepared silica gel 60 F254 glass plates. Compounds were visualized under ultraviolet (UV) light or by staining with iodine, phosphomolybdic acid, or <i>p</i>-anisaldehyde reagent. Flash column chromatography was carried out on a Biotage SP1, Biotage Isolera, or Interchim purification unit using prepacked columns from Reveleris, Biotage, and Luknova. Solvents used include hexanes, ethyl acetate, acetone, methanol, and dichloromethane. Characterization of compounds and their purity were established by a combination of HPLC, TLC, mass spectrometry, and NMR analyses. NMR spectra were recorded in dimethyl sulfoxide (DMSO)-<i>d</i><sub>6</sub>, and chloroform-<i>d</i>, on a Varian NMR spectrometer (<sup>1</sup>H NMR at 500 MHz and <sup>13</sup>C NMR at 100 MHz). Chemical shifts were recorded in parts per million (δ) relative to tetramethylsilane (TMS; 0.00 ppm) or solvent peaks as the internal reference. Multiplicities are indicated as br (broadened), s (singlet), d (doublet), t (triplet), q (quartet), quin (quintet), sept (septet), or m (multiplet). Coupling constants (<i>J</i>) are reported in hertz (Hz). All test compounds were greater than 95% pure as determined by LC/MS analysis performed using an Agilent Technologies 1260 Infinity reversed-phase HPLC, with dual-wavelength UV–visible detector and Agilent Technologies 6120 Quadrupole mass spectrometer (electrospray ionization). HRMS was done on SCIEX TOF/TOF 5800 System in a positive ion mode with a delay time of 100 ns. Each sample well was surveyed to find a “sweet spot”, and then 400 laser pulses were averaged to generate a spectrum.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> General Procedure for Synthesis</h3><div class="NLM_p">2-Phenyl indole (3 g, 15.5 mmol) and (<i>Z</i>)-(2-nitroprop-1-en-1-yl)benzene (3.8 g, 13.3 mmol) were dissolved in 50 mL of aqueous ethanol (10%) in a 100 mL round-bottom flask. Ammonium trifluoroacetate (1.01 g, 5 mol %) was added to the reaction mixture and heated under reflux for 24 h at 110 °C. After cooling, the solvent was removed under vacuum, and water was added. The reaction mixture was extracted with ethyl acetate, and the combined organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated under reduced pressure. The crude product was first purified by fractional crystallization where the only erythro isomer was isolated with 100% diastereomeric purity as a white solid. The mother liquor containing mixture of two isomers was further purified by repeated silica gel chromatography (20 μm silica gel columns). The overall yield for this reaction is 85% (based on recovered starting material), and the ratio of erythro to threo compound is approximately 9:1.</div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Erythro (±)3-(2-nitro-1-phenylpropyl)-2-phenyl-1<i>H</i>-indole <b>(9)</b></h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.03–7.98 (m, 2H), 7.51–7.46 (m, 5H), 7.38–7.32 (m, 3H), 7.28–7.19 (m, 5H), 5.90–5.82 (m, 1H), 4.76 (d, <i>J</i> = 11.7 Hz, 1H), 1.52 (d, <i>J</i> = 6.0 Hz, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 140.1, 136.8, 135.9, 132.5, 129.2, 128.8, 128.7, 128.5, 128.4, 127.1, 126.4, 122.1, 120.4, 120.2, 111.3, 110.8, 85.9, 48.6, 19.6; HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub> [M]<sup>+</sup>, 356.1525; found, 356.1520.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Threo (±)3-(2-nitro-1-phenylpropyl)-2-phenyl-1<i>H</i>-indole <b>(10)</b></h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.14 (bs, 1H), 7.78 (d, <i>J</i> = 8.2 Hz, 1H), 7.52–7.45 (m, 5H), 7.40–7.38 (m, 3H), 7.26–7.18 (m, 5H), 5.80–5.70 (m, 1H), 4.83 (d, <i>J</i> = 11.2 Hz, 1H), 1.42 (d, <i>J</i> = 6.4 Hz, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 140.6, 137.1, 135.9, 132.1, 128.9, 128.9, 128.7, 128.6, 127.5, 127.1, 126.6, 122.4, 120.4, 119.9, 111.5, 110.1, 86.9, 47.8, 19.3; HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub> [M]<sup>+</sup>, 356.1525; found, 356.1520.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 3-((1<i>S</i>,2<i>R</i>)-2-Nitro-1-phenylpropyl)-2-phenyl-1<i>H</i>-indole (<b>13)</b></h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.34 (bs, 1H), 8.15 (d, <i>J</i> = 8.0 Hz, 1H), 7.61–7.501 (m, 5H), 7.48–7.21 (m, 5H), 7.19–7.05 (m, 3H), 6.24–6.19 (m, 1H), 4.73 (d, <i>J</i> = 11.6 Hz, 1H), 1.45 (d, <i>J</i> = 6.4 Hz, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 140.1, 136.8, 135.9, 132.5, 129.2, 128.8, 128.7, 128.5, 128.4, 127.1, 126.4, 122.1, 120.4, 120.2, 111.3, 110.7, 85.9, 48.6, 19.6; [α]<sub>D</sub><sup>24</sup> = −10.72 (c 1 g/100 mL, MeOH); HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub> [M]<sup>+</sup>, 356.1525; found, 356.1544.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 3-((1<i>R</i>,2<i>S</i>)-2-nitro-1-phenylpropyl)-2-phenyl-1<i>H</i>-indole (<b>14)</b></h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.34 (bs, 1H), 8.15 (d, <i>J</i> = 8.0 Hz, 1H), 7.61–7.501 (m, 5H), 7.48–7.21 (m, 5H), 7.19–7.05 (m, 3H), 6.24–6.19 (m, 1H), 4.73 (d, <i>J</i> = 11.6 Hz, 1H), 1.45 (d, <i>J</i> = 6.4 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 140.1, 136.8, 135.9, 132.5, 129.2, 128.8, 128.7, 128.5, 128.4, 127.1, 126.5, 122.1, 120.41, 120.2, 111.3, 110.8, 85.9, 48.6, 19.6; [α]<sub>D</sub><sup>24</sup> = +10.40 (c 1 g/100 mL, MeOH); HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub> [M]<sup>+</sup>, 356.1525; found, 356.1505.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 3-((1<i>S</i>,2<i>S</i>)-2-Nitro-1-phenylpropyl)-2-phenyl-1<i>H</i>-indole (<b>15)</b></h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.50 (bs, 1H), 7.88 (d, <i>J</i> = 7.9 Hz, 1H), 7.63–7.51 (m, 5H), 7.39–7.24 (m, 5H), 7.19–7.04 (m, 3H), 6.03–5.99 (m, 1H), 4.78 (d, <i>J</i> = 11.4 Hz, 1H), 1.37 (d, <i>J</i> = 6.4 Hz, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 140.6, 137.1, 135.9, 132.1, 128.9, 128.9, 128.7, 128.6, 127.6, 127.1, 126.6, 122.5, 120.5, 119.9, 111.4, 110.1, 86.9, 47.7, 19.3; [α]<sub>D</sub><sup>24</sup> =+11.32 (c 1 g/100 mL, MeOH); HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub> [M]<sup>+</sup>, 356.1525; found, 356.1526.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 3-((1<i>R</i>,2<i>R</i>)-2-Nitro-1-phenylpropyl)-2-phenyl-1<i>H</i>-indole (<b>16)</b></h4><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.50 (bs, 1H), 7.88 (d, <i>J</i> = 7.9 Hz, 1H), 7.63–7.51 (m, 5H), 7.39–7.24 (m, 5H), 7.19–7.04 (m, 3H), 6.03–5.99 (m, 1H), 4.78 (d, <i>J</i> = 11.4 Hz, 1H), 1.37 (d, <i>J</i> = 6.4 Hz, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ 140.6, 137.1, 135.9, 132.1, 128.9, 128.9, 128.7, 128.6, 127.5, 127.1, 126.6, 122.4, 120.4, 119.9, 111.5, 110.1, 86.9, 47.8, 19.3; [α]<sub>D</sub><sup>24</sup> = −11.40 (c 1 g/100 mL, MeOH); HRMS (ESI): <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>20</sub>N<sub>2</sub>O<sub>2</sub> [M]<sup>+</sup>, 356.1525; found, 356.1518.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> X-ray Crystal Data</h3><div class="NLM_p">Single-crystal X-ray diffraction data on compounds (−)-(<i>S</i>,<i>R</i>)-<b>13</b>, (+)-(<i>R</i>,<i>S</i>)-<b>14</b>, (+)-(<i>S</i>,<i>S</i>)-<b>15</b>, and (−)-(<i>R</i>,<i>R</i>)-<b>16</b> were collected using Cu Kα radiation and a Bruker Photon 100 CMOS area detector. Crystals were prepared for data collection by coating with high-viscosity microscope oil. Oil-coated crystals were mounted on a micro-mesh mount (MiteGen, Inc.) and transferred to the diffractometer, and datasets were collected at room temperature. The structures were solved by direct methods and refined by full-matrix least squares on <i>F</i><sup>2</sup> values using SHELXL programs (Bruker, SHELXL v2014.7, 2014, Bruker AXS, Inc., Madison, WI). Corrections were applied for Lorentz, polarization, and absorption effects. Parameters refined included atomic coordinates and anisotropic thermal parameters for all nonhydrogen atoms. The H atoms were included using a riding model. Complete information on data collection and refinement is available in the <a href="/doi/suppl/10.1021/acs.jmedchem.1c00040/suppl_file/jm1c00040_si_001.pdf" class="ext-link">Supporting Information</a>.</div><div class="NLM_p">The 0.453 × 0.216 × 0.168 mm<sup>3</sup> crystal of (−)-(<i>S</i>,<i>R</i>)-<b>13</b> was orthorhombic in space group <i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub>, with unit cell dimensions <i>a</i> = 9.0947(2) Å, <i>b</i> = 12.2164(3) Å, <i>c</i> = 17.5047(4) Å, α = 90°, β = 90°, and γ = 90°. Data was 95.9% complete to 67.679° θ (∼0.83 Å) with an average redundancy of 5.29. The final anisotropic full matrix least-squares refinement on <i>F</i><sup>2</sup> with 245 variables converged at <i>R</i><sub>1</sub> = 4.99%, for the observed data and w<i>R</i><sub>2</sub> = 13.36% for all data.</div><div class="NLM_p">The 0.516 × 0.327 × 0.266 mm<sup>3</sup> crystal of (+)-(<i>R</i>,<i>S</i>)-<b>14</b> was orthorhombic in space group <i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub>, with unit cell dimensions <i>a</i> = 9.0955(5) Å, <i>b</i> = 12.2186(7) Å, <i>c</i> = 17.5055(9) Å, α = 90°, β = 90°, and γ = 90°. Data was 99.1% complete to 67.679° θ (∼0.83 Å) with an average redundancy of 5.88. The final anisotropic full matrix least-squares refinement on <i>F</i><sup>2</sup> with 244 variables converged at <i>R</i><sub>1</sub> = 3.69%, for the observed data and w<i>R</i><sub>2</sub> = 8.92% for all data.</div><div class="NLM_p">The 0.733 × 0.522 × 0.253 mm<sup>3</sup> crystal of (+)-(<i>S</i>,<i>S</i>)-<b>15</b> was orthorhombic in space group <i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub>, with unit cell dimensions <i>a</i> = 7.2977(10) Å, <i>b</i> = 16.2490(17) Å, <i>c</i> = 16.364(3) Å, α = 90°, β = 90°, and γ = 90°. Data was 96.7% complete to 67.684° θ (∼0.83 Å) with an average redundancy of 5.86. The final anisotropic full matrix least-squares refinement on <i>F</i><sup>2</sup> with 245 variables converged at <i>R</i><sub>1</sub> = 2.92%, for the observed data and w<i>R</i><sub>2</sub> = 8.19% for all data.</div><div class="NLM_p last">The 0.336 × 0.250 × 0.086 mm<sup>3</sup> crystal of (−)-(<i>R</i>,<i>R</i>)-<b>16</b> was orthorhombic in space group <i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub>, with unit cell dimensions <i>a</i> = 7.2968(5) Å, <i>b</i> = 16.2430(11) Å, <i>c</i> = 16.3592(11) Å, α = 90°, β = 90°, and γ = 90°. Data was 97.0% complete to 67.679° θ (∼0.83 Å) with an average redundancy of 5.11. The final anisotropic full matrix least-squares refinement on <i>F</i><sup>2</sup> with 246 variables converged at <i>R</i><sub>1</sub> = 3.38%, for the observed data and w<i>R</i><sub>2</sub> = 8.48% for all data.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Biological Evaluation</h3><div class="NLM_p">As we have carried out previously on parent compound <b>4</b> (GAT211),<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> we characterized the newly synthesized analogues disclosed herein in an extensive battery of functional assays.</div><div id="sec4_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Compounds</h4><div class="NLM_p last">All compounds and reagents for biological testing of test compounds were purchased from Sigma-Aldrich (Mississauga, ON), unless otherwise noted. CP55,940 was purchased from Cayman Chemical (Ann Arbor, MI). All compounds were initially dissolved in DMSO and diluted in a 10% DMSO solution in phosphate-buffered saline (PBS). Compounds were added directly to cell culture at the times and concentrations indicated at a final concentration of 0.1% DMSO.</div></div><div id="sec4_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Cell Culture</h4><div class="NLM_p">HitHunter (cAMP) and PathHunter (β-arrestin2) CHO-K1 cells stably expressing human CB1R (hCB1R) from DiscoveRx (Eurofins, Fremont, CA) were maintained between passage 5 and 35 at 37 °C, 5% CO<sub>2</sub> in F-12 Dulbecco’s modified Eagle’s medium (DMEM; Corning Cellgro, Manassas, VA) containing 10% fetal bovine saline (FBS) and 1% penicillin–streptomycin with 800 μg/mL geneticin (HitHunter) or 800 μg/mL geneticin and 300 μg/mL hygromycin B (PathHunter). HitHunter and PathHunter hCB1R CHO-K1 cells were used for data presented in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00040/suppl_file/jm1c00040_si_001.pdf" class="ext-link">Figure S1</a>.</div><div class="NLM_p last">CHO cells stably transfected with cDNA encoding hCB1R were maintained at 37 °C and 5% CO<sub>2</sub> in Ham’s F-12 nutrient mixture supplemented with 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine, 10% FBS, 0.6% penicillin–streptomycin (Gibco; Fisher Scientific U.K. Ltd.), and the disulfate salt of G418 [(2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>,6<i>S</i>)-5-amino-6-{[(1<i>R</i>,2<i>S</i>,3<i>S</i>,4<i>R</i>,6<i>S</i>)-4,6-diamino-3-{[(2<i>R</i>,3<i>R</i>,4<i>R</i>,5<i>R</i>)-3,5-dihydroxy-5-methyl-4-(methylamino)oxan-2-yl]oxy}-2-hydroxycyclohexyl]oxy}-2-[(1<i>R</i>)-1-hydroxyethyl]oxane-3,4-diol; 600 mg/mL] (Sigma-Aldrich, U.K.). All cells were incubated under a humidified 5% CO<sub>2</sub> atmosphere in their media and were passaged twice a week using nonenzymatic cell dissociation solution. For membrane preparation, cells were removed from flasks by scraping, centrifuged, and then frozen as a pellet at −20 °C until required. Before use in a radioligand binding assay, defrosted cell pellets were taken up in tris(hydroxymethyl)-aminomethane (Tris) buffer (50 mM Tris–HCl and 50 mM Tris–base). CHO-K1 cells stably expressing hCB1R were used for data presented in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> and <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>. Human embryonic kidney (HEK293) cells (American Type Culture Collection, Rockville, MD) were cultured in DMEM supplemented with 10% FBS (GE Healthcare Hyclone Laboratories, Logan, UT). HEK293 cell lines stably expressing GFP-tagged (N-terminus) GFP-rat CB1R (rCB1R) were generated through transfection with GFP-rCB1R-pcDNA3.1 using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) and selected in DMEM containing 10% FBS and geneticin (800 μg/mL). Colonies were picked two weeks after transfection and expanded before analysis of GFP-tagged receptor expression by fluorescence microscopy. Cell lines with moderate-to-high receptor expression were maintained in DMEM with 10% FBS and 500 μg/mL geneticin. HEK293 cells stably expressing rCB1R were used for data presented in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Tables <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a> and <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> and <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>.</div></div><div id="sec4_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> HitHunter cAMP Assay</h4><div class="NLM_p last">Inhibition of forskolin (FSK)-stimulated cAMP production was determined using the DiscoveRx HitHunter assay in hCB1R CHO-K1 cells. Cells (20 000 cells/well in low-volume 96-well plates) were incubated overnight in Opti-MEM (Invitrogen) containing 1% FBS at 37 °C and in a 5% CO<sub>2</sub> atmosphere. Following this, the Opti-MEM media was removed and replaced with cell assay buffer (DiscoveRx), and cells were treated at 37 °C with 10 μM FSK and hCB1R test ligand (0.10 nM–10 μM) for 30 min (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>; Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00040/suppl_file/jm1c00040_si_001.pdf" class="ext-link">Figure S1</a>). Cellular cAMP was then quantified immunochemically according to the manufacturer’s directions with chemiluminescence detection on a Cytation 5 plate reader (top read; gain, 200; integration time, 10 000 ms). Standard agonist properties in the assays used were as follows: CP55,940: EC<sub>50</sub> = 190 ± 4.2 nM; <i>E</i><sub>Max</sub> = 2.1 ± 0.05 (-fold over baseline).</div></div><div id="sec4_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> PathHunter β-Arrestin2 Recruitment Assay</h4><div class="NLM_p last">β-Arrestin2 recruitment was determined using the hCB1R CHO-K1 cell PathHunter assay (DiscoveRx). Cells (20 000 cells/well in low-volume 96-well plates) were incubated overnight in Opti-MEM (Invitrogen) containing 1% FBS at 37 °C and under a 5% CO<sub>2</sub> atmosphere. Following this, cells were co-treated at 37 °C with hCB1R ligands (0.10 nM–10 μM) for 90 min (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>; Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00040/suppl_file/jm1c00040_si_001.pdf" class="ext-link">Figure S1</a>). Detection solution was then added to cells according to the manufacturer’s directions, and cells were incubated for 60 min at room temperature. Chemiluminescence was measured on a Cytation 5 plate reader (top read; gain, 200; integration time, 10 000 ms). Standard agonist properties in the assays used were as follows: CP55,940: EC<sub>50</sub> = 7.6 ± 1.0 nM; <i>E</i><sub>Max</sub> = 11 ± 1.4 (-fold over baseline).</div></div><div id="sec4_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> Detection of cAMP in HEK293 Cells</h4><div class="NLM_p last">Cells stably expressing GFP-rCB1R<a onclick="showRef(event, 'ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref63 ref64">(63,64)</a> were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Corning Cellgro, Manassas, VA) supplemented with 10% fetal bovine serum (FBS) (GE Healthcare Hyclone Laboratories, Logan, UT). At 70–80% confluency, the cells were dissociated in trypsin (0.05%)–ethylenediaminetetraacetic acid (EDTA; 0.1%) (Quality Biological, Gaithersburg, MD), centrifuged at 200<i>g</i> for 5 min, and resuspended in stimulation buffer [0.1% bovine serum albumin (BSA) and 0.5 mM IBMX (MilliporeSigma, Burlington, MA)] in Hank’s Balanced Salt Solution (HBSS) (Corning Cellgro, Manassas, VA). The cell suspension was transferred to a white 384-well plate at a density of 500 cells/well and treated with a designated CB1R ligand along with 5 μM forskolin (Cayman Chemical, Ann Arbor, MI) for 30 min. After drug treatment, cAMP was quantified immunochemically using the LANCE Ultra cAMP detection kit (PerkinElmer, Waltham, MA) according to manufacturer’s instructions. Briefly, cells were lysed and incubated with europium (Eu) chelate-labeled cAMP and ULightTM dye-labeled anti-cAMP monoclonal antibody. After a 1 h incubation, light emissions at 665 and 615 nm were measured in an EnVision 2104 multilabel plate reader (PerkinElmer). Fluorescence counts at 665 nm were used to estimate cAMP levels by interpolating the concentration from a cAMP standard curve run in parallel. The amount of cAMP in each sample was normalized to samples treated with FSK only.</div></div><div id="sec4_4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Detection of β-Arrestin1 and β-Arrestin2 Recruitment in HEK293 Cells</h4><div class="NLM_p last">Assessment of β-arrestin recruitment was performed using HEK293 cells expressing β-arrestin1 or β-arrestin2 fused to a fragment of the β-galactosidase enzyme (acceptor) and hCB1R fused to a complementary fragment of the β-galactosidase enzyme (donor) on the C-terminus, as previously described.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> HEK293 cells stably expressing either β-arrestin1 or β-arrestin2 construct were generated by transfection with lipofectamine 2000 (Invitrogen, Carlsbad, CA), and clonal cells were selected with 200 μg/mL hygromycin B (Enzo Life Sciences). The cells were transiently transfected with hCB1R construct over 24 h. The cells were serum-starved overnight and treated with designated test compounds for 90 min. After drug treatment, the cells were lysed with Tropix Lysis Solution (Applied Biosystems, Foster City, CA) for 10 min at room temperature, and β-galactosidase enzyme activity was detected after 1 h incubation with Galacto-Star One-Step β-Galactosidase Reporter Gene Assay System (Applied Biosystems) detection reagents. Luminescence was measured in an EnVision 2104 multilabel plate reader (PerkinElmer), and relative luminescence units were normalized to the maximum response obtained with CP55,940.</div></div><div id="sec4_4_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> [<sup>3</sup>H]CP55,940 Radioligand Displacement Assay</h4><div class="NLM_p last">Assays were carried out with [<sup>3</sup>H]CP55,940 and Tris binding buffer (50 mM Tris–HCl, 50 mM Tris–base, 0.1% BSA, pH 7.4), in a total assay volume of 500 μL. Binding was initiated by the addition of transfected hCB1R CHO cell membranes (50 μg protein per well). All assays were performed at 37 °C for 60 min before termination upon addition of ice-cold Tris binding buffer followed by vacuum filtration using a 24-well sampling manifold (Brandel Cell Harvester; Brandel, Inc., Gaithersburg, MD) and Brandel GF/B filters that had been soaked in wash buffer at 4 °C for at least 24 h. Each reaction well was washed six times with 1.2 mL aliquots of Tris-binding buffer. The filters were oven-dried for 60 min and then placed in 3 mL of scintillation fluid (Ultima Gold XR, PerkinElmer, Seer Green, Buckinghamshire, U.K.). Radioactivity was quantified by liquid scintillation spectrometry. Specific binding was defined as the difference between the binding that occurred in the presence and absence of 1 μM unlabeled CP55,940. The concentration of [<sup>3</sup>H]CP55,940 used in our displacement assays was 0.7 nM. The compounds used in this assay were stored as 10 mM stock solutions in DMSO, and the vehicle concentration in all assay wells was 0.1% DMSO. Data are presented as % ligand bound.</div></div><div id="sec4_4_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> [<sup>35</sup>S]GTPγS Assay</h4><div class="NLM_p">Assays were carried out in the presence of [<sup>35</sup>S]GTPγS (0.1 nM), GDP (30 μM), GTPγS (30 μM), and CHO cell membranes (1 mg protein/mL) stably expressing hCB1R. The assay buffer contained 50 mM Tris, 10 mM MgCl<sub>2</sub>, 100 mM NaCl, 0.2 mM EDTA, and 1 mM dithiothreitol (DTT) at pH 7.4. Incubations were carried out at 30 °C for 90 min in a total volume of 500 μL.</div><div class="NLM_p">The reaction was terminated by the addition of ice-cold wash buffer (50 mM Tris and 1 mg/mL BSA, pH 7.4) followed by rapid filtration in a 24-well sampling manifold (Brandel Cell Harvester; Brandel, Inc., Gaithersburg, MD) and Brandel GF/B filters presoaked in wash buffer at 4 °C for at least 24 h.</div><div class="NLM_p last">Each reaction well was washed six times with 1.2 mL aliquots of Tris-binding buffer. The filters were oven-dried for 60 min and then placed in 3 mL of scintillation fluid (Ultima Gold XR, PerkinElmer, Seer Green, Buckinghamshire, U.K.). Radioactivity was determined by liquid scintillation spectrometry. Basal binding of [<sup>35</sup>S]GTPγS was determined in the presence of 20 mM GDP and absence of cannabinoid. Nonspecific binding was determined in the presence of 10 mM GTPγS. The compounds used in this assay were stored as stock solutions of 10 mM in DMSO. The vehicle concentration in all assay wells was 0.1% DMSO.</div></div><div id="sec4_4_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> Triad Assessment</h4><div class="NLM_p last">All animal experiments were performed in accordance with ethical guidelines from the Canadian Council for Animal Care and the ARRIVE guidelines for the use of animals. The study was approved by the University of Saskatchewan’s Animal Use and Care Committee. Male C57Bl/6 mice between 4 and 6 months of age were utilized for these studies (Charles River, Senneville, QC). Compounds administered ip were prepared in vehicle [ethanol and cremaphor in saline (1:1:8)]. Mouse weight was recorded daily. Catalepsy was assessed in the bar-holding assay 5 min after drug administration.<a onclick="showRef(event, 'ref66 ref67'); return false;" href="javascript:void(0);" class="ref ref66 ref67">(66,67)</a> The mice were placed such that their forepaws clasped a 0.7 cm ring clamp positioned 4.5 cm above the surface of the testing space. The length of time the ring was gripped by the animal was recorded. The trial was ended if the mouse turned its head or body or made three consecutive escape attempts.<a onclick="showRef(event, 'ref66 ref67'); return false;" href="javascript:void(0);" class="ref ref66 ref67">(66,67)</a> Body temperature was measured by rectal thermometer 15 min after drug administration. Antinociceptive effects were assessed in the standard warm-water (52 °C) tail-flick test 20 min after drug administration. Response was defined as the removal of the tail from the warm water, with a threshold time of 20 s. Catalepsy and tail flick data are presented as % maximum possible effect (MPE).<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> The animals were habituated to the treatment room for 2 days prior to experimentation.</div></div><div id="sec4_4_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Hippocampal Neuron Culture Preparation</h4><div class="NLM_p last">All procedures used in this study were approved by the Animal Care Committee of Indiana University and conform to the Guidelines of the National Institutes of Health on the Care and Use of Animals. Mouse hippocampal neurons isolated from the CA1-CA3 region were cultured on microislands, as described previously.<a onclick="showRef(event, 'ref69 ref70'); return false;" href="javascript:void(0);" class="ref ref69 ref70">(69,70)</a> Neurons were obtained from mice (C57Bl/6, postnatal day 0–2, of indeterminate sex) and plated onto a feeder layer of hippocampal astrocytes that had been laid down previously.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Cultures were grown in high-glucose (20 mM) DMEM containing 10% horse serum without mitotic inhibitors and used for recordings after 8 days in culture and for no more than 3 h after removal from culture medium.</div></div><div id="sec4_4_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> Autaptic Neuron Electrophysiology</h4><div class="NLM_p">A single neuron grown on a small island of permissive substrate forms synapses or “autapses” onto itself. Whole-cell voltage-clamp recordings from autaptic neurons were obtained at room temperature using an Axopatch 200A amplifier (Axon Instruments, Burlingame, CA). The extracellular solution contained (in mM) 119 NaCl, 5 KCl, 2.5 CaCl<sub>2</sub>, 1.5 MgCl<sub>2</sub>, 30 glucose, and 20 <i>N</i>-(2-hydroxyethyl)piperazine-<i>N</i>′-ethanesulfonic acid (HEPES). Continuous flow of solution through the bath chamber (∼2 mL/min) ensured rapid application and clearance of test compound. Test compounds were typically prepared as concentrated stocks and then diluted into extracellular solution at their final concentration to be used within a single experimental day.</div><div class="NLM_p last">For electrophysiology, recording pipettes of 1.8–3 MΩ were filled with (in mM) 121.5 K-gluconate, 17.5 KCl, 9 NaCl, 1 MgCl<sub>2</sub>, 10 HEPES, 0.2 EGTA, 2 MgATP, and 0.5 LiGTP. Access resistance and holding current were monitored, and only cells with both stable access resistance and holding current were included for data analysis. For the conventional stimulus protocol, the membrane potential was held at −70 mV, and excitatory postsynaptic currents (EPSCs) were evoked every 20 s by triggering an unclamped action current with a 1.0 ms depolarizing step. The resultant evoked waveform consisted of a brief stimulus artifact and a large downward spike representing inward sodium currents, followed by the slower EPSC. The size of the recorded EPSCs was calculated by integrating the evoked current to yield a charge value (in pC). Calculating the charge value in this manner yields an indirect measure of the amount of neurotransmitter released while minimizing the effects of cable distortion on currents generated far from the site of the recording electrode (the soma). Data were acquired at a sampling rate of 5 kHz. For DSE experiments, after establishing a 10–20 s 0.5 Hz baseline, DSE was evoked by depolarizing to 0 mV for 50 ms, 100 ms, 300 ms, 500 ms, 1 s, 3 s, and 10 s, followed in each case by resumption of a 0.5-Hz stimulus protocol for 20–80+ s, allowing EPSCs to recover to baseline values. This approach enabled us to determine the sensitivity of the synapses to DSE induction. For comparison, baseline values (prior to the DSE stimulus) were normalized to one. DSE inhibition values are presented as fractions of 1, i.e., a 50% inhibition from the baseline response is 0.50 ± standard error of the mean. The <i>x</i>-axis of DSE depolarization–response curves are log-scale seconds of the duration of the depolarization used to elicit DSE. Depolarization response curves are obtained to determine pharmacological properties of endogenous 2-AG signaling by depolarizing neurons for progressively longer durations (50 ms, 100 ms, 300 ms, 500 ms, 1 s, 3 s, and 10 s).</div></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> Intraocular Pressure (IOP) Assessment in Mice</h3><div class="NLM_p">Normotensive C57Bl/6J mice and Sh3pxd2b mice were obtained from Jackson Laboratory (Bar Harbor, Maine). The Sh3pxd2b mice were bred in-house, and their progenies with abnormal phenotypical morphology, identified as <i>nee</i> mice, were used for experiments, as these animals develop significant elevation in IOP. (±)-<b>9</b> (0.2%), (−)-(<i>S</i>,<i>R</i>)-<b>13</b> (0.2%), (+)-(<i>R</i>,<i>S</i>)-<b>14</b> (0.2%), and WIN55,212-2 (0.2%) (Bio-Techne, Abingdon, OX, U.K.) were dissolved in vehicle containing 2% DMSO (Sigma-Aldrich, Oakville, ON, Canada) and 4% Tween 20 in Tocrisolve (Bio-Techne, Minneapolis, MN). The drugs were administrated topically (5 μL/eye) immediately following baseline (time-0) IOP measurements. Measurement of IOP was performed by rebound tonometry (Tonolab, Icare, Finland), which afforded a noninvasive method for compound testing. IOP (10 measurements/eye/time point) was measured in mice anesthetized with 1–3% isoflurane at time 0 (baseline) and at 1, 6, and 12 h after topical administration of drug/vehicle (5 μL/eye). Between each time point, the animals were allowed to recover. All of the measurements were taken at the same time of the day to minimize variability from diurnal IOP fluctuations. Data were analyzed by GraphPad version 6.0 (GraphPad Software, Inc., La Jolla, CA). One-way ANOVA was used for statistical analysis followed by Dunnett’s multiple comparisons test. A <i>p</i> < 0.05 was considered significant.</div><div class="NLM_p last">All animal experiments were performed in accordance with ethical guidelines from the Canadian Council for Animal Care and the ARVO Statement for the use of Animals in Ophthalmic and Vision research. The study was approved by Dalhousie’s University Committee on Laboratory Animals.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> Computational Methods</h3><div id="sec4_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> Conformational Analysis</h4><div class="NLM_p">A complete conformational analysis of each of the stereoisomers was performed. First, the parameters in OPLS3e were checked for missing dihedrals using the Force Field Builder tool (Schrödinger Release 2020-1) (Schrödinger, LLC, New York, NY), and missing dihedrals parameters were added. A complete conformational analysis of each compound was then performed using the Mixed Torsional/Low-Mode Sampling technique as encoded in Macromodel (Schrödinger Release 2020-1: Schrödinger, LLC). Torsional moves of 30° were set for dihedrals containing an atom with sp<sup>3</sup> hybridization bonded to an atom with sp<sup>2</sup> hybridization in the rotatable bond and 60° for dihedrals containing sp<sup>3</sup> to sp<sup>3</sup> hybridizations in the rotatable bond. The search was composed of 15K Monte Carlo steps using the OPLS3e force field with a distance-dependent dielectric and a dielectric base constant of 2. An 8.0 Å nonbonded cutoff (updated every 10 steps), a 20.0 Å electrostatic cutoff, and a 4.0 hydrogen-bond cutoff were applied to the minimization of each conformation with a gradient of 0.01 (kcal/mol)/Å.</div><div class="NLM_p last">Duplicate conformations identified at an RMSD ≤ 0.7 were removed. Conformers were optimized using ab initio DFT M06-2X-D3 calculations at the 6-31G**<sup>++</sup> basis set level as encoded in Jaguar (Schrödinger Release 2020-1: Schrödinger, LLC), and any resulting additional duplicate conformations were removed.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> To calculate the energy difference between the global minimum energy conformer of (−)-(<i>S</i>,<i>R</i>)-<b>13</b> and its final docked conformation, rotatable bonds in the global minimum energy conformer were driven to their corresponding value in the final docked conformation using Jaguar with the same method and basis set. The unique conformers of GAT228/229 identified in previous work were also optimized in Jaguar in the same way for comparison of conformations with <b>13</b>–<b>16</b>.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div></div><div id="sec4_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> Modeling of the CB1R*/(−)-(<i>S</i>,<i>R</i>)-<b>13</b> Complex</h4><div class="NLM_p">The Ballesteros–Weinstein numbering system for GPCR amino acid residues is used. In this numbering system, the label 0.50 is assigned to the most highly conserved residue in class-A GPCRs in each transmembrane helix (TMH).<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> This is preceded by the TMH number. In this system, the most highly conserved residue in TMH6 is P6.50. The residue immediately before this would be labeled 6.49, and the residue immediately after this would be labeled 6.51.</div><div class="NLM_p last">The CB1R* model, based on PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6N4B">6N4B</a>, and previously described in detail was used for docking.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> (−)-(<i>S</i>,<i>R</i>)-<b>13</b> was docked in the allosteric agonist site located at the intracellular end of TMH1–2–4, with R(148), H2.41, F4.46, and W4.50 used as direct interactions. The receptor/ligand complex was energy-minimized in Prime (Suite 2020-1, Schrödinger, Inc.). The Prime implicit membrane functionality was employed. Hydrophilic residues facing the binding crevice and within the low dielectric region of the implicit membrane were excluded from the low dielectric via exclusion spheres placed on each residue. The generalized Born/surface area (GB/SA) continuum solvation model for water was used with the dielectric set to 80 outside of the implicit membrane region and 1 within. A truncated Newton conjugate gradient minimization was performed using the OPLS3e force field for one iteration, up to a maximum of 1000 steps and with a 0.1 kcal/mol gradient endpoint. To prevent the intracellular opening in the R* model from closing during the minimization, constraints of 1 kcal/mol were placed on the C-α atoms of R3.50, Y5.58, L6.33, and Y7.53. The conformational cost of (−)-(<i>S</i>,<i>R</i>)-<b>13</b> was determined after optimization of the complex to be 2.09 kcal/mol.</div></div><div id="sec4_6_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> Parameterization of (−)-(<i>S</i>,<i>R</i>)-<b>13</b></h4><div class="NLM_p last">(−)-(<i>S</i>,<i>R</i>)-<b>13</b> was parameterized using the process described by Mayne and co-workers based around the FFTK toolkit distributed as a plugin in visual molecular dynamics (VMD).<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> Atomic partial charges and initial parameters for the CGenFF, CHARMM general force field were acquired from the Paramchem website (<a href="https://cgenff.umaryland.edu" class="extLink">https://cgenff.umaryland.edu</a>).<a onclick="showRef(event, 'ref75 ref76'); return false;" href="javascript:void(0);" class="ref ref75 ref76">(75,76)</a> Gaussian versions 09e01 and 16a03 were used for <i>ab initio</i> calculations on the UNC Longleaf cluster.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Final parameters are provided in Supporting Information <a href="/doi/suppl/10.1021/acs.jmedchem.1c00040/suppl_file/jm1c00040_si_001.pdf" class="ext-link">Table S29</a>.</div></div><div id="sec4_6_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> Molecular Dynamics of the CB1R*/(−)-(<i>S</i>,<i>R</i>)-<b>13</b> Complex</h4><div class="NLM_p last">The CB1R*/(−)-(<i>S</i>,<i>R</i>)-<b>13</b> complex was oriented with the respect to the membrane using the template PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6N4B">6N4B</a> from the Orientation of Proteins in Membranes database.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> The MD simulation system consists of CB1R*/(−)-(<i>S</i>,<i>R</i>)-<b>13</b> complex suspended in a fully hydrated phospholipid bilayer consisting of 154 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) lipids, 0.15 M NaCl, and 16879 TIP3P water molecules. The lipids, ions, and water molecules were added using CHARMM-GUI server into a simulation cell of 80.2 Å × 80.2 Å × 128.6 Å.<a onclick="showRef(event, 'ref79 ref80'); return false;" href="javascript:void(0);" class="ref ref79 ref80">(79,80)</a> All MD runs employed the all-atom additive CHARMM36m force field for proteins and CHARMM36 for lipid and ions.<a onclick="showRef(event, 'ref81 ref82'); return false;" href="javascript:void(0);" class="ref ref81 ref82">(81,82)</a> The system was energy-minimized and relaxed using the multistep schedule, as described.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> An initial simulation wherein (−)-(<i>S</i>,<i>R</i>)-<b>13</b> stayed localized in the allosteric agonist site was run for 1000 ns as equilibration of the ligand in the binding pocket. Subsequently, four additional production simulations were spawned from the end of the initial equilibrium run. Unbiased MD was performed for 1000 ns for each of the four production runs. All MD simulations were performed with the GPU version of AMBER 18 in the semi-isotropic NPT ensemble using a Langevin thermostat (<i>T</i> = 310 K, using a friction coefficient of 1 ps<sup>–1</sup>) and a Monte Carlo barostat (<i>P</i> = 1 bar) as implemented in AMBER 16.<a onclick="showRef(event, 'ref83 ref84'); return false;" href="javascript:void(0);" class="ref ref83 ref84">(83,84)</a> Long-range electrostatics were treated using particle mesh Ewald (PME), and the Van der Waal force switching method was applied starting at 10 Å with a cutoff of 12 Å. High-frequency bonds to hydrogen were constrained using the SHAKE method, allowing the use of a 2 fs integration time step. RMSD plots for the TMH bundle vs time were used to analyze the bundle geometry stability in the bilayer.</div></div><div id="sec4_6_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> Assessment of Pairwise Interaction Energies</h4><div class="NLM_p last">After defining the atoms of (−)-(<i>S</i>,<i>R</i>)-<b>13</b> as one group (group 1) and the atoms corresponding to a residue that lines the respective binding site in the final ligand/CB1 R* complex as another group (group 2), Macromodel (version 8.6, Schrödinger, LLC, New York, NY) was used to output the pairwise interaction energy (coulombic and Van der Waals) for a given pair of atoms. The pairs corresponding to group 1 (ligand) and group 2 (residue of interest) were then summed to yield the interaction energy between the ligand and that residue. A snapshot of the protein and (−)-(<i>S</i>,<i>R</i>)-<b>13</b> from the third production trajectory at timepoint 991 ns was extracted and minimized in Prime as previously described, except that 10 kcal/mol constraints were placed on all c-α atoms and the C3, C8 atoms of (−)-(<i>S</i>,<i>R</i>)-<b>13</b>. The minimization was run for 500 steps before constraints were lowered to 1 kcal/mol and an additional 500 steps were performed. Pairwise energies were then calculated on that output with a resulting RMSD for all atoms of 0.44.</div></div><div id="sec4_6_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> Concentration–Response Curve Data Analysis for Profiling of Signaling Bias and Allosterism</h4><div class="NLM_p last">Data are presented as the mean ± the standard error of the mean (SEM) or 95% confidence interval (CI) of at least three independent experiments conducted in duplicate or triplicate, as indicated in the text/figure legends. Significance was determined by nonoverlapping 95% CI, unpaired Student’s <i>t</i>-test, or by one- or two-way ANOVA followed by Tukey’s post hoc test, as indicated. <i>p</i> < 0.05 was considered significant. Concentration–response curves are presented as % CP55,940 response or % stimulation above baseline (GTPγS only).<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Agonist concentration–response curves were fit to a nonlinear regression (four-parameter) model to determine EC<sub>50</sub>, <i>E</i><sub>min</sub>, and <i>E</i><sub>max</sub> in Prism (v. 8.0.1, GraphPad Software, Inc., San Diego, CA). To calculate agonist bias, concentration–response curves were globally fit to the operational model (<a class="ref internalNav" href="#eq1" aria-label="eq 1">eq 1</a>).<a onclick="showRef(event, 'ref85 ref86 ref87'); return false;" href="javascript:void(0);" class="ref ref85 ref86 ref87">(85−87)</a><span class="NLM_disp-formula" id="eq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_m001.gif" alt="" id="_i53" /></img><span class="labelSpan">(1)</span></span>To best fit data, the transduction coefficient log(τ/<i>K</i><sub>A</sub>) (i.e., log <i>R</i>), <i>n</i>, and <i>E</i><sub>max</sub> were shared across datasets, and log <i>K</i><sub>A</sub> was constrained between 0 and −12.<a onclick="showRef(event, 'ref86 ref87'); return false;" href="javascript:void(0);" class="ref ref86 ref87">(86,87)</a> Relative agonist activity was compared to CP55,940 as the reference agonist and was calculated as follows<span class="NLM_disp-formula" id="eq2"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_m002.gif" alt="" id="_i54" /></img><span class="labelSpan">(2)</span></span>Δlog <i>R</i> values are then compared for test compounds between assays measuring inhibition of cAMP, β-arrestin1 recruitment, and β-arrestin2 recruitment to determine bias factor (ΔΔlog<i> R</i>) (<a class="ref internalNav" href="#eq3" aria-label="eq 3">eq 3</a>).<a onclick="showRef(event, 'ref86 ref87'); return false;" href="javascript:void(0);" class="ref ref86 ref87">(86,87)</a><span class="NLM_disp-formula" id="eq3"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_m003.gif" alt="" id="_i55" /></img><span class="labelSpan">(3)</span></span>For data presented in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, concentration–response curves to CP55,940 for the inhibition of cAMP, β-arrestin1 recruitment, and β-arrestin2 recruitment were obtained in the absence and presence of a range of concentrations of (−)-(<i>S</i>,<i>R</i>)-<b>13</b> and (+)-(<i>R</i>,<i>S</i>)-<b>14</b>, as described previously.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The resulting patterns of response were fit to the functional allosteric model, which is the allosteric binding model<a onclick="showRef(event, 'ref88 ref89'); return false;" href="javascript:void(0);" class="ref ref88 ref89">(88,89)</a> combined with the Black–Leff operational model for agonism.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> In this model, the agonist [A] (CP55,940) binds to the receptor R and functions as a probe of receptor function; the allosteric modulators [B] [(−)-(<i>S</i>,<i>R</i>)-<b>13</b> and (+)-(<i>R</i>,<i>S</i>)-<b>14</b>] bind to a separate site on the receptor. Co-binding of these molecules reciprocally changes the affinity of binding of each by a factor α and the efficacy of the agonist through a factor β. The modulator itself may possess efficacy (denoted τ<sub>B</sub>) and may directly produce agonism. The equation for the production of response by an agonist in the presence of an allosteric modulator is described in <a class="ref internalNav" href="#eq4" aria-label="eq 4">eq 4</a>.<a onclick="showRef(event, 'ref87 ref88 ref90'); return false;" href="javascript:void(0);" class="ref ref87 ref88 ref90">(87,88,90)</a><span class="NLM_disp-formula" id="eq4"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_m004.gif" alt="" id="_i56" /></img><span class="labelSpan">(4)</span></span>The variable slope of this model can be derived utilizing the variable slope Black–Leff operational model as <a class="ref internalNav" href="#eq5" aria-label="eq 5">eq 5</a><a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a><span class="NLM_disp-formula" id="eq5"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_m005.gif" alt="" id="_i57" /></img><span class="labelSpan">(5)</span></span>Data for the three different signaling pathways assessed here were fit to obtain values of α, β, <i>K</i><sub>B</sub>, and τ<sub>B</sub> for (−)-(<i>S</i>,<i>R</i>)-<b>13</b> and (+)-(<i>R</i>,<i>S</i>)-<b>14</b> as allosteric CB1R modulators. Statistical assessment of the differences in log(αβ) values was made through calculation of 95% CI of the mean log(αβ) values utilizing a pooled variance.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> All concentration–response data were assessed for outliers using Grubb’s test. Using this method, one dataset was removed for β-arrestin1 recruitment as mean values for these data were greater than two standard deviations from the group’s mean.</div></div><div id="sec4_6_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> Statistical Analyses</h4><div class="NLM_p last">Two-way mixed ANOVA was used to analyze the main effect of drug treatments, and the main effect of groups, as well as interaction between drug treatments and groups. Tukey’s post hoc test was performed for all pairwise comparisons. SPSS 24 (IBM Corporation, Armonk, NY) was used to analyze <i>in vivo</i> data. <i>P</i> < 0.05 was considered statistically significant. Data were graphed using GraphPad Prism (v. 8.0.1). Data are expressed as mean ± SEM.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i59"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00040" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51726" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51726" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00040?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00040</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline"><sup>1</sup>H NMR spectra, HPLC chromatogram, XRD data, figures for preliminary cAMP and β-arrestin2 data, and additional computational figures (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00040/suppl_file/jm1c00040_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00040/suppl_file/jm1c00040_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">6n4b_CB1-Gi_2019 (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00040/suppl_file/jm1c00040_si_003.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00040/suppl_file/jm1c00040_si_001.pdf">jm1c00040_si_001.pdf (2.17 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00040/suppl_file/jm1c00040_si_002.csv">jm1c00040_si_002.csv (0.97 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00040/suppl_file/jm1c00040_si_003.pdb">jm1c00040_si_003.pdb (759.85 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00040" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50760" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50760" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert B. Laprairie</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology and Department of Ophthalmology and Visual Sciences, Dalhousie University, Halifax, Nova Scotia B3H 4R2, Canada</span>; 
    <span class="hlFld-Affiliation affiliation">College
of Pharmacy and Nutrition, University of
Saskatchewan, 104 Clinic Pl, Saskatoon, Saskatchewan S7N2Z4, Canada</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#02706d606770762c6e637270636b706b674277716371692c6163"><span class="__cf_email__" data-cfemail="2d5f424f485f5903414c5d5f4c445f44486d585e4c5e46034e4c">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ganesh A. Thakur</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts 02115, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-7468-8819" title="Orcid link">https://orcid.org/0000-0002-7468-8819</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#1e79306a767f756b6c5e70716c6a767b7f6d6a7b6c70307b7a6b"><span class="__cf_email__" data-cfemail="660148120e070d131426080914120e0307151203140848030213">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sumanta Garai</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luciana M. Leo</span> - <span class="hlFld-Affiliation affiliation">Center
for Substance Abuse Research, Lewis Katz
School of Medicine, Temple University, Philadelphia, Pennsylvania 19140, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anna-Maria Szczesniak</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology and Department of Ophthalmology and Visual Sciences, Dalhousie University, Halifax, Nova Scotia B3H 4R2, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dow P. Hurst</span> - <span class="hlFld-Affiliation affiliation">Center
for Drug Discovery, University of North
Carolina Greensboro, Greensboro, North Carolina 27402, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter C. Schaffer</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts 02115, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ayat Zagzoog</span> - <span class="hlFld-Affiliation affiliation">College
of Pharmacy and Nutrition, University of
Saskatchewan, 104 Clinic Pl, Saskatoon, Saskatchewan S7N2Z4, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tallan Black</span> - <span class="hlFld-Affiliation affiliation">College
of Pharmacy and Nutrition, University of
Saskatchewan, 104 Clinic Pl, Saskatoon, Saskatchewan S7N2Z4, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey R. Deschamps</span> - <span class="hlFld-Affiliation affiliation">Naval
Research Laboratory, Code 6930, 4555 Overlook Avenue, Washington, District of Columbia 20375, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elke Miess</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology and Toxicology, Jena University
Hospital—Friedrich Schiller University Jena, D-07747 Jena, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefan Schulz</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology and Toxicology, Jena University
Hospital—Friedrich Schiller University Jena, D-07747 Jena, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David R. Janero</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts 02115, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-4633-1038" title="Orcid link">https://orcid.org/0000-0002-4633-1038</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alex Straiker</span> - <span class="hlFld-Affiliation affiliation">The Gill
Center and the Department of Psychological & Brain Sciences, Indiana University, 1101 E. 10th St, Bloomington, Indiana 47405, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Roger G. Pertwee</span> - <span class="hlFld-Affiliation affiliation">School
of Medicine, Medical Sciences and Nutrition, Institute of Medical
Sciences, University of Aberdeen, Aberdeen AB25 2ZD, Scotland, U.K</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mary E. Abood</span> - <span class="hlFld-Affiliation affiliation">Center
for Substance Abuse Research, Lewis Katz
School of Medicine, Temple University, Philadelphia, Pennsylvania 19140, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-1744-2820" title="Orcid link">https://orcid.org/0000-0002-1744-2820</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Melanie E. M. Kelly</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology and Department of Ophthalmology and Visual Sciences, Dalhousie University, Halifax, Nova Scotia B3H 4R2, Canada</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Patricia H. Reggio</span> - <span class="hlFld-Affiliation affiliation">Center
for Drug Discovery, University of North
Carolina Greensboro, Greensboro, North Carolina 27402, United States</span></div></li></ul></li><li></li><li><span class="author-information-subsection-header">Funding</span><p>This work was supported by EY024727 (to G.A.T., R.G.P., A.S., and M.E.M.K.), R01 DA045698, T32 DA007237, and P30 DA013429 (to M.E.A. and L.M.L), a partnership grant to RBL from GlaxoSmithKline and the Canadian Institutes of Health Research (CIHR) (201704), and a Project Grant to RBL (201909). T.B. and A.Z. are supported by research scholarships from the College of Pharmacy and Nutrition, University of Saskatchewan.</p></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">cAMP</td><td class="NLM_def"><p class="first last">cyclic adenosine monophosphate</p></td></tr><tr><td class="NLM_term">CB1R</td><td class="NLM_def"><p class="first last">cannabinoid type-1 receptor</p></td></tr><tr><td class="NLM_term">CHO</td><td class="NLM_def"><p class="first last">Chinese hamster ovary cells</p></td></tr><tr><td class="NLM_term">CI</td><td class="NLM_def"><p class="first last">confidence interval</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">GPCRs</td><td class="NLM_def"><p class="first last">G-protein-coupled receptors</p></td></tr><tr><td class="NLM_term">[<sup>35</sup>S]GTPγS</td><td class="NLM_def"><p class="first last">guanosine 5′-O-(3- [<sup>35</sup>S]thio)triphosphate</p></td></tr><tr><td class="NLM_term">HEK293</td><td class="NLM_def"><p class="first last">human embryonic kidney 293 cells</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high performance liquid chromatography</p></td></tr><tr><td class="NLM_term">Hz</td><td class="NLM_def"><p class="first last">hertz</p></td></tr><tr><td class="NLM_term">MHz</td><td class="NLM_def"><p class="first last">megahertz</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methanol</p></td></tr><tr><td class="NLM_term">NAMs</td><td class="NLM_def"><p class="first last">negative allosteric modulators</p></td></tr><tr><td class="NLM_term">Na<sub>2</sub>SO<sub>4</sub></td><td class="NLM_def"><p class="first last">sodium sulfate</p></td></tr><tr><td class="NLM_term">NMR</td><td class="NLM_def"><p class="first last">nuclear magnetic resonance spectroscopy</p></td></tr><tr><td class="NLM_term">XRD</td><td class="NLM_def"><p class="first last">X-ray diffraction</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin-layer chromatography</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SEM</td><td class="NLM_def"><p class="first last">standard error of mean</p></td></tr><tr><td class="NLM_term">Tris</td><td class="NLM_def"><p class="first last">tris(hydroxymethyl)-aminomethane</p></td></tr><tr><td class="NLM_term">UV</td><td class="NLM_def"><p class="first last">ultraviolet</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i61">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32516" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32516" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 90 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aizpurua-Olaizola, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elezgarai, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rico-Barrio, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarandona, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etxebarria, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Usobiaga, A.</span></span> <span> </span><span class="NLM_article-title">Targeting the endocannabinoid system: future therapeutic strategies</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">110</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2016.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1016%2Fj.drudis.2016.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=27554802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVantL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=105-110&author=O.+Aizpurua-Olaizolaauthor=I.+Elezgaraiauthor=I.+Rico-Barrioauthor=I.+Zarandonaauthor=N.+Etxebarriaauthor=A.+Usobiaga&title=Targeting+the+endocannabinoid+system%3A+future+therapeutic+strategies&doi=10.1016%2Fj.drudis.2016.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the endocannabinoid system: future therapeutic strategies</span></div><div class="casAuthors">Aizpurua-Olaizola, Oier; Elezgarai, Izaskun; Rico-Barrio, Irantzu; Zarandona, Iratxe; Etxebarria, Nestor; Usobiaga, Aresatz</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">105-110</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The endocannabinoid system (ECS) is involved in many physiol. regulation pathways in the human body, which makes this system the target of many drugs and therapies.  In this review, we highlight the latest studies regarding the role of the ECS and the drugs that target it, with a particular focus on the basis for the discovery of new cannabinoid-based drugs.  In addn., we propose some key steps, such as the creation of a cannabinoid-receptor interaction matrix (CRIM) and the use of metabolomics, toward the development of improved and more specific drugs for each relevant disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorKmuBzuegJ7Vg90H21EOLACvtfcHk0lh0J7GTJvzfvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVantL3F&md5=19b739eb216107fb97cf8b362fa8f944</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DAizpurua-Olaizola%26aufirst%3DO.%26aulast%3DElezgarai%26aufirst%3DI.%26aulast%3DRico-Barrio%26aufirst%3DI.%26aulast%3DZarandona%26aufirst%3DI.%26aulast%3DEtxebarria%26aufirst%3DN.%26aulast%3DUsobiaga%26aufirst%3DA.%26atitle%3DTargeting%2520the%2520endocannabinoid%2520system%253A%2520future%2520therapeutic%2520strategies%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2017%26volume%3D22%26spage%3D105%26epage%3D110%26doi%3D10.1016%2Fj.drudis.2016.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Marzo, V.</span></span> <span> </span><span class="NLM_article-title">Targeting the endocannabinoid system: to enhance or reduce?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">438</span>– <span class="NLM_lpage">455</span>, <span class="refDoi"> DOI: 10.1038/nrd2553</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1038%2Fnrd2553" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=18446159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlt1agtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=438-455&author=V.+Di%0AMarzo&title=Targeting+the+endocannabinoid+system%3A+to+enhance+or+reduce%3F&doi=10.1038%2Fnrd2553"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the endocannabinoid system: to enhance or reduce?</span></div><div class="casAuthors">Di Marzo, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">438-455</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In this Review, the author discusses how prolonging the lifespan of endocannabinoids or toning down their action may be beneficial in a range of conditions such as pain, affective and neurodegenerative disorders, gastrointestinal inflammation, and obesity and metabolic dysfunctions.  As our understanding of the endocannabinoids improves, so does the awareness of their complexity.  During pathol. states, the levels of these mediators in tissues change, and their effects vary from those of protective endogenous compds. to those of dysregulated signals.  These observations led to the discovery of compds. that either prolong the lifespan of endocannabinoids or tone down their action for the potential future treatment of pain, affective and neurodegenerative disorders, gastrointestinal inflammation, obesity and metabolic dysfunctions, cardiovascular conditions and liver diseases.  When moving to the clinic, however, the pleiotropic nature of endocannabinoid functions will require careful judgement in the choice of patients and stage of the disorder for treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpebzNFDRaNEbVg90H21EOLACvtfcHk0lhwdJ0aYldcYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlt1agtbk%253D&md5=f0af1a666a7c51a594d94661bfb5a7d9</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd2553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2553%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26atitle%3DTargeting%2520the%2520endocannabinoid%2520system%253A%2520to%2520enhance%2520or%2520reduce%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D438%26epage%3D455%26doi%3D10.1038%2Fnrd2553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haspula, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, M. A.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid receptors: an update on cell signaling, pathophysiological roles and therapeutic opportunities in neurological, cardiovascular, and inflammatory diseases</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>, <span class="NLM_elocation-id">7693</span> <span class="refDoi"> DOI: 10.3390/ijms21207693</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.3390%2Fijms21207693" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFWitb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&author=D.+Haspulaauthor=M.+A.+Clark&title=Cannabinoid+receptors%3A+an+update+on+cell+signaling%2C+pathophysiological+roles+and+therapeutic+opportunities+in+neurological%2C+cardiovascular%2C+and+inflammatory+diseases&doi=10.3390%2Fijms21207693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid receptors: an update on cell signaling, pathophysiological roles and therapeutic opportunities in neurological, cardiovascular, and inflammatory diseases</span></div><div class="casAuthors">Haspula, Dhanush; Clark, Michelle A.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7693</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The identification of the human cannabinoid receptors and their roles in health and disease, has been one of the most significant biochem. and pharmacol. advancements to have occurred in the past few decades.  In spite of the major strides made in furthering endocannabinoid research, therapeutic exploitation of the endocannabinoid system has often been a challenging task.  Animpaired endocannabinoid tone often manifests as changes in expression and/or functions of type 1 and/or type 2 cannabinoid receptors.  It becomes important to understand how alterations in cannabinoid receptor cellular signaling can lead to disruptions in major physiol. and biol. functions, as they are often assocd. with the pathogenesis of several neurol., cardiovascular, metabolic, and inflammatory diseases.  This focuses mostly on the pathophysiol. roles of type 1 and type 2 cannabinoid receptors, and it attempts to integrate both cellular and physiol. functions of the cannabinoid receptors.  Apart from an updated of pre-clin. and clin. studies, the adequacy/inadequacy of cannabinoid-based therapeutics in various pathol. conditions is also highlighted.  Finally, alternative strategies to modulate endocannabinoid tone, and future directions are also emphasized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMlIrxHtyQ_bVg90H21EOLACvtfcHk0lhwdJ0aYldcYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFWitb%252FE&md5=350dc7b07fd8d858028cbffe1fad7988</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3390%2Fijms21207693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms21207693%26sid%3Dliteratum%253Aachs%26aulast%3DHaspula%26aufirst%3DD.%26aulast%3DClark%26aufirst%3DM.%2BA.%26atitle%3DCannabinoid%2520receptors%253A%2520an%2520update%2520on%2520cell%2520signaling%252C%2520pathophysiological%2520roles%2520and%2520therapeutic%2520opportunities%2520in%2520neurological%252C%2520cardiovascular%252C%2520and%2520inflammatory%2520diseases%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2020%26volume%3D21%26doi%3D10.3390%2Fijms21207693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janero, D. R.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists</span>. <i>Expert Opin. Emerging Drugs</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1517/14728214.2012.660916</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1517%2F14728214.2012.660916" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=22335400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC38XksVOktr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=17-29&author=D.+R.+Janero&title=Cannabinoid-1+receptor+%28CB1R%29+blockers+as+medicines%3A+beyond+obesity+and+cardiometabolic+disorders+to+substance+abuse%2Fdrug+addiction+with+CB1R+neutral+antagonists&doi=10.1517%2F14728214.2012.660916"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists</span></div><div class="casAuthors">Janero, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Emerging Drugs</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-29</span>CODEN:
                <span class="NLM_cas:coden">EOEDA3</span>;
        ISSN:<span class="NLM_cas:issn">1472-8214</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Addiction to chem. substances with abuse potential presents medical needs largely unsolved by extant therapeutic strategies.  Signal transmission through the cannabinoid-1 receptor (CB1R) in the central nervous system (CNS) modulates neurotransmitters/neuronal pathways contributing to the rewarding properties and hedonic effects of certain nondrug stimuli (e.g., food) and many prototypical addictive drugs, promoting excessive intake and its pathol. consequences.  Typical CB1R antagonists/inverse agonists reduce the rewarding effects and normalize behavioral phenotypes assocd. with food and abused drugs, but carry an unacceptable adverse-event profile that may reflect, at least partly, their intrinsic ability to alter basal homeostatic CB1R signaling in the CNS and elicit a neg. efficacy response.  Alternatively, peripherally biased CB1R inverse agonists with limited CNS permeability and putative CB1R neutral antagonists expressing modest (if any) inverse-agonist efficacy are garnering attention for treating obesity and related cardiometabolic complications with a potentially enhanced benefit-to-risk profile.Areas covered: This mini-review calls attention to the proposition that CB1R neutral antagonists offer attractive opportunities for pharmacotherapeutic exploitation in the substance abuse/drug addiction space, whereas the restricted CNS accessibility of peripherally biased CB1R inverse agonists circumscribes their therapeutic utility for this indication.Expert opinion: The unique preclin. pharmacol., efficacy profiles, and reduced adverse-event risk of CB1R neutral antagonists make them worthy of translational study for their potential therapeutic application beyond obesity/cardiometabolic disease to include substance-abuse/drug-addiction disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4VSyiuwP_nLVg90H21EOLACvtfcHk0lh3tnK_4r1ITA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksVOktr4%253D&md5=0af61a6a755b9b527934346cc4e860ba</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1517%2F14728214.2012.660916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728214.2012.660916%26sid%3Dliteratum%253Aachs%26aulast%3DJanero%26aufirst%3DD.%2BR.%26atitle%3DCannabinoid-1%2520receptor%2520%2528CB1R%2529%2520blockers%2520as%2520medicines%253A%2520beyond%2520obesity%2520and%2520cardiometabolic%2520disorders%2520to%2520substance%2520abuse%252Fdrug%2520addiction%2520with%2520CB1R%2520neutral%2520antagonists%26jtitle%3DExpert%2520Opin.%2520Emerging%2520Drugs%26date%3D2012%26volume%3D17%26spage%3D17%26epage%3D29%26doi%3D10.1517%2F14728214.2012.660916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, H. D.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid signaling in health and disease</span>. <i>Can. J. Physiol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">327</span>, <span class="refDoi"> DOI: 10.1139/cjpp-2016-0346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1139%2Fcjpp-2016-0346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=28263083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsl2gtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2017&pages=311-327&author=Y.+Luauthor=H.+D.+Anderson&title=Cannabinoid+signaling+in+health+and+disease&doi=10.1139%2Fcjpp-2016-0346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid signaling in health and disease</span></div><div class="casAuthors">Lu, Yan; Anderson, Hope D.</div><div class="citationInfo"><span class="NLM_cas:title">Canadian Journal of Physiology and Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">311-327</span>CODEN:
                <span class="NLM_cas:coden">CJPPA3</span>;
        ISSN:<span class="NLM_cas:issn">0008-4212</span>.
    
            (<span class="NLM_cas:orgname">Canadian Science Publishing</span>)
        </div><div class="casAbstract">Cannabis sativa has long been used for medicinal purposes.  To improve safety and efficacy, compds. from C.sativa were purified or synthesized and named under an umbrella group as cannabinoids.  Currently, several cannabinoids may be prescribed in Canada for a variety of indications such as nausea and pain.  More recently, an increasing no. of reports suggest other salutary effects assocd. with endogenous cannabinoid signaling including cardioprotection.  The therapeutic potential of cannabinoids is therefore extended; however, evidence is limited and mechanisms remain unclear.  In addn., the use of cannabinoids clin. has been hindered due to pronounced psychoactive side effects.  This review provides an overview on the endocannabinoid system, including known physiol. roles, and conditions in which cannabinoid receptor signaling has been implicated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsd9MesiR56LVg90H21EOLACvtfcHk0lh3tnK_4r1ITA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsl2gtb8%253D&md5=e3e1c0f219bd9e0d44c0c063dd61626d</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1139%2Fcjpp-2016-0346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1139%252Fcjpp-2016-0346%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DAnderson%26aufirst%3DH.%2BD.%26atitle%3DCannabinoid%2520signaling%2520in%2520health%2520and%2520disease%26jtitle%3DCan.%2520J.%2520Physiol.%2520Pharmacol.%26date%3D2017%26volume%3D95%26spage%3D311%26epage%3D327%26doi%3D10.1139%2Fcjpp-2016-0346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifulco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Petrocellis, L.</span></span> <span> </span><span class="NLM_article-title">The endocannabinoid system and its therapeutic exploitation</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">771</span>– <span class="NLM_lpage">784</span>, <span class="refDoi"> DOI: 10.1038/nrd1495</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1038%2Fnrd1495" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=15340387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntFCns7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=771-784&author=V.+Di%0AMarzoauthor=M.+Bifulcoauthor=L.+De+Petrocellis&title=The+endocannabinoid+system+and+its+therapeutic+exploitation&doi=10.1038%2Fnrd1495"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The endocannabinoid system and its therapeutic exploitation</span></div><div class="casAuthors">Di Marzo, Vincenzo; Bifulco, Maurizio; De Petrocellis, Luciano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">771-784</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with refs.  The term 'endocannabinoid' - originally coined in the mid-1990s after the discovery of membrane receptors for the psychoactive principle in Cannabis, Δ9-tetrahydrocannabinol and their endogenous ligands - now indicates a whole signalling system that comprises cannabinoid receptors, endogenous ligands and enzymes for ligand biosynthesis and inactivation.  This system seems to be involved in an ever-increasing no. of pathol. conditions.  With novel products already being aimed at the pharmaceutical market little more than a decade since the discovery of cannabinoid receptors, the endocannabinoid system seems to hold even more promise for the future development of therapeutic drugs.  We explore the conditions under which the potential of targeting the endocannabinoid system might be realized in the years to come.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-VBJpBWVazLVg90H21EOLACvtfcHk0lhh31u8HSo2Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntFCns7s%253D&md5=3a1b37143c5f6c8164228a7617d3f412</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrd1495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1495%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DBifulco%26aufirst%3DM.%26aulast%3DDe%2BPetrocellis%26aufirst%3DL.%26atitle%3DThe%2520endocannabinoid%2520system%2520and%2520its%2520therapeutic%2520exploitation%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D771%26epage%3D784%26doi%3D10.1038%2Fnrd1495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bátkai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunos, G.</span></span> <span> </span><span class="NLM_article-title">The endocannabinoid system as an emerging target of pharmacotherapy</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">462</span>, <span class="refDoi"> DOI: 10.1124/pr.58.3.2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1124%2Fpr.58.3.2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=16968947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVOhtLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2006&pages=389-462&author=P.+Pacherauthor=S.+B%C3%A1tkaiauthor=G.+Kunos&title=The+endocannabinoid+system+as+an+emerging+target+of+pharmacotherapy&doi=10.1124%2Fpr.58.3.2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The endocannabinoid system as an emerging target of pharmacotherapy</span></div><div class="casAuthors">Pacher, Pal; Batkai, Sandor; Kunos, George</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">389-462</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  The recent identification of cannabinoid receptors and their endogenous lipid ligands has triggered an exponential growth of studies exploring the endocannabinoid system and its regulatory functions in health and disease.  Such studies have been greatly facilitated by the introduction of selective cannabinoid receptor antagonists and inhibitors of endocannabinoid metab. and transport, as well as mice deficient in cannabinoid receptors or the endocannabinoid-degrading enzyme fatty acid amidohydrolase.  In the past decade, the endocannabinoid system has been implicated in a growing no. of physiol. functions, both in the central and peripheral nervous systems and in peripheral organs.  More importantly, modulating the activity of the endocannabinoid system turned out to hold therapeutic promise in a wide range of disparate diseases and pathol. conditions, ranging from mood and anxiety disorders, movement disorders such as Parkinson's and Huntington's disease, neuropathic pain, multiple sclerosis and spinal cord injury, to cancer, atherosclerosis, myocardial infarction, stroke, hypertension, glaucoma, obesity/metabolic syndrome, and osteoporosis, to name just a few.  An impediment to the development of cannabinoid medications has been the socially unacceptable psychoactive properties of plant-derived or synthetic agonists, mediated by CB1 receptors.  However, this problem does not arise when the therapeutic aim is achieved by treatment with a CB1 receptor antagonist, such as in obesity, and may also be absent when the action of endocannabinoids is enhanced indirectly through blocking their metab. or transport.  The use of selective CB2 receptor agonists, which lack psychoactive properties, could represent another promising avenue for certain conditions.  The abuse potential of plant-derived cannabinoids may also be limited through the use of prepns. with controlled compn. and the careful selection of does and route of administration.  The growing no. of preclin. studies and clin. trials with compds. that modulate the endocannabinoid system will probably result in novel therapeutic approaches in a no. of diseases for which current treatments do not fully address the patients' need.  Here, we provide a comprehensive overview on the current state of knowledge of the endocannabinoid system as a target of pharmacotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN_yobbKbuLbVg90H21EOLACvtfcHk0lj1H9VpazMnRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVOhtLfO&md5=f54e6d1303645a1c63809879ef2813f3</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1124%2Fpr.58.3.2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.58.3.2%26sid%3Dliteratum%253Aachs%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DB%25C3%25A1tkai%26aufirst%3DS.%26aulast%3DKunos%26aufirst%3DG.%26atitle%3DThe%2520endocannabinoid%2520system%2520as%2520an%2520emerging%2520target%2520of%2520pharmacotherapy%26jtitle%3DPharmacol.%2520Rev.%26date%3D2006%26volume%3D58%26spage%3D389%26epage%3D462%26doi%3D10.1124%2Fpr.58.3.2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luján, M. Á.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheer, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melis, M.</span></span> <span> </span><span class="NLM_article-title">Choosing the right drug: status and future of endocannabinoid research for the prevention of drug-seeking reinstatement</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2020.08.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1016%2Fj.coph.2020.08.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=33068883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A280%3ADC%252BB3s7islSktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2020&pages=29-38&author=M.+%C3%81.+Luj%C3%A1nauthor=J.+F.+Cheerauthor=M.+Melis&title=Choosing+the+right+drug%3A+status+and+future+of+endocannabinoid+research+for+the+prevention+of+drug-seeking+reinstatement&doi=10.1016%2Fj.coph.2020.08.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Choosing the right drug: status and future of endocannabinoid research for the prevention of drug-seeking reinstatement</span></div><div class="casAuthors">Lujan Miguel A; Cheer Joseph F; Melis Miriam</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">29-38</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Prolonged exposure to drugs of abuse leads to severe alterations in mesocorticolimbic dopamine circuitry deeply implicated in substance use disorders.  Despite considerable efforts, few medications to reduce relapse rates are currently available.  To solve this issue, researchers are uncovering therapeutic opportunities offered by the endocannabinoid system.  The cannabinoid receptor type 1 (CB1R), and its endogenous ligands, participate in orchestration of cue-triggered and stress-triggered responses leading to obtain natural and drug rewards.  Here, we review the evidence supporting the use of CB1R neutral antagonists, allosteric modulators, indirect agonists, as well as multi-target compounds, as improved alternatives compared to classical CB1R antagonists.  The promising therapeutic value of other substrates participating in endocannabinoid signaling, like peroxisome proliferator-activated receptors, is also covered.  Overall, a wide body of pre-clinical evidence avails novel pharmacological strategies interacting with the endocannabinoid system as clinically amenable candidates able to counteract drug-induced dopamine maladaptations contributing to increased risk of relapse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTn0x6l2FqpppVVjGoY74BafW6udTcc2eavCXpsOl6pU7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3s7islSktA%253D%253D&md5=54fae570c29dab96d9c4224813f05900</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2020.08.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2020.08.014%26sid%3Dliteratum%253Aachs%26aulast%3DLuj%25C3%25A1n%26aufirst%3DM.%2B%25C3%2581.%26aulast%3DCheer%26aufirst%3DJ.%2BF.%26aulast%3DMelis%26aufirst%3DM.%26atitle%3DChoosing%2520the%2520right%2520drug%253A%2520status%2520and%2520future%2520of%2520endocannabinoid%2520research%2520for%2520the%2520prevention%2520of%2520drug-seeking%2520reinstatement%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2020%26volume%3D56%26spage%3D29%26epage%3D38%26doi%3D10.1016%2Fj.coph.2020.08.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sholler, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huestis, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amendolara, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandrey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, Z. D.</span></span> <span> </span><span class="NLM_article-title">Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids</span>. <i>Pharmacol., Biochem. Behav.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>199</i></span>, <span class="NLM_elocation-id">173059</span> <span class="refDoi"> DOI: 10.1016/j.pbb.2020.173059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1016%2Fj.pbb.2020.173059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=33086126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit12ktr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=199&publication_year=2020&author=D.+J.+Shollerauthor=M.+A.+Huestisauthor=B.+Amendolaraauthor=R.+Vandreyauthor=Z.+D.+Cooper&title=Therapeutic+potential+and+safety+considerations+for+the+clinical+use+of+synthetic+cannabinoids&doi=10.1016%2Fj.pbb.2020.173059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids</span></div><div class="casAuthors">Sholler, Dennis J.; Huestis, Marilyn A.; Amendolara, Benjamin; Vandrey, Ryan; Cooper, Ziva D.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">199</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">173059</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The phytocannabinoid Δ9-tetrahydrocannabinol (THC) was isolated and synthesized in the 1960s.  Two synthetic cannabinoids (SCBs) targeting the cannabinoid 1 (CB1R) and 2 (CB2R) receptors were approved for medical use based on clin. safety and efficacy data: dronabinol (synthetic THC) and nabilone (synthetic THC analog).  To probe the function of the endocannabinoid system further, hundreds of investigational compds. were developed; in particular, agonists with (1) greater CB1/2R affinity relative to THC and (2) full CB1/2R agonist activity.  This pharmacol. profile may pose greater risks for misuse and adverse effects relative to THC, and these SCBs proliferated in retail markets as legal alternatives to cannabis (e.g., novel psychoactive substances [NPS], "Spice," "K2").  This highlights the potential therapeutic efficacy and safety considerations for unique SCBs, including CB1R partial and full agonists, peripherally-restricted CB1R agonists, selective CB2R agonists, selective CB1R antagonists/inverse agonists, CB1R allosteric modulators, endocannabinoid-degrading enzyme inhibitors, and cannabidiol.  We propose promising directions for SCB research that may optimize therapeutic efficacy and diminish potential for adverse events, for example, peripherally-restricted CB1R antagonists/inverse agonists and biased CB1/2R agonists.  Together, these strategies could lead to the discovery of new, therapeutically useful SCBs with reduced neg. public health impact.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8pw8MbqqjCLVg90H21EOLACvtfcHk0lj1H9VpazMnRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit12ktr%252FM&md5=acad53a99a0bd4ea220d9a5903d33e51</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.pbb.2020.173059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pbb.2020.173059%26sid%3Dliteratum%253Aachs%26aulast%3DSholler%26aufirst%3DD.%2BJ.%26aulast%3DHuestis%26aufirst%3DM.%2BA.%26aulast%3DAmendolara%26aufirst%3DB.%26aulast%3DVandrey%26aufirst%3DR.%26aulast%3DCooper%26aufirst%3DZ.%2BD.%26atitle%3DTherapeutic%2520potential%2520and%2520safety%2520considerations%2520for%2520the%2520clinical%2520use%2520of%2520synthetic%2520cannabinoids%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2020%26volume%3D199%26doi%3D10.1016%2Fj.pbb.2020.173059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ross, R. A.</span></span> <span> </span><span class="NLM_article-title">Allosterism and cannabinoid CB(1) receptors: the shape of things to come</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">567</span>– <span class="NLM_lpage">572</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2007.10.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1016%2Fj.tips.2007.10.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=18029031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1KgsLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2007&pages=567-572&author=R.+A.+Ross&title=Allosterism+and+cannabinoid+CB%281%29+receptors%3A+the+shape+of+things+to+come&doi=10.1016%2Fj.tips.2007.10.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Allosterism and cannabinoid CB1 receptors: the shape of things to come</span></div><div class="casAuthors">Ross, Ruth A.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">567-572</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In 2005, the first evidence was obtained that the cannabinoid CB1 receptor contains an allosteric binding site.  The site can be recognized by synthetic small mols., which display a markedly divergent effect on orthosteric ligand affinity vs. efficacy; these small mols. are allosteric enhancers of agonist binding affinity and allosteric inhibitors of agonist signaling efficacy.  Allosteric modulation heralds a new approach to the manipulation of the endocannabinoid system for therapeutic benefit; it promises to augment the existing portfolio of selective direct agonists, competitive antagonists and enzyme inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQCoxt-Z5_J7Vg90H21EOLACvtfcHk0lj1H9VpazMnRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1KgsLrM&md5=4d2d1dd40f0d4d468f3b597c33f51ee8</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2007.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2007.10.006%26sid%3Dliteratum%253Aachs%26aulast%3DRoss%26aufirst%3DR.%2BA.%26atitle%3DAllosterism%2520and%2520cannabinoid%2520CB%25281%2529%2520receptors%253A%2520the%2520shape%2520of%2520things%2520to%2520come%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2007%26volume%3D28%26spage%3D567%26epage%3D572%26doi%3D10.1016%2Fj.tips.2007.10.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hryhorowicz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaczmarek-Ryś, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrzejewska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staszak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hryhorowicz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korcz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Słomski, R.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulation of cannabinoid receptor 1-current challenges and future opportunities</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>, <span class="NLM_elocation-id">5874</span> <span class="refDoi"> DOI: 10.3390/ijms20235874</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.3390%2Fijms20235874" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtV2ltb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&author=S.+Hryhorowiczauthor=M.+Kaczmarek-Ry%C5%9Bauthor=A.+Andrzejewskaauthor=K.+Staszakauthor=M.+Hryhorowiczauthor=A.+Korczauthor=R.+S%C5%82omski&title=Allosteric+modulation+of+cannabinoid+receptor+1-current+challenges+and+future+opportunities&doi=10.3390%2Fijms20235874"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric modulation of cannabinoid receptor 1-current challenges and future opportunities</span></div><div class="casAuthors">Hryhorowicz, Szymon; Kaczmarek-Rys, Marta; Andrzejewska, Angelika; Staszak, Klaudia; Hryhorowicz, Magdalena; Korcz, Aleksandra; Slomski, Ryszard</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5874</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The cannabinoid receptor type 1 (CB1R), a G protein-coupled receptor (GPCR), plays an essential role in the control of many physiol. processes such as hunger, memory loss, gastrointestinal activity, catalepsy, fear, depression, and chronic pain.  Therefore, it is an attractive target for drug discovery to manage pain, neurodegenerative disorders, obesity, and substance abuse.  However, the psychoactive adverse effects, generated by CB1R activation in the brain, limit the use of the orthosteric CB1R ligands as drugs.  The discovery of CB1R allosteric modulators during the last decade provided new tools to target the CB1R.  Moreover, application of the site-directed mutagenesis in combination with advanced phys. methods, esp. X-ray crystallog. and computational modeling, has opened new horizons for understanding the complexity of the structure, function, and activity of cannabinoid receptors.  In this paper, we present the latest advances in research on the CB1R, its allosteric modulation and allosteric ligands, and their translational potential.  We focused on structural essentials of the cannabinoid 1 receptor- ligand (drug) interactions, as well as modes of CB1R signaling regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6F5JsG7qjmrVg90H21EOLACvtfcHk0ljtNBZT9JYt_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtV2ltb3O&md5=a2f28aadb588481a33180246d0b9f992</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.3390%2Fijms20235874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20235874%26sid%3Dliteratum%253Aachs%26aulast%3DHryhorowicz%26aufirst%3DS.%26aulast%3DKaczmarek-Ry%25C5%259B%26aufirst%3DM.%26aulast%3DAndrzejewska%26aufirst%3DA.%26aulast%3DStaszak%26aufirst%3DK.%26aulast%3DHryhorowicz%26aufirst%3DM.%26aulast%3DKorcz%26aufirst%3DA.%26aulast%3DS%25C5%2582omski%26aufirst%3DR.%26atitle%3DAllosteric%2520modulation%2520of%2520cannabinoid%2520receptor%25201-current%2520challenges%2520and%2520future%2520opportunities%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26doi%3D10.3390%2Fijms20235874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Immadi, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kendall, D. A.</span></span> <span> </span><span class="NLM_article-title">Translational potential of allosteric modulators targeting the cannabinoid CB1 receptor</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">324</span>– <span class="NLM_lpage">335</span>, <span class="refDoi"> DOI: 10.1038/s41401-018-0164-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1038%2Fs41401-018-0164-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=30333554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFKjtL%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2019&pages=324-335&author=D.+Luauthor=S.+S.+Immadiauthor=Z.+Wuauthor=D.+A.+Kendall&title=Translational+potential+of+allosteric+modulators+targeting+the+cannabinoid+CB1+receptor&doi=10.1038%2Fs41401-018-0164-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Translational potential of allosteric modulators targeting the cannabinoid CB1 receptor</span></div><div class="casAuthors">Lu, Dai; Immadi, Sri Sujana; Wu, Zhixing; Kendall, Debra A.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">324-335</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The cannabinoid type-1 (CB1) receptor, a G-protein-coupled receptor, is an attractive target for drug discovery due to its involvement in many physiol. processes.  Historically, drug discovery efforts targeting the CB1 receptor have focused on the development of orthosteric ligands that interact with the active site to which endogenous cannabinoids bind.  Research performed over the last several decades has revealed substantial difficulties in translating CB1 orthosteric ligands into druggable candidates.  The difficulty is mainly due to the adverse effects assocd. with orthosteric CB1 ligands.  Recent discoveries of allosteric CB1 modulators provide tremendous opportunities to develop CB1 ligands with novel mechanisms of action; these ligands may potentially improve the pharmacol. effects and enhance drug safety in treating the disorders by regulating the functions of the CB1 receptor.  In this paper, we review and summarize the complex pharmacol. profiles of each class of CB1 allosteric modulators, the development of new classes of CB1 allosteric modulators and the results from in vivo assessments of their therapeutic value.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNjvusPibM57Vg90H21EOLACvtfcHk0ljtNBZT9JYt_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFKjtL%252FL&md5=ebef475598356a12bee6d272783ef756</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fs41401-018-0164-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41401-018-0164-x%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DD.%26aulast%3DImmadi%26aufirst%3DS.%2BS.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DKendall%26aufirst%3DD.%2BA.%26atitle%3DTranslational%2520potential%2520of%2520allosteric%2520modulators%2520targeting%2520the%2520cannabinoid%2520CB1%2520receptor%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2019%26volume%3D40%26spage%3D324%26epage%3D335%26doi%3D10.1038%2Fs41401-018-0164-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dopart, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kendall, D. A.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulators of cannabinoid receptor 1: developing compounds for improved specificity</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1080/03602532.2018.1428342</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1080%2F03602532.2018.1428342" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=29355030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2hsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2018&pages=3-13&author=R.+Dopartauthor=D.+Luauthor=A.+H.+Lichtmanauthor=D.+A.+Kendall&title=Allosteric+modulators+of+cannabinoid+receptor+1%3A+developing+compounds+for+improved+specificity&doi=10.1080%2F03602532.2018.1428342"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric modulators of cannabinoid receptor 1: developing compounds for improved specificity</span></div><div class="casAuthors">Dopart, Rachel; Lu, Dai; Lichtman, Aron H.; Kendall, Debra A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-13</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The cannabinoid receptor 1 (CB1) is a G protein-coupled receptor (GPCR) that is located primarily in the central nervous system.  CB1 is a therapeutic target which may impact pathways to mediate pain, neurodegenerative disorders, hunger, and drug-seeking behavior.  Despite these benefits, development of orthosteric therapeutic compds., which target the endogenous ligand-binding site of CB1, has been challenging due to detrimental side effects including psychoactivity, depression, and suicidal thoughts.  However, CB1 also has an allosteric binding site(s), which is topog. distinct from the orthosteric site.  Allosteric modulation of CB1 has a no. of potential advantages including providing a mechanism for more precise control of downstream pathways and circumventing these side effects.  In this review, we summarize the concept of allosteric modulation and focus on the structure-activity relationship studies of the well-characterized allosteric modulators, ORG27569 and PSNCBAM-1 and their derivs., and a few other recent modulators.  We review studies on the properties of these modulators on CB1 signaling in cells and their effects in vivo.  While many current allosteric modulators also produce complex outcomes, they provide new advances for the design of CB1 centered therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQsmmRpD5OA7Vg90H21EOLACvtfcHk0lhpm2Kzjzhajg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2hsrw%253D&md5=4e999878b6dde69103305048cb4e7674</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1080%2F03602532.2018.1428342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F03602532.2018.1428342%26sid%3Dliteratum%253Aachs%26aulast%3DDopart%26aufirst%3DR.%26aulast%3DLu%26aufirst%3DD.%26aulast%3DLichtman%26aufirst%3DA.%2BH.%26aulast%3DKendall%26aufirst%3DD.%2BA.%26atitle%3DAllosteric%2520modulators%2520of%2520cannabinoid%2520receptor%25201%253A%2520developing%2520compounds%2520for%2520improved%2520specificity%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2018%26volume%3D50%26spage%3D3%26epage%3D13%26doi%3D10.1080%2F03602532.2018.1428342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiley, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenakin, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulation: an alternate approach targeting the cannabinoid cb1 receptor</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">474</span>, <span class="refDoi"> DOI: 10.1002/med.21418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1002%2Fmed.21418" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=27879006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmt1als70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=441-474&author=T.+Nguyenauthor=J.+X.+Liauthor=B.+F.+Thomasauthor=J.+L.+Wileyauthor=T.+P.+Kenakinauthor=Y.+Zhang&title=Allosteric+modulation%3A+an+alternate+approach+targeting+the+cannabinoid+cb1+receptor&doi=10.1002%2Fmed.21418"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor</span></div><div class="casAuthors">Nguyen, Thuy; Li, Jun-Xu; Thomas, Brian F.; Wiley, Jenny L.; Kenakin, Terry P.; Zhang, Yanan</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">441-474</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The cannabinoid CB1 receptor is a G protein coupled receptor and plays an important role in many biol. processes and physiol. functions.  A variety of CB1 receptor agonists and antagonists, including endocannabinoids, phytocannabinoids, and synthetic cannabinoids, have been discovered or developed over the past 20 years.  In 2005, it was discovered that the CB1 receptor contains allosteric site(s) that can be recognized by small mols. or allosteric modulators.  A no. of CB1 receptor allosteric modulators, both pos. and neg., have since been reported and importantly, they display pharmacol. characteristics that are distinct from those of orthosteric agonists and antagonists.  Given the psychoactive effects commonly assocd. with CB1 receptor agonists and antagonists/inverse agonists, allosteric modulation may offer an alternate approach to attain potential therapeutic benefits while avoiding inherent side effects of orthosteric ligands.  This review details the complex pharmacol. profiles of these allosteric modulators, their structure-activity relationships, and efforts in elucidating binding modes and mechanisms of actions of reported CB1 allosteric modulators.  The ultimate development of CB1 receptor allosteric ligands could potentially lead to improved therapies for CB1-mediated neurol. disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn_UmNHz3IfrVg90H21EOLACvtfcHk0lhpm2Kzjzhajg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmt1als70%253D&md5=3440e86c28aa07132de55c2c66640c2d</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fmed.21418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21418%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DJ.%2BX.%26aulast%3DThomas%26aufirst%3DB.%2BF.%26aulast%3DWiley%26aufirst%3DJ.%2BL.%26aulast%3DKenakin%26aufirst%3DT.%2BP.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DAllosteric%2520modulation%253A%2520an%2520alternate%2520approach%2520targeting%2520the%2520cannabinoid%2520cb1%2520receptor%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2017%26volume%3D37%26spage%3D441%26epage%3D474%26doi%3D10.1002%2Fmed.21418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janero, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, G. A.</span></span> <span> </span><span class="NLM_article-title">Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1223</span>– <span class="NLM_lpage">1237</span>, <span class="refDoi"> DOI: 10.1080/17460441.2016.1245289</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1080%2F17460441.2016.1245289" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=27712124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKltLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1223-1237&author=D.+R.+Janeroauthor=G.+A.+Thakur&title=Leveraging+allostery+to+improve+G+protein-coupled+receptor+%28GPCR%29-directed+therapeutics%3A+cannabinoid+receptor+1+as+discovery+target&doi=10.1080%2F17460441.2016.1245289"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target</span></div><div class="casAuthors">Janero, David R.; Thakur, Ganesh A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1223-1237</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Allosteric modulators of G-protein coupled receptors (GPCRs) hold the promise of improved pharmacol. and safety over typical orthosteric GPCR ligands.  These features are particularly relevant to the cannabinoid receptor 1 (CB1R) GPCR, since typical orthosteric CB1R ligands are assocd. with adverse events that limit their translational potential.  The contextual basis for applying allostery to CB1R is considered from pharmacol., drug-discovery, and medicinal standpoints.  Rational design of small-mol. CB1R allosteric modulators as potential pharmacotherapeutics would be greatly facilitated by direct exptl. characterization of structure-function correlates underlying the biol. activity of chem.-diverse CB1R allosteric modulators, CB1R allosteric ligand-binding binding pockets, and amino acid contact residues crit. to allosteric ligand engagement and activity.  In these regards, designer covalent probes exhibiting well-characterized mol. pharmacol. as CB1R allosteric modulators are emerging as valuable mol. reporters enabling exptl. interrogation of CB1R allosteric site(s) and informing the design of new CB1R agents as drugs.  Synthesis and pharmacol. profiling of CB1R allosteric ligands will continue to provide valuable insights into CB1R structure-function correlates.  The resulting data should expand the repertoire of novel agents capable of exerting therapeutic benefit by modulating CB1R-dependent signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooiQ3WE4T8X7Vg90H21EOLACvtfcHk0lg8KyzJ013XDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKltLbE&md5=d8cafb1a1f911a4ae292e029c4307609</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1080%2F17460441.2016.1245289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2016.1245289%26sid%3Dliteratum%253Aachs%26aulast%3DJanero%26aufirst%3DD.%2BR.%26aulast%3DThakur%26aufirst%3DG.%2BA.%26atitle%3DLeveraging%2520allostery%2520to%2520improve%2520G%2520protein-coupled%2520receptor%2520%2528GPCR%2529-directed%2520therapeutics%253A%2520cannabinoid%2520receptor%25201%2520as%2520discovery%2520target%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2016%26volume%3D11%26spage%3D1223%26epage%3D1237%26doi%3D10.1080%2F17460441.2016.1245289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janero, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, G. A.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of cannabinoid 1 receptor (cb1r) allosteric modulators: drug discovery applications</span>. <i>Methods Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>593</i></span>,  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1016/bs.mie.2017.06.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1016%2Fbs.mie.2017.06.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=28750808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmvVemtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=593&publication_year=2017&pages=281-315&author=A.+R.+Kulkarniauthor=S.+Garaiauthor=D.+R.+Janeroauthor=G.+A.+Thakur&title=Design+and+synthesis+of+cannabinoid+1+receptor+%28cb1r%29+allosteric+modulators%3A+drug+discovery+applications&doi=10.1016%2Fbs.mie.2017.06.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of cannabinoid 1 receptor (CB1R) allosteric modulators: drug discovery applications</span></div><div class="casAuthors">Kulkarni, Abhijit R.; Garai, Sumanta; Janero, David R.; Thakur, Ganesh A.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">593</span>
        (<span class="NLM_cas:issue">Cannabinoids and Their Receptors</span>),
    <span class="NLM_cas:pages">281-315</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Also expressed in various peripheral tissues, the type-1 cannabinoid receptor (CB1R) is the predominant G protein-coupled receptor (GPCR) in brain, where it is responsible for retrograde control of neurotransmitter release.  Cellular signaling mediated by CB1R is involved in numerous physiol. processes, and pharmacol. CB1R modulation is considered a tenable therapeutic approach for diseases ranging from substance-use disorders and glaucoma to metabolic syndrome.  Despite the design and synthesis of a variety of bioactive small mols. targeted to the CB1R orthosteric ligand-binding site, the potential of CB1R as a therapeutic GPCR has been largely unrealized due to adverse events assocd. with typical orthosteric CB1R agonists and antagonists/inverse agonists.  Modulation of CB1R-mediated signal transmission by targeting alternative allosteric ligand-binding site(s) on the receptor has garnered interest as a potentially safer and more effective therapeutic modality.  This chapter highlights the design and synthesis of novel, pharmacol. active CB1R allosteric modulators and emphasizes how their mol. properties and the pos. and neg. allosteric control they exert can lead to improved CB1R-targeted pharmacotherapeutics, as well as designer covalent probes that can be used to map CB1R allosteric binding domains and inform structure-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEArBHnXvjSLVg90H21EOLACvtfcHk0lg8KyzJ013XDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmvVemtbo%253D&md5=3054ad925dbee3174764b2bef86a37f7</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fbs.mie.2017.06.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.mie.2017.06.018%26sid%3Dliteratum%253Aachs%26aulast%3DKulkarni%26aufirst%3DA.%2BR.%26aulast%3DGarai%26aufirst%3DS.%26aulast%3DJanero%26aufirst%3DD.%2BR.%26aulast%3DThakur%26aufirst%3DG.%2BA.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520cannabinoid%25201%2520receptor%2520%2528cb1r%2529%2520allosteric%2520modulators%253A%2520drug%2520discovery%2520applications%26jtitle%3DMethods%2520Enzymol.%26date%3D2017%26volume%3D593%26spage%3D281%26epage%3D315%26doi%3D10.1016%2Fbs.mie.2017.06.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shonberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuano, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span> <span> </span><span class="NLM_article-title">Biased agonism at G protein-coupled receptors: the promise and the challenges--a medicinal chemistry perspective</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1286</span>– <span class="NLM_lpage">1330</span>, <span class="refDoi"> DOI: 10.1002/med.21318</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1002%2Fmed.21318" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=24796277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslalu7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=1286-1330&author=J.+Shonbergauthor=L.+Lopezauthor=P.+J.+Scammellsauthor=A.+Christopoulosauthor=B.+Capuanoauthor=J.+R.+Lane&title=Biased+agonism+at+G+protein-coupled+receptors%3A+the+promise+and+the+challenges%2D%2Da+medicinal+chemistry+perspective&doi=10.1002%2Fmed.21318"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Biased Agonism at G Protein-Coupled Receptors: The Promise and the Challenges-A Medicinal Chemistry Perspective</span></div><div class="casAuthors">Shonberg, Jeremy; Lopez, Laura; Scammells, Peter J.; Christopoulos, Arthur; Capuano, Ben; Lane, J. Robert</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1286-1330</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Historically, detn. of G protein-coupled receptor (GPCR) ligand efficacy has often been restricted to identifying the ligand as an agonist or antagonist at a given signaling pathway.  This classification was deemed sufficient to predict compd. efficacy at all signaling endpoints, including the therapeutically relevant one(s).  However, it is now apparent that ligands acting at the same GPCR can stabilize multiple, distinct, receptor conformations linked to different functional outcomes.  This phenomenon, known as biased agonism, stimulus bias, or functional selectivity offers the opportunity to sep. on-target therapeutic effects from side effects through the design of drugs that show pathway selectivity.  However, the medicinal chemist faces numerous challenges to develop biased ligands, including the detection and quantification of biased agonism.  This review summarizes the current state of the field of research into biased agonism at GPCRs, with a particular focus on efforts to relate biased agonism to ligand structure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg-egFZpSKvbVg90H21EOLACvtfcHk0lg8KyzJ013XDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslalu7rJ&md5=85a5b385750d21856ae044391c46ee75</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2Fmed.21318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21318%26sid%3Dliteratum%253Aachs%26aulast%3DShonberg%26aufirst%3DJ.%26aulast%3DLopez%26aufirst%3DL.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DCapuano%26aufirst%3DB.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26atitle%3DBiased%2520agonism%2520at%2520G%2520protein-coupled%2520receptors%253A%2520the%2520promise%2520and%2520the%2520challenges--a%2520medicinal%2520chemistry%2520perspective%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2014%26volume%3D34%26spage%3D1286%26epage%3D1330%26doi%3D10.1002%2Fmed.21318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bologna, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teoh, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayoumi, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I. M.</span></span> <span> </span><span class="NLM_article-title">Biased G protein-coupled receptor signaling: new player in modulating physiology and pathology</span>. <i>Biomol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.4062/biomolther.2016.165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.4062%2Fbiomolther.2016.165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A280%3ADC%252BC1c7gsFWhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=12-25&author=Z.+Bolognaauthor=J.+P.+Teohauthor=A.+S.+Bayoumiauthor=Y.+Tangauthor=I.+M.+Kim&title=Biased+G+protein-coupled+receptor+signaling%3A+new+player+in+modulating+physiology+and+pathology&doi=10.4062%2Fbiomolther.2016.165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Biased G Protein-Coupled Receptor Signaling: New Player in Modulating Physiology and Pathology</span></div><div class="casAuthors">Bologna Zuzana; Teoh Jian-Peng; Bayoumi Ahmed S; Tang Yaoliang; Kim Il-Man; Kim Il-Man</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecules & therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-25</span>
        ISSN:<span class="NLM_cas:issn">1976-9148</span>.
    </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are a family of cell-surface proteins that play critical roles in regulating a variety of pathophysiological processes and thus are targeted by almost a third of currently available therapeutics.  It was originally thought that GPCRs convert extracellular stimuli into intracellular signals through activating G proteins, whereas β-arrestins have important roles in internalization and desensitization of the receptor.  Over the past decade, several novel functional aspects of β-arrestins in regulating GPCR signaling have been discovered.  These previously unanticipated roles of β-arrestins to act as signal transducers and mediators of G protein-independent signaling have led to the concept of biased agonism.  Biased GPCR ligands are able to engage with their target receptors in a manner that preferentially activates only G protein- or β-arrestin-mediated downstream signaling.  This offers the potential for next generation drugs with high selectivity to therapeutically relevant GPCR signaling pathways.  In this review, we provide a summary of the recent studies highlighting G protein- or β-arrestin-biased GPCR signaling and the effects of biased ligands on disease pathogenesis and regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRshPzvVvIEzJVVjGoY74BafW6udTcc2eYIZwt2f6_tPrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7gsFWhtg%253D%253D&md5=7cfe8440b5d4e23b6c94d450662e8e54</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.4062%2Fbiomolther.2016.165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4062%252Fbiomolther.2016.165%26sid%3Dliteratum%253Aachs%26aulast%3DBologna%26aufirst%3DZ.%26aulast%3DTeoh%26aufirst%3DJ.%2BP.%26aulast%3DBayoumi%26aufirst%3DA.%2BS.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DI.%2BM.%26atitle%3DBiased%2520G%2520protein-coupled%2520receptor%2520signaling%253A%2520new%2520player%2520in%2520modulating%2520physiology%2520and%2520pathology%26jtitle%3DBiomol.%2520Ther.%26date%3D2017%26volume%3D25%26spage%3D12%26epage%3D25%26doi%3D10.4062%2Fbiomolther.2016.165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeWire, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span> <span> </span><span class="NLM_article-title">, Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">216</span>, <span class="refDoi"> DOI: 10.1161/CIRCRESAHA.110.231308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1161%2FCIRCRESAHA.110.231308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=21737816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFaisL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2011&pages=205-216&author=S.+M.+DeWireauthor=J.+D.+Violin&title=%2C+Biased+ligands+for+better+cardiovascular+drugs%3A+dissecting+G-protein-coupled+receptor+pharmacology&doi=10.1161%2FCIRCRESAHA.110.231308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Biased Ligands for Better Cardiovascular Drugs: Dissecting G-Protein-Coupled Receptor Pharmacology</span></div><div class="casAuthors">DeWire, Scott M.; Violin, Jonathan D.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">205-216</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Drug discovery efforts targeting G-protein-coupled receptors (GPCR) were immensely successful in creating new cardiovascular medicines.  Currently marketed GPCR drugs are broadly classified as either agonists that activate receptors or antagonists that prevent receptor activation by endogenous stimuli.  However, GPCR couple to a multitude of intracellular signaling pathways beyond classical G-protein signals, and these signals can be independently activated by biased ligands to vastly expand the potential for new drugs at these classic targets.  By selectively engaging only a subset of a receptor's potential intracellular partners, biased ligands may deliver more precise therapeutic benefit with fewer side effects than current GPCR-targeted drugs.  In this review, we discuss the history of biased ligand research, the current understanding of how biased ligands exert their unique pharmacol., and how research into GPCR signaling has uncovered previously unappreciated capabilities of receptor pharmacol.  We focus on several receptors to illustrate the approaches taken and discoveries made, and how these are steadily illuminating the intricacies of GPCR pharmacol.  Discoveries of biased ligands targeting the angiotensin II type 1 receptor and of separable pharmacol. suggesting the potential value of biased ligands targeting the β-adrenergic receptors and nicotinic acid receptor GPR109a highlight the powerful clin. promise of this new category of potential therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpULKUYGC9HqrVg90H21EOLACvtfcHk0lhlro1uFiYtrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFaisL8%253D&md5=5e3ba6c6b9e015cf52759f87dcdd62ed</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1161%2FCIRCRESAHA.110.231308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCRESAHA.110.231308%26sid%3Dliteratum%253Aachs%26aulast%3DDeWire%26aufirst%3DS.%2BM.%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26atitle%3D%252C%2520Biased%2520ligands%2520for%2520better%2520cardiovascular%2520drugs%253A%2520dissecting%2520G-protein-coupled%2520receptor%2520pharmacology%26jtitle%3DCirc.%2520Res.%26date%3D2011%26volume%3D109%26spage%3D205%26epage%3D216%26doi%3D10.1161%2FCIRCRESAHA.110.231308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span> <span> </span><span class="NLM_article-title">Biased ligands of g protein-coupled receptors (GPCRs): structure-functional selectivity relationships (SFSRs) and therapeutic potential</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9841</span>– <span class="NLM_lpage">9878</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00435</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00435" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Snu73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9841-9878&author=L.+Tanauthor=W.+Yanauthor=J.+D.+McCorvyauthor=J.+Cheng&title=Biased+ligands+of+g+protein-coupled+receptors+%28GPCRs%29%3A+structure-functional+selectivity+relationships+%28SFSRs%29+and+therapeutic+potential&doi=10.1021%2Facs.jmedchem.8b00435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential</span></div><div class="casAuthors">Tan, Liang; Yan, Wenzhong; McCorvy, John D.; Cheng, Jianjun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9841-9878</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  G protein-coupled receptors (GPCRs) signal through both G-protein-dependent and G-protein-independent pathways, and β-arrestin recruitment is the most recognized one of the latter.  Biased ligands selective for either pathway are expected to regulate biol. functions of GPCRs in a more precise way, therefore providing new drug mols. with superior efficacy and/or reduced side effects.  During the past decade, biased ligands have been discovered and developed for many GPCRs, such as the μ opioid receptor, the angiotensin II receptor type 1, the dopamine D2 receptor, and many others.  In this Perspective, recent advances in this field are reviewed by discussing the structure-functional selectivity relationships (SFSRs) of GPCR biased ligands and the therapeutic potential of these mols.  Further understanding of the biol. functions assocd. with each signaling pathway and structural basis for biased signaling will facilitate future drug design in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNFjkAvar29LVg90H21EOLACvtfcHk0lhlro1uFiYtrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Snu73N&md5=a7bd605b82666357f5a0a209002225e5</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00435%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DL.%26aulast%3DYan%26aufirst%3DW.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DCheng%26aufirst%3DJ.%26atitle%3DBiased%2520ligands%2520of%2520g%2520protein-coupled%2520receptors%2520%2528GPCRs%2529%253A%2520structure-functional%2520selectivity%2520relationships%2520%2528SFSRs%2529%2520and%2520therapeutic%2520potential%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9841%26epage%3D9878%26doi%3D10.1021%2Facs.jmedchem.8b00435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunyady, L.</span></span> <span> </span><span class="NLM_article-title">Signal transduction of the CB1 cannabinoid receptor</span>. <i>J. Mol. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1677/JME-08-0190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1677%2FJME-08-0190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=19620237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvFSitr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2010&pages=75-85&author=G.+Turuauthor=L.+Hunyady&title=Signal+transduction+of+the+CB1+cannabinoid+receptor&doi=10.1677%2FJME-08-0190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Signal transduction of the CB1 cannabinoid receptor</span></div><div class="casAuthors">Turu, Gabor; Hunyady, Laszlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Endocrinology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1,2</span>),
    <span class="NLM_cas:pages">75-85</span>CODEN:
                <span class="NLM_cas:coden">JMLEEI</span>;
        ISSN:<span class="NLM_cas:issn">0952-5041</span>.
    
            (<span class="NLM_cas:orgname">Society for Endocrinology</span>)
        </div><div class="casAbstract">A review.  The CB1 cannabinoid receptor (CB1R) is the major cannabinoid receptor in neuronal cells and the brain, but it also occurs in endocrine cells and other peripheral tissues.  CB1R is a member of the superfamily of G-protein-coupled receptors (GPCRs), which are characterized by 7 transmembrane helixes.  The major mediators of CB1R are the G proteins of the Gi/o family, which inhibit adenylyl cyclases in most tissues and cells, and regulate ion channels, including calcium and potassium ion channels.  Regulation of ion channels is an important component of neurotransmission modulation by endogenous cannabinoid compds. released in response to depolarization and Ca2+-mobilizing hormones.  However, evidence exists that CB1Rs can also stimulate adenylyl cyclase via Gs, induce receptor-mediated Ca2+ fluxes and stimulate phospholipases in some exptl. models.  Stimulation of CB1R also leads to phosphorylation and activation of mitogen-activated protein kinases (MAPK), such as p42/p44 MAPK, p38 MAPK, and c-Jun N-terminal kinase, which can regulate nuclear transcription factors.  Activated and phosphorylated CB1Rs also assoc. with β-arrestin mols., which can induce the formation of signaling complexes and participate in the regulation of GPCR signaling.  Recent data also suggest that CB1Rs can form homo- and heterodimers/oligomers, and the altered pharmacol. properties of these receptor complexes may explain the pharmacol. differences obsd. in various tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG11cTBkJabrVg90H21EOLACvtfcHk0lg_S_JG8I5H0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvFSitr0%253D&md5=cc2688221938d5e7908b254ce8116340</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1677%2FJME-08-0190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1677%252FJME-08-0190%26sid%3Dliteratum%253Aachs%26aulast%3DTuru%26aufirst%3DG.%26aulast%3DHunyady%26aufirst%3DL.%26atitle%3DSignal%2520transduction%2520of%2520the%2520CB1%2520cannabinoid%2520receptor%26jtitle%3DJ.%2520Mol.%2520Endocrinol.%26date%3D2010%26volume%3D44%26spage%3D75%26epage%3D85%26doi%3D10.1677%2FJME-08-0190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laprairie, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span> <span> </span><span class="NLM_article-title">Approaches to assess biased signaling at the CB1R receptor</span>. <i>Methods Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>593</i></span>,  <span class="NLM_fpage">259</span>– <span class="NLM_lpage">279</span>, <span class="refDoi"> DOI: 10.1016/bs.mie.2017.06.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1016%2Fbs.mie.2017.06.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=28750807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmvVemtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=593&publication_year=2017&pages=259-279&author=R.+B.+Laprairieauthor=E.+L.+Stahlauthor=L.+M.+Bohn&title=Approaches+to+assess+biased+signaling+at+the+CB1R+receptor&doi=10.1016%2Fbs.mie.2017.06.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Approaches to assess biased signaling at the CB1R receptor</span></div><div class="casAuthors">Laprairie, Robert B.; Stahl, Edward L.; Bohn, Laura M.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">593</span>
        (<span class="NLM_cas:issue">Cannabinoids and Their Receptors</span>),
    <span class="NLM_cas:pages">259-279</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">G protein-coupled receptors, such as the cannabinoid type 1 receptor (CB1R), have been shown to interact with multiple binding partners to transmit signals.  In both transfected cell systems and in endogenously expressing cell lines, CB1R signaling has been described as multifaceted.  The question remains as to how this highly widely expressed receptor signals in a given cell at a given time in vivo.  The concept of functional selectivity, or biased agonism, describes the ability of an agonist to engage the receptor in a manner that preferentially engages certain signaling interactions (e.g., G proteins) over others (e.g., β-arrestins), presumably by stabilizing certain receptor conformations.  There is growing interest in using such properties of ligands to direct signaling downstream of CB1R toward desirable therapeutic outcomes and to avoid adverse side effects.  While it is not currently clear what pathways should be engaged and which should be avoided, the development of biased agonist tool compds. will aid in answering these questions.  In this chapter, we discuss the approaches and caveats to assessing biased agonism at the CB1R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGEt-ToYWUh7Vg90H21EOLACvtfcHk0lg_S_JG8I5H0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmvVemtb0%253D&md5=2c02853c478dbe994bc0a97694d2f9b7</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fbs.mie.2017.06.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.mie.2017.06.031%26sid%3Dliteratum%253Aachs%26aulast%3DLaprairie%26aufirst%3DR.%2BB.%26aulast%3DStahl%26aufirst%3DE.%2BL.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26atitle%3DApproaches%2520to%2520assess%2520biased%2520signaling%2520at%2520the%2520CB1R%2520receptor%26jtitle%3DMethods%2520Enzymol.%26date%3D2017%26volume%3D593%26spage%3D259%26epage%3D279%26doi%3D10.1016%2Fbs.mie.2017.06.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mallipeddi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janero, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvonok, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makriyannis, A.</span></span> <span> </span><span class="NLM_article-title">Functional selectivity at G-protein coupled receptors: advancing cannabinoid receptors as drug targets</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2016.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1016%2Fj.bcp.2016.11.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=27890725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCnsL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2017&pages=1-11&author=S.+Mallipeddiauthor=D.+R.+Janeroauthor=N.+Zvonokauthor=A.+Makriyannis&title=Functional+selectivity+at+G-protein+coupled+receptors%3A+advancing+cannabinoid+receptors+as+drug+targets&doi=10.1016%2Fj.bcp.2016.11.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Functional selectivity at G-protein coupled receptors: Advancing cannabinoid receptors as drug targets</span></div><div class="casAuthors">Mallipeddi, Srikrishnan; Janero, David R.; Zvonok, Nikolai; Makriyannis, Alexandros</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-11</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The phenomenon of functional selectivity, whereby a ligand preferentially directs the information output of a G-protein coupled receptor (GPCR) along (a) particular effector pathway(s) and away from others, has redefined traditional GPCR signaling paradigms to provide a new approach to structure-based drug design.  The two principal cannabinoid receptors (CBRs) 1 and 2 belong to the class-A GPCR subfamily and are considered tenable therapeutic targets for several indications.  Yet conventional orthosteric ligands (agonists, antagonists/inverse agonists) for these receptors have had very limited clin. utility due to their propensity to incite on-target adverse events.  Chem. distinct classes of cannabinergic ligands exhibit signaling bias at CBRs towards individual subsets of signal transduction pathways.  In this review, we discuss the known signaling pathways regulated by CBRs and examine the current evidence for functional selectivity at CBRs in response to endogenous and exogenous cannabinergic ligands as biased agonists.  We further discuss the receptor and ligand structural features allowing for selective activation of CBR-dependent functional responses.  The design and development of biased ligands may offer a pathway to therapeutic success for novel CBR-targeted drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeBMv00pJezbVg90H21EOLACvtfcHk0lg_S_JG8I5H0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCnsL3K&md5=a447353e190125cdd3d7e363eab0e137</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2016.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2016.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DMallipeddi%26aufirst%3DS.%26aulast%3DJanero%26aufirst%3DD.%2BR.%26aulast%3DZvonok%26aufirst%3DN.%26aulast%3DMakriyannis%26aufirst%3DA.%26atitle%3DFunctional%2520selectivity%2520at%2520G-protein%2520coupled%2520receptors%253A%2520advancing%2520cannabinoid%2520receptors%2520as%2520drug%2520targets%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2017%26volume%3D128%26spage%3D1%26epage%3D11%26doi%3D10.1016%2Fj.bcp.2016.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ibsen, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glass, M.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid CB(1) and CB(2) receptor signaling and bias</span>. <i>Cannabis Cannabinoid Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1089/can.2016.0037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1089%2Fcan.2016.0037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=28861504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkslGmtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2017&pages=48-60&author=M.+S.+Ibsenauthor=M.+Connorauthor=M.+Glass&title=Cannabinoid+CB%281%29+and+CB%282%29+receptor+signaling+and+bias&doi=10.1089%2Fcan.2016.0037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid CB1 and CB2 receptor signaling and bias</span></div><div class="casAuthors">Ibsen, Mikkel Soes; Connor, Mark; Glass, Michelle</div><div class="citationInfo"><span class="NLM_cas:title">Cannabis and Cannabinoid Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-60</span>CODEN:
                <span class="NLM_cas:coden">CCRAEP</span>;
        ISSN:<span class="NLM_cas:issn">2378-8763</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">A review.  An agonist that acts through a single receptor can activate numerous signaling pathways.  Recent studies have suggested that different ligands can differentially activate these pathways by stabilizing a limited range of receptor conformations, which in turn preferentially drive different downstream signaling cascades.  This concept, termed "biased signaling" represents an exciting therapeutic opportunity to target specific pathways that elicit only desired effects, while avoiding undesired effects mediated by different signaling cascades.  The cannabinoid receptors CB1 and CB2 each activate multiple pathways, and evidence is emerging for bias within these pathways.  This review will summarize the current evidence for biased signaling through cannabinoid receptor subtypes CB1 and CB2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUIt-yOeNWv7Vg90H21EOLACvtfcHk0lho9mKC45I8vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkslGmtbg%253D&md5=17eb23b3331bdb8ca7050d2307180702</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1089%2Fcan.2016.0037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fcan.2016.0037%26sid%3Dliteratum%253Aachs%26aulast%3DIbsen%26aufirst%3DM.%2BS.%26aulast%3DConnor%26aufirst%3DM.%26aulast%3DGlass%26aufirst%3DM.%26atitle%3DCannabinoid%2520CB%25281%2529%2520and%2520CB%25282%2529%2520receptor%2520signaling%2520and%2520bias%26jtitle%3DCannabis%2520Cannabinoid%2520Res.%26date%3D2017%26volume%3D2%26spage%3D48%26epage%3D60%26doi%3D10.1089%2Fcan.2016.0037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laprairie, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagher, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denovan-Wright, E. M.</span></span> <span> </span><span class="NLM_article-title">Biased type 1 cannabinoid receptor signaling influences neuronal viability in a cell culture model of Huntington disease</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">364</span>– <span class="NLM_lpage">375</span>, <span class="refDoi"> DOI: 10.1124/mol.115.101980</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1124%2Fmol.115.101980" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=26700564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFeltLnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2016&pages=364-375&author=R.+B.+Laprairieauthor=A.+M.+Bagherauthor=M.+E.+Kellyauthor=E.+M.+Denovan-Wright&title=Biased+type+1+cannabinoid+receptor+signaling+influences+neuronal+viability+in+a+cell+culture+model+of+Huntington+disease&doi=10.1124%2Fmol.115.101980"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Biased type 1 cannabinoid receptor signaling influences neuronal viability in a cell culture model of Huntington disease</span></div><div class="casAuthors">Laprairie, Robert B.; Bagher, Amina M.; Kelly, Melanie E. M.; Denovan-Wright, Eileen M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">364-375</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Huntington disease (HD) is an inherited, autosomal dominant, neurodegenerative disorder with limited treatment options.  Prior to motor symptom onset or neuronal cell loss in HD, levels of the type 1 cannabinoid receptor (CB1) decrease in the basal ganglia.  Decreasing CB1 levels are strongly correlated with chorea and cognitive deficit.  CB1 agonists are functionally selective (biased) for divergent signaling pathways.  In this study, six cannabinoids were tested for signaling bias in in vitro models of medium spiny projection neurons expressing wild-type (STHdhQ7/Q7) or mutant huntingtin protein (STHdhQ111/Q111).  Signaling bias was assessed using the Black and Leff operational model.  Relative activity [ΔlogR (τ/KA)] and system bias (ΔΔlogR) were calcd. relative to the ref. compd. WIN55,212-2 for Gαi/o, Gas, Gαq, Gβγ, and β-arrestin1 signaling following treatment with 2-arachidonoylglycerol (2-AG), anandamide (AEA), CP55,940, Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and THC+CBD (1:1), and compared between wild-type and HD cells.  The Emax of Gαi/o-dependent extracellular signal-regulated kinase (ERK) signaling was 50% lower in HD cells compared with wild-type cells.  2-AG and AEA displayed Gαi/o/Gβγ bias and normalized CB1 protein levels and improved cell viability, whereas CP55,940 and THC displayed β-arrestin1 bias and reduced CB1 protein levels and cell viability in HD cells.  CBD was not a CB1 agonist but inhibited THC-dependent signaling (THC+CBD).  Therefore, enhancing Gαi/o-biased endocannabinoid signaling may be therapeutically beneficial in HD.  In contrast, cannabinoids that are β-arrestin-biased-such as THC found at high levels in modern varieties of marijuana-may be detrimental to CB1 signaling, particularly in HD where CB1 levels are already reduced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdgxoxZrX1ObVg90H21EOLACvtfcHk0lho9mKC45I8vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFeltLnP&md5=fe544fe3afc0ab0ca739ab887be7c971</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1124%2Fmol.115.101980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.115.101980%26sid%3Dliteratum%253Aachs%26aulast%3DLaprairie%26aufirst%3DR.%2BB.%26aulast%3DBagher%26aufirst%3DA.%2BM.%26aulast%3DKelly%26aufirst%3DM.%2BE.%26aulast%3DDenovan-Wright%26aufirst%3DE.%2BM.%26atitle%3DBiased%2520type%25201%2520cannabinoid%2520receptor%2520signaling%2520influences%2520neuronal%2520viability%2520in%2520a%2520cell%2520culture%2520model%2520of%2520Huntington%2520disease%26jtitle%3DMol.%2520Pharmacol.%26date%3D2016%26volume%3D89%26spage%3D364%26epage%3D375%26doi%3D10.1124%2Fmol.115.101980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Zoubi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reggio, P. H.</span></span> <span> </span><span class="NLM_article-title">Structural insights into CB1 receptor biased signaling</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>, <span class="NLM_elocation-id">1837</span> <span class="refDoi"> DOI: 10.3390/ijms20081837</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.3390%2Fijms20081837" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFGlt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&author=R.+Al-Zoubiauthor=P.+Moralesauthor=P.+H.+Reggio&title=Structural+insights+into+CB1+receptor+biased+signaling&doi=10.3390%2Fijms20081837"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into CB1 receptor biased signaling</span></div><div class="casAuthors">Al-Zoubi, Rufaa; Morales, Paula; Reggio, Patricia H.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1837</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The endocannabinoid system has emerged as a promising target for the treatment of numerous diseases, including cancer, neurodegenerative disorders, and metabolic syndromes.  Thus far, two cannabinoid receptors, CB1 and CB2, have been discovered, which are found predominantly in the central nervous system (CB1) or the immune system (CB2), among other organs and tissues.  CB1 receptor ligands have been shown to induce a complex pattern of intracellular effects.  The binding of a ligand induces distinct conformational changes in the receptor, which will eventually translate into distinct intracellular signaling pathways through coupling to specific intracellular effector proteins.  These proteins can mediate receptor desensitization, trafficking, or signaling.  Ligand specificity and selectivity, complex cellular components, and the concomitant expression of other proteins (which either regulate the CB1 receptor or are regulated by the CB1 receptor) will affect the therapeutic outcome of its targeting.  With an increased interest in G protein-coupled receptors (GPCR) research, in-depth studies using mutations, biol. assays, and spectroscopic techniques (such as NMR, EPR, MS, FRET, and X-ray crystallog.), as well as computational modeling, have begun to reveal a set of concerted structural features in Class A GPCRs which relate to signaling pathways and the mechanisms of ligand-induced activation, deactivation, or activity modulation.  This review will focus on the structural features of the CB1 receptor, mutations known to bias its signaling, and reported studies of CB1 receptor ligands to control its specific signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhpn5qpenLKrVg90H21EOLACvtfcHk0lho9mKC45I8vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFGlt7w%253D&md5=2ef4a63e0feebbffa453cb5d17600247</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.3390%2Fijms20081837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20081837%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Zoubi%26aufirst%3DR.%26aulast%3DMorales%26aufirst%3DP.%26aulast%3DReggio%26aufirst%3DP.%2BH.%26atitle%3DStructural%2520insights%2520into%2520CB1%2520receptor%2520biased%2520signaling%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26doi%3D10.3390%2Fijms20081837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Vallée, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitiello, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellocchio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hébert-Chatelain, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monlezun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Garcia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasanetz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cathala, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roullot-Lacarrière, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shore, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deroche-Gamonet, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spampinato, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Revest, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maldonado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reggio, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsicano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piazza, P. V.</span></span> <span> </span><span class="NLM_article-title">Pregnenolone can protect the brain from cannabis intoxication</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>343</i></span>,  <span class="NLM_fpage">94</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1126/science.1243985</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1126%2Fscience.1243985" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=24385629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkslyn" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2014&pages=94-98&author=M.+Vall%C3%A9eauthor=S.+Vitielloauthor=L.+Bellocchioauthor=E.+H%C3%A9bert-Chatelainauthor=S.+Monlezunauthor=E.+Martin-Garciaauthor=F.+Kasanetzauthor=G.+L.+Baillieauthor=F.+Paninauthor=A.+Cathalaauthor=V.+Roullot-Lacarri%C3%A8reauthor=S.+Fabreauthor=D.+P.+Hurstauthor=D.+L.+Lynchauthor=D.+M.+Shoreauthor=V.+Deroche-Gamonetauthor=U.+Spampinatoauthor=J.+M.+Revestauthor=R.+Maldonadoauthor=P.+H.+Reggioauthor=R.+A.+Rossauthor=G.+Marsicanoauthor=P.+V.+Piazza&title=Pregnenolone+can+protect+the+brain+from+cannabis+intoxication&doi=10.1126%2Fscience.1243985"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27aR"><div class="casContent"><span class="casTitleNuber">27a</span><div class="casTitle"><span class="NLM_cas:atitle">Pregnenolone Can Protect the Brain from Cannabis Intoxication</span></div><div class="casAuthors">Vallee, Monique; Vitiello, Sergio; Bellocchio, Luigi; Hebert-Chatelain, Etienne; Monlezun, Stephanie; Martin-Garcia, Elena; Kasanetz, Fernando; Baillie, Gemma L.; Panin, Francesca; Cathala, Adeline; Roullot-Lacarriere, Valerie; Fabre, Sandy; Hurst, Dow P.; Lynch, Diane L.; Shore, Derek M.; Deroche-Gamonet, Veronique; Spampinato, Umberto; Revest, Jean-Michel; Maldonado, Rafael; Reggio, Patricia H.; Ross, Ruth A.; Marsicano, Giovanni; Piazza, Pier Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">6166</span>),
    <span class="NLM_cas:pages">94-98</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Pregnenolone is considered the inactive precursor of all steroid hormones, and its potential functional effects have been largely uninvestigated.  The administration of the main active principle of Cannabis sativa (marijuana), [Δ]9-tetrahydrocannabinol (THC), substantially increases the synthesis of pregnenolone in the brain via activation of the type-1 cannabinoid (CB1) receptor.  Pregnenolone then, acting as a signaling-specific inhibitor of the CB1 receptor, reduces several effects of THC.  This neg. feedback mediated by pregnenolone reveals a previously unknown paracrine/autocrine loop protecting the brain from CB1 receptor overactivation that could open an unforeseen approach for the treatment of cannabis intoxication and addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxyr3EtybQNbVg90H21EOLACvtfcHk0li-n96Atj0A6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkslyn&md5=b3e34c241de1f660c134329045966865</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.1126%2Fscience.1243985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1243985%26sid%3Dliteratum%253Aachs%26aulast%3DVall%25C3%25A9e%26aufirst%3DM.%26aulast%3DVitiello%26aufirst%3DS.%26aulast%3DBellocchio%26aufirst%3DL.%26aulast%3DH%25C3%25A9bert-Chatelain%26aufirst%3DE.%26aulast%3DMonlezun%26aufirst%3DS.%26aulast%3DMartin-Garcia%26aufirst%3DE.%26aulast%3DKasanetz%26aufirst%3DF.%26aulast%3DBaillie%26aufirst%3DG.%2BL.%26aulast%3DPanin%26aufirst%3DF.%26aulast%3DCathala%26aufirst%3DA.%26aulast%3DRoullot-Lacarri%25C3%25A8re%26aufirst%3DV.%26aulast%3DFabre%26aufirst%3DS.%26aulast%3DHurst%26aufirst%3DD.%2BP.%26aulast%3DLynch%26aufirst%3DD.%2BL.%26aulast%3DShore%26aufirst%3DD.%2BM.%26aulast%3DDeroche-Gamonet%26aufirst%3DV.%26aulast%3DSpampinato%26aufirst%3DU.%26aulast%3DRevest%26aufirst%3DJ.%2BM.%26aulast%3DMaldonado%26aufirst%3DR.%26aulast%3DReggio%26aufirst%3DP.%2BH.%26aulast%3DRoss%26aufirst%3DR.%2BA.%26aulast%3DMarsicano%26aufirst%3DG.%26aulast%3DPiazza%26aufirst%3DP.%2BV.%26atitle%3DPregnenolone%2520can%2520protect%2520the%2520brain%2520from%2520cannabis%2520intoxication%26jtitle%3DScience%26date%3D2014%26volume%3D343%26spage%3D94%26epage%3D98%26doi%3D10.1126%2Fscience.1243985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit27b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Laprairie, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohamed, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zagzoog, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, M. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denovan-Wright, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, G. A.</span></span> <span> </span><span class="NLM_article-title">Indomethacin enhances type 1 cannabinoid receptor signaling</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">12070</span> <span class="refDoi"> DOI: 10.3389/fnmol.2019.00257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.3389%2Ffnmol.2019.00257" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&author=R.+B.+Laprairieauthor=K.+A.+Mohamedauthor=A.+Zagzoogauthor=M.+E.+M.+Kellyauthor=L.+A.+Stevensonauthor=R.+Pertweeauthor=E.+M.+Denovan-Wrightauthor=G.+A.+Thakur&title=Indomethacin+enhances+type+1+cannabinoid+receptor+signaling&doi=10.3389%2Ffnmol.2019.00257"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2019.00257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2019.00257%26sid%3Dliteratum%253Aachs%26aulast%3DLaprairie%26aufirst%3DR.%2BB.%26aulast%3DMohamed%26aufirst%3DK.%2BA.%26aulast%3DZagzoog%26aufirst%3DA.%26aulast%3DKelly%26aufirst%3DM.%2BE.%2BM.%26aulast%3DStevenson%26aufirst%3DL.%2BA.%26aulast%3DPertwee%26aufirst%3DR.%26aulast%3DDenovan-Wright%26aufirst%3DE.%2BM.%26aulast%3DThakur%26aufirst%3DG.%2BA.%26atitle%3DIndomethacin%2520enhances%2520type%25201%2520cannabinoid%2520receptor%2520signaling%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2019%26volume%3D12%26doi%3D10.3389%2Ffnmol.2019.00257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit27c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pamplona, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes de Lima, O.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duarte, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bento, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villarinho, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellocchio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wotjak, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monory, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canetti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matias, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calixto, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsicano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guimarães, M. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, R. N.</span></span> <span> </span><span class="NLM_article-title">Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">21134</span>– <span class="NLM_lpage">21139</span>, <span class="refDoi"> DOI: 10.1073/pnas.1202906109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1073%2Fpnas.1202906109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=23150578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnt1eksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=21134-21139&author=F.+A.+Pamplonaauthor=J.+Ferreiraauthor=O.+Menezes+de+Limaauthor=F.+S.+Duarteauthor=A.+F.+Bentoauthor=S.+Fornerauthor=J.+G.+Villarinhoauthor=L.+Bellocchioauthor=C.+T.+Wotjakauthor=R.+Lernerauthor=K.+Monoryauthor=B.+Lutzauthor=C.+Canettiauthor=I.+Matiasauthor=J.+B.+Calixtoauthor=G.+Marsicanoauthor=M.+Z.+Guimar%C3%A3esauthor=R.+N.+Takahashi&title=Anti-inflammatory+lipoxin+A4+is+an+endogenous+allosteric+enhancer+of+CB1+cannabinoid+receptor&doi=10.1073%2Fpnas.1202906109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27cR"><div class="casContent"><span class="casTitleNuber">27c</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor</span></div><div class="casAuthors">Pamplona, Fabricio A.; Ferreira, Juliano; Menezes de Lima, Octavio, Jr.; Duarte, Filipe Silveira; Bento, Allisson Freire; Forner, Stefania; Villarinho, Jardel G.; Bellocchio, Luigi; Wotjak, Carsten T.; Lerner, Raissa; Monory, Krisztina; Lutz, Beat; Canetti, Claudio; Matias, Isabelle; Calixto, Joao Batista; Marsicano, Giovanni; Guimaraes, Marilia Z. P.; Takahashi, Reinaldo N.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">21134-21139, S21134/1-S21134/6</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Allosteric modulation of G-protein-coupled receptors represents a key goal of current pharmacol.  In particular, endogenous allosteric modulators might represent important targets of interventions aimed at maximizing therapeutic efficacy and reducing side effects of drugs.  The anti-inflammatory lipid lipoxin A4 is an endogenous allosteric enhancer of the CB1 cannabinoid receptor.  Lipoxin A4 was detected in brain tissues, did not compete for the orthosteric binding site of the CB1 receptor (vs. 3H-SR141716A), and did not alter endocannabinoid metab. (as opposed to URB597 and MAFP), but it enhanced affinity of anandamide at the CB1 receptor, thereby potentiating the effects of this endocannabinoid both in vitro and in vivo.  In addn., lipoxin A4 displayed a CB1 receptor-dependent protective effect against β-amyloid (1-40)-induced spatial memory impairment in mice.  The discovery of lipoxins as a class of endogenous allosteric modulators of CB1 receptors may foster the therapeutic exploitation of the endocannabinoid system, in particular for the treatment of neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtolBezEx077Vg90H21EOLACvtfcHk0li-n96Atj0A6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnt1eksw%253D%253D&md5=594b68271d19309dcdc26f1c59738bdc</span></div><a href="/servlet/linkout?suffix=cit27c&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1202906109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1202906109%26sid%3Dliteratum%253Aachs%26aulast%3DPamplona%26aufirst%3DF.%2BA.%26aulast%3DFerreira%26aufirst%3DJ.%26aulast%3DMenezes%2Bde%2BLima%26aufirst%3DO.%26aulast%3DDuarte%26aufirst%3DF.%2BS.%26aulast%3DBento%26aufirst%3DA.%2BF.%26aulast%3DForner%26aufirst%3DS.%26aulast%3DVillarinho%26aufirst%3DJ.%2BG.%26aulast%3DBellocchio%26aufirst%3DL.%26aulast%3DWotjak%26aufirst%3DC.%2BT.%26aulast%3DLerner%26aufirst%3DR.%26aulast%3DMonory%26aufirst%3DK.%26aulast%3DLutz%26aufirst%3DB.%26aulast%3DCanetti%26aufirst%3DC.%26aulast%3DMatias%26aufirst%3DI.%26aulast%3DCalixto%26aufirst%3DJ.%2BB.%26aulast%3DMarsicano%26aufirst%3DG.%26aulast%3DGuimar%25C3%25A3es%26aufirst%3DM.%2BZ.%26aulast%3DTakahashi%26aufirst%3DR.%2BN.%26atitle%3DAnti-inflammatory%2520lipoxin%2520A4%2520is%2520an%2520endogenous%2520allosteric%2520enhancer%2520of%2520CB1%2520cannabinoid%2520receptor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2012%26volume%3D109%26spage%3D21134%26epage%3D21139%26doi%3D10.1073%2Fpnas.1202906109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singla, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skobieranda, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soergel, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salamea, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burt, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demitrack, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viscusi, E. R.</span></span> <span> </span><span class="NLM_article-title">APOLLO-2: a randomized, placebo and active-controlled phase iii study investigating oliceridine (TRV130), a G protein-biased ligand at the μ-opioid receptor, for management of moderate to severe acute pain following abdominoplasty</span>. <i>Pain pract.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">715</span>– <span class="NLM_lpage">731</span>, <span class="refDoi"> DOI: 10.1111/papr.12801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1111%2Fpapr.12801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=31162798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A280%3ADC%252BB3M3jtFClsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=715-731&author=N.+K.+Singlaauthor=F.+Skobierandaauthor=D.+G.+Soergelauthor=M.+Salameaauthor=D.+A.+Burtauthor=M.+A.+Demitrackauthor=E.+R.+Viscusi&title=APOLLO-2%3A+a+randomized%2C+placebo+and+active-controlled+phase+iii+study+investigating+oliceridine+%28TRV130%29%2C+a+G+protein-biased+ligand+at+the+%CE%BC-opioid+receptor%2C+for+management+of+moderate+to+severe+acute+pain+following+abdominoplasty&doi=10.1111%2Fpapr.12801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">APOLLO-2: A Randomized, Placebo and Active-Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein-Biased Ligand at the μ-Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty</span></div><div class="casAuthors">Singla Neil K; Skobieranda Franck; Soergel David G; Salamea Monica; Burt David A; Demitrack Mark A; Viscusi Eugene R</div><div class="citationInfo"><span class="NLM_cas:title">Pain practice : the official journal of World Institute of Pain</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">715-731</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  The clinical utility of conventional IV opioids is limited by the occurrence of opioid-related adverse events.  Oliceridine is a novel G protein-biased μ-opioid receptor agonist designed to provide analgesia with an improved safety and tolerability profile.  This phase III, double-blind, randomized trial (APOLLO-2 [NCT02820324]) evaluated the efficacy and safety of oliceridine for acute pain following abdominoplasty.  METHODS:  Patients received a loading dose of either placebo, oliceridine (1.5 mg), or morphine (4 mg), followed by demand doses via patient-controlled analgesia (0.1, 0.35, or 0.5 mg oliceridine; 1 mg morphine; or placebo) with a 6-minute lockout interval.  The primary endpoint was the proportion of treatment responders over 24 hours for oliceridine regimens compared to placebo.  Secondary outcomes included a predefined composite measure of respiratory safety burden (RSB, representing the cumulative duration of respiratory safety events) and the proportion of treatment responders vs. morphine.  RESULTS:  A total of 401 patients were treated with study medication.  Effective analgesia was observed for all oliceridine regimens, with responder rates of 61.0%, 76.3%, and 70.0% for the 0.1-, 0.35-, and 0.5-mg regimens, respectively, compared with 45.7% for placebo (all P < 0.05) and 78.3% for morphine.  Oliceridine 0.35- and 0.5-mg demand dose regimens were equi-analgesic to morphine using a noninferiority analysis.  RSB showed a dose-dependent increase across oliceridine regimens (mean hours [standard deviation], 0.1 mg: 0.43 [1.56]; 0.35 mg: 1.48 [3.83]; 0.5 mg: 1.59 [4.26]; all comparisons not significant at P > 0.05 vs. placebo: 0.60 [2.82]).  The RSB measure for morphine was 1.72 (3.86) (P < 0.05 vs. placebo).  Gastrointestinal adverse events increased in a dose-dependent manner across oliceridine demand dose regimens (0.1 mg: 49.4%; 0.35 mg: 65.8%; 0.5 mg: 78.8%; vs. placebo: 47.0%; and morphine: 79.3%).  In comparison to morphine, the proportion of patients experiencing nausea or vomiting was lower with the 2 equi-analgesic dose regimens of 0.35 and 0.5 mg oliceridine.  CONCLUSIONS:  Oliceridine is a safe and effective IV analgesic for the relief of moderate to severe acute postoperative pain in patients undergoing abdominoplasty.  Since the low-dose regimen of 0.1 mg oliceridine was superior to placebo but not as effective as the morphine regimen, safety comparisons to morphine are relevant only to the 2 equi-analgesic dose groups of 0.35 and 0.5 mg, which showed a favorable safety and tolerability profile regarding respiratory and gastrointestinal adverse effects compared to morphine.  These findings support that oliceridine may provide a new treatment option for patients with moderate to severe acute pain where an IV opioid is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSpVn3NtI2fPmZyxfu64m4ffW6udTcc2ebac2Px_3tAt7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3jtFClsQ%253D%253D&md5=7654216d8ca422cdd285f73d7774c87b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1111%2Fpapr.12801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fpapr.12801%26sid%3Dliteratum%253Aachs%26aulast%3DSingla%26aufirst%3DN.%2BK.%26aulast%3DSkobieranda%26aufirst%3DF.%26aulast%3DSoergel%26aufirst%3DD.%2BG.%26aulast%3DSalamea%26aufirst%3DM.%26aulast%3DBurt%26aufirst%3DD.%2BA.%26aulast%3DDemitrack%26aufirst%3DM.%2BA.%26aulast%3DViscusi%26aufirst%3DE.%2BR.%26atitle%3DAPOLLO-2%253A%2520a%2520randomized%252C%2520placebo%2520and%2520active-controlled%2520phase%2520iii%2520study%2520investigating%2520oliceridine%2520%2528TRV130%2529%252C%2520a%2520G%2520protein-biased%2520ligand%2520at%2520the%2520%25CE%25BC-opioid%2520receptor%252C%2520for%2520management%2520of%2520moderate%2520to%2520severe%2520acute%2520pain%2520following%2520abdominoplasty%26jtitle%3DPain%2520pract.%26date%3D2019%26volume%3D19%26spage%3D715%26epage%3D731%26doi%3D10.1111%2Fpapr.12801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotchev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rominger, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koblish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewire, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crombie, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, D. S.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships and discovery of a G protein biased μ opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8019</span>– <span class="NLM_lpage">8031</span>, <span class="refDoi"> DOI: 10.1021/jm4010829</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4010829" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFSmsrjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8019-8031&author=X.+T.+Chenauthor=P.+Pitisauthor=G.+Liuauthor=C.+Yuanauthor=D.+Gotchevauthor=C.+L.+Cowanauthor=D.+H.+Romingerauthor=M.+Koblishauthor=S.+M.+Dewireauthor=A.+L.+Crombieauthor=J.+D.+Violinauthor=D.+S.+Yamashita&title=Structure-activity+relationships+and+discovery+of+a+G+protein+biased+%CE%BC+opioid+receptor+ligand%2C+%5B%283-methoxythiophen-2-yl%29methyl%5D%28%7B2-%5B%289R%29-9-%28pyridin-2-yl%29-6-oxaspiro-%5B4.5%5Ddecan-9-yl%5Dethyl%7D%29amine+%28TRV130%29%2C+for+the+treatment+of+acute+severe+pain&doi=10.1021%2Fjm4010829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationships and Discovery of a G Protein Biased μ Opioid Receptor Ligand, [(3-Methoxythiophen-2-yl)methyl]({2-[(9R)9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the Treatment of Acute Severe Pain</span></div><div class="casAuthors">Chen, Xiao-Tao; Pitis, Philip; Liu, Guodong; Yuan, Catherine; Gotchev, Dimitar; Cowan, Conrad L.; Rominger, David H.; Koblish, Michael; DeWire, Scott M.; Crombie, Aimee L.; Violin, Jonathan D.; Yamashita, Dennis S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8019-8031</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The concept of ligand bias at G protein coupled receptors has been introduced to describe ligands which preferentially stimulate one intracellular signaling pathway over another.  There is growing interest in developing biased G protein coupled receptor ligands to yield safer, better tolerated, and more efficacious drugs.  The classical μ opioid morphine elicited increased efficacy and duration of analgesic response with reduced side effects in β-arrestin-2 knockout mice compared to wild-type mice, suggesting that G protein biased μ opioid receptor agonists would be more efficacious with reduced adverse events.  Here we describe our efforts to identify a potent, selective, and G protein biased μ opioid receptor agonist, TRV130 (I).  This novel mol. demonstrated an improved therapeutic index (analgesia vs adverse effects) in rodent models and characteristics appropriate for clin. development.  It is currently being evaluated in human clin. trials for the treatment of acute severe pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-rI0Et_vFqrVg90H21EOLACvtfcHk0liO2lpKCcti9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFSmsrjK&md5=c80bd62062f31418f18392f97c880bea</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm4010829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4010829%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%2BT.%26aulast%3DPitis%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DGotchev%26aufirst%3DD.%26aulast%3DCowan%26aufirst%3DC.%2BL.%26aulast%3DRominger%26aufirst%3DD.%2BH.%26aulast%3DKoblish%26aufirst%3DM.%26aulast%3DDewire%26aufirst%3DS.%2BM.%26aulast%3DCrombie%26aufirst%3DA.%2BL.%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26aulast%3DYamashita%26aufirst%3DD.%2BS.%26atitle%3DStructure-activity%2520relationships%2520and%2520discovery%2520of%2520a%2520G%2520protein%2520biased%2520%25CE%25BC%2520opioid%2520receptor%2520ligand%252C%2520%255B%25283-methoxythiophen-2-yl%2529methyl%255D%2528%257B2-%255B%25289R%2529-9-%2528pyridin-2-yl%2529-6-oxaspiro-%255B4.5%255Ddecan-9-yl%255Dethyl%257D%2529amine%2520%2528TRV130%2529%252C%2520for%2520the%2520treatment%2520of%2520acute%2520severe%2520pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8019%26epage%3D8031%26doi%3D10.1021%2Fjm4010829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeWire, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rominger, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graczyk, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitis, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotchev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koblish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lark, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span> <span> </span><span class="NLM_article-title">A G protein-biased ligand at the μ–opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>344</i></span>,  <span class="NLM_fpage">708</span>– <span class="NLM_lpage">717</span>, <span class="refDoi"> DOI: 10.1124/jpet.112.201616</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1124%2Fjpet.112.201616" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=23300227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvVaisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2013&pages=708-717&author=S.+M.+DeWireauthor=D.+S.+Yamashitaauthor=D.+H.+Romingerauthor=G.+Liuauthor=C.+L.+Cowanauthor=T.+M.+Graczykauthor=X.-T.+Chenauthor=P.+M.+Pitisauthor=D.+Gotchevauthor=C.+Yuanauthor=M.+Koblishauthor=M.+W.+Larkauthor=J.+D.+Violin&title=A+G+protein-biased+ligand+at+the+%CE%BC%E2%80%93opioid+receptor+is+potently+analgesic+with+reduced+gastrointestinal+and+respiratory+dysfunction+compared+with+morphine&doi=10.1124%2Fjpet.112.201616"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine</span></div><div class="casAuthors">DeWire, Scott M.; Yamashita, Dennis S.; Rominger, David H.; Liu, Guodong; Cowan, Conrad L.; Graczyk, Thomas M.; Chen, Xiao-Tao; Pitis, Philip M.; Gotchev, Dimitar; Yuan, Catherine; Koblish, Michael; Lark, Michael W.; Violin, Jonathan D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">708-717</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The concept of ligand bias at G protein-coupled receptors broadens the possibilities for agonist activities and provides the opportunity to develop safer, more selective therapeutics.  Morphine pharmacol. in β-arrestin-2 knockout mice suggested that a ligand that promotes coupling of the μ-opioid receptor (MOR) to G proteins, but not β-arrestins, would result in higher analgesic efficacy, less gastrointestinal dysfunction, and less respiratory suppression than morphine.  Here we report the discovery of TRV130 ([(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl]ethyl})amine), a novel MOR G protein-biased ligand.  In cell-based assays, TRV130 elicits robust G protein signaling, with potency and efficacy similar to morphine, but with far less β-arrestin recruitment and receptor internalization.  In mice and rats, TRV130 is potently analgesic while causing less gastrointestinal dysfunction and respiratory suppression than morphine at equianalgesic doses.  TRV130 successfully translates evidence that analgesic and adverse MOR signaling pathways are distinct into a biased ligand with differentiated pharmacol.  These preclin. data suggest that TRV130 may be a safer and more tolerable therapeutic for treating severe pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps3tTP2BOOKrVg90H21EOLACvtfcHk0liO2lpKCcti9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvVaisro%253D&md5=33a685cd1952dd9cb1fb82afe78452af</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.201616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.201616%26sid%3Dliteratum%253Aachs%26aulast%3DDeWire%26aufirst%3DS.%2BM.%26aulast%3DYamashita%26aufirst%3DD.%2BS.%26aulast%3DRominger%26aufirst%3DD.%2BH.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DCowan%26aufirst%3DC.%2BL.%26aulast%3DGraczyk%26aufirst%3DT.%2BM.%26aulast%3DChen%26aufirst%3DX.-T.%26aulast%3DPitis%26aufirst%3DP.%2BM.%26aulast%3DGotchev%26aufirst%3DD.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DKoblish%26aufirst%3DM.%26aulast%3DLark%26aufirst%3DM.%2BW.%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26atitle%3DA%2520G%2520protein-biased%2520ligand%2520at%2520the%2520%25CE%25BC%25E2%2580%2593opioid%2520receptor%2520is%2520potently%2520analgesic%2520with%2520reduced%2520gastrointestinal%2520and%2520respiratory%2520dysfunction%2520compared%2520with%2520morphine%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D344%26spage%3D708%26epage%3D717%26doi%3D10.1124%2Fjpet.112.201616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tae, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choo, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of β-arrestin biased ligands of 5-HT(7)R</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7218</span>– <span class="NLM_lpage">7233</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00642</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00642" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlGit7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7218-7233&author=Y.+Kimauthor=H.+Kimauthor=J.+Leeauthor=J.+K.+Leeauthor=S.+J.+Minauthor=J.+Seongauthor=H.+Rhimauthor=J.+Taeauthor=H.+J.+Leeauthor=H.+Choo&title=Discovery+of+%CE%B2-arrestin+biased+ligands+of+5-HT%287%29R&doi=10.1021%2Facs.jmedchem.8b00642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of β-Arrestin Biased Ligands of 5-HT7R</span></div><div class="casAuthors">Kim, Youngjae; Kim, Hyunguk; Lee, Jieon; Lee, Jae Kyun; Min, Sun-Joon; Seong, Jihye; Rhim, Hyewhon; Tae, Jinsung; Lee, Hyunjoo Jenny; Choo, Hyunah</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7218-7233</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Though many studies have been published about therapeutic potentials of selective 5-HT7R ligands, there have been few biased ligands of 5-HT7R.  The development of potent and selective biased ligands of 5-HT7R would be of great help in understanding the relationship between pharmacol. effects and G protein/β-arrestin signaling pathways of 5-HT7R.  To identify 5-HT7R ligands with biased agonism, the authors designed and synthesized a series of tetrahydroazepine derivs. 1 and 2 with arylpyrazolo moiety or arylisoxazolo moiety.  Through several biol. evaluations such as binding affinity, selectivity profile, and functions in G protein and β-arrestin signaling pathways, 3-(4-chlorophenyl)-1,4,5,6,7,8-hexahydropyrazolo[3,4-d]azepine 1g was discovered as the β-arrestin biased ligand of 5-HT7R.  In an EEG test, 1g increased total non-rapid eye movement (NREM) sleep time and decreased total rapid eye movement (REM) sleep time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiLWYVPSvmwbVg90H21EOLACvtfcHk0li7OnhYFvyW3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlGit7jK&md5=07149c8e43780d20812d7f5dd835ed7e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00642%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%2BK.%26aulast%3DMin%26aufirst%3DS.%2BJ.%26aulast%3DSeong%26aufirst%3DJ.%26aulast%3DRhim%26aufirst%3DH.%26aulast%3DTae%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DChoo%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520%25CE%25B2-arrestin%2520biased%2520ligands%2520of%25205-HT%25287%2529R%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7218%26epage%3D7233%26doi%3D10.1021%2Facs.jmedchem.8b00642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cook, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mistry, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furness, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conigrave, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, K.</span></span> <span> </span><span class="NLM_article-title">Biased allosteric modulation at the CaS receptor engendered by structurally diverse calcimimetics</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">200</span>, <span class="refDoi"> DOI: 10.1111/bph.12937</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1111%2Fbph.12937" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=25220431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWlsL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=185-200&author=A.+E.+Cookauthor=S.+N.+Mistryauthor=K.+J.+Gregoryauthor=S.+G.+Furnessauthor=P.+M.+Sextonauthor=P.+J.+Scammellsauthor=A.+D.+Conigraveauthor=A.+Christopoulosauthor=K.+Leach&title=Biased+allosteric+modulation+at+the+CaS+receptor+engendered+by+structurally+diverse+calcimimetics&doi=10.1111%2Fbph.12937"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Biased allosteric modulation at the CaS receptor engendered by structurally diverse calcimimetics</span></div><div class="casAuthors">Cook, A. E.; Mistry, S. N.; Gregory, K. J.; Furness, S. G. B.; Sexton, P. M.; Scammells, P. J.; Conigrave, A. D.; Christopoulos, A.; Leach, K.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">185-200</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Clin. use of cinacalcet in hyperparathyroidism is complicated by its tendency to induce hypocalcemia, arising partly from activation of calcium-sensing receptors (CaS receptors) in the thyroid and stimulation of calcitonin release.  CaS receptor allosteric modulators that selectively bias signalling towards pathways that mediate desired effects [e.g. parathyroid hormone (PTH) suppression] rather than those mediating undesirable effects (e.g. elevated serum calcitonin), may offer better therapies.  Exptl. Approach : We characterized the ligand-biased profile of novel calcimimetics in HEK293 cells stably expressing human CaS receptors, by monitoring intracellular calcium (Ca2+i) mobilization, inositol phosphate (IP)1 accumulation, ERK1/2 phosphorylation (pERK1/2) and receptor expression.  Key Results : Phenylalkylamine calcimimetics were biased towards allosteric modulation of Ca2+i mobilization and IP1 accumulation.  S,R-calcimimetic B was biased only towards IP1 accumulation.  R,R-calcimimetic B and AC-265347 were biased towards IP1 accumulation and pERK1/2.  Nor-calcimimetic B was unbiased.  In contrast to phenylalkylamines and calcimimetic B analogs, AC-265347 did not promote trafficking of a loss-of-expression, naturally occurring, CaS receptor mutation (G670E).  Conclusions and Implications : The ability of R,R-calcimimetic B and AC-265347 to bias signalling towards pERK1/2 and IP1 accumulation may explain their suppression of PTH levels in vivo at concns. that have no effect on serum calcitonin levels.  The demonstration that AC-265347 promotes CaS receptor receptor signalling, but not trafficking reveals a novel profile of ligand-biased modulation at CaS receptors The identification of allosteric modulators that bias CaS receptor signalling towards distinct intracellular pathways provides an opportunity to develop desirable biased signalling profiles in vivo for mediating selective physiol. responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOAjm2vqgRE7Vg90H21EOLACvtfcHk0li7OnhYFvyW3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWlsL3P&md5=238f469a40ace3cf598dc49584bf0497</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1111%2Fbph.12937&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12937%26sid%3Dliteratum%253Aachs%26aulast%3DCook%26aufirst%3DA.%2BE.%26aulast%3DMistry%26aufirst%3DS.%2BN.%26aulast%3DGregory%26aufirst%3DK.%2BJ.%26aulast%3DFurness%26aufirst%3DS.%2BG.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DConigrave%26aufirst%3DA.%2BD.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DLeach%26aufirst%3DK.%26atitle%3DBiased%2520allosteric%2520modulation%2520at%2520the%2520CaS%2520receptor%2520engendered%2520by%2520structurally%2520diverse%2520calcimimetics%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D185%26epage%3D200%26doi%3D10.1111%2Fbph.12937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rook, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghoshal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerson, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinson, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byun, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nedelcovych, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gould, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavreysen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conde-Ceide, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcazar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolomé-Nebreda, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talpos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steckler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span> <span> </span><span class="NLM_article-title">Biased mGlu5-positive allosteric modulators provide in vivo efficacy without potentiating mGlu5 modulation of NMDAR currents</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">1029</span>– <span class="NLM_lpage">1040</span>, <span class="refDoi"> DOI: 10.1016/j.neuron.2015.03.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1016%2Fj.neuron.2015.03.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=25937172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnslOisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2015&pages=1029-1040&author=J.+M.+Rookauthor=Z.+Xiangauthor=X.+Lvauthor=A.+Ghoshalauthor=J.+W.+Dickersonauthor=T.+M.+Bridgesauthor=K.+A.+Johnsonauthor=D.+J.+Fosterauthor=K.+J.+Gregoryauthor=P.+N.+Vinsonauthor=A.+D.+Thompsonauthor=N.+Byunauthor=R.+L.+Collierauthor=M.+Bubserauthor=M.+T.+Nedelcovychauthor=R.+W.+Gouldauthor=S.+R.+Staufferauthor=J.+S.+Danielsauthor=C.+M.+Niswenderauthor=H.+Lavreysenauthor=C.+Mackieauthor=S.+Conde-Ceideauthor=J.+Alcazarauthor=J.+M.+Bartolom%C3%A9-Nebredaauthor=G.+J.+Macdonaldauthor=J.+C.+Talposauthor=T.+Stecklerauthor=C.+K.+Jonesauthor=C.+W.+Lindsleyauthor=P.+J.+Conn&title=Biased+mGlu5-positive+allosteric+modulators+provide+in+vivo+efficacy+without+potentiating+mGlu5+modulation+of+NMDAR+currents&doi=10.1016%2Fj.neuron.2015.03.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents</span></div><div class="casAuthors">Rook, Jerri M.; Xiang, Zixiu; Lv, Xiaohui; Ghoshal, Ayan; Dickerson, Jonathan W.; Bridges, Thomas M.; Johnson, Kari A.; Foster, Daniel J.; Gregory, Karen J.; Vinson, Paige N.; Thompson, Analisa D.; Byun, Nellie; Collier, Rebekah L.; Bubser, Michael; Nedelcovych, Michael T.; Gould, Robert W.; Stauffer, Shaun R.; Daniels, J. Scott; Niswender, Colleen M.; Lavreysen, Hilde; Mackie, Claire; Conde-Ceide, Susana; Alcazar, Jesus; Bartolome-Nebreda, Jose M.; MacDonald, Gregor J.; Talpos, John C.; Steckler, Thomas; Jones, Carrie K.; Lindsley, Craig W.; Conn, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1029-1040</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Schizophrenia is assocd. with disruptions in N-methyl-D-aspartate glutamate receptor subtype (NMDAR)-mediated excitatory synaptic signaling.  The metabotropic glutamate receptor subtype 5 (mGlu5) is a closely assocd. signaling partner with NMDARs and regulates NMDAR function in forebrain regions implicated in the pathol. of schizophrenia.  Efficacy of mGlu5 pos. allosteric modulators (PAMs) in animal models of psychosis and cognition was previously attributed to potentiation of NMDAR function.  To directly test this hypothesis, we identified VU0409551 as a novel mGlu5 PAM that exhibits distinct stimulus bias and selectively potentiates mGlu5 coupling to Gαq-mediated signaling but not mGlu5 modulation of NMDAR currents or NMDAR-dependent synaptic plasticity in the rat hippocampus.  Interestingly, VU0409551 produced robust antipsychotic-like and cognition-enhancing activity in animal models.  These data provide surprising new mechanistic insights into the actions of mGlu5 PAMs and suggest that modulation of NMDAR currents is not crit. for in vivo efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouKRBBcza96rVg90H21EOLACvtfcHk0lgGehfjs42S4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnslOisLc%253D&md5=c5f0a8cf83e1b2d8e0d3541a39cd0529</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.neuron.2015.03.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuron.2015.03.063%26sid%3Dliteratum%253Aachs%26aulast%3DRook%26aufirst%3DJ.%2BM.%26aulast%3DXiang%26aufirst%3DZ.%26aulast%3DLv%26aufirst%3DX.%26aulast%3DGhoshal%26aufirst%3DA.%26aulast%3DDickerson%26aufirst%3DJ.%2BW.%26aulast%3DBridges%26aufirst%3DT.%2BM.%26aulast%3DJohnson%26aufirst%3DK.%2BA.%26aulast%3DFoster%26aufirst%3DD.%2BJ.%26aulast%3DGregory%26aufirst%3DK.%2BJ.%26aulast%3DVinson%26aufirst%3DP.%2BN.%26aulast%3DThompson%26aufirst%3DA.%2BD.%26aulast%3DByun%26aufirst%3DN.%26aulast%3DCollier%26aufirst%3DR.%2BL.%26aulast%3DBubser%26aufirst%3DM.%26aulast%3DNedelcovych%26aufirst%3DM.%2BT.%26aulast%3DGould%26aufirst%3DR.%2BW.%26aulast%3DStauffer%26aufirst%3DS.%2BR.%26aulast%3DDaniels%26aufirst%3DJ.%2BS.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DLavreysen%26aufirst%3DH.%26aulast%3DMackie%26aufirst%3DC.%26aulast%3DConde-Ceide%26aufirst%3DS.%26aulast%3DAlcazar%26aufirst%3DJ.%26aulast%3DBartolom%25C3%25A9-Nebreda%26aufirst%3DJ.%2BM.%26aulast%3DMacdonald%26aufirst%3DG.%2BJ.%26aulast%3DTalpos%26aufirst%3DJ.%2BC.%26aulast%3DSteckler%26aufirst%3DT.%26aulast%3DJones%26aufirst%3DC.%2BK.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DBiased%2520mGlu5-positive%2520allosteric%2520modulators%2520provide%2520in%2520vivo%2520efficacy%2520without%2520potentiating%2520mGlu5%2520modulation%2520of%2520NMDAR%2520currents%26jtitle%3DNeuron%26date%3D2015%26volume%3D86%26spage%3D1029%26epage%3D1040%26doi%3D10.1016%2Fj.neuron.2015.03.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khoury, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clément, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laporte, S. A.</span></span> <span> </span><span class="NLM_article-title">Allosteric and biased g protein-coupled receptor signaling regulation: potentials for new therapeutics</span>. <i>Front. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">339</span> <span class="refDoi"> DOI: 10.3389/fendo.2014.00068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.3389%2Ffendo.2014.00068" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&author=E.+Khouryauthor=S.+Cl%C3%A9mentauthor=S.+A.+Laporte&title=Allosteric+and+biased+g+protein-coupled+receptor+signaling+regulation%3A+potentials+for+new+therapeutics&doi=10.3389%2Ffendo.2014.00068"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.3389%2Ffendo.2014.00068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffendo.2014.00068%26sid%3Dliteratum%253Aachs%26aulast%3DKhoury%26aufirst%3DE.%26aulast%3DCl%25C3%25A9ment%26aufirst%3DS.%26aulast%3DLaporte%26aufirst%3DS.%2BA.%26atitle%3DAllosteric%2520and%2520biased%2520g%2520protein-coupled%2520receptor%2520signaling%2520regulation%253A%2520potentials%2520for%2520new%2520therapeutics%26jtitle%3DFront.%2520Endocrinol.%26date%3D2014%26volume%3D5%26doi%3D10.3389%2Ffendo.2014.00068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laprairie, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschamps, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, M. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janero, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascio, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenakin, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denovan-Wright, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, G. A.</span></span> <span> </span><span class="NLM_article-title">Enantiospecific allosteric modulation of cannabinoid 1 receptor</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1188</span>– <span class="NLM_lpage">1203</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.6b00310</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.6b00310" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1ehsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1188-1203&author=R.+B.+Laprairieauthor=P.+M.+Kulkarniauthor=J.+R.+Deschampsauthor=M.+E.+M.+Kellyauthor=D.+R.+Janeroauthor=M.+G.+Cascioauthor=L.+A.+Stevensonauthor=R.+G.+Pertweeauthor=T.+P.+Kenakinauthor=E.+M.+Denovan-Wrightauthor=G.+A.+Thakur&title=Enantiospecific+allosteric+modulation+of+cannabinoid+1+receptor&doi=10.1021%2Facschemneuro.6b00310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor</span></div><div class="casAuthors">Laprairie, Robert B.; Kulkarni, Pushkar M.; Deschamps, Jeffrey R.; Kelly, Melanie E. M.; Janero, David R.; Cascio, Maria G.; Stevenson, Lesley A.; Pertwee, Roger G.; Kenakin, Terrence P.; Denovan-Wright, Eileen M.; Thakur, Ganesh A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1188-1203</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The cannabinoid 1 receptor (CB1R) is one of the most widely expressed metabotropic G protein-coupled receptors in brain, and its participation in various (patho)physiol. processes has made CB1R activation a viable therapeutic modality.  Adverse psychotropic effects limit the clin. utility of CB1R orthosteric agonists and have promoted the search for CB1R pos. allosteric modulators (PAMs) with the promise of improved drug-like pharmacol. and enhanced safety over typical CB1R agonists.  In this study, the authors describe the synthesis and in vitro and ex vivo pharmacol. of the novel allosteric CB1R modulator GAT211 (racemic) and its resolved enantiomers, GAT228 (R) and GAT229 (S).  GAT211 engages CB1R allosteric site(s), enhances the binding of the orthosteric full agonist [3H]CP55,490 and reduces the binding of the orthosteric antagonist/inverse agonist [3H]SR141716A.  GAT211 displayed both PAM and agonist activity in HEK293A and Neuro2a cells expressing human recombinant CB1R (hCB1R) and, in mouse-brain membranes rich in native CB1R.  GAT211 also exhibited a strong PAM effect in isolated vas deferens endogenously expressing CB1R.  Each resolved and crystd. GAT211 enantiomer showed a markedly distinctive pharmacol. as a CB1R allosteric modulator.  In all biol. systems examd., GAT211's allosteric agonist activity resided with the R-(+)-enantiomer (GAT228), whereas its PAM activity resided with the S-(-)-enantiomer (GAT229), which lacked intrinsic activity.  These results constitute the first demonstration of enantiomer-selective CB1R pos. allosteric modulation and set a precedent whereby enantiomeric resoln. can decisively define the mol. pharmacol. of a CB1R allosteric ligand.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooxvSjynl3_LVg90H21EOLACvtfcHk0lgGehfjs42S4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1ehsrY%253D&md5=3b8735a91bd9026c10dea58687d339de</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.6b00310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.6b00310%26sid%3Dliteratum%253Aachs%26aulast%3DLaprairie%26aufirst%3DR.%2BB.%26aulast%3DKulkarni%26aufirst%3DP.%2BM.%26aulast%3DDeschamps%26aufirst%3DJ.%2BR.%26aulast%3DKelly%26aufirst%3DM.%2BE.%2BM.%26aulast%3DJanero%26aufirst%3DD.%2BR.%26aulast%3DCascio%26aufirst%3DM.%2BG.%26aulast%3DStevenson%26aufirst%3DL.%2BA.%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26aulast%3DKenakin%26aufirst%3DT.%2BP.%26aulast%3DDenovan-Wright%26aufirst%3DE.%2BM.%26aulast%3DThakur%26aufirst%3DG.%2BA.%26atitle%3DEnantiospecific%2520allosteric%2520modulation%2520of%2520cannabinoid%25201%2520receptor%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2017%26volume%3D8%26spage%3D1188%26epage%3D1203%26doi%3D10.1021%2Facschemneuro.6b00310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffer, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reggio, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, G. A.</span></span> <span> </span><span class="NLM_article-title">Identification of CB1 receptor allosteric sites using force-biased MMC simulated annealing and validation by structure-activity relationship studies</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1216</span>– <span class="NLM_lpage">1221</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00256</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00256" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlGjs7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1216-1221&author=D.+P.+Hurstauthor=S.+Garaiauthor=P.+M.+Kulkarniauthor=P.+C.+Schafferauthor=P.+H.+Reggioauthor=G.+A.+Thakur&title=Identification+of+CB1+receptor+allosteric+sites+using+force-biased+MMC+simulated+annealing+and+validation+by+structure-activity+relationship+studies&doi=10.1021%2Facsmedchemlett.9b00256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of CB1 Receptor Allosteric Sites Using Force-Biased MMC Simulated Annealing and Validation by Structure-Activity Relationship Studies</span></div><div class="casAuthors">Hurst, Dow P.; Garai, Sumanta; Kulkarni, Pushkar M.; Schaffer, Peter C.; Reggio, Patricia H.; Thakur, Ganesh A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1216-1221</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pos. allosteric modulation of the cannabinoid 1 receptor (CB1R) has demonstrated distinct therapeutic advantages that address several limitations assocd. with orthosteric agonism and has opened a promising therapeutic avenue for further drug development.  To advance the development of CB1R pos. allosteric modulators, it is important to understand the mol. architecture of CB1R allosteric site(s).  The goal of this work was to use Force-Biased MMC Simulated Annealing to identify binding sites for GAT228 (R), a partial allosteric agonist, and GAT229 (S), a pos. allosteric modulator (PAM) at the CB1R.  Our studies suggest that GAT228 binds in an intracellular (IC) TMH1-2-4 exosite that would allow this compd. to act as a CB1 allosteric agonist as well as a CB1 PAM.  In contrast, GAT229 binds at the extracellular (EC) ends of TMH2/3, just beneath the EC1 loop.  At this site, this compd. can act as CB1 PAM only.  Finally, these results were successfully validated through the synthesis and biochem. evaluation of a focused library of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovBTh9777IpLVg90H21EOLACvtfcHk0lgGehfjs42S4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlGjs7rK&md5=b031138e216be74d13caf799fc5f151c</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00256%26sid%3Dliteratum%253Aachs%26aulast%3DHurst%26aufirst%3DD.%2BP.%26aulast%3DGarai%26aufirst%3DS.%26aulast%3DKulkarni%26aufirst%3DP.%2BM.%26aulast%3DSchaffer%26aufirst%3DP.%2BC.%26aulast%3DReggio%26aufirst%3DP.%2BH.%26aulast%3DThakur%26aufirst%3DG.%2BA.%26atitle%3DIdentification%2520of%2520CB1%2520receptor%2520allosteric%2520sites%2520using%2520force-biased%2520MMC%2520simulated%2520annealing%2520and%2520validation%2520by%2520structure-activity%2520relationship%2520studies%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D1216%26epage%3D1221%26doi%3D10.1021%2Facsmedchemlett.9b00256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffer, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leo, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zagzoog, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janero, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abood, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmowitch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straiker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szczesniak, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denovan-Wright, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohmann, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reggio, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laprairie, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, G. A.</span></span> <span> </span><span class="NLM_article-title">Application of fluorine- and nitrogen-walk approaches: defining the structural and functional diversity of 2-phenylindole class of cannabinoid 1 receptor positive allosteric modulators</span>. <i>J. Med. Chem</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">542</span>– <span class="NLM_lpage">568</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01142</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01142" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1WktrbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=542-568&author=S.+Garaiauthor=P.+M.+Kulkarniauthor=P.+C.+Schafferauthor=L.+M.+Leoauthor=A.+L.+Brandtauthor=A.+Zagzoogauthor=T.+Blackauthor=X.+Linauthor=D.+P.+Hurstauthor=D.+R.+Janeroauthor=M.+E.+Aboodauthor=A.+Zimmowitchauthor=A.+Straikerauthor=R.+G.+Pertweeauthor=M.+Kellyauthor=A.+M.+Szczesniakauthor=E.+M.+Denovan-Wrightauthor=K.+Mackieauthor=A.+G.+Hohmannauthor=P.+H.+Reggioauthor=R.+B.+Laprairieauthor=G.+A.+Thakur&title=Application+of+fluorine-+and+nitrogen-walk+approaches%3A+defining+the+structural+and+functional+diversity+of+2-phenylindole+class+of+cannabinoid+1+receptor+positive+allosteric+modulators&doi=10.1021%2Facs.jmedchem.9b01142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Application of Fluorine- and Nitrogen-Walk Approaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of Cannabinoid 1 Receptor Positive Allosteric Modulators</span></div><div class="casAuthors">Garai, Sumanta; Kulkarni, Pushkar M.; Schaffer, Peter C.; Leo, Luciana M.; Brandt, Asher L.; Zagzoog, Ayat; Black, Tallan; Lin, Xiaoyan; Hurst, Dow P.; Janero, David R.; Abood, Mary E.; Zimmowitch, Anaelle; Straiker, Alex; Pertwee, Roger G.; Kelly, Melanie; Szczesniak, Anna-Maria; Denovan-Wright, Eileen M.; Mackie, Ken; Hohmann, Andrea G.; Reggio, Patricia H.; Laprairie, Robert B.; Thakur, Ganesh A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">542-568</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cannabinoid 1 receptor (CB1R) allosteric ligands hold far-reaching therapeutic promise.  We report application of fluoro- and nitrogen-walk approaches to enhance the drug-like properties of GAT211, a prototype CB1R allosteric agonist-pos. allosteric modulator (ago-PAM).  Several analogs exhibited improved functional potency (cAMP, arrestin2), metabolic stability, and aq. soly.  Two key analogs, GAT591 (6r) and GAT593 (6s), exhibited augmented allosteric-agonist and PAM activities in neuronal cultures, improved metabolic stability, and enhanced orthosteric agonist binding (CP55,940).  Both also exhibited good analgesic potency in the CFA inflammatory-pain model with longer duration of action over GAT211 while devoid of adverse cannabimimetic effects.  Another analog, GAT592 (9j), exhibited moderate ago-PAM potency and improved aq. soly. with therapeutic redn. of intraocular pressure in murine glaucoma models.  The SAR findings and the enhanced allosteric activity in this class of allosteric modulators were accounted for in our recently developed computational model for CB1R allosteric activation and pos. allosteric modulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOfHY8Dr6ugbVg90H21EOLACvtfcHk0lisOroKsMFAyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1WktrbF&md5=42e8edb208751b040c3f6d7481381834</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01142%26sid%3Dliteratum%253Aachs%26aulast%3DGarai%26aufirst%3DS.%26aulast%3DKulkarni%26aufirst%3DP.%2BM.%26aulast%3DSchaffer%26aufirst%3DP.%2BC.%26aulast%3DLeo%26aufirst%3DL.%2BM.%26aulast%3DBrandt%26aufirst%3DA.%2BL.%26aulast%3DZagzoog%26aufirst%3DA.%26aulast%3DBlack%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DHurst%26aufirst%3DD.%2BP.%26aulast%3DJanero%26aufirst%3DD.%2BR.%26aulast%3DAbood%26aufirst%3DM.%2BE.%26aulast%3DZimmowitch%26aufirst%3DA.%26aulast%3DStraiker%26aufirst%3DA.%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26aulast%3DKelly%26aufirst%3DM.%26aulast%3DSzczesniak%26aufirst%3DA.%2BM.%26aulast%3DDenovan-Wright%26aufirst%3DE.%2BM.%26aulast%3DMackie%26aufirst%3DK.%26aulast%3DHohmann%26aufirst%3DA.%2BG.%26aulast%3DReggio%26aufirst%3DP.%2BH.%26aulast%3DLaprairie%26aufirst%3DR.%2BB.%26aulast%3DThakur%26aufirst%3DG.%2BA.%26atitle%3DApplication%2520of%2520fluorine-%2520and%2520nitrogen-walk%2520approaches%253A%2520defining%2520the%2520structural%2520and%2520functional%2520diversity%2520of%25202-phenylindole%2520class%2520of%2520cannabinoid%25201%2520receptor%2520positive%2520allosteric%2520modulators%26jtitle%3DJ.%2520Med.%2520Chem%26date%3D2020%26volume%3D63%26spage%3D542%26epage%3D568%26doi%3D10.1021%2Facs.jmedchem.9b01142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cairns, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szczesniak, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straiker, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldridge, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, M. E. M.</span></span> <span> </span><span class="NLM_article-title">The in vivo effects of the CB(1)-positive allosteric modulator GAT229 on intraocular pressure in ocular normotensive and hypertensive mice</span>. <i>J. Ocul. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">582</span>– <span class="NLM_lpage">590</span>, <span class="refDoi"> DOI: 10.1089/jop.2017.0037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1089%2Fjop.2017.0037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=28719234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFygsb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2017&pages=582-590&author=E.+A.+Cairnsauthor=A.+M.+Szczesniakauthor=A.+J.+Straikerauthor=P.+M.+Kulkarniauthor=R.+G.+Pertweeauthor=G.+A.+Thakurauthor=W.+H.+Baldridgeauthor=M.+E.+M.+Kelly&title=The+in+vivo+effects+of+the+CB%281%29-positive+allosteric+modulator+GAT229+on+intraocular+pressure+in+ocular+normotensive+and+hypertensive+mice&doi=10.1089%2Fjop.2017.0037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The In Vivo Effects of the CB1-Positive Allosteric Modulator GAT229 on Intraocular Pressure in Ocular Normotensive and Hypertensive Mice</span></div><div class="casAuthors">Cairns, Elizabeth A.; Szczesniak, Anna-Maria; Straiker, Alex J.; Kulkarni, Pushkar M.; Pertwee, Roger G.; Thakur, Ganesh A.; Baldridge, William H.; Kelly, Melanie E. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Ocular Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">582-590</span>CODEN:
                <span class="NLM_cas:coden">JOPTFU</span>;
        ISSN:<span class="NLM_cas:issn">1080-7683</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Purpose: Orthosteric cannabinoid receptor 1 (CB1) activation leads to decreases in intraocular pressure (IOP).  However, use of orthosteric CB1 agonists chronically has several disadvantages, limiting their usefulness as clin. relevant drugs.  Allosteric modulators interact with topog. distinct sites to orthosteric ligands and may be useful to circumvent some of these disadvantages.  The purpose of this study was to investigate the effects of the novel CB1-pos. allosteric modulator (PAM) GAT229 on IOP.  Methods: IOP was measured using rebound tonometry in anesthetized normotensive C57Bl/6 mice and in a genetic model of ocular hypertension [nose, eyes, ears (nee) mice] before drug administration, and at 1, 6, and 12 h thereafter.  Results: In normotensive mice, topical administration of 5 μL GAT229 alone at either 0.2% or 2% did not reduce IOP.  However, a subthreshold dose (0.25%) of the nonselective orthosteric CB1 agonist WIN 55,212-2, when combined with 0.2% GAT229, significantly reduced IOP compared with vehicle at 6 and 12 h.  Similarly, combination of subthreshold Δ9-tetrahydrocannabinol (a nonselective orthosteric CB1 agonist; 1 mg/kg) with topical 0.2% GAT229 produced IOP lowering at 6 h.  In nee mice, administration of topical 0.2% GAT229 or 10 mg/kg GAT229 alone was sufficient to lower IOP at 6 and 12 h, and 12 h, resp.  Conclusions: The CB1 PAM GAT229 reduces IOP in ocular hypertensive mice and enhanced CB1-mediated IOP redn. when combined with subthreshold CB1 orthosteric ligands in normotensive mice.  Administration of CB1 PAMs may provide a novel approach to reduce IOP with fewer of the disadvantages assocd. with orthosteric CB1 activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg-prZqx6SbLVg90H21EOLACvtfcHk0lisOroKsMFAyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFygsb%252FN&md5=e371ae4c2384fe7ad9080b14f55a114d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1089%2Fjop.2017.0037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fjop.2017.0037%26sid%3Dliteratum%253Aachs%26aulast%3DCairns%26aufirst%3DE.%2BA.%26aulast%3DSzczesniak%26aufirst%3DA.%2BM.%26aulast%3DStraiker%26aufirst%3DA.%2BJ.%26aulast%3DKulkarni%26aufirst%3DP.%2BM.%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26aulast%3DThakur%26aufirst%3DG.%2BA.%26aulast%3DBaldridge%26aufirst%3DW.%2BH.%26aulast%3DKelly%26aufirst%3DM.%2BE.%2BM.%26atitle%3DThe%2520in%2520vivo%2520effects%2520of%2520the%2520CB%25281%2529-positive%2520allosteric%2520modulator%2520GAT229%2520on%2520intraocular%2520pressure%2520in%2520ocular%2520normotensive%2520and%2520hypertensive%2520mice%26jtitle%3DJ.%2520Ocul.%2520Pharmacol.%2520Ther.%26date%3D2017%26volume%3D33%26spage%3D582%26epage%3D590%26doi%3D10.1089%2Fjop.2017.0037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slivicki, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohmann, A. G.</span></span> <span> </span><span class="NLM_article-title">Positive allosteric modulation of cannabinoid receptor type 1 suppresses pathological pain without producing tolerance or dependence</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">722</span>– <span class="NLM_lpage">733</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2017.06.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1016%2Fj.biopsych.2017.06.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=28823711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlKnu7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2018&pages=722-733&author=R.+A.+Slivickiauthor=Z.+Xuauthor=P.+M.+Kulkarniauthor=R.+G.+Pertweeauthor=K.+Mackieauthor=G.+A.+Thakurauthor=A.+G.+Hohmann&title=Positive+allosteric+modulation+of+cannabinoid+receptor+type+1+suppresses+pathological+pain+without+producing+tolerance+or+dependence&doi=10.1016%2Fj.biopsych.2017.06.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence</span></div><div class="casAuthors">Slivicki, Richard A.; Xu, Zhili; Kulkarni, Pushkar M.; Pertwee, Roger G.; Mackie, Ken; Thakur, Ganesh A.; Hohmann, Andrea G.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">722-733</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Activation of cannabinoid CB1 receptors suppresses pathol. pain but also produces unwanted central side effects.  We hypothesized that a pos. allosteric modulator of CB1 signaling would suppress inflammatory and neuropathic pain without producing cannabimimetic effects or phys. dependence.  We also asked whether a CB1 pos. allosteric modulator would synergize with inhibitors of endocannabinoid deactivation and/or an orthosteric cannabinoid agonist.  GAT211, a novel CB1 pos. allosteric modulator, was evaluated for antinociceptive efficacy and tolerance in models of neuropathic and/or inflammatory pain.  Cardinal signs of direct CB1-receptor activation were evaluated together with the propensity to induce reward or aversion and phys. dependence.  Comparisons were made with inhibitors of endocannabinoid deactivation (JZL184, URB597) or an orthosteric cannabinoid agonist (WIN55,212-2).  All studies used 4 to 11 subjects per group.  GAT211 suppressed allodynia induced by complete Freund's adjuvant and the chemotherapeutic agent paclitaxel in wild-type but not CB1 knockout mice.  GAT211 did not impede paclitaxel-induced tumor cell line toxicity.  GAT211 did not produce cardinal signs of direct CB1-receptor activation in the presence or absence of pathol. pain.  GAT211 produced synergistic antiallodynic effects with fatty acid amide hydrolase and monoacylglycerol lipase inhibitors in paclitaxel-treated mice.  Therapeutic efficacy was preserved over 19 days of chronic dosing with GAT211, but it was not preserved with the monoacylglycerol lipase inhibitor JZL184.  The CB1 antagonist rimonabant pptd. withdrawal in mice treated chronically with WIN55,212-2 but not in mice treated with GAT211.  GAT211 did not induce conditioned place preference or aversion.  Pos. allosteric modulation of CB1-receptor signaling shows promise as a safe and effective analgesic strategy that lacks tolerance, dependence, and abuse liability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGywGwzs6XErVg90H21EOLACvtfcHk0liKQU1c6BphiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlKnu7fF&md5=836de2b8e00dc1db269a2bf9247b26bc</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2017.06.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2017.06.032%26sid%3Dliteratum%253Aachs%26aulast%3DSlivicki%26aufirst%3DR.%2BA.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DKulkarni%26aufirst%3DP.%2BM.%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26aulast%3DMackie%26aufirst%3DK.%26aulast%3DThakur%26aufirst%3DG.%2BA.%26aulast%3DHohmann%26aufirst%3DA.%2BG.%26atitle%3DPositive%2520allosteric%2520modulation%2520of%2520cannabinoid%2520receptor%2520type%25201%2520suppresses%2520pathological%2520pain%2520without%2520producing%2520tolerance%2520or%2520dependence%26jtitle%3DBiol.%2520Psychiatry%26date%3D2018%26volume%3D84%26spage%3D722%26epage%3D733%26doi%3D10.1016%2Fj.biopsych.2017.06.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitjavila, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanato, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greig, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straiker, A.</span></span> <span> </span><span class="NLM_article-title">Enantiomer-specific positive allosteric modulation of CB(1) signaling in autaptic hippocampal neurons</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">475</span>– <span class="NLM_lpage">481</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2017.11.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1016%2Fj.phrs.2017.11.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=29158048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFaht73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2018&pages=475-481&author=J.+Mitjavilaauthor=D.+Yinauthor=P.+M.+Kulkarniauthor=C.+Zanatoauthor=G.+A.+Thakurauthor=R.+Rossauthor=I.+Greigauthor=K.+Mackieauthor=A.+Straiker&title=Enantiomer-specific+positive+allosteric+modulation+of+CB%281%29+signaling+in+autaptic+hippocampal+neurons&doi=10.1016%2Fj.phrs.2017.11.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Enantiomer-specific positive allosteric modulation of CB1 signaling in autaptic hippocampal neurons</span></div><div class="casAuthors">Mitjavila, Jose; Yin, Danielle; Kulkarni, Pushkar M.; Zanato, Chiara; Thakur, Ganesh A.; Ross, Ruth; Greig, Iain; Mackie, Ken; Straiker, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">475-481</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The cannabinoid signaling system is found throughout the CNS and its involvement in several pathol. processes makes it an attractive therapeutic target.  Because orthosteric CB1 cannabinoid receptor ligands have undesirable adverse effects there has been great interest in the development of allosteric modulators - both neg. (NAMs) and pos. (PAMs) - of these receptors.  NAMs of CB1 appeared first on the scene, followed more recently by PAMs.  Because allosteric modulation can vary depending on the orthosteric ligand it is important to study their function in a system that employs endogenous cannabinoids.  We have recently surveyed first generation NAMs using cultured autaptic hippocampal neurons.  These neurons express depolarization induced suppression of excitation (DSE), a form of synaptic plasticity that is mediated by CB1 and 2-arachidonoyl glycerol (2-AG); they are therefore an excellent neuronal model of endogenous cannabinoid signaling in which to test CB1 modulators.  In this study we find that while two related compds., GAT211 and ZCZ011, each show PAM-like responses in autaptic hippocampal neurons, they also exhibit complex pharmacol.  Notably we were able to sep. the PAM- and agonist-like responses of GAT211 by examg. the enantiomers of this racemic compd.: GAT228 and GAT229.  We find that GAT229 exhibits PAM-like behavior while GAT228 appears to directly activate the CB1 receptor.  Both GAT229 and ZCZ011 represent the first PAMs that we have found to be effective in using this 2-AG utilizing neuronal model system.  Because these compds. may exhibit both probe selectivity and biased signaling it will be important to test them with anandamide as well as other signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqP6o0WGEOh57Vg90H21EOLACvtfcHk0liKQU1c6BphiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFaht73K&md5=ddf0047d224cadbd6f5449f325dfee6e</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2017.11.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2017.11.019%26sid%3Dliteratum%253Aachs%26aulast%3DMitjavila%26aufirst%3DJ.%26aulast%3DYin%26aufirst%3DD.%26aulast%3DKulkarni%26aufirst%3DP.%2BM.%26aulast%3DZanato%26aufirst%3DC.%26aulast%3DThakur%26aufirst%3DG.%2BA.%26aulast%3DRoss%26aufirst%3DR.%26aulast%3DGreig%26aufirst%3DI.%26aulast%3DMackie%26aufirst%3DK.%26aulast%3DStraiker%26aufirst%3DA.%26atitle%3DEnantiomer-specific%2520positive%2520allosteric%2520modulation%2520of%2520CB%25281%2529%2520signaling%2520in%2520autaptic%2520hippocampal%2520neurons%26jtitle%3DPharmacol.%2520Res.%26date%3D2018%26volume%3D129%26spage%3D475%26epage%3D481%26doi%3D10.1016%2Fj.phrs.2017.11.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laprairie, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagher, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rourke, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zrein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cairns, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, M. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinal, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denovan-Wright, E. M.</span></span> <span> </span><span class="NLM_article-title">Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington’s disease in the R6/2 mouse model</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2019.03.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1016%2Fj.neuropharm.2019.03.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=30940536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmvFSntLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2019&pages=1-12&author=R.+B.+Laprairieauthor=A.+M.+Bagherauthor=J.+L.+Rourkeauthor=A.+Zreinauthor=E.+A.+Cairnsauthor=M.+E.+M.+Kellyauthor=C.+J.+Sinalauthor=P.+M.+Kulkarniauthor=G.+A.+Thakurauthor=E.+M.+Denovan-Wright&title=Positive+allosteric+modulation+of+the+type+1+cannabinoid+receptor+reduces+the+signs+and+symptoms+of+Huntington%E2%80%99s+disease+in+the+R6%2F2+mouse+model&doi=10.1016%2Fj.neuropharm.2019.03.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model</span></div><div class="casAuthors">Laprairie, Robert B.; Bagher, Amina M.; Rourke, Jillian L.; Zrein, Adel; Cairns, Elizabeth A.; Kelly, Melanie E. M.; Sinal, Christopher J.; Kulkarni, Pushkar M.; Thakur, Ganesh A.; Denovan-Wright, Eileen M.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Huntington's disease (HD) is an inherited progressive neurodegenerative disease characterized by motor, cognitive, and behavioral changes.  One of the earliest changes to occur in HD is a redn. in cannabinoid 1 receptor (CB1) levels in the striatum, which is strongly correlated with HD pathogenesis.  CB1 pos. allosteric modulators (PAM) enhance receptor affinity for, and efficacy of activation by, orthosteric ligands, including the endocannabinoids anandamide and 2-arachidonoylglycerol.  The goal of this study was to det. whether the recently characterized CB1 allosteric modulators GAT211 (racemic), GAT228 (R-enantiomer), and GAT229 (S-enantiomer), affected the signs and symptoms of HD.  GAT211, GAT228, and GAT229 were evaluated in normal and HD cell models, and in a transgenic mouse model of HD (7-wk-old male R6/2 mice, 10 mg/kg/d, 21 d, i.p.).  GAT229 was a CB1 PAM that improved cell viability in HD cells and improved motor coordination, delayed symptom onset, and normalized gene expression in R6/2 HD mice.  GAT228 was an allosteric agonist that did not enhance endocannabinoid signaling or change symptom progression in R6/2 mice.  GAT211 displayed intermediate effects between its enantiomers.  Changes in gene expression, and not protein, were quantified in R6/2 HD mice because HD pathogenesis is assocd. with dysregulation of mRNA levels.  The data presented here provide the first proof of principle for the use of CB1 PAMs to treat the signs and symptoms of HD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSECuO-Cj0_7Vg90H21EOLACvtfcHk0liKQU1c6BphiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmvFSntLc%253D&md5=87a0af0b3a176875c6859e95d65f4fa4</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2019.03.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2019.03.033%26sid%3Dliteratum%253Aachs%26aulast%3DLaprairie%26aufirst%3DR.%2BB.%26aulast%3DBagher%26aufirst%3DA.%2BM.%26aulast%3DRourke%26aufirst%3DJ.%2BL.%26aulast%3DZrein%26aufirst%3DA.%26aulast%3DCairns%26aufirst%3DE.%2BA.%26aulast%3DKelly%26aufirst%3DM.%2BE.%2BM.%26aulast%3DSinal%26aufirst%3DC.%2BJ.%26aulast%3DKulkarni%26aufirst%3DP.%2BM.%26aulast%3DThakur%26aufirst%3DG.%2BA.%26aulast%3DDenovan-Wright%26aufirst%3DE.%2BM.%26atitle%3DPositive%2520allosteric%2520modulation%2520of%2520the%2520type%25201%2520cannabinoid%2520receptor%2520reduces%2520the%2520signs%2520and%2520symptoms%2520of%2520Huntington%25E2%2580%2599s%2520disease%2520in%2520the%2520R6%252F2%2520mouse%2520model%26jtitle%3DNeuropharmacology%26date%3D2019%26volume%3D151%26spage%3D1%26epage%3D12%26doi%3D10.1016%2Fj.neuropharm.2019.03.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neuhofer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chioma, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beloate, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalivas, P. W.</span></span> <span> </span><span class="NLM_article-title">The loss of NMDAR-dependent LTD following cannabinoid self-administration is restored by positive allosteric modulation of CB1 receptors</span>. <i>Addict. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span>, <span class="NLM_elocation-id">e12843</span> <span class="refDoi"> DOI: 10.1111/adb.12843</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1111%2Fadb.12843" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=31733097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit1elurnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&author=D.+Neuhoferauthor=S.+M.+Spencerauthor=V.+C.+Chiomaauthor=L.+N.+Beloateauthor=D.+Schwartzauthor=P.+W.+Kalivas&title=The+loss+of+NMDAR-dependent+LTD+following+cannabinoid+self-administration+is+restored+by+positive+allosteric+modulation+of+CB1+receptors&doi=10.1111%2Fadb.12843"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">The loss of NMDAR-dependent LTD following cannabinoid self-administration is restored by positive allosteric modulation of CB1 receptors</span></div><div class="casAuthors">Neuhofer, Daniela; Spencer, Sade M.; Chioma, Vivian C.; Beloate, Lauren N.; Schwartz, Danielle; Kalivas, Peter W.</div><div class="citationInfo"><span class="NLM_cas:title">Addiction Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e12843</span>CODEN:
                <span class="NLM_cas:coden">ADBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1369-1600</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Glutamatergic plasticity in the nucleus accumbens core (NAcore) is a key neuronal process in appetitive learning and contributes to pathologies such as drug addiction.  Understanding how this plasticity factors into cannabis addiction and relapse has been hampered by the lack of a rodent model of cannabis self-administration.  We used i.v. self-administration of two constituents of cannabis, Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) to examine how contingent cannabis use and cue-induced cannabinoid-seeking alters glutamatergic neurotransmission and synaptic plasticity in NAcore.  NMDA receptor (NMDAR)-dependent long-term depression (LTD) in the NAcore was lost after cannabinoid, but not sucrose self-administration.  Surprisingly, when rats underwent cue-induced cannabinoid seeking, LTD was restored.  Loss of LTD was accompanied by desensitization of cannabinoid receptor 1 (CB1R).  CB1R are positioned to regulate synaptic plasticity by being expressed on glutamatergic terminals and neg. regulating presynaptic excitability and glutamate release.  Supporting this possibility, LTD was restored by promoting CB1R signaling with the CB1 pos. allosteric modulator GAT211.  These data implicate NAcore CB1R as crit. regulators of metaplasticity induced by cannabis self-administration and the cues predicting cannabis availability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEDquDs9RsC7Vg90H21EOLACvtfcHk0lgXmVeEjRDu7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit1elurnL&md5=6af1e44992e78cb475f6f07fb5362ae3</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1111%2Fadb.12843&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fadb.12843%26sid%3Dliteratum%253Aachs%26aulast%3DNeuhofer%26aufirst%3DD.%26aulast%3DSpencer%26aufirst%3DS.%2BM.%26aulast%3DChioma%26aufirst%3DV.%2BC.%26aulast%3DBeloate%26aufirst%3DL.%2BN.%26aulast%3DSchwartz%26aufirst%3DD.%26aulast%3DKalivas%26aufirst%3DP.%2BW.%26atitle%3DThe%2520loss%2520of%2520NMDAR-dependent%2520LTD%2520following%2520cannabinoid%2520self-administration%2520is%2520restored%2520by%2520positive%2520allosteric%2520modulation%2520of%2520CB1%2520receptors%26jtitle%3DAddict.%2520Biol.%26date%3D2020%26volume%3D25%26doi%3D10.1111%2Fadb.12843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thapa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cairns, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szczesniak, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straiker, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, M. E. M.</span></span> <span> </span><span class="NLM_article-title">Allosteric cannabinoid receptor 1 (CB1) ligands reduce ocular pain and inflammation</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span>, <span class="NLM_elocation-id">417</span> <span class="refDoi"> DOI: 10.3390/molecules25020417</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.3390%2Fmolecules25020417" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktVSjtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&author=D.+Thapaauthor=E.+A.+Cairnsauthor=A.+M.+Szczesniakauthor=P.+M.+Kulkarniauthor=A.+J.+Straikerauthor=G.+A.+Thakurauthor=M.+E.+M.+Kelly&title=Allosteric+cannabinoid+receptor+1+%28CB1%29+ligands+reduce+ocular+pain+and+inflammation&doi=10.3390%2Fmolecules25020417"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric cannabinoid receptor 1 (CB1) ligands reduce ocular pain and inflammation</span></div><div class="casAuthors">Thapa, Dinesh; Cairns, Elizabeth A.; Szczesniak, Anna-Maria; Kulkarni, Pushkar M.; Straiker, Alex J.; Thakur, Ganesh A.; Kelly, Melanie E. M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">417</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Cannabinoid receptor 1 (CB1) activation has been reported to reduce transient receptor potential cation channel subfamily V member 1 (TRPV1)-induced inflammatory responses and is anti-nociceptive and anti-inflammatory in corneal injury.  We examd. whether allosteric ligands, can modulate CB1 signaling to reduce pain and inflammation in corneal hyperalgesia.  Corneal hyperalgesia was generated by chem. cauterization of cornea in wildtype and CB2 knockout (CB2-/-) mice.  The novel racemic CB1 allosteric ligand GAT211 and its enantiomers GAT228 and GAT229 were examd. alone or in combination with the orthosteric CB1 agonist delta8 -tetrahydrocannabinol (delta8 -THC).  Pain responses were assessed following capsaicin (1 microM) stimulation of injured corneas at 6 h post-cauterization.  Corneal neutrophil infiltration was also analyzed.  GAT228, but not GAT229 or GAT211, reduced pain scores in response to capsaicin stimulation.  Combination treatments of 0.5% GAT229 or 1% GAT211 with subthreshold delta8 -THC (0.4%) significantly reduced pain scores following capsaicin stimulation.  The anti-nociceptive effects of both GAT229 and GAT228 were blocked with CB1 antagonist AM251, but remained unaffected in CB2-/- mice.  Two percent GAT228, or the combination of 0.2% delta8 -THC with 0.5% GAT229 also significantly reduced corneal inflammation.  CB1 allosteric ligands could offer a novel approach for treating corneal pain and inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_doQTvEiJSbVg90H21EOLACvtfcHk0lgXmVeEjRDu7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktVSjtbs%253D&md5=3e5bf9cc7c7a43bcb10fece203eacf55</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.3390%2Fmolecules25020417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules25020417%26sid%3Dliteratum%253Aachs%26aulast%3DThapa%26aufirst%3DD.%26aulast%3DCairns%26aufirst%3DE.%2BA.%26aulast%3DSzczesniak%26aufirst%3DA.%2BM.%26aulast%3DKulkarni%26aufirst%3DP.%2BM.%26aulast%3DStraiker%26aufirst%3DA.%2BJ.%26aulast%3DThakur%26aufirst%3DG.%2BA.%26aulast%3DKelly%26aufirst%3DM.%2BE.%2BM.%26atitle%3DAllosteric%2520cannabinoid%2520receptor%25201%2520%2528CB1%2529%2520ligands%2520reduce%2520ocular%2520pain%2520and%2520inflammation%26jtitle%3DMolecules%26date%3D2020%26volume%3D25%26doi%3D10.3390%2Fmolecules25020417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slivicki, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mali, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crystal, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohmann, A. G.</span></span> <span> </span><span class="NLM_article-title">Positive allosteric modulation of CB(1) cannabinoid receptor signaling enhances morphine antinociception and attenuates morphine tolerance without enhancing morphine- induced dependence or reward</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">54</span> <span class="refDoi"> DOI: 10.3389/fnmol.2020.00054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.3389%2Ffnmol.2020.00054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=32410959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlCiurnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2020&author=R.+A.+Slivickiauthor=V.+Iyerauthor=S.+S.+Maliauthor=S.+Garaiauthor=G.+A.+Thakurauthor=J.+D.+Crystalauthor=A.+G.+Hohmann&title=Positive+allosteric+modulation+of+CB%281%29+cannabinoid+receptor+signaling+enhances+morphine+antinociception+and+attenuates+morphine+tolerance+without+enhancing+morphine-+induced+dependence+or+reward&doi=10.3389%2Ffnmol.2020.00054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Positive allosteric modulation of CB1 cannabinoid receptor signaling enhances morphine antinociception and attenuates morphine tolerance without enhancing morphine- induced dependence or reward</span></div><div class="casAuthors">Slivicki, Richard A.; Iyer, Vishakh; Mali, Sonali S.; Garai, Sumanta; Thakur, Ganesh A.; Crystal, Jonathon D.; Hohmann, Andrea G.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">54</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Opioid analgesics represent a crit. treatment for chronic pain in the analgesic ladder of the World Health Organization.  However, their use can result in a no. of unwanted side-effects including incomplete efficacy, constipation, phys. dependence, and overdose liability.  Cannabinoids enhance the pain-relieving effects of opioids in preclin. studies and dampen unwanted side-effects resulting from excessive opioid intake.  We recently reported that a CB1 pos. allosteric modulator (PAM) exhibits antinociceptive efficacy in models of pathol. pain and lacks the adverse side effects of direct CB1 receptor activation.  In the present study, we evaluated whether a CB1 PAM would enhance morphine's therapeutic efficacy in an animal model of chemotherapyinduced neuropathic pain and characterized its impact on unwanted side-effects assocd. with chronic opioid administration.  In paclitaxel-treated mice, both the CB1 PAM GAT211 and the opioid analgesic morphine reduced paclitaxel-induced behavioral hypersensitivities to mech. and cold stimulation in a dose-dependent manner.  Isobolog. anal. revealed that combinations of GAT211 and morphine resulted in anti-allodynic synergism.  In paclitaxel-treated mice, a sub-threshold dose of GAT211 prevented the development of tolerance to the anti-allodynic effects of morphine over 20 days of once daily dosing.  However, GAT211 did not reliably alter somatic withdrawal signs (i.e., jumps, paw tremors) in morphine-dependent neuropathic mice challenged with naloxone.  In otherwise na.ovrddot.ive mice, GAT211 also prolonged antinociceptive efficacy of morphine in the tail-flick test and reduced the overall right-ward shift in the ED50 for morphine to produce antinociception in the tail-flick test, consistent with attenuation of morphine tolerance.  Pretreatment with GAT211 did not alter somatic signs of μ opioid receptor dependence in mice rendered dependent upon morphine via s.c. implantation of a morphine pellet.  Moreover, GAT211 did not reliably alter μ-opioid receptor-mediated reward as measured by conditioned place preference to morphine.  Our results suggest that a CB1 PAM may be beneficial in enhancing and prolonging the therapeutic properties of opioids while potentially sparing unwanted side-effects (e.g., tolerance) that occur with repeated opioid treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf78yT9Yo5I7Vg90H21EOLACvtfcHk0li_aQ9d_FLdjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlCiurnI&md5=faabe8b5ba0f5fba03d10fba5a9eaaab</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2020.00054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2020.00054%26sid%3Dliteratum%253Aachs%26aulast%3DSlivicki%26aufirst%3DR.%2BA.%26aulast%3DIyer%26aufirst%3DV.%26aulast%3DMali%26aufirst%3DS.%2BS.%26aulast%3DGarai%26aufirst%3DS.%26aulast%3DThakur%26aufirst%3DG.%2BA.%26aulast%3DCrystal%26aufirst%3DJ.%2BD.%26aulast%3DHohmann%26aufirst%3DA.%2BG.%26atitle%3DPositive%2520allosteric%2520modulation%2520of%2520CB%25281%2529%2520cannabinoid%2520receptor%2520signaling%2520enhances%2520morphine%2520antinociception%2520and%2520attenuates%2520morphine%2520tolerance%2520without%2520enhancing%2520morphine-%2520induced%2520dependence%2520or%2520reward%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2020%26volume%3D13%26doi%3D10.3389%2Ffnmol.2020.00054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Datta, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilpin, N. W.</span></span> <span> </span><span class="NLM_article-title">Positive allosteric modulation of the cannabinoid type-1 receptor (CB1R) in periaqueductal gray (PAG) antagonizes anti-nociceptive and cellular effects of a mu-opioid receptor agonist in morphine-withdrawn rats</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>237</i></span>,  <span class="NLM_fpage">3729</span>– <span class="NLM_lpage">3739</span>, <span class="refDoi"> DOI: 10.1007/s00213-020-05650-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1007%2Fs00213-020-05650-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=32857187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A280%3ADC%252BB38bhs1WisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=237&publication_year=2020&pages=3729-3739&author=U.+Dattaauthor=L.+K.+Kelleyauthor=J.+W.+Middletonauthor=N.+W.+Gilpin&title=Positive+allosteric+modulation+of+the+cannabinoid+type-1+receptor+%28CB1R%29+in+periaqueductal+gray+%28PAG%29+antagonizes+anti-nociceptive+and+cellular+effects+of+a+mu-opioid+receptor+agonist+in+morphine-withdrawn+rats&doi=10.1007%2Fs00213-020-05650-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Positive allosteric modulation of the cannabinoid type-1 receptor (CB1R) in periaqueductal gray (PAG) antagonizes anti-nociceptive and cellular effects of a mu-opioid receptor agonist in morphine-withdrawn rats</span></div><div class="casAuthors">Datta Udita; Kelley Leslie K; Gilpin Nicholas W; Datta Udita; Middleton Jason W; Middleton Jason W; Gilpin Nicholas W; Middleton Jason W; Gilpin Nicholas W; Gilpin Nicholas W</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">237</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3729-3739</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Opioid drugs are a first-line treatment for severe acute pain and other chronic pain conditions, but long-term opioid drug use produces opioid-induced hyperalgesia (OIH).  Co-administration of cannabinoids with opioid receptor agonists produce anti-nociceptive synergy, but cannabinoid receptor agonists may also produce undesirable side effects.  Therefore, positive allosteric modulators (PAM) of cannabinoid type-1 receptors (CB1R) may provide an option reducing pain and/or enhancing the anti-hyperalgesic effects of opioids without the side effects, tolerance, and dependence observed with the use of ligands that target the orthosteric binding sites.  This study tested GAT211, a PAM of cannabinoid type-1 receptors (CB1R), for its ability to enhance the anti-hyperalgesic effects of the mu-opioid receptor (MOR) agonist DAMGO in rats treated chronically with morphine (or saline) and tested during withdrawal.  We tested the effects of intra-periaqueductal gray (PAG) injections of (1) DAMGO, (2) GAT211, or (3) DAMGO + GAT211 on thermal nociception in chronic morphine-treated rats that were hyperalgesic and also in saline-treated control rats.  We used slice electrophysiology to test the effects of DAMGO/GAT211 bath application on synaptic transmission in the vlPAG.  Intra-PAG DAMGO infusions dose-dependently reversed chronic morphine-induced hyperalgesia, but intra-PAG GAT211 did not alter nociception at the doses we tested.  When co-administered into the PAG, GAT211 antagonized the anti-nociceptive effects of DAMGO in morphine-withdrawn rats.  DAMGO suppressed synaptic inhibition in the vlPAG of brain slices taken from saline- and morphine-treated rats, and GAT211 attenuated DAMGO-induced suppression of synaptic inhibition in vlPAG neurons via actions at CB1R.  These findings show that positive allosteric modulation of CB1R antagonizes the behavioral and cellular effects of a MOR agonist in the PAG of rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRmNuShziTDJQHqQV89nF-2fW6udTcc2ebzuNH0qyYe17ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38bhs1WisA%253D%253D&md5=68c3282a5ab5a1a7da020a1f1c651791</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1007%2Fs00213-020-05650-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-020-05650-5%26sid%3Dliteratum%253Aachs%26aulast%3DDatta%26aufirst%3DU.%26aulast%3DKelley%26aufirst%3DL.%2BK.%26aulast%3DMiddleton%26aufirst%3DJ.%2BW.%26aulast%3DGilpin%26aufirst%3DN.%2BW.%26atitle%3DPositive%2520allosteric%2520modulation%2520of%2520the%2520cannabinoid%2520type-1%2520receptor%2520%2528CB1R%2529%2520in%2520periaqueductal%2520gray%2520%2528PAG%2529%2520antagonizes%2520anti-nociceptive%2520and%2520cellular%2520effects%2520of%2520a%2520mu-opioid%2520receptor%2520agonist%2520in%2520morphine-withdrawn%2520rats%26jtitle%3DPsychopharmacology%26date%3D2020%26volume%3D237%26spage%3D3729%26epage%3D3739%26doi%3D10.1007%2Fs00213-020-05650-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schaffer, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janero, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, G. A.</span></span> <span> </span><span class="NLM_article-title">Focused structure-activity relationship profiling around the 2-phenylindole scaffold of a cannabinoid type-1 receptor agonist-positive allosteric modulator: site-III aromatic-ring congeners with enhanced activity and solubility</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>28</i></span>, <span class="NLM_elocation-id">115727</span> <span class="refDoi"> DOI: 10.1016/j.bmc.2020.115727</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1016%2Fj.bmc.2020.115727" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2020&author=P.+C.+Schafferauthor=P.+M.+Kulkarniauthor=D.+R.+Janeroauthor=G.+A.+Thakur&title=Focused+structure-activity+relationship+profiling+around+the+2-phenylindole+scaffold+of+a+cannabinoid+type-1+receptor+agonist-positive+allosteric+modulator%3A+site-III+aromatic-ring+congeners+with+enhanced+activity+and+solubility&doi=10.1016%2Fj.bmc.2020.115727"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2020.115727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2020.115727%26sid%3Dliteratum%253Aachs%26aulast%3DSchaffer%26aufirst%3DP.%2BC.%26aulast%3DKulkarni%26aufirst%3DP.%2BM.%26aulast%3DJanero%26aufirst%3DD.%2BR.%26aulast%3DThakur%26aufirst%3DG.%2BA.%26atitle%3DFocused%2520structure-activity%2520relationship%2520profiling%2520around%2520the%25202-phenylindole%2520scaffold%2520of%2520a%2520cannabinoid%2520type-1%2520receptor%2520agonist-positive%2520allosteric%2520modulator%253A%2520site-III%2520aromatic-ring%2520congeners%2520with%2520enhanced%2520activity%2520and%2520solubility%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D28%26doi%3D10.1016%2Fj.bmc.2020.115727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schönherr, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cernak, T.</span></span> <span> </span><span class="NLM_article-title">Profound methyl effects in drug discovery and a call for new C-H methylation reactions</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">12256</span>– <span class="NLM_lpage">12267</span>, <span class="refDoi"> DOI: 10.1002/anie.201303207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1002%2Fanie.201303207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252FptVahuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=12256-12267&author=H.+Sch%C3%B6nherrauthor=T.+Cernak&title=Profound+methyl+effects+in+drug+discovery+and+a+call+for+new+C-H+methylation+reactions&doi=10.1002%2Fanie.201303207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Profound methyl effects in drug discovery and a call for new C-H methylation reactions</span></div><div class="casAuthors">Schonherr Heike; Cernak Tim</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie (International ed. in English)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">12256-67</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The methyl group is one of the most commonly occurring carbon fragments in small-molecule drugs.  This simplest alkyl fragment appears in more than 67 % of the top-selling drugs of 2011 and can modulate both the biological and physical properties of a molecule.  This Review focuses on so-called magic methyl effects on binding potency, where the seemingly mundane change of C H to C Me improves the IC50  value of a drug candidate more than 100-fold.  This discussion is followed by a survey of recent advances in synthetic chemistry that allow the direct methylation of C(sp(2) ) H and C(sp(3) ) H bonds.  It is our hope that the relevance of the meager methyl group to drug discovery as presented herein will inspire reports on new C H methylation reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTyoLZDDgvsMh0LsK7uFuY7fW6udTcc2eZqkxsCncdfh7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252FptVahuw%253D%253D&md5=ef08f80e55b2c530b49e4306da024902</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fanie.201303207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201303207%26sid%3Dliteratum%253Aachs%26aulast%3DSch%25C3%25B6nherr%26aufirst%3DH.%26aulast%3DCernak%26aufirst%3DT.%26atitle%3DProfound%2520methyl%2520effects%2520in%2520drug%2520discovery%2520and%2520a%2520call%2520for%2520new%2520C-H%2520methylation%2520reactions%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D12256%26epage%3D12267%26doi%3D10.1002%2Fanie.201303207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barreiro, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kümmerle, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraga, C. A.</span></span> <span> </span><span class="NLM_article-title">The methylation effect in medicinal chemistry</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">5215</span>– <span class="NLM_lpage">5246</span>, <span class="refDoi"> DOI: 10.1021/cr200060g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr200060g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFChsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2011&pages=5215-5246&author=E.+J.+Barreiroauthor=A.+E.+K%C3%BCmmerleauthor=C.+A.+Fraga&title=The+methylation+effect+in+medicinal+chemistry&doi=10.1021%2Fcr200060g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">The Methylation Effect in Medicinal Chemistry</span></div><div class="casAuthors">Barreiro, Eliezer J.; Kummerle, Arthur E.; Fraga, Carlos A. M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5215-5246</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this review, we aimed to highlight the importance of the simple Me group as a very useful structural modification in the rational design of bioactive compds. and drugs.  We selected different examples from distinct classes of org. compds. with several pharmacol. properties in order to illustrate that an apparent subtle mol. modification can strongly alter the biol. profile of a drug.  The Me effect alter both biol. phases of a drug, represented by its pharmacodynamic and pharmacokinetc profile, due to the modifications introduced in the stereoeletronic properties.  In fact, it was illustrated that distinct metabolic behavior or receptor affinity could be modified by the Me effect.  Among the examples included many other important ones could be used, such as the importance of the Me in modified the bioprofile of Ph ethanolamines with differentiation in the mol. recognition pattern among different adrenergic receptor subtypes.  The introduction of an simple extra Me connected to the N-alkylpiperidine moiety present in PDE5 inhibitor raisng the discovery of me-too drug vardenafil for erectile dysfunction.  In fact, the correct use of this strategy for mol. modification and design of drugs or drug-candidate compds. may be useful from both a pharmacokinetic and a pharmacodynamic point of view, representing an important tool for the medicinal chemist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx5w0XiOyJ7bVg90H21EOLACvtfcHk0lgxVzT7NQZmqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFChsrk%253D&md5=1cfdacf68ea53408c0f671a1dffb6d3a</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fcr200060g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr200060g%26sid%3Dliteratum%253Aachs%26aulast%3DBarreiro%26aufirst%3DE.%2BJ.%26aulast%3DK%25C3%25BCmmerle%26aufirst%3DA.%2BE.%26aulast%3DFraga%26aufirst%3DC.%2BA.%26atitle%3DThe%2520methylation%2520effect%2520in%2520medicinal%2520chemistry%26jtitle%3DChem.%2520Rev.%26date%3D2011%26volume%3D111%26spage%3D5215%26epage%3D5246%26doi%3D10.1021%2Fcr200060g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirado-Rives, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span> <span> </span><span class="NLM_article-title">Methyl effects on protein-ligand binding</span>. <i>J. Med. Chem</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4489</span>– <span class="NLM_lpage">5000</span>, <span class="refDoi"> DOI: 10.1021/jm3003697</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003697" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsV2iu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4489-5000&author=C.+S.+Leungauthor=S.+S.+Leungauthor=J.+Tirado-Rivesauthor=W.+L.+Jorgensen&title=Methyl+effects+on+protein-ligand+binding&doi=10.1021%2Fjm3003697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Methyl Effects on Protein-Ligand Binding</span></div><div class="casAuthors">Leung, Cheryl S.; Leung, Siegfried S. F.; Tirado-Rives, Julian; Jorgensen, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4489-4500</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The effects of addn. of a Me group to a lead compd. on biol. activity are examd.  A literature anal. of >2000 cases reveals that an activity boost of a factor of 10 or more is found with an 8% frequency, and a 100-fold boost is a 1 in 200 event.  Four cases in the latter category are analyzed in depth to elucidate any unusual aspects of the protein-ligand binding, distribution of water mols., and changes in conformational energetics.  The analyses include Monte Carlo/free-energy perturbation (MC/FEP) calcns. for Me replacements in inhibitor series for p38α MAP kinase, ACK1, PTP1B, and thrombin.  Me substitutions ortho to an aryl ring can be particularly effective at improving activity by inducing a propitious conformational change.  The greatest improvements in activity arise from coupling the conformational gain with the burial of the Me group in a hydrophobic region of the protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX0Czyhgy6KbVg90H21EOLACvtfcHk0lhtn9YeDQPaig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsV2iu7Y%253D&md5=0ea58d9c1bf845d383931b6a017f9b37</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm3003697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003697%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DC.%2BS.%26aulast%3DLeung%26aufirst%3DS.%2BS.%26aulast%3DTirado-Rives%26aufirst%3DJ.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26atitle%3DMethyl%2520effects%2520on%2520protein-ligand%2520binding%26jtitle%3DJ.%2520Med.%2520Chem%26date%3D2012%26volume%3D55%26spage%3D4489%26epage%3D5000%26doi%3D10.1021%2Fjm3003697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharbanda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakkaniga, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frett, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.-Y.</span></span> <span> </span><span class="NLM_article-title">The Exploration of Chirality for Improved Druggability within the Human Kinome</span>. <i>J. Med. Chem</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">469</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00640</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00640" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVCntLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=441-469&author=D.+Sahaauthor=A.+Kharbandaauthor=W.+Yanauthor=N.+R.+Lakkanigaauthor=B.+Frettauthor=H.-Y.+Li&title=The+Exploration+of+Chirality+for+Improved+Druggability+within+the+Human+Kinome&doi=10.1021%2Facs.jmedchem.9b00640"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">The Exploration of Chirality for Improved Druggability within the Human Kinome</span></div><div class="casAuthors">Saha, Debasmita; Kharbanda, Anupreet; Yan, Wei; Lakkaniga, Naga Rajiv; Frett, Brendan; Li, Hong-Yu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">441-469</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Chirality is important in drug discovery because stereoselective drugs can ameliorate therapeutic difficulties including adverse toxicity and poor pharmacokinetic profiles.  The human kinome, a major druggable enzyme class has been exploited to treat a wide range of diseases.  However, many kinase inhibitors are planar and overlap in chem. space, which leads to selectivity and toxicity issues.  By exploring chirality within the kinome, a new iteration of kinase inhibitors is being developed to better utilize the three-dimensional nature of the kinase active site.  Exploration into novel chem. space, in turn, will also improve drug soly. and pharmacokinetic profiles.  This perspective explores the role of chirality to improve kinome druggability and will serve as a resource for pioneering kinase inhibitor development to address current therapeutic needs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-wP_4kQzQNrVg90H21EOLACvtfcHk0lhtn9YeDQPaig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVCntLzE&md5=5feba0b73e6ab003971feb705ad2d7ac</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00640%26sid%3Dliteratum%253Aachs%26aulast%3DSaha%26aufirst%3DD.%26aulast%3DKharbanda%26aufirst%3DA.%26aulast%3DYan%26aufirst%3DW.%26aulast%3DLakkaniga%26aufirst%3DN.%2BR.%26aulast%3DFrett%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DH.-Y.%26atitle%3DThe%2520Exploration%2520of%2520Chirality%2520for%2520Improved%2520Druggability%2520within%2520the%2520Human%2520Kinome%26jtitle%3DJ.%2520Med.%2520Chem%26date%3D2020%26volume%3D63%26spage%3D441%26epage%3D469%26doi%3D10.1021%2Facs.jmedchem.9b00640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guida, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, K. G.</span></span> <span> </span><span class="NLM_article-title">The significance of chirality in drug design and development</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">760</span>– <span class="NLM_lpage">770</span>, <span class="refDoi"> DOI: 10.2174/156802611795165098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.2174%2F156802611795165098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=21291399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1Ojsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=760-770&author=W.+H.+Brooksauthor=W.+C.+Guidaauthor=K.+G.+Daniel&title=The+significance+of+chirality+in+drug+design+and+development&doi=10.2174%2F156802611795165098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">The significance of chirality in drug design and development</span></div><div class="casAuthors">Brooks, W. H.; Guida, W. C.; Daniel, K. G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">760-770</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Proteins are often enantioselective towards their binding partners.  When designing small mols. to interact with these targets, one should consider stereoselectivity.  As considerations for exploring structure space evolve, chirality is increasingly important.  Binding affinity for a chiral drug can differ for diastereomers and between enantiomers.  For the virtual screening and computational design stage of drug development, this problem can be compounded by incomplete stereochem. information in structure libraries leading to a "coin toss" as to whether or not the "ideal" chiral structure is present.  Creating every stereoisomer for each chiral compd. in a structure library leads to an exponential increase in the no. of structures resulting in potentially unmanageable file sizes and screening times.  Therefore, only key chiral structures, enantiomeric pairs based on relative stereochem. need be included, and lead to a compromise between exploration of chem. space and maintaining manageable libraries.  In clin. environments, enantiomers of chiral drugs can have reduced, no, or even deleterious effects.  This underscores the need to avoid mixts. of compds. and focus on chiral synthesis.  Governmental regulations emphasizing the need to monitor chirality in drug development have increased.  The United States Food and Drug Administration issued guidelines and policies in 1992 concerning the development of chiral compds.  These guidelines require that abs. stereochem. be known for compds. with chiral centers and that this information should be established early in drug development in order that the anal. can be considered valid.  From exploration of structure space to governmental regulations it is clear that the question of chirality in drug design is of vital importance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4TgZ0W1QUdrVg90H21EOLACvtfcHk0lhtn9YeDQPaig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1Ojsrw%253D&md5=eb78aca17518a7fd04d8cfc3c5d0ec78</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.2174%2F156802611795165098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611795165098%26sid%3Dliteratum%253Aachs%26aulast%3DBrooks%26aufirst%3DW.%2BH.%26aulast%3DGuida%26aufirst%3DW.%2BC.%26aulast%3DDaniel%26aufirst%3DK.%2BG.%26atitle%3DThe%2520significance%2520of%2520chirality%2520in%2520drug%2520design%2520and%2520development%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D760%26epage%3D770%26doi%3D10.2174%2F156802611795165098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranade, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, G. A.</span></span> <span> </span><span class="NLM_article-title">Microwave-accelerated conjugate addition of 2-arylindoles to substituted β-nitrostyrenes in the presence of ammonium trifluoroacetate: an efficient approach for the synthesis of a novel class of CB1 cannabinoid receptor allosteric modulators</span>. <i>J. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2079</span>– <span class="NLM_lpage">2084</span>, <span class="refDoi"> DOI: 10.1002/jhet.2861</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1002%2Fjhet.2861" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1Oru78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2017&pages=2079-2084&author=P.+M.+Kulkarniauthor=A.+Ranadeauthor=S.+Garaiauthor=G.+A.+Thakur&title=Microwave-accelerated+conjugate+addition+of+2-arylindoles+to+substituted+%CE%B2-nitrostyrenes+in+the+presence+of+ammonium+trifluoroacetate%3A+an+efficient+approach+for+the+synthesis+of+a+novel+class+of+CB1+cannabinoid+receptor+allosteric+modulators&doi=10.1002%2Fjhet.2861"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Microwave-accelerated Conjugate Addition of 2-Arylindoles to Substituted β-Nitrostyrenes in the Presence of Ammonium Trifluoroacetate: An Efficient Approach for the Synthesis of a Novel Class of CB1 Cannabinoid Receptor Allosteric Modulators</span></div><div class="casAuthors">Kulkarni, Pushkar M.; Ranade, Ameya; Garai, Sumanta; Thakur, Ganesh A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Heterocyclic Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">2079-2084</span>CODEN:
                <span class="NLM_cas:coden">JHTCAD</span>;
        ISSN:<span class="NLM_cas:issn">1943-5193</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">2-Arylindoles, in general, exhibit reduced reactivity towards the conjugate addn. to substituted nitrostyrenes, when compared with indoles.  An efficient, expeditious, and high-yielding conjugate addn. of 2-arylindoles to substituted β-nitrostyrenes in the presence of ammonium trifluoroacetate under microwave irradn is reported here.  This method is mild with high and reproducible yields and is selective for addn. of β-nitrostyrenes when compared with other electrophiles.  The results obtained from the optimized microwave method consistently provided improved yields of the title compds., e.g., I, in a shorter time compared with those of the conventional heating synthetic route.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHYh9vHbyRDLVg90H21EOLACvtfcHk0liem58O2pa9OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1Oru78%253D&md5=523324377e4551828ea3c8b22905b307</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1002%2Fjhet.2861&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.2861%26sid%3Dliteratum%253Aachs%26aulast%3DKulkarni%26aufirst%3DP.%2BM.%26aulast%3DRanade%26aufirst%3DA.%26aulast%3DGarai%26aufirst%3DS.%26aulast%3DThakur%26aufirst%3DG.%2BA.%26atitle%3DMicrowave-accelerated%2520conjugate%2520addition%2520of%25202-arylindoles%2520to%2520substituted%2520%25CE%25B2-nitrostyrenes%2520in%2520the%2520presence%2520of%2520ammonium%2520trifluoroacetate%253A%2520an%2520efficient%2520approach%2520for%2520the%2520synthesis%2520of%2520a%2520novel%2520class%2520of%2520CB1%2520cannabinoid%2520receptor%2520allosteric%2520modulators%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D2017%26volume%3D54%26spage%3D2079%26epage%3D2084%26doi%3D10.1002%2Fjhet.2861" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span> <span> </span><span class="NLM_article-title">The [<sup>35</sup>S]GTPgammaS binding assay: approaches and applications in pharmacology</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">489</span>– <span class="NLM_lpage">508</span>, <span class="refDoi"> DOI: 10.1016/j.lfs.2003.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1016%2Fj.lfs.2003.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=14609727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovVGgur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2003&pages=489-508&author=C.+Harrisonauthor=J.+R.+Traynor&title=The+%5B35S%5DGTPgammaS+binding+assay%3A+approaches+and+applications+in+pharmacology&doi=10.1016%2Fj.lfs.2003.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">The [35S]GTPγS binding assay: approaches and applications in pharmacology</span></div><div class="casAuthors">Harrison, C.; Traynor, J. R.</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">489-508</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review.  Receptors of the of seven transmembrane spanning, heterotrimeric G protein coupled family (GPCR) play crucial roles in regulating physiol. functions and consequently are targets for the action of many classes of drugs.  Activation of receptor by agonist leads to the dissocn. of GDP from Gα of the Gαβγ heterotrimer, followed by the binding of GTP to Gα and subsequent modulation of downstream effectors.  The G protein heterotrimer is reformed by GTPase activity of the Gα subunit, forming Gα-GDP and so allowing Gα and Gβγ to recombine.  The [35S]GTPγS assay measures the level of G protein activation following agonist occupation of a GPCR, by detg. the binding of the non-hydrolyzable analog [35S]GTPγS to Gα subunits.  Thus, the assay measures a functional consequence of receptor occupancy at one of the earliest receptor-mediated events.  The assay allows for traditional pharmacol. parameters of potency, efficacy and antagonist affinity, with the advantage that agonist measures are not subjected to amplification or other modulation that may occur when analyzing parameters further downstream of the receptor.  In general the assay is exptl. more feasible for receptors coupled to the abundant Gi/o proteins.  Nevertheless, [35S]GTPγS binding assays are used with GPCRs that couple to the Gs and Gq families of G proteins, esp. in artificial expression systems, or using receptor-Gα constructs or immunopptn. of [35S]GTPγS-labeled Gα.  The relative simplicity of the assay has made it very popular and its use is providing insights into contemporary pharmacol. topics including the roles of accessory proteins in signaling, constitutive activity of receptors and agonist specific signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxfMRPq_yzZLVg90H21EOLACvtfcHk0lgW-WVGALARjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovVGgur8%253D&md5=e7f4c739fd78cda7029439c9ff48e570</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2003.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2003.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DC.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520%255B35S%255DGTPgammaS%2520binding%2520assay%253A%2520approaches%2520and%2520applications%2520in%2520pharmacology%26jtitle%3DLife%2520Sci.%26date%3D2003%26volume%3D74%26spage%3D489%26epage%3D508%26doi%3D10.1016%2Fj.lfs.2003.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasanetz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friemel, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lassalle, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steindel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monory, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäfer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miederer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leweke, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreckenberger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reggio, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manzoni, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spanagel, R.</span></span> <span> </span><span class="NLM_article-title">Enhanced functional activity of the cannabinoid type-1 receptor mediates adolescent behavior</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">13975</span>– <span class="NLM_lpage">13988</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.1937-15.2015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1523%2FJNEUROSCI.1937-15.2015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=26468198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvFyru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=13975-13988&author=M.+Schneiderauthor=F.+Kasanetzauthor=D.+L.+Lynchauthor=C.+M.+Friemelauthor=O.+Lassalleauthor=D.+P.+Hurstauthor=F.+Steindelauthor=K.+Monoryauthor=C.+Sch%C3%A4ferauthor=I.+Miedererauthor=F.+M.+Lewekeauthor=M.+Schreckenbergerauthor=B.+Lutzauthor=P.+H.+Reggioauthor=O.+J.+Manzoniauthor=R.+Spanagel&title=Enhanced+functional+activity+of+the+cannabinoid+type-1+receptor+mediates+adolescent+behavior&doi=10.1523%2FJNEUROSCI.1937-15.2015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54aR"><div class="casContent"><span class="casTitleNuber">54a</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced functional activity of the cannabinoid type-1 receptor mediates adolescent behavior</span></div><div class="casAuthors">Schneider, Miriam; Kasanetz, Fernando; Lynch, Diane L.; Friemel, Chris M.; Lassalle, Olivier; Hurst, Dow P.; Steindel, Frauke; Monory, Krisztina; Schaefer, Carola; Miederer, Isabelle; Leweke, F. Markus; Schreckenberger, Mathias; Lutz, Beat; Reggio, Patricia H.; Manzoni, Olivier J.; Spanagel, Rainer</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">13975-13988</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Adolescence is characterized by drastic behavioral adaptations and comprises a particularly vulnerable period for the emergence of various psychiatric disorders.  Growing evidence reveals that the pathophysiol. of these disorders might derive from aberrations of normal neurodevelopmental changes in the adolescent brain.  Understanding the mol. underpinnings of adolescent behavior is therefore crit. for understanding the origin of psychopathol., but the mol. mechanisms that trigger adolescent behavior are unknown.  Here, we hypothesize that the cannabinoid type-1 receptor (CB1R) may play a crit. role in mediating adolescent behavior because enhanced endocannabinoid (eCB) signaling has been suggested to occur transiently during adolescence.  To study enhanced CB1R signaling, we introduced a missense mutation (F238L) into the rat Cnr1 gene that encodes for the CB1R.  According to our hypothesis, rats with the F238L mutation (Cnr1F238L) should sustain features of adolescent behavior into adulthood.  Gain of function of the mutated receptor was demonstrated by in silico modeling and was verified functionally in a series of biochem. and electrophysiol. expts.  Mutant rats exhibit an adolescent-like phenotype during adulthood compared with wild-type littermates, with typical high risk/novelty seeking, increased peer interaction, enhanced impulsivity, and augmented reward sensitivity for drug and nondrug reward.  Partial inhibition of CB1R activity in Cnr1F238L mutant rats normalized behavior and led to a wild-type phenotype.  We conclude that the activity state and functionality of the CB1R is crit. for mediating adolescent behavior.  These findings implicate the eCB system as an important research target for the neuropathol. of adolescent-onset mental health disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRQPO9k5w-hrVg90H21EOLACvtfcHk0lgW-WVGALARjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvFyru70%253D&md5=a4b96441d101d2816c3148e7bfe3fed4</span></div><a href="/servlet/linkout?suffix=cit54a&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.1937-15.2015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.1937-15.2015%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DM.%26aulast%3DKasanetz%26aufirst%3DF.%26aulast%3DLynch%26aufirst%3DD.%2BL.%26aulast%3DFriemel%26aufirst%3DC.%2BM.%26aulast%3DLassalle%26aufirst%3DO.%26aulast%3DHurst%26aufirst%3DD.%2BP.%26aulast%3DSteindel%26aufirst%3DF.%26aulast%3DMonory%26aufirst%3DK.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DC.%26aulast%3DMiederer%26aufirst%3DI.%26aulast%3DLeweke%26aufirst%3DF.%2BM.%26aulast%3DSchreckenberger%26aufirst%3DM.%26aulast%3DLutz%26aufirst%3DB.%26aulast%3DReggio%26aufirst%3DP.%2BH.%26aulast%3DManzoni%26aufirst%3DO.%2BJ.%26aulast%3DSpanagel%26aufirst%3DR.%26atitle%3DEnhanced%2520functional%2520activity%2520of%2520the%2520cannabinoid%2520type-1%2520receptor%2520mediates%2520adolescent%2520behavior%26jtitle%3DJ.%2520Neurosci.%26date%3D2015%26volume%3D35%26spage%3D13975%26epage%3D13988%26doi%3D10.1523%2FJNEUROSCI.1937-15.2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit54b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramesh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrell, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenbaum, D. M.</span></span> <span> </span><span class="NLM_article-title">Structure of an allosteric modulator bound to the CB1 cannabinoid receptor</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1199</span>– <span class="NLM_lpage">1205</span>, <span class="refDoi"> DOI: 10.1038/s41589-019-0387-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1038%2Fs41589-019-0387-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=31659318" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVCksLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=1199-1205&author=Z.+Shaoauthor=W.+Yanauthor=K.+Chapmanauthor=K.+Rameshauthor=A.+J.+Ferrellauthor=J.+Yinauthor=X.+Wangauthor=Q.+Xuauthor=D.+M.+Rosenbaum&title=Structure+of+an+allosteric+modulator+bound+to+the+CB1+cannabinoid+receptor&doi=10.1038%2Fs41589-019-0387-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54bR"><div class="casContent"><span class="casTitleNuber">54b</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of an allosteric modulator bound to the CB1 cannabinoid receptor</span></div><div class="casAuthors">Shao, Zhenhua; Yan, Wei; Chapman, Karen; Ramesh, Karthik; Ferrell, Aaron J.; Yin, Jie; Wang, Xuehui; Xu, Qingping; Rosenbaum, Daniel M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1199-1205</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The CB1 receptor mediates the central nervous system response to cannabinoids, and is a drug target for pain, anxiety and seizures.  CB1 also responds to allosteric modulators, which influence cannabinoid binding and efficacy.  To understand the mechanism of these compds., we solved the crystal structure of CB1 with the neg. allosteric modulator (NAM) ORG27569 and the agonist CP55940.  The structure reveals that the NAM binds to an extrahelical site within the inner leaflet of the membrane, which overlaps with a conserved site of cholesterol interaction in many G protein-coupled receptors (GPCRs).  The ternary structure with ORG27569 and CP55940 captures an intermediate state of the receptor, in which arom. residues at the base of the agonist-binding pocket adopt an inactive conformation despite the large contraction of the orthosteric pocket.  The structure illustrates a potential strategy for drug modulation of CB1 and other class A GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqz52KMEDfkTbVg90H21EOLACvtfcHk0ljAq5exaTXRHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVCksLnM&md5=58150bc1805c874c5dce7ed13fcf7c68</span></div><a href="/servlet/linkout?suffix=cit54b&amp;dbid=16384&amp;doi=10.1038%2Fs41589-019-0387-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41589-019-0387-2%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DZ.%26aulast%3DYan%26aufirst%3DW.%26aulast%3DChapman%26aufirst%3DK.%26aulast%3DRamesh%26aufirst%3DK.%26aulast%3DFerrell%26aufirst%3DA.%2BJ.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DRosenbaum%26aufirst%3DD.%2BM.%26atitle%3DStructure%2520of%2520an%2520allosteric%2520modulator%2520bound%2520to%2520the%2520CB1%2520cannabinoid%2520receptor%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2019%26volume%3D15%26spage%3D1199%26epage%3D1205%26doi%3D10.1038%2Fs41589-019-0387-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Straiker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, K.</span></span> <span> </span><span class="NLM_article-title">Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones</span>. <i>J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>569</i></span>,  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">517</span>, <span class="refDoi"> DOI: 10.1113/jphysiol.2005.091918</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1113%2Fjphysiol.2005.091918" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=16179366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsVagug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=569&publication_year=2005&pages=501-517&author=A.+Straikerauthor=K.+Mackie&title=Depolarization-induced+suppression+of+excitation+in+murine+autaptic+hippocampal+neurones&doi=10.1113%2Fjphysiol.2005.091918"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones</span></div><div class="casAuthors">Straiker, Alex; Mackie, Ken</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physiology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">569</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">501-517</span>CODEN:
                <span class="NLM_cas:coden">JPHYA7</span>;
        ISSN:<span class="NLM_cas:issn">0022-3751</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Depolarization-induced suppression of excitation and inhibition (DSE and DSI) appear to be important forms of short-term retrograde neuronal plasticity involving endocannabinoids (eCB) and the activation of presynaptic cannabinoid CB1 receptors.  We report here that CB1-dependent DSE can be elicited from autaptic cultures of excitatory mouse hippocampal neurons.  DSE in autaptic cultures is both more robust and elicited with a more physiol. relevant stimulus than has been thus far reported for conventional hippocampal cultures.  An addnl. requirement for autaptic DSE is filled internal calcium stores.  Pharmacol. expts. favor a role for 2-arachidonyl glycerol (2-AG) rather than arachidonyl ethanolamide (AEA) or Noladin ether as the relevant endocannabinoid to elicit DSE.  In particular, the latter two compds. fail to reversibly inhibit EPSCs, a quality inconsistent with the role of bona fide eCB mediating DSE.  Δ9-Tetrahydrocannabinol (Δ9-THC) fails to inhibit EPSCs, yet readily occludes both DSE and EPSC inhibition by a synthetic CB1 agonist, WIN 55212-2.  With long-term exposure (∼18 h), Δ9-THC also desensitizes CB1 receptors.  Lastly, a functional endocannabinoid transporter is necessary for the expression of DSE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhFvlhyemQq7Vg90H21EOLACvtfcHk0ljAq5exaTXRHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsVagug%253D%253D&md5=40ce0ec2c297af8d70bcd84db3736e64</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1113%2Fjphysiol.2005.091918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1113%252Fjphysiol.2005.091918%26sid%3Dliteratum%253Aachs%26aulast%3DStraiker%26aufirst%3DA.%26aulast%3DMackie%26aufirst%3DK.%26atitle%3DDepolarization-induced%2520suppression%2520of%2520excitation%2520in%2520murine%2520autaptic%2520hippocampal%2520neurones%26jtitle%3DJ.%2520Physiol.%26date%3D2005%26volume%3D569%26spage%3D501%26epage%3D517%26doi%3D10.1113%2Fjphysiol.2005.091918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cvenkel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolko, M.</span></span> <span> </span><span class="NLM_article-title">Current medical therapy and future trends in the management of glaucoma treatment</span>. <i>J. Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>2020</i></span>, <span class="NLM_elocation-id">6138132</span> <span class="refDoi"> DOI: 10.1155/2020/6138132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1155%2F2020%2F6138132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=32774906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A280%3ADC%252BB38fjsVCkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2020&publication_year=2020&author=B.+Cvenkelauthor=M.+Kolko&title=Current+medical+therapy+and+future+trends+in+the+management+of+glaucoma+treatment&doi=10.1155%2F2020%2F6138132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Current Medical Therapy and Future Trends in the Management of Glaucoma Treatment</span></div><div class="casAuthors">Cvenkel Barbara; Cvenkel Barbara; Kolko Miriam; Kolko Miriam</div><div class="citationInfo"><span class="NLM_cas:title">Journal of ophthalmology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">2020</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6138132</span>
        ISSN:<span class="NLM_cas:issn">2090-004X</span>.
    </div><div class="casAbstract">Glaucoma is a neurodegenerative disease characterized by progressive loss of retinal ganglion cells and their axons.  Lowering of intraocular pressure (IOP) is currently the only proven treatment strategy for glaucoma.  However, some patients show progressive loss of visual field and quality of life despite controlled IOP which indicates that other factors are implicated in glaucoma.  Therefore, approaches that could prevent or decrease the rate of progression and do not rely on IOP lowering have gained much attention.  Effective neuroprotection has been reported in animal models of glaucoma, but till now, no neuroprotective agents have been clinically approved.  The present update provides an overview of currently available IOP-lowering medications.  Moreover, potential new treatment targets for IOP-lowering and neuroprotective therapy are discussed.  Finally, future trends in glaucoma therapy are addressed, including sustained drug delivery systems and progress toward personalized medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSMFibbL4rTiMuCWE5mhx1RfW6udTcc2eb4V-bJlhRrJ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38fjsVCkuw%253D%253D&md5=36f6ca225337e170e92fbdfe9e9735be</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1155%2F2020%2F6138132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2020%252F6138132%26sid%3Dliteratum%253Aachs%26aulast%3DCvenkel%26aufirst%3DB.%26aulast%3DKolko%26aufirst%3DM.%26atitle%3DCurrent%2520medical%2520therapy%2520and%2520future%2520trends%2520in%2520the%2520management%2520of%2520glaucoma%2520treatment%26jtitle%3DJ.%2520Ophthalmol.%26date%3D2020%26volume%3D2020%26doi%3D10.1155%2F2020%2F6138132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittag, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podos, S. M.</span></span> <span> </span><span class="NLM_article-title">Effect of WIN 55212-2, a cannabinoid receptor agonist, on aqueous humor dynamics in monkeys</span>. <i>Arch. Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1001/archopht.121.1.87</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1001%2Farchopht.121.1.87" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=12523891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BD3sXps1Kqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2003&pages=87-90&author=F.+Y.+Chienauthor=R.+F.+Wangauthor=T.+W.+Mittagauthor=S.+M.+Podos&title=Effect+of+WIN+55212-2%2C+a+cannabinoid+receptor+agonist%2C+on+aqueous+humor+dynamics+in+monkeys&doi=10.1001%2Farchopht.121.1.87"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57aR"><div class="casContent"><span class="casTitleNuber">57a</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of WIN 55212-2, a cannabinoid receptor agonist, on aqueous humor dynamics in monkeys</span></div><div class="casAuthors">Chien, Fred Y.; Wang, Rong-Fang; Mittag, Thomas W.; Podos, Steven M.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Ophthalmology (Chicago, IL, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-90</span>CODEN:
                <span class="NLM_cas:coden">AROPAW</span>;
        ISSN:<span class="NLM_cas:issn">0003-9950</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">The aim of this study was to evaluate the effects of WIN 55212-2, a cannabinoid receptor agonist, on intraocular pressure and aq. humor dynamics in normal monkeys and monkeys with glaucoma.  Intraocular pressure was measured prior to and up to 6 h after the topical administration of WIN 55212-2 to 1 eye of 5 normal monkeys and to the glaucomatous eye of 8 monkeys with unilateral laser-induced glaucoma.  Tonog. outflow facility and fluorophotometric flow rates of aq. humor were measured in 6 normal monkeys before and after treatment.  In normal monkeys, a single dose of WIN 55212-2 reduced intraocular pressure for 4, 5, or 6 h, with a max. redn. of 1.4±0.4 (mean±SEM) mm Hg, 2.9±0.4 mm Hg, and 3.4±0.6 mm Hg following the 0.07%, 0.2%, and 0.5% concns., resp. (P=.08).  In 8 glaucomatous monkey eyes, the ocular hypotensive effect was maintained for 5 days with twice-daily administration of 0.5% WIN 55212-2.  Outflow facility was unchanged (P=.34) and aq. humor flow was decreased by 18% (P=.04) in the treated eyes compared with vehicle-treated contralateral control eyes in normal monkeys.  WIN 55212-2, a cannabinoid agonist at the CB1 receptor, reduces intraocular pressure in both normal and glaucomatous monkey eyes.  A decrease of aq. flow appears to account for the intraocular pressure redn. in normal monkey eyes.  Cannabinoid agonists at the CB1 receptor, a new class of antiglaucoma agents that is different from currently used clin. drugs, may have clin. potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJOplBIeXYnbVg90H21EOLACvtfcHk0ljxAGCQmtGyvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXps1Kqtw%253D%253D&md5=9ef2302217f126972c45800eb190d760</span></div><a href="/servlet/linkout?suffix=cit57a&amp;dbid=16384&amp;doi=10.1001%2Farchopht.121.1.87&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchopht.121.1.87%26sid%3Dliteratum%253Aachs%26aulast%3DChien%26aufirst%3DF.%2BY.%26aulast%3DWang%26aufirst%3DR.%2BF.%26aulast%3DMittag%26aufirst%3DT.%2BW.%26aulast%3DPodos%26aufirst%3DS.%2BM.%26atitle%3DEffect%2520of%2520WIN%252055212-2%252C%2520a%2520cannabinoid%2520receptor%2520agonist%252C%2520on%2520aqueous%2520humor%2520dynamics%2520in%2520monkeys%26jtitle%3DArch.%2520Ophthalmol.%26date%3D2003%26volume%3D121%26spage%3D87%26epage%3D90%26doi%3D10.1001%2Farchopht.121.1.87" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit57b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hodges, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reggio, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, K.</span></span> <span> </span><span class="NLM_article-title">Evidence against cannabinoid receptor involvement in intraocular pressure effects of cannabinoids in rabbits</span>. <i>Ophthalmic Res.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">5</span>, <span class="refDoi"> DOI: 10.1159/000267984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1159%2F000267984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=9112260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADyaK2sXis1Kktrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1997&pages=1-5&author=L.+C.+Hodgesauthor=P.+H.+Reggioauthor=K.+Green&title=Evidence+against+cannabinoid+receptor+involvement+in+intraocular+pressure+effects+of+cannabinoids+in+rabbits&doi=10.1159%2F000267984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57bR"><div class="casContent"><span class="casTitleNuber">57b</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence against cannabinoid receptor involvement in intraocular pressure effects of cannabinoids in rabbits</span></div><div class="casAuthors">Hodges, Linda C.; Reggio, Patricia H.; Green, Keith</div><div class="citationInfo"><span class="NLM_cas:title">Ophthalmic Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-5</span>CODEN:
                <span class="NLM_cas:coden">OPRSAQ</span>;
        ISSN:<span class="NLM_cas:issn">0030-3747</span>.
    
            (<span class="NLM_cas:orgname">Karger</span>)
        </div><div class="casAbstract">A possible cannabinoid receptor involvement of cannabinoids was investigated in the intraocular-pressure (IOP)-lowering effect.  The IOP effect in normotensive rabbits after systemic administration of an aminoalkylindole, WIN-55,212-2, and of (R)-(+)-methanandamide, a hydrolysis-resistant endogenous ligand deriv., was examd.  The decrease in IOP for animals treated with WIN-55,212-2 was marginal and for animals treated with (R)-(+)-methanandamide was negligible.  The IOP-lowering effect of cannabinoids cannot be mediated by a cannabinoid receptor in rabbits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEAHm_NCO19rVg90H21EOLACvtfcHk0lgJoDABdECltg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXis1Kktrs%253D&md5=90c952537426634a3e04ebe4fead1d3c</span></div><a href="/servlet/linkout?suffix=cit57b&amp;dbid=16384&amp;doi=10.1159%2F000267984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000267984%26sid%3Dliteratum%253Aachs%26aulast%3DHodges%26aufirst%3DL.%2BC.%26aulast%3DReggio%26aufirst%3DP.%2BH.%26aulast%3DGreen%26aufirst%3DK.%26atitle%3DEvidence%2520against%2520cannabinoid%2520receptor%2520involvement%2520in%2520intraocular%2520pressure%2520effects%2520of%2520cannabinoids%2520in%2520rabbits%26jtitle%3DOphthalmic%2520Res.%26date%3D1997%26volume%3D29%26spage%3D1%26epage%3D5%26doi%3D10.1159%2F000267984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beazley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szczesniak, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straiker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, M. E.</span></span> <span> </span><span class="NLM_article-title">Indirect sympatholytic actions at β-adrenoceptors account for the ocular hypotensive actions of cannabinoid receptor agonists</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>339</i></span>,  <span class="NLM_fpage">757</span>– <span class="NLM_lpage">767</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.185769</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1124%2Fjpet.111.185769" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=21885619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtVSks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=2011&pages=757-767&author=B.+D.+Hudsonauthor=M.+Beazleyauthor=A.+M.+Szczesniakauthor=A.+Straikerauthor=M.+E.+Kelly&title=Indirect+sympatholytic+actions+at+%CE%B2-adrenoceptors+account+for+the+ocular+hypotensive+actions+of+cannabinoid+receptor+agonists&doi=10.1124%2Fjpet.111.185769"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Indirect sympatholytic actions at β-adrenoceptors account for the ocular hypotensive actions of cannabinoid receptor agonists</span></div><div class="casAuthors">Hudson, Brian D.; Beazley, Meggie; Szczesniak, Anna-Maria; Straiker, Alex; Kelly, Melanie E. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">339</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">757-767</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Intraocular pressure (IOP) is the primary risk factor for glaucoma, a blinding eye disease.  Cannabinoid agonists have long been known to decrease IOP, suggesting they may be useful in glaucoma treatment.  However, the specific mechanism by which cannabinoids generate this ocular hypotensive effect remains unknown.  The current evidence suggests the cannabinoids reduce IOP through actions at cannabinoid 1 (CB1) receptors within the eye, and adrenergic receptors (ARs) may also contribute to this action of cannabinoids.  Considering this, the present study aimed to elucidate the mechanism behind the ocular hypotensive properties of cannabinoids through the use of mice genetically lacking either cannabinoid receptors or βARs.  Cannabinoid agonists, βAR antagonists, and βAR agonists decreased IOP in wild-type mice and CB2(-/-) mice.  In contrast, none of these compds. were found to reduce IOP in βAR(-/-) or CB1(-/-) mice.  Desensitization of the βARs and depletion of catecholamines in wild-type mice also eliminated the ability of the cannabinoid agonist (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone mesylate (WIN 55,212-2) to reduce IOP, strongly implicating a role for both βARs and catecholamines in the ocular hypotensive properties of cannabinoids.  Finally, CB1 receptors were shown to colocalize with tyrosine hydroxylase, a marker for adrenergic neurons.  Taken together, these findings suggest that βARs are required for the ocular hypotensive properties of cannabinoids, and cannabinoids reduce IOP by acting as indirect sympatholytics and inhibiting norepinephrine release within the eye.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrz4eDDne9ip7Vg90H21EOLACvtfcHk0lgJoDABdECltg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtVSks7Y%253D&md5=6a96e5b99beecaa26be1c49e78358d11</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.185769&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.185769%26sid%3Dliteratum%253Aachs%26aulast%3DHudson%26aufirst%3DB.%2BD.%26aulast%3DBeazley%26aufirst%3DM.%26aulast%3DSzczesniak%26aufirst%3DA.%2BM.%26aulast%3DStraiker%26aufirst%3DA.%26aulast%3DKelly%26aufirst%3DM.%2BE.%26atitle%3DIndirect%2520sympatholytic%2520actions%2520at%2520%25CE%25B2-adrenoceptors%2520account%2520for%2520the%2520ocular%2520hypotensive%2520actions%2520of%2520cannabinoid%2520receptor%2520agonists%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D339%26spage%3D757%26epage%3D767%26doi%3D10.1124%2Fjpet.111.185769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laine, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Järvinen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mechoulam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breuer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Järvinen, T.</span></span> <span> </span><span class="NLM_article-title">Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">3216</span>– <span class="NLM_lpage">3222</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=12356827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A280%3ADC%252BD38vpsFCktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2002&pages=3216-3222&author=K.+Laineauthor=K.+J%C3%A4rvinenauthor=R.+Mechoulamauthor=A.+Breuerauthor=T.+J%C3%A4rvinen&title=Comparison+of+the+enzymatic+stability+and+intraocular+pressure+effects+of+2-arachidonylglycerol+and+noladin+ether%2C+a+novel+putative+endocannabinoid"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid</span></div><div class="casAuthors">Laine Krista; Jarvinen Kristiina; Mechoulam Raphael; Breuer Aviva; Jarvinen Tomi</div><div class="citationInfo"><span class="NLM_cas:title">Investigative ophthalmology & visual science</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3216-22</span>
        ISSN:<span class="NLM_cas:issn">0146-0404</span>.
    </div><div class="casAbstract">PURPOSE:  The endogenous cannabinoids N-arachidonylethanolamide (AEA) and 2-arachidonylglycerol (2-AG) are known to decrease intraocular pressure (IOP).  Recently, a novel putative endogenous cannabinoid, noladin ether, was isolated in porcine and rat brains.  In the present study, both the degradation of endogenous cannabinoids in ocular tissues and the effect on IOP of 2-AG and noladin ether were compared.  METHODS:  The rates of enzymatic degradation for AEA, 2-AG, and noladin ether were determined in bovine cornea and iris-ciliary body homogenates. 2-AG and noladin ether were dissolved in either hydroxypropyl-beta-cyclodextrin (HP-beta-CD) or propylene glycol and administered unilaterally to the rabbit eye.  IOPs were measured in the treated and untreated eyes.  The CB1 receptor antagonist AM251 was administered topically 15 minutes before the cannabinoids to investigate whether CB1 receptors mediate the effect on IOP produced by 2-AG and noladin ether.  RESULTS:  Noladin ether degraded more slowly than either 2-AG or AEA in the iris-ciliary body and cornea homogenates.  The effect on IOP of 2-AG was biphasic (i.e., an initial increase in IOP followed by a reduction in the treated eye).  Noladin ether decreased IOP immediately after topical administration, and no initial IOP increase was observed in the treated eye.  The CB1 receptor antagonist AM251 (25 micro g) blocked the effect on IOP of noladin ether but did not affect the action of 2-AG.  CONCLUSIONS:  Topical administration of the novel putative endogenous cannabinoid noladin ether decreased IOP in rabbits.  This IOP reduction was most probably mediated through the CB1 receptor.  The effect on IOP of noladin ether differed from those of the known endogenous cannabinoids AEA and 2-AG, probably because of its more stable chemical structure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAdY8KXZB9SB0LsK7uFuY7fW6udTcc2eaENat7H9gCo7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38vpsFCktQ%253D%253D&md5=46611db5d2af4d4fb66c4593d1f32a4a</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLaine%26aufirst%3DK.%26aulast%3DJ%25C3%25A4rvinen%26aufirst%3DK.%26aulast%3DMechoulam%26aufirst%3DR.%26aulast%3DBreuer%26aufirst%3DA.%26aulast%3DJ%25C3%25A4rvinen%26aufirst%3DT.%26atitle%3DComparison%2520of%2520the%2520enzymatic%2520stability%2520and%2520intraocular%2520pressure%2520effects%2520of%25202-arachidonylglycerol%2520and%2520noladin%2520ether%252C%2520a%2520novel%2520putative%2520endocannabinoid%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2002%26volume%3D43%26spage%3D3216%26epage%3D3222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedberg-Buenz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M. G.</span></span> <span> </span><span class="NLM_article-title">Anterior segment dysgenesis and early-onset glaucoma in nee mice with mutation of Sh3pxd2b</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">2679</span>– <span class="NLM_lpage">2688</span>, <span class="refDoi"> DOI: 10.1167/iovs.10-5993</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1167%2Fiovs.10-5993" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=21282566" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmslSqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2011&pages=2679-2688&author=M.+Maoauthor=A.+Hedberg-Buenzauthor=D.+Koehnauthor=S.+W.+Johnauthor=M.+G.+Anderson&title=Anterior+segment+dysgenesis+and+early-onset+glaucoma+in+nee+mice+with+mutation+of+Sh3pxd2b&doi=10.1167%2Fiovs.10-5993"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Anterior segment dysgenesis and early-onset glaucoma in nee mice with mutation of Sh3pxd2b</span></div><div class="casAuthors">Mao, Mao; Hedberg-Buenz, Adam; Koehn, Demelza; John, Simon W. M.; Anderson, Michael G.</div><div class="citationInfo"><span class="NLM_cas:title">Investigative Ophthalmology & Visual Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2679-2688</span>CODEN:
                <span class="NLM_cas:coden">IOVSDA</span>;
        ISSN:<span class="NLM_cas:issn">1552-5783</span>.
    
            (<span class="NLM_cas:orgname">Association for Research in Vision and Ophthalmology</span>)
        </div><div class="casAbstract">PURPOSE: Mutations in SH3PXD2B cause Frank-Ter Haar syndrome, a rare condition characterized by congenital glaucoma, as well as craniofacial, skeletal, and cardiac anomalies.  The nee strain of mice carries a spontaneously arising mutation in Sh3pxd2b.  The purpose of this study was to test whether nee mice develop glaucoma.  METHODS: Eyes of nee mutants and strain-matched controls were comparatively analyzed at multiple ages by slit lamp examn., intraocular pressure recording, and histol. anal.  Cross sections of the optic nerve were analyzed to confirm glaucomatous progression.  RESULTS: Slit lamp examn. showed that, from an early age, nee mice uniformly exhibited severe iridocorneal adhesions around the entire circumference of the eye.  Presumably as a consequence of aq. humor outflow blockage, they rapidly developed multiple indexes of glaucoma.  By 3 to 4 mo of age, they exhibited high intraocular pressure (30.8 ± 12.5 mmHg; mean ± SD), corneal opacity, and enlarged anterior chambers.  Although histol. analyses at P17 did not reveal any indexes of damage, similar anal. at 3 to 4 mo of age revealed a course of progressive retinal ganglion cell loss, optic nerve head excavation, and axon loss.  CONCLUSIONS: Eyes of nee mice exhibit anterior segment dysgenesis and early-onset glaucoma.  Because SH3PXD2B is predicted to be a podosome adaptor protein, these findings implicate podosomes in normal development of the iridocorneal angle and the genes influencing podosomes as candidates in glaucoma.  Because of the early-onset, high-penetrance glaucoma, nee mice offer many potential advantages as a new mouse model of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgj1Mi_HwQyrVg90H21EOLACvtfcHk0ljqaXMUweP20w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmslSqt70%253D&md5=a996b8713e0987b89b2abc3e18b3118a</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1167%2Fiovs.10-5993&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.10-5993%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DM.%26aulast%3DHedberg-Buenz%26aufirst%3DA.%26aulast%3DKoehn%26aufirst%3DD.%26aulast%3DJohn%26aufirst%3DS.%2BW.%26aulast%3DAnderson%26aufirst%3DM.%2BG.%26atitle%3DAnterior%2520segment%2520dysgenesis%2520and%2520early-onset%2520glaucoma%2520in%2520nee%2520mice%2520with%2520mutation%2520of%2520Sh3pxd2b%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2011%26volume%3D52%26spage%3D2679%26epage%3D2688%26doi%3D10.1167%2Fiovs.10-5993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Järvinen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pate, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laine, K.</span></span> <span> </span><span class="NLM_article-title">Cannabinoids in the treatment of glaucoma</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1016/S0163-7258(02)00259-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1016%2FS0163-7258%2802%2900259-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=12182967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtlKjsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2002&pages=203-220&author=T.+J%C3%A4rvinenauthor=D.+W.+Pateauthor=K.+Laine&title=Cannabinoids+in+the+treatment+of+glaucoma&doi=10.1016%2FS0163-7258%2802%2900259-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoids in the treatment of glaucoma</span></div><div class="casAuthors">Jarvinen, Tomi; Pate, David W.; Laine, Krista</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">203-220</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review.  The leading cause of irreversible blindness is glaucoma, a disease normally characterized by the development of ocular hypertension and consequent damage to the optic nerve at its point of retinal attachment.  This results in a narrowing of the visual field, and eventually results in blindness.  A no. of drugs are available to lower intraocular pressure (IOP), but, occasionally, they are ineffective or have intolerable side-effects for some patients and can lose efficacy with chronic administration.  The smoking of marijuana has decreased IOP in glaucoma patients.  Cannabinoid drugs, therefore, are thought to have significant potential for pharmaceutical development.  However, as the mechanism surrounding their effect on IOP initially was thought to involve the CNS, issues of psychoactivity hindered progress.  The discovery of ocular cannabinoid receptors implied an explanation for the induction of hypotension by topical cannabinoid applications, and has stimulated a new phase of ophthalmic cannabinoid research.  Featured within these investigations is the possibility that at least some cannabinoids may ameliorate optic neuronal damage through suppression of N-methyl-D-aspartate receptor hyperexcitability, stimulation of neural microcirculation, and the suppression of both apoptosis and damaging free radical reactions, among other mechanisms.  Sepn. of therapeutic actions from side-effects now seems possible through a diverse array of novel chem., pharmacol., and formulation strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZPQjQHx9cVrVg90H21EOLACvtfcHk0ljJEqrlZS82mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtlKjsrs%253D&md5=6237e2d43288e40e6257757283116d02</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2802%2900259-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252802%252900259-0%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25A4rvinen%26aufirst%3DT.%26aulast%3DPate%26aufirst%3DD.%2BW.%26aulast%3DLaine%26aufirst%3DK.%26atitle%3DCannabinoids%2520in%2520the%2520treatment%2520of%2520glaucoma%26jtitle%3DPharmacol.%2520Ther.%26date%3D2002%26volume%3D95%26spage%3D203%26epage%3D220%26doi%3D10.1016%2FS0163-7258%2802%2900259-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cairns, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldridge, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, M. E.</span></span> <span> </span><span class="NLM_article-title">The endocannabinoid system as a therapeutic target in glaucoma</span>. <i>Neural Plast.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2016</i></span>, <span class="NLM_elocation-id">9364091</span> <span class="refDoi"> DOI: 10.1155/2016/9364091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1155%2F2016%2F9364091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=26881140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A280%3ADC%252BC28jhtVymuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2016&publication_year=2016&author=E.+A.+Cairnsauthor=W.+H.+Baldridgeauthor=M.+E.+Kelly&title=The+endocannabinoid+system+as+a+therapeutic+target+in+glaucoma&doi=10.1155%2F2016%2F9364091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">The Endocannabinoid System as a Therapeutic Target in Glaucoma</span></div><div class="casAuthors">Cairns Elizabeth A; Baldridge William H; Kelly Melanie E M</div><div class="citationInfo"><span class="NLM_cas:title">Neural plasticity</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2016</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9364091</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Glaucoma is an irreversible blinding eye disease which produces progressive retinal ganglion cell (RGC) loss.  Intraocular pressure (IOP) is currently the only modifiable risk factor, and lowering IOP results in reduced risk of progression of the disorder.  The endocannabinoid system (ECS) has attracted considerable attention as a potential target for the treatment of glaucoma, largely due to the observed IOP lowering effects seen after administration of exogenous cannabinoids.  However, recent evidence has suggested that modulation of the ECS may also be neuroprotective.  This paper will review the use of cannabinoids in glaucoma, presenting pertinent information regarding the pathophysiology of glaucoma and how alterations in cannabinoid signalling may contribute to glaucoma pathology.  Additionally, the mechanisms and potential for the use of cannabinoids and other novel agents that target the endocannabinoid system in the treatment of glaucoma will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRRFS7HBs9MUmLFM_lbR1VmfW6udTcc2ea7jVhElPaknLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jhtVymuw%253D%253D&md5=ee545657c1713957eee166b3ebcf8fdb</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1155%2F2016%2F9364091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2016%252F9364091%26sid%3Dliteratum%253Aachs%26aulast%3DCairns%26aufirst%3DE.%2BA.%26aulast%3DBaldridge%26aufirst%3DW.%2BH.%26aulast%3DKelly%26aufirst%3DM.%2BE.%26atitle%3DThe%2520endocannabinoid%2520system%2520as%2520a%2520therapeutic%2520target%2520in%2520glaucoma%26jtitle%3DNeural%2520Plast.%26date%3D2016%26volume%3D2016%26doi%3D10.1155%2F2016%2F9364091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gamage, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abood, M. E.</span></span> <span> </span><span class="NLM_article-title">CB(1) allosteric modulator Org27569 is an antagonist/inverse agonist of ERK1/2 signaling</span>. <i>Cannabis Cannabinoid Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">272</span>– <span class="NLM_lpage">280</span>, <span class="refDoi"> DOI: 10.1089/can.2016.0028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1089%2Fcan.2016.0028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=28660254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkslGntLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2016&pages=272-280&author=T.+F.+Gamageauthor=J.+C.+Andersonauthor=M.+E.+Abood&title=CB%281%29+allosteric+modulator+Org27569+is+an+antagonist%2Finverse+agonist+of+ERK1%2F2+signaling&doi=10.1089%2Fcan.2016.0028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">CB1 allosteric modulator Org27569 is an antagonist/inverse agonist of ERK1/2 signaling</span></div><div class="casAuthors">Gamage, Thomas F.; Anderson, Johnathon C.; Abood, Mary E.</div><div class="citationInfo"><span class="NLM_cas:title">Cannabis and Cannabinoid Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">272-280</span>CODEN:
                <span class="NLM_cas:coden">CCRAEP</span>;
        ISSN:<span class="NLM_cas:issn">2378-8763</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Allosteric modulation of cannabinoid type-1 receptors (CB1) is a novel means through which signaling bias may be exerted.  Org27569 remains the most-characterized CB1 allosteric modulator, yet there are conflicting reports regarding its effects on extracellular signal-regulated kinase (ERK) signaling.  We conducted a systematic evaluation of Org27569's effects on cannabinoid agonists and ERK signaling.  HEK293 cells transfected with the human cannabinoid type-1 receptor (hCB1) were treated with Org27569 alone or in combination with the endocannabinoid 2-arachidonoylglycerol (2-AG), the synthetic cannabinoid CP55,940, or the phytocannabinoid delta-9-tetrahydrocannabinol (THC) and ERK activation was measured by western blot.  Overnight treatment with pertussis toxin (PTX) was used to det. the role of Gi/o in Org27569's inverse agonist effects.  HEK293 cells transfected with green fluorescent protein tagged hCB1 receptor were used to assess effects of Org27569 on CP55,940-induced receptor internalization.  Subcellular fractionation was used to det. effects of Org27569 on ERK phosphorylation in both nuclear and cytosolic compartments.  We found that Org27569 is an antagonist of hCB1-mediated ERK signaling in HEK293 cells where it fully blocks CP55,940-but does not completely inhibit THC- and 2-AG-stimulated ERK1/2 activation following 5 min treatment.  In hCB1 HEK293 cells, CP55,940 (1 μM) treatment produced a significant increase in puncta at 20, 40, 60, and 120 min, consistent with receptor internalization.  Org27569 (10 μM) co-treatment prevented internalization at each time point and alone had no effect.  Org27569 reduced basal ERK phosphorylation in hCB1 HEK293 cells but not in untransfected cells following 20 min treatment.  Overnight treatment with PTX abated this response.  Following subcellular fractionation, Org27569 produced a significant decrease in ERK phosphorylation in the nuclear-enriched and cytosolic fractions.  These data are consistent with previous studies demonstrating that CB1-mediated ERK1/2 activation is Gi/o-dependent and that Org27569 is an inverse agonist of CB1 receptors.  Abrogation of Org27569's ability to reduce basal ERK phosphorylation following treatment with PTX and lack of inverse agonist effects in untransfected HEK293 cells demonstrates that Org27569 acts via CB1-Gi/o to produce this effect.  To our knowledge, this is the first reported demonstration of inverse agonism of ERK signaling by Org27569.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqBloG3aPcHrVg90H21EOLACvtfcHk0lgq5I_g8oXqwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkslGntLo%253D&md5=36afa6bf4fe1821e54a5dc662d20891b</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1089%2Fcan.2016.0028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fcan.2016.0028%26sid%3Dliteratum%253Aachs%26aulast%3DGamage%26aufirst%3DT.%2BF.%26aulast%3DAnderson%26aufirst%3DJ.%2BC.%26aulast%3DAbood%26aufirst%3DM.%2BE.%26atitle%3DCB%25281%2529%2520allosteric%2520modulator%2520Org27569%2520is%2520an%2520antagonist%252Finverse%2520agonist%2520of%2520ERK1%252F2%2520signaling%26jtitle%3DCannabis%2520Cannabinoid%2520Res.%26date%3D2016%26volume%3D1%26spage%3D272%26epage%3D280%26doi%3D10.1089%2Fcan.2016.0028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abood, M. E.</span></span> <span> </span><span class="NLM_article-title">Mutation of a highly conserved aspartate residue in the second transmembrane domain of the cannabinoid receptors, CB1 and CB2, disrupts G-protein coupling</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">651</span>– <span class="NLM_lpage">658</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=9580609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADyaK1cXjtF2gu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=1998&pages=651-658&author=Q.+Taoauthor=M.+E.+Abood&title=Mutation+of+a+highly+conserved+aspartate+residue+in+the+second+transmembrane+domain+of+the+cannabinoid+receptors%2C+CB1+and+CB2%2C+disrupts+G-protein+coupling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Mutation of a highly conserved aspartate residue in the second transmembrane domain of the cannabinoid receptors, CB1 and CB2, disrupts G-protein coupling</span></div><div class="casAuthors">Tao, Qing; Abood, Mary E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">651-658</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The cannabinoid receptors, CB1 and CB2, are members of the G-protein coupled receptor family and share many of this family's structural features.  A highly conserved aspartic acid residue in the second transmembrane domain of G-protein coupled receptors has been shown for many of these receptors to be functionally important for agonist binding and/or G-protein coupling.  To det. whether this residue is involved in cannabinoid receptor function, we used site-directed mutagenesis of receptor cDNA followed by expression of the mutant receptor in HEK 293 cells.  Aspartate 163 (in CB1) and aspartate 80 (in CB2) were substituted with either asparagine or glutamate.  Stably transfected cell lines were tested for radioligand binding and inhibition of cAMP accumulation.  Binding of the cannabinoid receptor agonist [3H]CP-55,940 was not affected by either mutation in either the CB1 or CB2 receptor, nor were the affinities of anandamide or (-)-Δ9-tetrahydrocannabinol.  Binding of the CB1-selective receptor antagonist SR141716A also was unaltered.  However, the affinity of WIN 55,212-2 was attenuated significantly in the CB1, but not the CB2, mutant receptors.  Studies examg. inhibition of cAMP accumulation showed reduced effects of cannabinoid agonists in the mutated receptors.  Our data suggest that this aspartate residue is not generally important for ligand recognition in the cannabinoid receptors; however, it is required for communication with G proteins and signal transduction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIV5bwm7yRiLVg90H21EOLACvtfcHk0lgq5I_g8oXqwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjtF2gu7w%253D&md5=4a99aa57ccb002fc02e301400d439da8</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTao%26aufirst%3DQ.%26aulast%3DAbood%26aufirst%3DM.%2BE.%26atitle%3DMutation%2520of%2520a%2520highly%2520conserved%2520aspartate%2520residue%2520in%2520the%2520second%2520transmembrane%2520domain%2520of%2520the%2520cannabinoid%2520receptors%252C%2520CB1%2520and%2520CB2%252C%2520disrupts%2520G-protein%2520coupling%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1998%26volume%3D285%26spage%3D651%26epage%3D658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miess, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gondin, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yousuf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinborn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mösslein, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Göldner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruland, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bünemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halls, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canals, M.</span></span> <span> </span><span class="NLM_article-title">Multisite phosphorylation is required for sustained interaction with GRKs and arrestins during rapid μ-opioid receptor desensitization</span>. <i>Sci. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">eaas9609</span> <span class="refDoi"> DOI: 10.1126/scisignal.aas9609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1126%2Fscisignal.aas9609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=30018083" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&author=E.+Miessauthor=A.+B.+Gondinauthor=A.+Yousufauthor=R.+Steinbornauthor=N.+M%C3%B6ssleinauthor=Y.+Yangauthor=M.+G%C3%B6ldnerauthor=J.+G.+Rulandauthor=M.+B%C3%BCnemannauthor=C.+Kraselauthor=M.+J.+Christieauthor=M.+L.+Hallsauthor=S.+Schulzauthor=M.+Canals&title=Multisite+phosphorylation+is+required+for+sustained+interaction+with+GRKs+and+arrestins+during+rapid+%CE%BC-opioid+receptor+desensitization&doi=10.1126%2Fscisignal.aas9609"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.aas9609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.aas9609%26sid%3Dliteratum%253Aachs%26aulast%3DMiess%26aufirst%3DE.%26aulast%3DGondin%26aufirst%3DA.%2BB.%26aulast%3DYousuf%26aufirst%3DA.%26aulast%3DSteinborn%26aufirst%3DR.%26aulast%3DM%25C3%25B6sslein%26aufirst%3DN.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DG%25C3%25B6ldner%26aufirst%3DM.%26aulast%3DRuland%26aufirst%3DJ.%2BG.%26aulast%3DB%25C3%25BCnemann%26aufirst%3DM.%26aulast%3DKrasel%26aufirst%3DC.%26aulast%3DChristie%26aufirst%3DM.%2BJ.%26aulast%3DHalls%26aufirst%3DM.%2BL.%26aulast%3DSchulz%26aufirst%3DS.%26aulast%3DCanals%26aufirst%3DM.%26atitle%3DMultisite%2520phosphorylation%2520is%2520required%2520for%2520sustained%2520interaction%2520with%2520GRKs%2520and%2520arrestins%2520during%2520rapid%2520%25CE%25BC-opioid%2520receptor%2520desensitization%26jtitle%3DSci.%2520Signaling%26date%3D2018%26volume%3D11%26doi%3D10.1126%2Fscisignal.aas9609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R. G.</span></span> <span> </span><span class="NLM_article-title">The ring test: a quantitative method for assessing the ‘cataleptic’ effect of cannabis in mice</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1972</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">753</span>– <span class="NLM_lpage">763</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.1972.tb06900.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1111%2Fj.1476-5381.1972.tb06900.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=4655271" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADyaE3sXms1Oltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=1972&pages=753-763&author=R.+G.+Pertwee&title=The+ring+test%3A+a+quantitative+method+for+assessing+the+%E2%80%98cataleptic%E2%80%99+effect+of+cannabis+in+mice&doi=10.1111%2Fj.1476-5381.1972.tb06900.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Ring test.  Quantitative method for assessing the cataleptic effect of cannabis in mice</span></div><div class="casAuthors">Pertwee, R. G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1972</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">753-63</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    </div><div class="casAbstract">The length of time a mouse remained completely immobile when placed in a prone position across a horizontally suspended wire ring 5.5 cm in diam. could be used to assess the cataleptic effect of cannabis.  The effect of cannabis on motility was a dose-related, graded response.  Threshold doses of cannabis ext. were 12.5 mg per kg when injected i.v. and 100 mg per kg when injected i.p. or s.c.  Characteristic changes in behavior on the ring induced by cannabis ext. were also produced by chlorpromazine-HCl, but not by Na barbitone.  Δ1-Tetrahydrocannabinol (THC) [1972-08-3] was largely responsible for the effect of cannabis ext. on motility; the potency ratio of THC to cannabis ext. was between 10 and 20.  Δ1-Tetrahydrocannabidivarol [31262-37-0] also affected mobility but was less active than THC.  Cannabidiol [13956-29-1] had no effect, even at doses up to 100 mg per kg, i.p.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2Lm_ZL8Wp5rVg90H21EOLACvtfcHk0ljPe89hX25UbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3sXms1Oltg%253D%253D&md5=e3ed3a63360b54de7f394e1afb399328</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1972.tb06900.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1972.tb06900.x%26sid%3Dliteratum%253Aachs%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26atitle%3DThe%2520ring%2520test%253A%2520a%2520quantitative%2520method%2520for%2520assessing%2520the%2520%25E2%2580%2598cataleptic%25E2%2580%2599%2520effect%2520of%2520cannabis%2520in%2520mice%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1972%26volume%3D46%26spage%3D753%26epage%3D763%26doi%3D10.1111%2Fj.1476-5381.1972.tb06900.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ignatowska-Jankowska, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinsey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damaj, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poklis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiley, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanato, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greig, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, R. A.</span></span> <span> </span><span class="NLM_article-title">A cannabinoid cb1 receptor-positive allosteric modulator reduces neuropathic pain in the mouse with no psychoactive effects</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2948</span>– <span class="NLM_lpage">2959</span>, <span class="refDoi"> DOI: 10.1038/npp.2015.148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1038%2Fnpp.2015.148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=26052038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Chu7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2015&pages=2948-2959&author=B.+M.+Ignatowska-Jankowskaauthor=G.+L.+Baillieauthor=S.+Kinseyauthor=M.+Croweauthor=S.+Ghoshauthor=R.+A.+Owensauthor=I.+M.+Damajauthor=J.+Poklisauthor=J.+L.+Wileyauthor=M.+Zandaauthor=C.+Zanatoauthor=I.+R.+Greigauthor=A.+H.+Lichtmanauthor=R.+A.+Ross&title=A+cannabinoid+cb1+receptor-positive+allosteric+modulator+reduces+neuropathic+pain+in+the+mouse+with+no+psychoactive+effects&doi=10.1038%2Fnpp.2015.148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">A Cannabinoid CB1 Receptor-Positive Allosteric Modulator Reduces Neuropathic Pain in the Mouse with No Psychoactive Effects</span></div><div class="casAuthors">Ignatowska-Jankowska, Bogna M.; Baillie, Gemma L.; Kinsey, Steven; Crowe, Molly; Ghosh, Sudeshna; Owens, Robert A.; Damaj, Imad M.; Poklis, Justin; Wiley, Jenny L.; Zanda, Matteo; Zanato, Chiara; Greig, Iain R.; Lichtman, Aron H.; Ross, Ruth A.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2948-2959</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The CB1 receptor represents a promising target for the treatment of several disorders including pain-related disease states.  However, therapeutic applications of Δ9-tetrahydrocannabinol and other CB1 orthosteric receptor agonists remain limited because of psychoactive side effects.  Pos. allosteric modulators (PAMs) offer an alternative approach to enhance CB1 receptor function for therapeutic gain with the promise of reduced side effects.  Here we describe the development of the novel synthetic CB1 PAM, 6-methyl-3-(2-nitro-1-(thiophen-2-yl)ethyl)-2-phenyl-1H-indole (ZCZ011), which augments the in vitro and in vivo pharmacol. actions of the CB1 orthosteric agonists CP55,940 and N-arachidonoylethanolamine (AEA).  ZCZ011 potentiated binding of [3H]CP55,940 to the CB1 receptor as well as enhancing AEA-stimulated [35S]GTPγS binding in mouse brain membranes and β-arrestin recruitment and ERK phosphorylation in hCB1 cells.  In the whole animal, ZCZ011 is brain penetrant, increased the potency of these orthosteric agonists in mouse behavioral assays indicative of cannabimimetic activity, including antinociception, hypothermia, catalepsy, locomotor activity, and in the drug discrimination paradigm.  Administration of ZCZ011 alone was devoid of activity in these assays and did not produce a conditioned place preference or aversion, but elicited CB1 receptor-mediated antinociceptive effects in the chronic constriction nerve injury model of neuropathic pain and carrageenan model of inflammatory pain.  These data suggest that ZCZ011 acts as a CB1 PAM and provide the first proof of principle that CB1 PAMs offer a promising strategy to treat neuropathic and inflammatory pain with minimal or no cannabimimetic side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGrwc1SxmigLVg90H21EOLACvtfcHk0ljPe89hX25UbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Chu7jI&md5=353f294dc5044468997e98fb49711abf</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2015.148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2015.148%26sid%3Dliteratum%253Aachs%26aulast%3DIgnatowska-Jankowska%26aufirst%3DB.%2BM.%26aulast%3DBaillie%26aufirst%3DG.%2BL.%26aulast%3DKinsey%26aufirst%3DS.%26aulast%3DCrowe%26aufirst%3DM.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DOwens%26aufirst%3DR.%2BA.%26aulast%3DDamaj%26aufirst%3DI.%2BM.%26aulast%3DPoklis%26aufirst%3DJ.%26aulast%3DWiley%26aufirst%3DJ.%2BL.%26aulast%3DZanda%26aufirst%3DM.%26aulast%3DZanato%26aufirst%3DC.%26aulast%3DGreig%26aufirst%3DI.%2BR.%26aulast%3DLichtman%26aufirst%3DA.%2BH.%26aulast%3DRoss%26aufirst%3DR.%2BA.%26atitle%3DA%2520cannabinoid%2520cb1%2520receptor-positive%2520allosteric%2520modulator%2520reduces%2520neuropathic%2520pain%2520in%2520the%2520mouse%2520with%2520no%2520psychoactive%2520effects%26jtitle%3DNeuropsychopharmacology%26date%3D2015%26volume%3D40%26spage%3D2948%26epage%3D2959%26doi%3D10.1038%2Fnpp.2015.148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grim, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiley, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endres, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negus, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtman, A. H.</span></span> <span> </span><span class="NLM_article-title">Apparent CB(1) receptor rimonabant affinity estimates: combination with thc and synthetic cannabinoids in the mouse in vivo triad model</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>362</i></span>,  <span class="NLM_fpage">210</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.1124/jpet.117.240192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1124%2Fjpet.117.240192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=28442584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOqsb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2017&pages=210-218&author=T.+W.+Grimauthor=A.+J.+Moralesauthor=B.+F.+Thomasauthor=J.+L.+Wileyauthor=G.+W.+Endresauthor=S.+S.+Negusauthor=A.+H.+Lichtman&title=Apparent+CB%281%29+receptor+rimonabant+affinity+estimates%3A+combination+with+thc+and+synthetic+cannabinoids+in+the+mouse+in+vivo+triad+model&doi=10.1124%2Fjpet.117.240192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Apparent CB1 Receptor rimonabant affinity estimates: combination with THC and synthetic cannabinoids in the mouse in vivo triad model</span></div><div class="casAuthors">Grim, T. W.; Morales, A. J.; Thomas, B. F.; Wiley, J. L.; Endres, G. W.; Negus, S. S.; Lichtman, A. H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">362</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">210-218</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Synthetic cannabinoids (SCs) represent an emerging class of abused drugs assocd. with psychiatric complications and other substantial health risks.  These ligands are largely sold over the internet for human consumption, presumably because of their high cannabinoid 1 receptor (CB1R) affinity and their potency in eliciting pharmacol. effects similar to Δ9-tetrahydrocannabinol (THC), as well as circumventing laws illegalizing this plant.  Factors potentially contributing to the increased prevalence of SC abuse and related hospitalizations, such as increased CB1R efficacy and non-CB1R targets, highlight the need for quant. pharmacol. analyses to det. receptor mediation of the pharmacol. effects of cannabinoids.  Accordingly, the present study used pA2 and pKB analyses for quant. detn. of CB1R mediation in which we utilized the CB1R-selective inverse agonist/antagonist rimonabant to elicit rightward shifts in the dose-response curves of five SCs (i.e., A-834,735D; WIN55,212-2; CP55,950; JWH-073; and CP47,497) and THC in producing common cannabimimetic effects (i.e., catalepsy, antinociception, and hypothermia).  The results revealed overall similarity of pA2 and pKB values for these compds. and suggest that CB1Rs, and not other pharmacol. targets, largely mediated the central pharmacol. effects of SCs.  More generally, affinity estn. offers a powerful pharmacol. approach to assess potential receptor heterogeneity subserving in vivo pharmacol. effects of SCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVV1fny3iBx7Vg90H21EOLACvtfcHk0ljqKW8cDKarPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOqsb3L&md5=3d8f408cdc6911b513e1f303b799fe95</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1124%2Fjpet.117.240192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.117.240192%26sid%3Dliteratum%253Aachs%26aulast%3DGrim%26aufirst%3DT.%2BW.%26aulast%3DMorales%26aufirst%3DA.%2BJ.%26aulast%3DThomas%26aufirst%3DB.%2BF.%26aulast%3DWiley%26aufirst%3DJ.%2BL.%26aulast%3DEndres%26aufirst%3DG.%2BW.%26aulast%3DNegus%26aufirst%3DS.%2BS.%26aulast%3DLichtman%26aufirst%3DA.%2BH.%26atitle%3DApparent%2520CB%25281%2529%2520receptor%2520rimonabant%2520affinity%2520estimates%253A%2520combination%2520with%2520thc%2520and%2520synthetic%2520cannabinoids%2520in%2520the%2520mouse%2520in%2520vivo%2520triad%2520model%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D362%26spage%3D210%26epage%3D218%26doi%3D10.1124%2Fjpet.117.240192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bekkers, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, C. F.</span></span> <span> </span><span class="NLM_article-title">Excitatory and inhibitory autaptic currents in isolated hippocampal neurons maintained in cell culture</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">7834</span>– <span class="NLM_lpage">7838</span>, <span class="refDoi"> DOI: 10.1073/pnas.88.17.7834</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1073%2Fpnas.88.17.7834" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1679238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A280%3ADyaK3Mzlt1Srtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=1991&pages=7834-7838&author=J.+M.+Bekkersauthor=C.+F.+Stevens&title=Excitatory+and+inhibitory+autaptic+currents+in+isolated+hippocampal+neurons+maintained+in+cell+culture&doi=10.1073%2Fpnas.88.17.7834"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Excitatory and inhibitory autaptic currents in isolated hippocampal neurons maintained in cell culture</span></div><div class="casAuthors">Bekkers J M; Stevens C F</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7834-8</span>
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Individual rat hippocampal neurons, grown in isolation from other neurons on small spots of permissive substrate, were studied in order to characterize the electrical properties of the synapses that such cells formed with themselves (autapses).  Excitatory (probably glutamatergic) or inhibitory (probably type A gamma-aminobutyratergic) autapses were frequently found.  Excitatory autaptic currents reversed near the potential expected for monovalent cations were blocked by the glutamatergic antagonist kynurenic acid, and possessed a slow component with the pharmacological profile of N-methyl-D-aspartate-type channels.  These currents also exhibited trial-to-trial statistical fluctuations in their amplitudes, this being well-described by quantal analysis.  Inhibitory autaptic currents reversed at hyperpolarized potentials, as expected for chloride-permeable pores and were blocked by picrotoxin, a type A gamma-aminobutyric receptor antagonist.  It is concluded that autaptic currents in culture are identical to those found at synapses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQhZyx5UjrkLNTiMd2aNQVUfW6udTcc2eY_AMoceJcoj7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3Mzlt1Srtw%253D%253D&md5=27a067146b950d6a65dc4038a97da464</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1073%2Fpnas.88.17.7834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.88.17.7834%26sid%3Dliteratum%253Aachs%26aulast%3DBekkers%26aufirst%3DJ.%2BM.%26aulast%3DStevens%26aufirst%3DC.%2BF.%26atitle%3DExcitatory%2520and%2520inhibitory%2520autaptic%2520currents%2520in%2520isolated%2520hippocampal%2520neurons%2520maintained%2520in%2520cell%2520culture%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1991%26volume%3D88%26spage%3D7834%26epage%3D7838%26doi%3D10.1073%2Fpnas.88.17.7834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furshpan, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLeish, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Lague, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, D. D.</span></span> <span> </span><span class="NLM_article-title">Chemical transmission between rat sympathetic neurons and cardiac myocytes developing in microcultures: evidence for cholinergic, adrenergic, and dual-function neurons</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">4225</span>– <span class="NLM_lpage">4229</span>, <span class="refDoi"> DOI: 10.1073/pnas.73.11.4225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1073%2Fpnas.73.11.4225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=186792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADyaE2sXktV2ntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1976&pages=4225-4229&author=E.+J.+Furshpanauthor=P.+R.+MacLeishauthor=P.+H.+O%E2%80%99Lagueauthor=D.+D.+Potter&title=Chemical+transmission+between+rat+sympathetic+neurons+and+cardiac+myocytes+developing+in+microcultures%3A+evidence+for+cholinergic%2C+adrenergic%2C+and+dual-function+neurons&doi=10.1073%2Fpnas.73.11.4225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical transmission between rat sympathetic neurons and cardiac myocytes developing in microcultures:  Evidence for cholinergic, adrenergic, and dual-function neurons</span></div><div class="casAuthors">Furshpan, E. J.; MacLeish, P. R.; O'Lague, P. H.; Potter, D. D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4225-9</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Electrophysiol. studies were made on microcultures (300-500 μm in diameter) in which solitary sympathetic principal neurons from newborn rats grew on previously dissocd. rat heart cells.  Some neurons inhibited, some excited, and others 1st inhibited and then excited the cardiac myocytes.  Application of drugs provided evidence for the secretion of acetylcholine by the 1st group, catecholamines by the 2nd, and both acetylcholine and catecholamines by the 3rd.  Solitary neurons which inhibited the myocytes usually excited themselves at nicotinic synapses (autapses).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgFtcbbCa32bVg90H21EOLACvtfcHk0ljVWtEfhQLCnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXktV2ntg%253D%253D&md5=627484d1d91c7ec1168d90d7d48ef507</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1073%2Fpnas.73.11.4225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.73.11.4225%26sid%3Dliteratum%253Aachs%26aulast%3DFurshpan%26aufirst%3DE.%2BJ.%26aulast%3DMacLeish%26aufirst%3DP.%2BR.%26aulast%3DO%25E2%2580%2599Lague%26aufirst%3DP.%2BH.%26aulast%3DPotter%26aufirst%3DD.%2BD.%26atitle%3DChemical%2520transmission%2520between%2520rat%2520sympathetic%2520neurons%2520and%2520cardiac%2520myocytes%2520developing%2520in%2520microcultures%253A%2520evidence%2520for%2520cholinergic%252C%2520adrenergic%252C%2520and%2520dual-function%2520neurons%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1976%26volume%3D73%26spage%3D4225%26epage%3D4229%26doi%3D10.1073%2Fpnas.73.11.4225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levison, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, K. D.</span></span> <span> </span><span class="NLM_article-title">Characterization and partial purification of AIM: a plasma protein that induces rat cerebral type 2 astroglia from bipotential glial progenitors</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">782</span>– <span class="NLM_lpage">794</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.1991.tb08220.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1111%2Fj.1471-4159.1991.tb08220.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1861150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADyaK3MXlt1ynu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1991&pages=782-794&author=S.+W.+Levisonauthor=K.+D.+McCarthy&title=Characterization+and+partial+purification+of+AIM%3A+a+plasma+protein+that+induces+rat+cerebral+type+2+astroglia+from+bipotential+glial+progenitors&doi=10.1111%2Fj.1471-4159.1991.tb08220.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization and partial purification of AIM:  a plasma protein that induces rat cerebral type 2 astroglia from bipotential glial progenitors</span></div><div class="casAuthors">Levison, Steven W.; McCarthy, Ken D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">782-94</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    </div><div class="casAbstract">Studies on glial cultures have demonstrated that fetal bovine serum contains a factor that induces bipotential glial precursors known as oligodendrocyte-type 2 astrocyte (O-2A) progenitors to become type 2 astroglia rather than oligodendroglia.  The goal of this research was to characterize and purify this factor, termed the astroglia-inducing mol. (AIM).  The use of cultures enriched in O-2A progenitors indicated that AIM is present in human and bovine sera and that fetal bovine serum qualified as the best serum for purifying AIM.  AIM is heat and trypsin labile and may be a plasma glycoprotein.  A 240-fold enriched AIM prepn. was produced by applying an (NH4)2SO4 ppt. of fetal bovine serum to heparin and then lentil lectin-agarose, followed by gel filtration chromatog.  In crude prepns., AIM activity migrated at 50 kDa by gel filtration.  With enrichment, activity was seen at several mol. masses, all of which were approx. multiples of 50 kDa.  Treatment with 6 M guanidine-HCl generated an AIM with a mol. mass between 12 and 18 kDa, a result suggesting that AIM aggregates.  On a preparative isoelec. focusing gel, AIM activity most frequently migrated between pH values of 3 and 4; however, proteins with isoelec. points of >9 or at 6 also had activity in several expts.  These data suggest that either multiple AIMs exist or a single AIM exists that assocs. with other proteins.  Immunofluorescence for ganglioside GD3 and glial fibrillary acidic protein confirmed that AIM prepns. induce type 2 astroglia from O-2A progenitors and suggests that AIM has little effect on type 1 astroglia.  None of the known growth factors that have been tested to date mimics its effects, so AIM may be a novel differentiation factor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRq9szkAlHpLVg90H21EOLACvtfcHk0liwnQIUP5-ECA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXlt1ynu7g%253D&md5=2cd50a1094f8e42552919e9987518ebc</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.1991.tb08220.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.1991.tb08220.x%26sid%3Dliteratum%253Aachs%26aulast%3DLevison%26aufirst%3DS.%2BW.%26aulast%3DMcCarthy%26aufirst%3DK.%2BD.%26atitle%3DCharacterization%2520and%2520partial%2520purification%2520of%2520AIM%253A%2520a%2520plasma%2520protein%2520that%2520induces%2520rat%2520cerebral%2520type%25202%2520astroglia%2520from%2520bipotential%2520glial%2520progenitors%26jtitle%3DJ.%2520Neurochem.%26date%3D1991%26volume%3D57%26spage%3D782%26epage%3D794%26doi%3D10.1111%2Fj.1471-4159.1991.tb08220.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bochevarov, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braden, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philipp, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinaldo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halls, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span> <span> </span><span class="NLM_article-title">Jaguar: A high-performance quantum chemistry software program with strengths in life and materials sciences</span>. <i>Int. J. Quantum Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">2110</span>– <span class="NLM_lpage">2142</span>, <span class="refDoi"> DOI: 10.1002/qua.24481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1002%2Fqua.24481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVCqs7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2013&pages=2110-2142&author=A.+D.+Bochevarovauthor=E.+Harderauthor=T.+F.+Hughesauthor=J.+R.+Greenwoodauthor=D.+A.+Bradenauthor=D.+M.+Philippauthor=D.+Rinaldoauthor=M.+D.+Hallsauthor=J.+Zhangauthor=R.+A.+Friesner&title=Jaguar%3A+A+high-performance+quantum+chemistry+software+program+with+strengths+in+life+and+materials+sciences&doi=10.1002%2Fqua.24481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Jaguar: A high-performance quantum chemistry software program with strengths in life and materials sciences</span></div><div class="casAuthors">Bochevarov, Art D.; Harder, Edward; Hughes, Thomas F.; Greenwood, Jeremy R.; Braden, Dale A.; Philipp, Dean M.; Rinaldo, David; Halls, Mathew D.; Zhang, Jing; Friesner, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Quantum Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2110-2142</span>CODEN:
                <span class="NLM_cas:coden">IJQCB2</span>;
        ISSN:<span class="NLM_cas:issn">0020-7608</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Jaguar is an ab initio quantum chem. program that specializes in fast electronic structure predictions for mol. systems of medium and large size.  Jaguar focuses on computational methods with reasonable computational scaling with the size of the system, such as d. functional theory (DFT) and local second-order Moller-Plesset perturbation theory.  The favorable scaling of the methods and the high efficiency of the program make it possible to conduct routine computations involving several thousand MOs.  This performance is achieved through a utilization of the pseudospectral approxn. and several levels of parallelization.  The speed advantages are beneficial for applying Jaguar in biomol. computational modeling.  Addnl., owing to its superior wave function guess for transition-metal-contg. systems, Jaguar finds applications in inorg. and bioinorg. chem.  The emphasis on larger systems and transition metal elements paves the way toward developing Jaguar for its use in materials science modeling.  The article describes the historical and new features of Jaguar, such as improved parallelization of many modules, innovations in ab initio pKa prediction, and new semiempirical corrections for nondynamic correlation errors in DFT.  Jaguar applications in drug discovery, materials science, force field parameterization, and other areas of computational research are reviewed.  Timing benchmarks and other results obtained from the most recent Jaguar code are provided.  The article concludes with a discussion of challenges and directions for future development of the program. © 2013 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt_0dnCf0Yq7Vg90H21EOLACvtfcHk0liwnQIUP5-ECA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVCqs7%252FP&md5=2fc119bb9e0501e55d7292f7735c24ea</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1002%2Fqua.24481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fqua.24481%26sid%3Dliteratum%253Aachs%26aulast%3DBochevarov%26aufirst%3DA.%2BD.%26aulast%3DHarder%26aufirst%3DE.%26aulast%3DHughes%26aufirst%3DT.%2BF.%26aulast%3DGreenwood%26aufirst%3DJ.%2BR.%26aulast%3DBraden%26aufirst%3DD.%2BA.%26aulast%3DPhilipp%26aufirst%3DD.%2BM.%26aulast%3DRinaldo%26aufirst%3DD.%26aulast%3DHalls%26aufirst%3DM.%2BD.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26atitle%3DJaguar%253A%2520A%2520high-performance%2520quantum%2520chemistry%2520software%2520program%2520with%2520strengths%2520in%2520life%2520and%2520materials%2520sciences%26jtitle%3DInt.%2520J.%2520Quantum%2520Chem.%26date%3D2013%26volume%3D113%26spage%3D2110%26epage%3D2142%26doi%3D10.1002%2Fqua.24481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ballesteros, J. A.</span>; <span class="NLM_string-name">Weinstein, H.</span></span> <span> </span><span class="NLM_article-title">[19] Integrated Methods for the Construction of Three-dimensional Models and Computational Probing of Structure-function Relations in G Protein-coupled Receptors</span>. In  <i>Methods in Neuroscience</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sealfon, S. C.</span></span>, Ed.; <span class="NLM_publisher-name">Academic Press</span>, <span class="NLM_year">1995</span>; Vol.  <span class="NLM_volume">25</span>, pp  <span class="NLM_fpage">366</span>– <span class="NLM_lpage">428</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1016%2FS1043-9471%2805%2980049-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1995&pages=366-428&author=J.+A.+Ballesteros&author=H.+Weinsteinauthor=S.+C.+Sealfon&title=Methods+in+Neuroscience"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2FS1043-9471%2805%2980049-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FS1043-9471%252805%252980049-7%26sid%3Dliteratum%253Aachs%26aulast%3DBallesteros%26aufirst%3DJ.%2BA.%26atitle%3D%255B19%255D%2520Integrated%2520Methods%2520for%2520the%2520Construction%2520of%2520Three-dimensional%2520Models%2520and%2520Computational%2520Probing%2520of%2520Structure-function%2520Relations%2520in%2520G%2520Protein-coupled%2520Receptors%26btitle%3DMethods%2520in%2520Neuroscience%26aulast%3DSealfon%26aufirst%3DS.%2BC.%26pub%3DAcademic%2520Press%26date%3D1995%26volume%3D25%26spage%3D366%26epage%3D428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mayne, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tajkhorshid, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gumbart, J. C.</span></span> <span> </span><span class="NLM_article-title">Rapid parameterization of small molecules using the Force Field Toolkit</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">2757</span>– <span class="NLM_lpage">2770</span>, <span class="refDoi"> DOI: 10.1002/jcc.23422</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1002%2Fjcc.23422" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=24000174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlyrt73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=2757-2770&author=C.+G.+Mayneauthor=J.+Saamauthor=K.+Schultenauthor=E.+Tajkhorshidauthor=J.+C.+Gumbart&title=Rapid+parameterization+of+small+molecules+using+the+Force+Field+Toolkit&doi=10.1002%2Fjcc.23422"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid parameterization of small molecules using the force field toolkit</span></div><div class="casAuthors">Mayne, Christopher G.; Saam, Jan; Schulten, Klaus; Tajkhorshid, Emad; Gumbart, James C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">2757-2770</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The inability to rapidly generate accurate and robust parameters for novel chem. matter continues to severely limit the application of mol. dynamics simulations to many biol. systems of interest, esp. in fields such as drug discovery.  Although the release of generalized versions of common classical force fields, for example, General Amber Force Field and CHARMM General Force Field, have posited guidelines for parameterization of small mols., many tech. challenges remain that have hampered their wide-scale extension.  The Force Field Toolkit (ffTK), described herein, minimizes common barriers to ligand parameterization through algorithm and method development, automation of tedious and error-prone tasks, and graphical user interface design.  Distributed as a VMD plugin, ffTK facilitates the traversal of a clear and organized workflow resulting in a complete set of CHARMM-compatible parameters.  A variety of tools are provided to generate quantum mech. target data, setup multidimensional optimization routines, and analyze parameter performance.  Parameters developed for a small test set of mols. using ffTK were comparable to existing CGenFF parameters in their ability to reproduce exptl. measured values for pure-solvent properties (<15% error from expt.) and free energy of solvation (±0.5 kcal/mol from expt.). © 2013 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBvn6UpP2II7Vg90H21EOLACvtfcHk0ljrvDe5hI2-0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlyrt73J&md5=73e241b77bcc903ab94acb2f187be578</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1002%2Fjcc.23422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.23422%26sid%3Dliteratum%253Aachs%26aulast%3DMayne%26aufirst%3DC.%2BG.%26aulast%3DSaam%26aufirst%3DJ.%26aulast%3DSchulten%26aufirst%3DK.%26aulast%3DTajkhorshid%26aufirst%3DE.%26aulast%3DGumbart%26aufirst%3DJ.%2BC.%26atitle%3DRapid%2520parameterization%2520of%2520small%2520molecules%2520using%2520the%2520Force%2520Field%2520Toolkit%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2013%26volume%3D34%26spage%3D2757%26epage%3D2770%26doi%3D10.1002%2Fjcc.23422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vanommeslaeghe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatcher, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acharya, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darian, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guvench, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vorobyov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackerell, A. D.,  Jr.</span></span> <span> </span><span class="NLM_article-title">CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">671</span>– <span class="NLM_lpage">690</span>, <span class="refDoi"> DOI: 10.1002/jcc.21367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1002%2Fjcc.21367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=19575467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlentbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=671-690&author=K.+Vanommeslaegheauthor=E.+Hatcherauthor=C.+Acharyaauthor=S.+Kunduauthor=S.+Zhongauthor=J.+Shimauthor=E.+Darianauthor=O.+Guvenchauthor=P.+Lopesauthor=I.+Vorobyovauthor=A.+D.+Mackerell&title=CHARMM+general+force+field%3A+A+force+field+for+drug-like+molecules+compatible+with+the+CHARMM+all-atom+additive+biological+force+fields&doi=10.1002%2Fjcc.21367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields</span></div><div class="casAuthors">Vanommeslaeghe, K.; Hatcher, E.; Acharya, C.; Kundu, S.; Zhong, S.; Shim, J.; Darian, E.; Guvench, O.; Lopes, P.; Vorobyov, I.; Mackerell, A. D., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">671-690</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The widely used CHARMM additive all-atom force field includes parameters for proteins, nucleic acids, lipids, and carbohydrates.  In the present article, an extension of the CHARMM force field to drug-like mols. is presented.  The resulting CHARMM General Force Field (CGenFF) covers a wide range of chem. groups present in biomols. and drug-like mols., including a large no. of heterocyclic scaffolds.  The parametrization philosophy behind the force field focuses on quality at the expense of transferability, with the implementation concg. on an extensible force field.  Statistics related to the quality of the parametrization with a focus on exptl. validation are presented.  Addnl., the parametrization procedure, described fully in the present article in the context of the model systems, pyrrolidine, and 3-phenoxymethyl-pyrrolidine will allow users to readily extend the force field to chem. groups that are not explicitly covered in the force field as well as add functional groups to and link together mols. already available in the force field.  CGenFF thus makes it possible to perform "all-CHARMM" simulations on drug-target interactions thereby extending the utility of CHARMM force fields to medicinally relevant systems. © 2009 Wiley Periodicals, Inc.J Comput Chem, 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCuh0CLdmxN7Vg90H21EOLACvtfcHk0liWJhx9o4QtEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlentbc%253D&md5=26212e0e4f73bded0c89d4b411cd3833</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21367%26sid%3Dliteratum%253Aachs%26aulast%3DVanommeslaeghe%26aufirst%3DK.%26aulast%3DHatcher%26aufirst%3DE.%26aulast%3DAcharya%26aufirst%3DC.%26aulast%3DKundu%26aufirst%3DS.%26aulast%3DZhong%26aufirst%3DS.%26aulast%3DShim%26aufirst%3DJ.%26aulast%3DDarian%26aufirst%3DE.%26aulast%3DGuvench%26aufirst%3DO.%26aulast%3DLopes%26aufirst%3DP.%26aulast%3DVorobyov%26aufirst%3DI.%26aulast%3DMackerell%26aufirst%3DA.%2BD.%26atitle%3DCHARMM%2520general%2520force%2520field%253A%2520A%2520force%2520field%2520for%2520drug-like%2520molecules%2520compatible%2520with%2520the%2520CHARMM%2520all-atom%2520additive%2520biological%2520force%2520fields%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2010%26volume%3D31%26spage%3D671%26epage%3D690%26doi%3D10.1002%2Fjcc.21367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vanommeslaeghe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raman, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKerell, A. D.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Automation of the CHARMM General Force Field (CGenFF) II: assignment of bonded parameters and partial atomic charges</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">3155</span>– <span class="NLM_lpage">3168</span>, <span class="refDoi"> DOI: 10.1021/ci3003649</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci3003649" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Gns7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=3155-3168&author=K.+Vanommeslaegheauthor=E.+P.+Ramanauthor=A.+D.+MacKerell&title=Automation+of+the+CHARMM+General+Force+Field+%28CGenFF%29+II%3A+assignment+of+bonded+parameters+and+partial+atomic+charges&doi=10.1021%2Fci3003649"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Automation of the CHARMM General Force Field (CGenFF) II: Assignment of Bonded Parameters and Partial Atomic Charges</span></div><div class="casAuthors">Vanommeslaeghe, K.; Raman, E. Prabhu; MacKerell, A. D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3155-3168</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mol. mechanics force fields are widely used in computer-aided drug design for the study of drug candidates interacting with biol. systems.  In these simulations, the biol. part is typically represented by a specialized biomol. force field, while the drug is represented by a matching general (org.) force field.  In order to apply these general force fields to an arbitrary drug-like mol., functionality for assignment of atom types, parameters, and partial at. charges is required.  In the present article, algorithms for the assignment of parameters and charges for the CHARMM General Force Field (CGenFF) are presented.  These algorithms rely on the existing parameters and charges that were detd. as part of the parametrization of the force field.  Bonded parameters are assigned based on the similarity between the atom types that define said parameters, while charges are detd. using an extended bond-charge increment scheme.  Charge increments were optimized to reproduce the charges on model compds. that were part of the parametrization of the force field.  Case studies are presented to clarify the functioning of the algorithms and the significance of their output data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0zgm66CLdn7Vg90H21EOLACvtfcHk0liWJhx9o4QtEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Gns7fF&md5=e676ad1f42cb1e98dd353d4d285e8d13</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Fci3003649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci3003649%26sid%3Dliteratum%253Aachs%26aulast%3DVanommeslaeghe%26aufirst%3DK.%26aulast%3DRaman%26aufirst%3DE.%2BP.%26aulast%3DMacKerell%26aufirst%3DA.%2BD.%26atitle%3DAutomation%2520of%2520the%2520CHARMM%2520General%2520Force%2520Field%2520%2528CGenFF%2529%2520II%253A%2520assignment%2520of%2520bonded%2520parameters%2520and%2520partial%2520atomic%2520charges%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2012%26volume%3D52%26spage%3D3155%26epage%3D3168%26doi%3D10.1021%2Fci3003649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frisch, M. J.</span>; <span class="NLM_string-name">Trucks, G. W.</span>; <span class="NLM_string-name">Schlegel, H. B.</span>; <span class="NLM_string-name">Scuseria, G. E.</span>; <span class="NLM_string-name">Robb, M. A.</span>; <span class="NLM_string-name">Cheeseman, J. R.</span>; <span class="NLM_string-name">Scalmani, G.</span>; <span class="NLM_string-name">Barone, V.</span>; <span class="NLM_string-name">Petersson, G. A.</span>; <span class="NLM_string-name">Nakatsuji, H.</span>; <span class="NLM_string-name">Li, X.</span>; <span class="NLM_string-name">Caricato, M.</span>; <span class="NLM_string-name">Marenich, A. V.</span>; <span class="NLM_string-name">Bloino, J.</span>; <span class="NLM_string-name">Janesko, B. G.</span>; <span class="NLM_string-name">Gomperts, R.</span>; <span class="NLM_string-name">Mennucci, B.</span>; <span class="NLM_string-name">Hratchian, H. P.</span>; <span class="NLM_string-name">Ortiz, J. V.</span>; <span class="NLM_string-name">Izmaylov, A. F.</span>; <span class="NLM_string-name">Sonnenberg, J. L.</span>; <span class="NLM_string-name">Williams-Young, D.</span>; <span class="NLM_string-name">Ding, F.</span>; <span class="NLM_string-name">Lipparini, F.</span>; <span class="NLM_string-name">Egidi, F.</span>; <span class="NLM_string-name">Goings, J.</span>; <span class="NLM_string-name">Peng, B.</span>; <span class="NLM_string-name">Petrone, A.</span>; <span class="NLM_string-name">Henderson, T.</span>; <span class="NLM_string-name">Ranasinghe, D.</span>; <span class="NLM_string-name">Zakrzewski, V. G.</span>; <span class="NLM_string-name">Gao, J.</span>; <span class="NLM_string-name">Rega, N.</span>; <span class="NLM_string-name">Zheng, G.</span>; <span class="NLM_string-name">Liang, W.</span>; <span class="NLM_string-name">Hada, M.</span>; <span class="NLM_string-name">Ehara, M.</span>; <span class="NLM_string-name">Toyota, K.</span>; <span class="NLM_string-name">Fukuda, R.</span>; <span class="NLM_string-name">Hasegawa, J.</span>; <span class="NLM_string-name">Ishida, M.</span>; <span class="NLM_string-name">Nakajima, T.</span>; <span class="NLM_string-name">Honda, Y.</span>; <span class="NLM_string-name">Kitao, O.</span>; <span class="NLM_string-name">Nakai, H.</span>; <span class="NLM_string-name">Vreven, T.</span>; <span class="NLM_string-name">Throssell, K.,  Jr.</span>; <span class="NLM_string-name">Montgomery, J. A.</span>; <span class="NLM_string-name">Peralta, J. E.</span>; <span class="NLM_string-name">Ogliaro, F.</span>; <span class="NLM_string-name">Bearpark, M. J.</span>; <span class="NLM_string-name">Heyd, J. J.</span>; <span class="NLM_string-name">Brothers, E. N.</span>; <span class="NLM_string-name">Kudin, K. N.</span>; <span class="NLM_string-name">Staroverov, V. N.</span>; <span class="NLM_string-name">Keith, T. A.</span>; <span class="NLM_string-name">Kobayashi, R.</span>; <span class="NLM_string-name">Normand, J.</span>; <span class="NLM_string-name">Raghavachari, K.</span>; <span class="NLM_string-name">Rendell, A. P.</span>; <span class="NLM_string-name">Burant, J. C.</span>; <span class="NLM_string-name">Iyengar, S. S.</span>; <span class="NLM_string-name">Tomasi, J.</span>; <span class="NLM_string-name">Cossi, M.</span>; <span class="NLM_string-name">Millam, J. M.</span>; <span class="NLM_string-name">Klene, M.</span>; <span class="NLM_string-name">Adamo, C.</span>; <span class="NLM_string-name">Cammi, R.</span>; <span class="NLM_string-name">Ochterski, J. W.</span>; <span class="NLM_string-name">Martin, R. L.</span>; <span class="NLM_string-name">Morokuma, K.</span>; <span class="NLM_string-name">Farkas, O.</span>; <span class="NLM_string-name">Foresman, J. B.</span>; <span class="NLM_string-name">Fox, D. J.</span></span> <i>Gaussian 16</i>, revision C.01; <span class="NLM_publisher-name">Gaussian Inc.</span>: <span class="NLM_publisher-loc">Wallingford, CT</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.17265%2F2159-5313%2F2016.09.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=M.+J.+Frisch&author=G.+W.+Trucks&author=H.+B.+Schlegel&author=G.+E.+Scuseria&author=M.+A.+Robb&author=J.+R.+Cheeseman&author=G.+Scalmani&author=V.+Barone&author=G.+A.+Petersson&author=H.+Nakatsuji&author=X.+Li&author=M.+Caricato&author=A.+V.+Marenich&author=J.+Bloino&author=B.+G.+Janesko&author=R.+Gomperts&author=B.+Mennucci&author=H.+P.+Hratchian&author=J.+V.+Ortiz&author=A.+F.+Izmaylov&author=J.+L.+Sonnenberg&author=D.+Williams-Young&author=F.+Ding&author=F.+Lipparini&author=F.+Egidi&author=J.+Goings&author=B.+Peng&author=A.+Petrone&author=T.+Henderson&author=D.+Ranasinghe&author=V.+G.+Zakrzewski&author=J.+Gao&author=N.+Rega&author=G.+Zheng&author=W.+Liang&author=M.+Hada&author=M.+Ehara&author=K.+Toyota&author=R.+Fukuda&author=J.+Hasegawa&author=M.+Ishida&author=T.+Nakajima&author=Y.+Honda&author=O.+Kitao&author=H.+Nakai&author=T.+Vreven&author=K.+Throssell&author=J.+A.+Montgomery&author=J.+E.+Peralta&author=F.+Ogliaro&author=M.+J.+Bearpark&author=J.+J.+Heyd&author=E.+N.+Brothers&author=K.+N.+Kudin&author=V.+N.+Staroverov&author=T.+A.+Keith&author=R.+Kobayashi&author=J.+Normand&author=K.+Raghavachari&author=A.+P.+Rendell&author=J.+C.+Burant&author=S.+S.+Iyengar&author=J.+Tomasi&author=M.+Cossi&author=J.+M.+Millam&author=M.+Klene&author=C.+Adamo&author=R.+Cammi&author=J.+W.+Ochterski&author=R.+L.+Martin&author=K.+Morokuma&author=O.+Farkas&author=J.+B.+Foresman&author=D.+J.+Fox&title=Gaussian+16"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.17265%2F2159-5313%2F2016.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26id%3Ddoi%3A10.17265%252F2159-5313%252F2016.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DFrisch%26aufirst%3DM.%2BJ.%26jtitle%3DGaussian%252016%26pub%3DGaussian%2520Inc%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lomize, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pogozheva, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosberg, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lomize, A. L.</span></span> <span> </span><span class="NLM_article-title">OPM database and PPM web server: resources for positioning of proteins in membranes</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">D370</span>– <span class="NLM_lpage">D376</span>, <span class="refDoi"> DOI: 10.1093/nar/gkr703</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1093%2Fnar%2Fgkr703" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=21890895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs12hurzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=D370-D376&author=M.+A.+Lomizeauthor=I.+D.+Pogozhevaauthor=H.+Jooauthor=H.+I.+Mosbergauthor=A.+L.+Lomize&title=OPM+database+and+PPM+web+server%3A+resources+for+positioning+of+proteins+in+membranes&doi=10.1093%2Fnar%2Fgkr703"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">OPM database and PPM web server: resources for positioning of proteins in membranes</span></div><div class="casAuthors">Lomize, Mikhail A.; Pogozheva, Irina D.; Joo, Hyeon; Mosberg, Henry I.; Lomize, Andrei L.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">D1</span>),
    <span class="NLM_cas:pages">D370-D376</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The Orientations of Proteins in Membranes (OPM) database is a curated web resource that provides spatial positions of membrane-bound peptides and proteins of known three-dimensional structure in the lipid bilayer, together with their structural classification, topol. and intracellular localization.  OPM currently contains more than 1200 transmembrane and peripheral proteins and peptides from approx. 350 organisms that represent approx. 3800 Protein Data Bank entries.  Proteins are classified into classes, superfamilies and families and assigned to 21 distinct membrane types.  Spatial positions of proteins with respect to the lipid bilayer are optimized by the PPM 2.0 method that accounts for the hydrophobic, hydrogen bonding and electrostatic interactions of the proteins with the anisotropic water-lipid environment described by the dielec. const. and hydrogen-bonding profiles.  The OPM database is freely accessible at http://opm.phar.umich.edu.  Data can be sorted, searched or retrieved using the hierarchical classification, source organism, localization in different types of membranes.  The database offers downloadable coordinates of proteins and peptides with membrane boundaries.  A gallery of protein images and several visualization tools are provided.  The database is supplemented by the PPM server (http://opm.phar.umich.edu/server.php) which can be used for calcg. spatial positions in membranes of newly detd. proteins structures or theor. models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo76Y6X6BHLRbVg90H21EOLACvtfcHk0lhH7JsVowvdhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs12hurzJ&md5=b931126c56d227ab0eb6c5762c1dae6b</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkr703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkr703%26sid%3Dliteratum%253Aachs%26aulast%3DLomize%26aufirst%3DM.%2BA.%26aulast%3DPogozheva%26aufirst%3DI.%2BD.%26aulast%3DJoo%26aufirst%3DH.%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26aulast%3DLomize%26aufirst%3DA.%2BL.%26atitle%3DOPM%2520database%2520and%2520PPM%2520web%2520server%253A%2520resources%2520for%2520positioning%2520of%2520proteins%2520in%2520membranes%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2012%26volume%3D40%26spage%3DD370%26epage%3DD376%26doi%3D10.1093%2Fnar%2Fgkr703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, W.</span></span> <span> </span><span class="NLM_article-title">Automated builder and database of protein/membrane complexes for molecular dynamics simulations</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">e880</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0000880</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1371%2Fjournal.pone.0000880" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=17849009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A280%3ADC%252BD2srjsFyjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&author=S.+Joauthor=T.+Kimauthor=W.+Im&title=Automated+builder+and+database+of+protein%2Fmembrane+complexes+for+molecular+dynamics+simulations&doi=10.1371%2Fjournal.pone.0000880"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Automated builder and database of protein/membrane complexes for molecular dynamics simulations</span></div><div class="casAuthors">Jo Sunhwan; Kim Taehoon; Im Wonpil</div><div class="citationInfo"><span class="NLM_cas:title">PloS one</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e880</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Molecular dynamics simulations of membrane proteins have provided deeper insights into their functions and interactions with surrounding environments at the atomic level.  However, compared to solvation of globular proteins, building a realistic protein/membrane complex is still challenging and requires considerable experience with simulation software.  Membrane Builder in the CHARMM-GUI website (http://www.charmm-gui.org) helps users to build such a complex system using a web browser with a graphical user interface.  Through a generalized and automated building process including system size determination as well as generation of lipid bilayer, pore water, bulk water, and ions, a realistic membrane system with virtually any kinds and shapes of membrane proteins can be generated in 5 minutes to 2 hours depending on the system size.  Default values that were elaborated and tested extensively are given in each step to provide reasonable options and starting points for both non-expert and expert users.  The efficacy of Membrane Builder is illustrated by its applications to 12 transmembrane and 3 interfacial membrane proteins, whose fully equilibrated systems with three different types of lipid molecules (DMPC, DPPC, and POPC) and two types of system shapes (rectangular and hexagonal) are freely available on the CHARMM-GUI website.  One of the most significant advantages of using the web environment is that, if a problem is found, users can go back and re-generate the whole system again before quitting the browser.  Therefore, Membrane Builder provides the intuitive and easy way to build and simulate the biologically important membrane system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAsncNNJLqIBfKb6ELK8t0fW6udTcc2eabfXFHqxvd57ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2srjsFyjsQ%253D%253D&md5=d2384741fc1d18b33cff16b254fc006b</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0000880&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0000880%26sid%3Dliteratum%253Aachs%26aulast%3DJo%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DT.%26aulast%3DIm%26aufirst%3DW.%26atitle%3DAutomated%2520builder%2520and%2520database%2520of%2520protein%252Fmembrane%2520complexes%2520for%2520molecular%2520dynamics%2520simulations%26jtitle%3DPLoS%2520One%26date%3D2007%26volume%3D2%26doi%3D10.1371%2Fjournal.pone.0000880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swails, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeom, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastman, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemkul, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pande, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Case, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, C. L.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKerell, A. D.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klauda, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, W.</span></span> <span> </span><span class="NLM_article-title">CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM simulations using the CHARMM36 additive force field</span>. <i>J. Chem. Theory Comput.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">413</span>, <span class="refDoi"> DOI: 10.1021/acs.jctc.5b00935</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jctc.5b00935" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVWru7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=405-413&author=J.+Leeauthor=X.+Chengauthor=J.+M.+Swailsauthor=M.+S.+Yeomauthor=P.+K.+Eastmanauthor=J.+A.+Lemkulauthor=S.+Weiauthor=J.+Bucknerauthor=J.+C.+Jeongauthor=Y.+Qiauthor=S.+Joauthor=V.+S.+Pandeauthor=D.+A.+Caseauthor=C.+L.+Brooksauthor=A.+D.+MacKerellauthor=J.+B.+Klaudaauthor=W.+Im&title=CHARMM-GUI+input+generator+for+NAMD%2C+GROMACS%2C+AMBER%2C+OpenMM%2C+and+CHARMM%2FOpenMM+simulations+using+the+CHARMM36+additive+force+field&doi=10.1021%2Facs.jctc.5b00935"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM Simulations Using the CHARMM36 Additive Force Field</span></div><div class="casAuthors">Lee, Jumin; Cheng, Xi; Swails, Jason M.; Yeom, Min Sun; Eastman, Peter K.; Lemkul, Justin A.; Wei, Shuai; Buckner, Joshua; Jeong, Jong Cheol; Qi, Yifei; Jo, Sunhwan; Pande, Vijay S.; Case, David A.; Brooks, Charles L.; MacKerell, Alexander D.; Klauda, Jeffery B.; Im, Wonpil</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Theory and Computation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">405-413</span>CODEN:
                <span class="NLM_cas:coden">JCTCCE</span>;
        ISSN:<span class="NLM_cas:issn">1549-9618</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Proper treatment of nonbonded interactions is essential for the accuracy of mol. dynamics (MD) simulations, esp. in studies of lipid bilayers.  The use of the CHARMM36 force field (C36 FF) in different MD simulation programs can result in disagreements with published simulations performed with CHARMM due to differences in the protocols used to treat the long-range and 1-4 nonbonded interactions.  In this study, we systematically test the use of the C36 lipid FF in NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM.  A wide range of Lennard-Jones (LJ) cutoff schemes and integrator algorithms were tested to find the optimal simulation protocol to best match bilayer properties of six lipids with varying acyl chain satn. and head groups.  MD simulations of a 1,2-dipalmitoyl-sn-phosphatidylcholine (DPPC) bilayer were used to obtain the optimal protocol for each program.  MD simulations with all programs were found to reasonably match the DPPC bilayer properties (surface area per lipid, chain order parameters, and area compressibility modulus) obtained using the std. protocol used in CHARMM as well as from expts.  The optimal simulation protocol was then applied to the other five lipid simulations and resulted in excellent agreement between results from most simulation programs as well as with exptl. data.  AMBER compared least favorably with the expected membrane properties, which appears to be due to its use of the hard-truncation in the LJ potential vs. a force-based switching function used to smooth the LJ potential as it approaches the cutoff distance.  The optimal simulation protocol for each program has been implemented in CHARMM-GUI.  This protocol is expected to be applicable to the remainder of the additive C36 FF including the proteins, nucleic acids, carbohydrates, and small mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrioKQ5MoVZkrVg90H21EOLACvtfcHk0lgD7zMlDL36uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVWru7nI&md5=1e986f2c205aca8fb80442bc9c95b229</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Facs.jctc.5b00935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jctc.5b00935%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DX.%26aulast%3DSwails%26aufirst%3DJ.%2BM.%26aulast%3DYeom%26aufirst%3DM.%2BS.%26aulast%3DEastman%26aufirst%3DP.%2BK.%26aulast%3DLemkul%26aufirst%3DJ.%2BA.%26aulast%3DWei%26aufirst%3DS.%26aulast%3DBuckner%26aufirst%3DJ.%26aulast%3DJeong%26aufirst%3DJ.%2BC.%26aulast%3DQi%26aufirst%3DY.%26aulast%3DJo%26aufirst%3DS.%26aulast%3DPande%26aufirst%3DV.%2BS.%26aulast%3DCase%26aufirst%3DD.%2BA.%26aulast%3DBrooks%26aufirst%3DC.%2BL.%26aulast%3DMacKerell%26aufirst%3DA.%2BD.%26aulast%3DKlauda%26aufirst%3DJ.%2BB.%26aulast%3DIm%26aufirst%3DW.%26atitle%3DCHARMM-GUI%2520input%2520generator%2520for%2520NAMD%252C%2520GROMACS%252C%2520AMBER%252C%2520OpenMM%252C%2520and%2520CHARMM%252FOpenMM%2520simulations%2520using%2520the%2520CHARMM36%2520additive%2520force%2520field%26jtitle%3DJ.%2520Chem.%2520Theory%2520Comput.%26date%3D2016%26volume%3D12%26spage%3D405%26epage%3D413%26doi%3D10.1021%2Facs.jctc.5b00935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauscher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawrocki, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feig, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Groot, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grubmüller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKerell, A. D.,  Jr.</span></span> <span> </span><span class="NLM_article-title">CHARMM36m: an improved force field for folded and intrinsically disordered proteins</span>. <i>Nat. Methods</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">71</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1038/nmeth.4067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1038%2Fnmeth.4067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=27819658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVSiu77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=71-73&author=J.+Huangauthor=S.+Rauscherauthor=G.+Nawrockiauthor=T.+Ranauthor=M.+Feigauthor=B.+L.+de+Grootauthor=H.+Grubm%C3%BCllerauthor=A.+D.+MacKerell&title=CHARMM36m%3A+an+improved+force+field+for+folded+and+intrinsically+disordered+proteins&doi=10.1038%2Fnmeth.4067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">CHARMM36m: an improved force field for folded and intrinsically disordered proteins</span></div><div class="casAuthors">Huang, Jing; Rauscher, Sarah; Nawrocki, Grzegorz; Ran, Ting; Feig, Michael; de Groot, Bert L.; Grubmuller, Helmut; MacKerell, Alexander D. Jr</div><div class="citationInfo"><span class="NLM_cas:title">Nature Methods</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">71-73</span>CODEN:
                <span class="NLM_cas:coden">NMAEA3</span>;
        ISSN:<span class="NLM_cas:issn">1548-7091</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The all-atom additive CHARMM36 protein force field is widely used in mol. modeling and simulations.  We present its refinement, CHARMM36m (http://mackerell.umaryland.edu/charmm_ff.shtml), with improved accuracy in generating polypeptide backbone conformational ensembles for intrinsically disordered peptides and proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2_cEd6RiZUbVg90H21EOLACvtfcHk0li0ohiPskd4Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVSiu77I&md5=0aa151fbef2ee0b5e2cfb593c54330c2</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1038%2Fnmeth.4067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnmeth.4067%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DRauscher%26aufirst%3DS.%26aulast%3DNawrocki%26aufirst%3DG.%26aulast%3DRan%26aufirst%3DT.%26aulast%3DFeig%26aufirst%3DM.%26aulast%3Dde%2BGroot%26aufirst%3DB.%2BL.%26aulast%3DGrubm%25C3%25BCller%26aufirst%3DH.%26aulast%3DMacKerell%26aufirst%3DA.%2BD.%26atitle%3DCHARMM36m%253A%2520an%2520improved%2520force%2520field%2520for%2520folded%2520and%2520intrinsically%2520disordered%2520proteins%26jtitle%3DNat.%2520Methods%26date%3D2017%26volume%3D14%26spage%3D71%26epage%3D73%26doi%3D10.1038%2Fnmeth.4067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klauda, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venable, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freites, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tobias, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mondragon-Ramirez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vorobyov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKerell, A. D.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastor, R. W.</span></span> <span> </span><span class="NLM_article-title">Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types</span>. <i>J. Phys. Chem. B</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">7830</span>– <span class="NLM_lpage">7843</span>, <span class="refDoi"> DOI: 10.1021/jp101759q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jp101759q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmsVGjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2010&pages=7830-7843&author=J.+B.+Klaudaauthor=R.+M.+Venableauthor=J.+A.+Freitesauthor=J.+W.+O%E2%80%99Connorauthor=D.+J.+Tobiasauthor=C.+Mondragon-Ramirezauthor=I.+Vorobyovauthor=A.+D.+MacKerellauthor=R.+W.+Pastor&title=Update+of+the+CHARMM+all-atom+additive+force+field+for+lipids%3A+validation+on+six+lipid+types&doi=10.1021%2Fjp101759q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Update of the CHARMM All-Atom Additive Force Field for Lipids: Validation on Six Lipid Types</span></div><div class="casAuthors">Klauda, Jeffery B.; Venable, Richard M.; Freites, J. Alfredo; O'Connor, Joseph W.; Tobias, Douglas J.; Mondragon-Ramirez, Carlos; Vorobyov, Igor; MacKerell, Alexander D., Jr.; Pastor, Richard W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry B</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7830-7843</span>CODEN:
                <span class="NLM_cas:coden">JPCBFK</span>;
        ISSN:<span class="NLM_cas:issn">1520-6106</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A significant modification to the additive all-atom CHARMM lipid force field (FF) is developed and applied to phospholipid bilayers with both choline and ethanolamine contg. head groups and with both satd. and unsatd. aliph. chains.  Motivated by the current CHARMM lipid FF (C27 and C27r) systematically yielding values of the surface area per lipid that are smaller than exptl. ests. and gel-like structures of bilayers well above the gel transition temp., selected torsional, Lennard-Jones and partial at. charge parameters were modified by targeting both quantum mech. (QM) and exptl. data.  QM calcns. ranging from high-level ab initio calcns. on small mols. to semiempirical QM studies on a 1,2-dipalmitoyl-sn-phosphatidylcholine (DPPC) bilayer in combination with exptl. thermodn. data were used as target data for parameter optimization.  These changes were tested with simulations of pure bilayers at high hydration of the following six lipids: DPPC, 1,2-dimyristoyl-sn-phosphatidylcholine (DMPC), 1,2-dilauroyl-sn-phosphatidylcholine (DLPC), 1-palmitoyl-2-oleoyl-sn-phosphatidylcholine (POPC), 1,2-dioleoyl-sn-phosphatidylcholine (DOPC), and 1-palmitoyl-2-oleoyl-sn-phosphatidylethanolamine (POPE); simulations of a low hydration DOPC bilayer were also performed.  Agreement with exptl. surface area is on av. within 2%, and the d. profiles agree well with neutron and x-ray diffraction expts.  NMR deuterium order parameters (SCD) are well predicted with the new FF, including proper splitting of the SCD for the aliph. carbon adjacent to the carbonyl for DPPC, POPE, and POPC bilayers.  The area compressibility modulus and frequency dependence of 13C NMR relaxation rates of DPPC and the water distribution of low hydration DOPC bilayers also agree well with expt.  Accordingly, the presented lipid FF, referred to as C36, allows for mol. dynamics simulations to be run in the tensionless ensemble (NPT), and is anticipated to be of utility for simulations of pure lipid systems as well as heterogeneous systems including membrane proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhTVhlLR7mEbVg90H21EOLACvtfcHk0li0ohiPskd4Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmsVGjtrk%253D&md5=04c4d3aa1a59740190994d7df80cbb71</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1021%2Fjp101759q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp101759q%26sid%3Dliteratum%253Aachs%26aulast%3DKlauda%26aufirst%3DJ.%2BB.%26aulast%3DVenable%26aufirst%3DR.%2BM.%26aulast%3DFreites%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DJ.%2BW.%26aulast%3DTobias%26aufirst%3DD.%2BJ.%26aulast%3DMondragon-Ramirez%26aufirst%3DC.%26aulast%3DVorobyov%26aufirst%3DI.%26aulast%3DMacKerell%26aufirst%3DA.%2BD.%26aulast%3DPastor%26aufirst%3DR.%2BW.%26atitle%3DUpdate%2520of%2520the%2520CHARMM%2520all-atom%2520additive%2520force%2520field%2520for%2520lipids%253A%2520validation%2520on%2520six%2520lipid%2520types%26jtitle%3DJ.%2520Phys.%2520Chem.%2520B%26date%3D2010%26volume%3D114%26spage%3D7830%26epage%3D7843%26doi%3D10.1021%2Fjp101759q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Case, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheatham, T. E.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darden, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gohlke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merz, K. M.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onufriev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmerling, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, R. J.</span></span> <span> </span><span class="NLM_article-title">The Amber biomolecular simulation programs</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1668</span>– <span class="NLM_lpage">1688</span>, <span class="refDoi"> DOI: 10.1002/jcc.20290</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1002%2Fjcc.20290" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=16200636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1SlsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2005&pages=1668-1688&author=D.+A.+Caseauthor=T.+E.+Cheathamauthor=T.+Dardenauthor=H.+Gohlkeauthor=R.+Luoauthor=K.+M.+Merzauthor=A.+Onufrievauthor=C.+Simmerlingauthor=B.+Wangauthor=R.+J.+Woods&title=The+Amber+biomolecular+simulation+programs&doi=10.1002%2Fjcc.20290"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">The amber biomolecular simulation programs</span></div><div class="casAuthors">Case, David A.; Cheatham, Thomas E., III; Darden, Tom; Gohlke, Holger; Luo, Ray; Merz, Kenneth M., Jr.; Onufriev, Alexey; Simmerling, Carlos; Wang, Bing; Woods, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1668-1688</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The authors describe the development, current features, and some directions for future development of the Amber package of computer programs.  This package evolved from a program that was constructed in the late 1970s to do Assisted Model Building with Energy Refinement, and now contains a group of programs embodying a no. of powerful tools of modern computational chem., focused on mol. dynamics and free energy calcns. of proteins, nucleic acids, and carbohydrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGre0tZP_Umb7rVg90H21EOLACvtfcHk0lg3izJTPcP9qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1SlsbbM&md5=93be29ff894bab96c783d24e9886c7d0</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1002%2Fjcc.20290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.20290%26sid%3Dliteratum%253Aachs%26aulast%3DCase%26aufirst%3DD.%2BA.%26aulast%3DCheatham%26aufirst%3DT.%2BE.%26aulast%3DDarden%26aufirst%3DT.%26aulast%3DGohlke%26aufirst%3DH.%26aulast%3DLuo%26aufirst%3DR.%26aulast%3DMerz%26aufirst%3DK.%2BM.%26aulast%3DOnufriev%26aufirst%3DA.%26aulast%3DSimmerling%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWoods%26aufirst%3DR.%2BJ.%26atitle%3DThe%2520Amber%2520biomolecular%2520simulation%2520programs%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2005%26volume%3D26%26spage%3D1668%26epage%3D1688%26doi%3D10.1002%2Fjcc.20290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salomon-Ferrer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Götz, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poole, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Grand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, R. C.</span></span> <span> </span><span class="NLM_article-title">Routine microsecond molecular dynamics simulations with AMBER on GPUs. 2. explicit solvent particle mesh ewald</span>. <i>J. Chem. Theory Comput.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">3878</span>– <span class="NLM_lpage">3888</span>, <span class="refDoi"> DOI: 10.1021/ct400314y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ct400314y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1arsrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=3878-3888&author=R.+Salomon-Ferrerauthor=A.+W.+G%C3%B6tzauthor=D.+Pooleauthor=S.+Le+Grandauthor=R.+C.+Walker&title=Routine+microsecond+molecular+dynamics+simulations+with+AMBER+on+GPUs.+2.+explicit+solvent+particle+mesh+ewald&doi=10.1021%2Fct400314y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 2. Explicit Solvent Particle Mesh Ewald</span></div><div class="casAuthors">Salomon-Ferrer, Romelia; Gotz, Andreas W.; Poole, Duncan; Le Grand, Scott; Walker, Ross C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Theory and Computation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3878-3888</span>CODEN:
                <span class="NLM_cas:coden">JCTCCE</span>;
        ISSN:<span class="NLM_cas:issn">1549-9618</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We present an implementation of explicit solvent all atom classical mol. dynamics (MD) within the AMBER program package that runs entirely on CUDA-enabled GPUs.  First released publicly in Apr. 2010 as part of version 11 of the AMBER MD package and further improved and optimized over the last two years, this implementation supports the three most widely used statistical mech. ensembles (NVE, NVT, and NPT), uses particle mesh Ewald (PME) for the long-range electrostatics, and runs entirely on CUDA-enabled NVIDIA graphics processing units (GPUs), providing results that are statistically indistinguishable from the traditional CPU version of the software and with performance that exceeds that achievable by the CPU version of AMBER software running on all conventional CPU-based clusters and supercomputers.  We briefly discuss three different precision models developed specifically for this work (SPDP, SPFP, and DPDP) and highlight the tech. details of the approach as it extends beyond previously reported work [Goetz et al., J.  Chem.  Theory Comput.2012, DOI: 10.1021/ct200909j; Le Grand et al., Comp.  Phys.  Comm.2013, DOI: 10.1016/j.cpc.2012.09.022].We highlight the substantial improvements in performance that are seen over traditional CPU-only machines and provide validation of our implementation and precision models.  We also provide evidence supporting our decision to deprecate the previously described fully single precision (SPSP) model from the latest release of the AMBER software package.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY-M2E_jgUmLVg90H21EOLACvtfcHk0lg3izJTPcP9qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1arsrzP&md5=57e18d35e8b81e9a79788ef5af17d19f</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1021%2Fct400314y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fct400314y%26sid%3Dliteratum%253Aachs%26aulast%3DSalomon-Ferrer%26aufirst%3DR.%26aulast%3DG%25C3%25B6tz%26aufirst%3DA.%2BW.%26aulast%3DPoole%26aufirst%3DD.%26aulast%3DLe%2BGrand%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DR.%2BC.%26atitle%3DRoutine%2520microsecond%2520molecular%2520dynamics%2520simulations%2520with%2520AMBER%2520on%2520GPUs.%25202.%2520explicit%2520solvent%2520particle%2520mesh%2520ewald%26jtitle%3DJ.%2520Chem.%2520Theory%2520Comput.%26date%3D2013%26volume%3D9%26spage%3D3878%26epage%3D3888%26doi%3D10.1021%2Fct400314y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehlert, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span> <span> </span><span class="NLM_article-title">A novel method for analyzing extremely biased agonism at G protein-coupled receptors</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">866</span>– <span class="NLM_lpage">877</span>, <span class="refDoi"> DOI: 10.1124/mol.114.096503</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1124%2Fmol.114.096503" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=25680753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFOntb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2015&pages=866-877&author=E.+L.+Stahlauthor=L.+Zhouauthor=F.+J.+Ehlertauthor=L.+M.+Bohn&title=A+novel+method+for+analyzing+extremely+biased+agonism+at+G+protein-coupled+receptors&doi=10.1124%2Fmol.114.096503"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">A novel method for analyzing extremely biased agonism at G protein-coupled receptors</span></div><div class="casAuthors">Stahl, Edward L.; Zhou, Lei; Ehlert, Frederick J.; Bohn, Laura M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">866-877</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Seven transmembrane receptors were originally named and characterized based on their ability to couple to heterotrimeric G proteins.  The assortment of coupling partners for G protein-coupled receptors has subsequently expanded to include other effectors (most notably the βarrestins).  This diversity of partners available to the receptor has prompted the pursuit of ligands that selectively activate only a subset of the available partners.  A biased or functionally selective ligand may be able to distinguish between different active states of the receptor, and this would result in the preferential activation of one signaling cascade more than another.  Although application of the "std." operational model for analyzing ligand bias is useful and suitable in most cases, there are limitations that arise when the biased agonist fails to induce a significant response in one of the assays being compared.  In this article, we describe a quant. method for measuring ligand bias that is particularly useful for such cases of extreme bias.  Using simulations and exptl. evidence from several κ opioid receptor agonists, we illustrate a "competitive" model for quantitating the degree and direction of bias.  By comparing the results obtained from the competitive model with the std. model, we demonstrate that the competitive model expands the potential for evaluating the bias of very partial agonists.  We conclude the competitive model provides a useful mechanism for analyzing the bias of partial agonists that exhibit extreme bias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmxvwRDHZE07Vg90H21EOLACvtfcHk0lgLPTO_OX9Oog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFOntb4%253D&md5=213952bf90b981cc66dc31bab8afe8df</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1124%2Fmol.114.096503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.114.096503%26sid%3Dliteratum%253Aachs%26aulast%3DStahl%26aufirst%3DE.%2BL.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DEhlert%26aufirst%3DF.%2BJ.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26atitle%3DA%2520novel%2520method%2520for%2520analyzing%2520extremely%2520biased%2520agonism%2520at%2520G%2520protein-coupled%2520receptors%26jtitle%3DMol.%2520Pharmacol.%26date%3D2015%26volume%3D87%26spage%3D866%26epage%3D877%26doi%3D10.1124%2Fmol.114.096503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Black, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leff, P.</span></span> <span> </span><span class="NLM_article-title">Operational models of pharmacological agonism</span>. <i>Proc. R. Soc. B</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>220</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1098/rspb.1983.0093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1098%2Frspb.1983.0093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=6141562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADyaL2cXmtFaqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=220&publication_year=1983&pages=141-162&author=J.+W.+Blackauthor=P.+Leff&title=Operational+models+of+pharmacological+agonism&doi=10.1098%2Frspb.1983.0093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Operational models of pharmacological agonism</span></div><div class="casAuthors">Black, J. W.; Leff, P.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the Royal Society of London, Series B:  Biological Sciences</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">220</span>
        (<span class="NLM_cas:issue">1219</span>),
    <span class="NLM_cas:pages">141-62</span>CODEN:
                <span class="NLM_cas:coden">PRLBA4</span>;
        ISSN:<span class="NLM_cas:issn">0080-4649</span>.
    </div><div class="casAbstract">A general, operational model is presented which explicitly describes pharmacol. agonism in terms of 3 parameters: an agonist-receptor dissocn. const., the total receptor concn. [Ro], and a parameter (KE) which defines the transduction of the agonist-receptor complex into pharmacol. effect.  The ratio RO/KE, the transducer ratio (τ), is a logical definition for the efficacy of an agonist in a system.  The model provides a chem. definition of intrinsic efficacy, making this parameter exptl. accessible in principle.  Alternate models are compared and contrasted with regard to their practical and conceptual utilities in exptl. pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonpXVldFQ_nbVg90H21EOLACvtfcHk0lgLPTO_OX9Oog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXmtFaqtA%253D%253D&md5=a0421df9c56495d48d076010acf44b65</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1098%2Frspb.1983.0093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frspb.1983.0093%26sid%3Dliteratum%253Aachs%26aulast%3DBlack%26aufirst%3DJ.%2BW.%26aulast%3DLeff%26aufirst%3DP.%26atitle%3DOperational%2520models%2520of%2520pharmacological%2520agonism%26jtitle%3DProc.%2520R.%2520Soc.%2520B%26date%3D1983%26volume%3D220%26spage%3D141%26epage%3D162%26doi%3D10.1098%2Frspb.1983.0093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kenakin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muniz-Medina, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novick, S.</span></span> <span> </span><span class="NLM_article-title">A simple method for quantifying functional selectivity and agonist bias</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1021/cn200111m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn200111m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ChtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=193-203&author=T.+Kenakinauthor=C.+Watsonauthor=V.+Muniz-Medinaauthor=A.+Christopoulosauthor=S.+Novick&title=A+simple+method+for+quantifying+functional+selectivity+and+agonist+bias&doi=10.1021%2Fcn200111m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">A Simple Method for Quantifying Functional Selectivity and Agonist Bias</span></div><div class="casAuthors">Kenakin, Terry; Watson, Christian; Muniz-Medina, Vanessa; Christopoulos, Arthur; Novick, Steven</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">193-203</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Activation of seven-transmembrane (7TM) receptors by agonists does not always lead to uniform activation of all signaling pathways mediated by a given receptor.  Relative to other ligands, many agonists are "biased" toward producing subsets of receptor behaviors.  A hallmark of such "functional selectivity" is cell type dependence; this poses a particular problem for the profiling of agonists in whole cell test systems removed from the therapeutic one(s).  Such response-specific cell-based variability makes it difficult to guide medicinal chem. efforts aimed at identifying and optimizing therapeutically meaningful agonist bias.  For this reason, we present a scale, based on the Black and Leff operational model, that contains the key elements required to describe 7TM agonism, namely, affinity (KA-1) for the receptor and efficacy (τ) in activating a particular signaling pathway.  Utilizing a "transduction coeff." term, log(τ/KA), this scale can statistically evaluate selective agonist effects in a manner that can theor. inform structure-activity studies and/or drug candidate selection matrixes.  The bias of four chemokines for CCR5-mediated inositol phosphate prodn. vs. internalization is quantified to illustrate the practical application of this method.  The independence of this method with respect to receptor d. and the calcn. of statistical ests. of confidence of differences are specifically discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxSkELs1bHQLVg90H21EOLACvtfcHk0lg8rdVixjlPqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ChtLvN&md5=270841d11f9720caaf3e59a6fe0aee74</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Fcn200111m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn200111m%26sid%3Dliteratum%253Aachs%26aulast%3DKenakin%26aufirst%3DT.%26aulast%3DWatson%26aufirst%3DC.%26aulast%3DMuniz-Medina%26aufirst%3DV.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DNovick%26aufirst%3DS.%26atitle%3DA%2520simple%2520method%2520for%2520quantifying%2520functional%2520selectivity%2520and%2520agonist%2520bias%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2012%26volume%3D3%26spage%3D193%26epage%3D203%26doi%3D10.1021%2Fcn200111m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ehlert, F. J.</span></span> <span> </span><span class="NLM_article-title">Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">194</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=2828914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADyaL1cXhsValurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1988&pages=187-194&author=F.+J.+Ehlert&title=Estimation+of+the+affinities+of+allosteric+ligands+using+radioligand+binding+and+pharmacological+null+methods"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods</span></div><div class="casAuthors">Ehlert, Frederick J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">187-94</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">The theor. basis for using radioligand binding and pharmacol. techniques to est. the dissocn. consts. of drugs which interact allosterically with receptors is described.  This theory predicts that an allosteric ligand changes the affinity of another ligand which binds at the primary recognition site on the receptor complex without affecting the binding capacity of the primary ligand.  The magnitude of this effect depends on the amt. of cooperativity (pos. or neg.) between the binding of ligands at the allosteric and primary recognition sites.  It is possible to est. the dissocn. const. of an allosteric ligand by measuring its effect on the binding of a radioligand at a fixed concn.  In this situation, the dissocn. const. of the allosteric ligand can be calcd. from the concn. of ligand which causes half of its maximal effect on radioligand binding.  The effects of an allosteric ligand on the pharmacol. responses to an agonist can be attributed to changes in affinity and intrinsic efficacy of the agonist-receptor complex.  If the agonist used in the pharmacol. expts. has a large receptor reserve, or if, the allosteric ligand only influences the affinity of the agonist, then the dissocn. const. of the allosteric ligand can be calcd. from the results of expts. in which the concn. of agonist required for half-maximal response (EC50) is measured in the presence of various concns. of the allosteric ligand.  If the agonist used in the pharmacol. expts. is a partial agonist with little receptor reserve, then the shift in the EC50 of the agonist caused by the allosteric ligand may be dependent on the affinity of the agonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjQE02Mx2NPLVg90H21EOLACvtfcHk0lg8rdVixjlPqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXhsValurs%253D&md5=f987788cd58fb05902ff94e390917c18</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEhlert%26aufirst%3DF.%2BJ.%26atitle%3DEstimation%2520of%2520the%2520affinities%2520of%2520allosteric%2520ligands%2520using%2520radioligand%2520binding%2520and%2520pharmacological%2520null%2520methods%26jtitle%3DMol.%2520Pharmacol.%26date%3D1988%26volume%3D33%26spage%3D187%26epage%3D194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stockton, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birdsall, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgen, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulme, E. C.</span></span> <span> </span><span class="NLM_article-title">Modification of the binding properties of muscarinic receptors by gallamine</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">551</span>– <span class="NLM_lpage">557</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=6865905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADyaL3sXktFKntrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1983&pages=551-557&author=J.+M.+Stocktonauthor=N.+J.+Birdsallauthor=A.+S.+Burgenauthor=E.+C.+Hulme&title=Modification+of+the+binding+properties+of+muscarinic+receptors+by+gallamine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Modification of the binding properties of muscarinic receptors by gallamine</span></div><div class="casAuthors">Stockton, J. M.; Birdsall, N. J. M.; Burgen, A. S. V.; Hulme, E. C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">551-7</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">The interaction of gallamine (I)  [153-76-4] with muscarinic receptors from different tissues was investigated.  Gallamine binds to a site distinct from the conventional muscarinic ligand binding site and modulates the binding of agonists and antagonists to the conventional binding site.  In agreement with reported pharmacol. studies, the effects of gallamine on the binding of muscarinic ligands are much greater in heart than in other tissues.  These findings suggest the possibility of developing novel and selective muscarinic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcmXxiIuzlm7Vg90H21EOLACvtfcHk0lg8rdVixjlPqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXktFKntrs%253D&md5=4087dbe9e26b089b2ff1e251ca66fca3</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStockton%26aufirst%3DJ.%2BM.%26aulast%3DBirdsall%26aufirst%3DN.%2BJ.%26aulast%3DBurgen%26aufirst%3DA.%2BS.%26aulast%3DHulme%26aufirst%3DE.%2BC.%26atitle%3DModification%2520of%2520the%2520binding%2520properties%2520of%2520muscarinic%2520receptors%2520by%2520gallamine%26jtitle%3DMol.%2520Pharmacol.%26date%3D1983%26volume%3D23%26spage%3D551%26epage%3D557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Price, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntosh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westwood, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, R. A.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulation of the cannabinoid CB1 receptor</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">1484</span>– <span class="NLM_lpage">1495</span>, <span class="refDoi"> DOI: 10.1124/mol.105.016162</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1124%2Fmol.105.016162" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=16113085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtF2it7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2005&pages=1484-1495&author=M.+R.+Priceauthor=G.+L.+Baillieauthor=A.+Thomasauthor=L.+A.+Stevensonauthor=M.+Eassonauthor=R.+Goodwinauthor=A.+McLeanauthor=L.+McIntoshauthor=G.+Goodwinauthor=G.+Walkerauthor=P.+Westwoodauthor=J.+Marrsauthor=F.+Thomsonauthor=P.+Cowleyauthor=A.+Christopoulosauthor=R.+G.+Pertweeauthor=R.+A.+Ross&title=Allosteric+modulation+of+the+cannabinoid+CB1+receptor&doi=10.1124%2Fmol.105.016162"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric modulation of the cannabinoid CB1 receptor</span></div><div class="casAuthors">Price, Martin R.; Baillie, Gemma L.; Thomas, Adele; Stevenson, Lesley A.; Easson, Morag; Goodwin, Richard; McLean, Adele; McIntosh, Lorraine; Goodwin, Gillian; Walker, Glenn; Westwood, Paul; Marrs, Julia; Thomson, Fiona; Cowley, Phillip; Christopoulos, Arthur; Pertwee, Roger G.; Ross, Ruth A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1484-1495</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The authors investigated the pharmacol. of three novel compds., Org 27569, Org 27759 and Org 29647 at the cannabinoid CB1 receptor.  In equil. binding assays, the Org compds. significantly increased the binding of the CB1 receptor agonist [3H]CP 55,940 [(1R,3R,4R)-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-4-(3-hydroxypropyl) cyclohexan-1-ol], indicative of a pos. cooperative allosteric effect.  The same compds. caused a significant, but incomplete, decrease in the specific binding of the CB1 receptor inverse agonist [3H]SR 141716A [N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H -pyrazole-3-carboximide hydrochloride], indicative of a limited neg. binding cooperativity.  Anal. of the data according to an allosteric ternary complex model revealed that the estd. affinity of each Org compd. was not significantly different when the radioligand was [3H]CP 55,940 or [3H]SR 141716A.  However, the estd. cooperatively factor for the interaction between modulator and radioligand was greater than 1 when detd. against [3H]CP 55,940 and less than 1 when detd. against [3H]SR 141716A.  [3H]CP 55,940 dissocn. kinetic studies also validated the allosteric nature of the Org compds., because they all significantly decreased radioligand dissocn.  These data suggest that the Org compds. bind allosterically to the CB1 receptor and elicit a conformational change that increases agonist affinity for the orthosteric binding site.  In contrast to the binding assays, however, the Org compds. behaved as insurmountable antagonists of receptor function; in the reporter gene assay, the guanosine 5'-O-(3-[35S]thio)triphosphate binding assay and the mouse vas deferens assay they elicited a significant redn. in the Emax value for CB1 receptor agonists.  The data presented clearly demonstrate, for the first time, that the cannabinoid CB1 receptor contains an allosteric binding site that can be recognized by synthetic small mol. ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq98nUa2ffQ7bVg90H21EOLACvtfcHk0liW5HNyotpEXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtF2it7nM&md5=a342d304a8157b1e7b962755a775154d</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1124%2Fmol.105.016162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.105.016162%26sid%3Dliteratum%253Aachs%26aulast%3DPrice%26aufirst%3DM.%2BR.%26aulast%3DBaillie%26aufirst%3DG.%2BL.%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DStevenson%26aufirst%3DL.%2BA.%26aulast%3DEasson%26aufirst%3DM.%26aulast%3DGoodwin%26aufirst%3DR.%26aulast%3DMcLean%26aufirst%3DA.%26aulast%3DMcIntosh%26aufirst%3DL.%26aulast%3DGoodwin%26aufirst%3DG.%26aulast%3DWalker%26aufirst%3DG.%26aulast%3DWestwood%26aufirst%3DP.%26aulast%3DMarrs%26aufirst%3DJ.%26aulast%3DThomson%26aufirst%3DF.%26aulast%3DCowley%26aufirst%3DP.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26aulast%3DRoss%26aufirst%3DR.%2BA.%26atitle%3DAllosteric%2520modulation%2520of%2520the%2520cannabinoid%2520CB1%2520receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2005%26volume%3D68%26spage%3D1484%26epage%3D1495%26doi%3D10.1124%2Fmol.105.016162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27a','cit27b','cit27c'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54a','cit54b'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57a','cit57b'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 1 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="NLM_string-name hlFld-ContribAuthor">Federico Corelli</span>. </span><span class="cited-content_cbyCitation_article-title">Has a “Chemical Magic” Opened up New Prospects for Glaucoma?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 8101-8103. <a href="https://doi.org/10.1021/acs.jmedchem.1c00843" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00843</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00843&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00843%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHas%252Ba%252B%2525E2%252580%25259CChemical%252BMagic%2525E2%252580%25259D%252BOpened%252Bup%252BNew%252BProspects%252Bfor%252BGlaucoma%25253F%26aulast%3DCorelli%26aufirst%3DFederico%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D10052021%26date%3D21052021%26volume%3D64%26issue%3D12%26spage%3D8101%26epage%3D8103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00040&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of representative CB1R allosteric modulators.<a onclick="showRef(event, 'ref27 ref35 ref37'); return false;" href="javascript:void(0);" class="ref ref27 ref35 ref37">(27,35,37)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00040&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Ligand design using magic methyl effect strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00040&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. ORTEP diagram of (−)-<b>13</b> (a, CCDC no. 1861405), (+)-<b>14</b> (b, CCDC no. 1861417), (+)-<b>15</b> (c, CCDC no. 1861406), and (−)-<b>16</b> (d, CCDC no. 1861407) and determination of absolute stereochemistry.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00040&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0017.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Reagents and Conditions: (a) NH<sub>4</sub>CF<sub>3</sub>CO<sub>2</sub>, 10% aq EtOH, Reflux, 36 h, <b>9</b>:<b>10</b> (9:1), 85%; (b) Chiral High-Performance Liquid Chromatography (HPLC), MeOH, and Super Fluid</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00040&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effect of test compounds on (a, b) the binding of 0.7 nM [<sup>3</sup>H]CP55,940 to membranes obtained from CHO cells stably expressing hCB1R or on (c–f) the binding of [<sup>35</sup>S]GTPγS to G protein in membranes obtained from CHO cells stably expressing hCB1R and treated with either (c, d) test compounds alone or (e, f) CP55,940 + 1 μM test compound. Data were fit to a variable-slope (four-parameter) nonlinear regression model in GraphPad (v. 8.0.1) and are given as mean ± SEM for <i>n</i> = 4–6 independent experiments performed in duplicate. <i>K<sub>i</sub></i>, EC<sub>50</sub>, and <i>E</i><sub>max</sub> values derived from these plots are presented in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00040&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effect of test compounds on forskolin (FSK)-stimulated cAMP production (a, d), recruitment of β-arrestin1 (b, e), and recruitment of β-arrestin2 (c, f) in HEK293 cells expressing CB1R. (a, d) HEK293 cells stably expressing CB1R were treated with 5 μM FSK and 0.01 nM–10 μM CP55,940 or test compound alone (a) or with 10 nM CP55,940 + 0.01 nM–10 μM test compound (d) for 30 min, and cAMP inhibition was then quantified in the LANCE Ultra cAMP assay. (b, e) HEK293 cells stably expressing β-arrestin1 and transiently expressing rat CB1R (CB1R) were treated with 0.01 nM–10 μM CP55,940 or test compound alone (b) or with 100 nM CP55,940 + 0.01 nM–10 μM test compound (e) for 90 min, and β-arrestin1 recruitment was then quantified in the β-arrestin recruitment enzyme complementation assay. (c, f) HEK293 cells stably expressing β-arrestin2 and transiently expressing CB1R were treated with 0.01 nM–30 μM CP55,940 or test compound alone (c) or with 100 nM CP55,940 + 0.01 nM–10 μM test compound (f) for 90 min, and β-arrestin2 recruitment was then quantified in the β-arrestin recruitment enzyme complementation assay. Data are expressed as % CP55,940 response and were fit to a nonlinear regression (four-parameter) model (GraphPad v. 8.0.1) (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). (g–l) Data were fit to the Black–Leff operational model to estimate bias (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>) with CP55,940 as the reference agonist. Data are mean ± SEM for <i>n</i> = 3–4 independent experiments performed in triplicate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00040&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Effect of test compounds on inhibition of forskolin (FSK)-stimulated cAMP production (a, d, g), β-arrestin1 recruitment (b, e, h), or β-arrestin2 recruitment (c, f, i) in HEK293 cells stably expressing hCB1R. (a, d, g) HEK293 cells stably expressing CB1R were treated with 5 μM FSK and 0.01 nM–10 μM CP55,940 ± 10–300 nM (±)-<b>9</b> (a), (−)-(<i>S</i>,<i>R</i>)-<b>13</b> (d), or (+)-(<i>R</i>,<i>S</i>)-<b>14</b> (g) for 30 min, and cAMP inhibition was then quantified. (b, e, h) HEK293 cells stably expressing β-arrestin1 and transiently expressing CB1R were treated with 0.01 nM–10 μM CP55,940 ± 10–300 nM (±)-<b>9</b> (b), (−)-(<i>S</i>,<i>R</i>)-<b>13</b> (e), or (+)-(<i>R</i>,<i>S</i>)-<b>14</b> (h) for 90 min, and β-arrestin1 recruitment was then quantified. (c, f, i) HEK293 cells stably expressing β-arrestin2 and transiently expressing CB1R were treated with 0.01 nM–10 μM CP55,940 ± 10–300 nM (±)-<b>9</b> (c), (−)-(<i>S</i>,<i>R</i>)-<b>13</b> (f), or (+)-(<i>R</i>,<i>S</i>)-<b>14</b> (i) for 90 min, and β-arrestin2 recruitment was then quantified. Data are expressed as % CP55,940 response and were analyzed with the combined allosteric binding model and Black–Leff operational model for agonism to estimate cooperativity factors (α, β) with CP55,940 as the reference agonist (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Data are mean ± SEM for <i>n</i> = 3–4 independent experiments performed in triplicate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00040&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Global minimum conformers of compounds <b>13</b>–<b>16</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00040&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Lowest energy minima that have the nitro group in a generally similar position relative to the indole ring seen in the binding conformation of (−)-(<i>S</i>,<i>R</i>)-<b>13</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00040&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) Separate PAM and allosteric-agonist sites occupied by (−)-(<i>S</i>,<i>R</i>)-<b>13</b> (ligand carbons in green CPK style). (B) Closeup view of (−)-(<i>S</i>,<i>R</i>)-<b>13</b> is shown at the allosteric-agonist site with F4.46 in red; source target for the model is PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6N4B">6N4B</a>. Other closely interacting residues are shown in cyan. (C) A slightly pulled back, but similar, viewpoint of the allosteric-agonist site compared to (B) is rendered as a Connolly surface in gray. Of the four molecular dynamics production trajectories, the coordinates for images (B) and (C) are taken from the end of the third molecular dynamics production trajectory at 991 ns as a representative orientation of (−)-(<i>S</i>,<i>R</i>)-<b>13</b> at the allosteric-agonist site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00040&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. (A) (−)-(<i>S</i>,<i>R</i>)-<b>13</b> (green carbons) complexed at both the allosteric-agonist and PAM CB1 sites. CB1 residues (light tan carbons) in close contact with each (−)-(<i>S</i>,<i>R</i>)-<b>13</b> molecule are displayed; source target for the model is PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6N4B">6N4B</a>. The PAM site is located underneath the EC1 loop at the extracellular ends of TMH2/3. The allosteric-agonist site is located at the intracellular ends of TMH1/2/4; (B) (+)-(<i>R</i>,<i>S</i>)-<b>14</b> (pink carbons) has steric clashes with Y2.57 (light tan carbons) inhibiting access to the PAM site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00040&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Ago-PAM properties of (+)-(<i>R</i>,<i>S</i>)-<b>14</b> and (±)-<b>9</b> in autaptic hippocampal neurons. (a) Sample time course showing inhibition of EPSCs upon treatment with (±)-<b>9</b>. (b) Averaged direct inhibition of EPSCs upon 1 μM (±)-<b>9</b> application. (c) Sample DSE time course before and after (±)-<b>9</b> showing that (±)-<b>9</b> agonist effects occlude DSE responses. (d) Sample time course showing inhibition of EPSCs upon treatment with (+)-(<i>R</i>,<i>S</i>)-<b>14</b>. (e) Averaged direct inhibition of EPSCs upon 1 μM (+)-(<i>R</i>,<i>S</i>)-<b>14</b> application. (f) Sample DSE time course from a cell showing a slowed DSE recovery after (+)-(<i>R</i>,<i>S</i>)-<b>14</b> treatment. * <i>p</i> < 0.05 by <i>t</i>-test vs 1.0 (no effect).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00040&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. IOP-lowering effect of subthreshold WIN55,212-2 (WIN; 0.25%) is potentiated by the PAM (±)-<b>9</b> (0.2%) in ocular normotensive C57Bl/6 mice (<i>n</i> = 6–13). Values are represented as a change in IOP (mean ± SEM) from baseline (time-0). *<i>p</i> < 0.05, **<i>p</i> < 0.01, ***<i>p</i> < 0.001 (one-way ANOVA, followed by Dunnett’s multiple comparisons test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00040&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Effects of PAM (−)-(<i>S</i>,<i>R</i>)-<b>13</b> on IOP in hypertensive <i>nee</i> mice at 1, 6, and 12 h after topical administration (<i>n</i> = 11–18). IOP was significantly lower in eyes receiving 1.0% (−)-(<i>S</i>,<i>R</i>)-<b>13</b> compared to vehicle at all times examined. Values are represented as a change in IOP (mean ± SEM) from the baseline (time-0). *<i>p</i> < 0.05, **<i>p</i> < 0.01 (one-way ANOVA, followed by Dunnett’s multiple comparisons test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00040&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Effects of PAMs (±)-<b>9</b>, (−)-(<i>S</i>,<i>R</i>)-<b>13</b>, and (+)-(<i>R</i>,<i>S</i>)-<b>14</b> on IOP in ocular hypertensive <i>nee</i> mice at 1, 6, and 12 h after topical administration (<i>n</i> = 7–18). IOP was significantly lower in eyes receiving 0.2% (+)-(<i>R</i>,<i>S</i>)-<b>14</b>, compared to vehicle at each time point examined. Values are represented as a change in IOP (mean ± SEM) from the baseline (time 0). *<i>p</i> < 0.05, **<i>p</i> < 0.01 (one-way ANOVA, followed by Dunnett’s multiple comparisons test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00040&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/medium/jm1c00040_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Male C57Bl/6 mice were treated with 0.1–10 mg/kg ip test compound or vehicle (1:1:18 ethanol/cremaphor/saline). Physiological assessments of (a) catalepsy (5 min, % maximum possible effect (MPE) 60 s), (b) body temperature (15 min), and (c) nociception in the tail flick assay (52 °C) (20 min, % MPE 20 s) were then made. Data are mean ± SD, <i>n</i> = 6–13 animals/treatment. <sup>***</sup><i>p</i> < 0.001 relative to vehicle (two-way ANOVA followed by Bonferroni’s post hoc test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.1c00040/20210616/images/large/jm1c00040_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00040&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i61">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25587" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25587" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 90 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aizpurua-Olaizola, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elezgarai, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rico-Barrio, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarandona, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etxebarria, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Usobiaga, A.</span></span> <span> </span><span class="NLM_article-title">Targeting the endocannabinoid system: future therapeutic strategies</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">105</span>– <span class="NLM_lpage">110</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2016.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1016%2Fj.drudis.2016.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=27554802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVantL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=105-110&author=O.+Aizpurua-Olaizolaauthor=I.+Elezgaraiauthor=I.+Rico-Barrioauthor=I.+Zarandonaauthor=N.+Etxebarriaauthor=A.+Usobiaga&title=Targeting+the+endocannabinoid+system%3A+future+therapeutic+strategies&doi=10.1016%2Fj.drudis.2016.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the endocannabinoid system: future therapeutic strategies</span></div><div class="casAuthors">Aizpurua-Olaizola, Oier; Elezgarai, Izaskun; Rico-Barrio, Irantzu; Zarandona, Iratxe; Etxebarria, Nestor; Usobiaga, Aresatz</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">105-110</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The endocannabinoid system (ECS) is involved in many physiol. regulation pathways in the human body, which makes this system the target of many drugs and therapies.  In this review, we highlight the latest studies regarding the role of the ECS and the drugs that target it, with a particular focus on the basis for the discovery of new cannabinoid-based drugs.  In addn., we propose some key steps, such as the creation of a cannabinoid-receptor interaction matrix (CRIM) and the use of metabolomics, toward the development of improved and more specific drugs for each relevant disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorKmuBzuegJ7Vg90H21EOLACvtfcHk0ljZ181wvRI6Nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVantL3F&md5=19b739eb216107fb97cf8b362fa8f944</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DAizpurua-Olaizola%26aufirst%3DO.%26aulast%3DElezgarai%26aufirst%3DI.%26aulast%3DRico-Barrio%26aufirst%3DI.%26aulast%3DZarandona%26aufirst%3DI.%26aulast%3DEtxebarria%26aufirst%3DN.%26aulast%3DUsobiaga%26aufirst%3DA.%26atitle%3DTargeting%2520the%2520endocannabinoid%2520system%253A%2520future%2520therapeutic%2520strategies%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2017%26volume%3D22%26spage%3D105%26epage%3D110%26doi%3D10.1016%2Fj.drudis.2016.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Marzo, V.</span></span> <span> </span><span class="NLM_article-title">Targeting the endocannabinoid system: to enhance or reduce?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">438</span>– <span class="NLM_lpage">455</span>, <span class="refDoi"> DOI: 10.1038/nrd2553</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1038%2Fnrd2553" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=18446159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlt1agtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=438-455&author=V.+Di%0AMarzo&title=Targeting+the+endocannabinoid+system%3A+to+enhance+or+reduce%3F&doi=10.1038%2Fnrd2553"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the endocannabinoid system: to enhance or reduce?</span></div><div class="casAuthors">Di Marzo, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">438-455</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In this Review, the author discusses how prolonging the lifespan of endocannabinoids or toning down their action may be beneficial in a range of conditions such as pain, affective and neurodegenerative disorders, gastrointestinal inflammation, and obesity and metabolic dysfunctions.  As our understanding of the endocannabinoids improves, so does the awareness of their complexity.  During pathol. states, the levels of these mediators in tissues change, and their effects vary from those of protective endogenous compds. to those of dysregulated signals.  These observations led to the discovery of compds. that either prolong the lifespan of endocannabinoids or tone down their action for the potential future treatment of pain, affective and neurodegenerative disorders, gastrointestinal inflammation, obesity and metabolic dysfunctions, cardiovascular conditions and liver diseases.  When moving to the clinic, however, the pleiotropic nature of endocannabinoid functions will require careful judgement in the choice of patients and stage of the disorder for treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpebzNFDRaNEbVg90H21EOLACvtfcHk0lh1q6VouT33XA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlt1agtbk%253D&md5=f0af1a666a7c51a594d94661bfb5a7d9</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd2553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2553%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26atitle%3DTargeting%2520the%2520endocannabinoid%2520system%253A%2520to%2520enhance%2520or%2520reduce%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D438%26epage%3D455%26doi%3D10.1038%2Fnrd2553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haspula, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, M. A.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid receptors: an update on cell signaling, pathophysiological roles and therapeutic opportunities in neurological, cardiovascular, and inflammatory diseases</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>, <span class="NLM_elocation-id">7693</span> <span class="refDoi"> DOI: 10.3390/ijms21207693</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.3390%2Fijms21207693" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFWitb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&author=D.+Haspulaauthor=M.+A.+Clark&title=Cannabinoid+receptors%3A+an+update+on+cell+signaling%2C+pathophysiological+roles+and+therapeutic+opportunities+in+neurological%2C+cardiovascular%2C+and+inflammatory+diseases&doi=10.3390%2Fijms21207693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid receptors: an update on cell signaling, pathophysiological roles and therapeutic opportunities in neurological, cardiovascular, and inflammatory diseases</span></div><div class="casAuthors">Haspula, Dhanush; Clark, Michelle A.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7693</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The identification of the human cannabinoid receptors and their roles in health and disease, has been one of the most significant biochem. and pharmacol. advancements to have occurred in the past few decades.  In spite of the major strides made in furthering endocannabinoid research, therapeutic exploitation of the endocannabinoid system has often been a challenging task.  Animpaired endocannabinoid tone often manifests as changes in expression and/or functions of type 1 and/or type 2 cannabinoid receptors.  It becomes important to understand how alterations in cannabinoid receptor cellular signaling can lead to disruptions in major physiol. and biol. functions, as they are often assocd. with the pathogenesis of several neurol., cardiovascular, metabolic, and inflammatory diseases.  This focuses mostly on the pathophysiol. roles of type 1 and type 2 cannabinoid receptors, and it attempts to integrate both cellular and physiol. functions of the cannabinoid receptors.  Apart from an updated of pre-clin. and clin. studies, the adequacy/inadequacy of cannabinoid-based therapeutics in various pathol. conditions is also highlighted.  Finally, alternative strategies to modulate endocannabinoid tone, and future directions are also emphasized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMlIrxHtyQ_bVg90H21EOLACvtfcHk0lh1q6VouT33XA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFWitb%252FE&md5=350dc7b07fd8d858028cbffe1fad7988</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3390%2Fijms21207693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms21207693%26sid%3Dliteratum%253Aachs%26aulast%3DHaspula%26aufirst%3DD.%26aulast%3DClark%26aufirst%3DM.%2BA.%26atitle%3DCannabinoid%2520receptors%253A%2520an%2520update%2520on%2520cell%2520signaling%252C%2520pathophysiological%2520roles%2520and%2520therapeutic%2520opportunities%2520in%2520neurological%252C%2520cardiovascular%252C%2520and%2520inflammatory%2520diseases%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2020%26volume%3D21%26doi%3D10.3390%2Fijms21207693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janero, D. R.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists</span>. <i>Expert Opin. Emerging Drugs</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">29</span>, <span class="refDoi"> DOI: 10.1517/14728214.2012.660916</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1517%2F14728214.2012.660916" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=22335400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC38XksVOktr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=17-29&author=D.+R.+Janero&title=Cannabinoid-1+receptor+%28CB1R%29+blockers+as+medicines%3A+beyond+obesity+and+cardiometabolic+disorders+to+substance+abuse%2Fdrug+addiction+with+CB1R+neutral+antagonists&doi=10.1517%2F14728214.2012.660916"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists</span></div><div class="casAuthors">Janero, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Emerging Drugs</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-29</span>CODEN:
                <span class="NLM_cas:coden">EOEDA3</span>;
        ISSN:<span class="NLM_cas:issn">1472-8214</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Addiction to chem. substances with abuse potential presents medical needs largely unsolved by extant therapeutic strategies.  Signal transmission through the cannabinoid-1 receptor (CB1R) in the central nervous system (CNS) modulates neurotransmitters/neuronal pathways contributing to the rewarding properties and hedonic effects of certain nondrug stimuli (e.g., food) and many prototypical addictive drugs, promoting excessive intake and its pathol. consequences.  Typical CB1R antagonists/inverse agonists reduce the rewarding effects and normalize behavioral phenotypes assocd. with food and abused drugs, but carry an unacceptable adverse-event profile that may reflect, at least partly, their intrinsic ability to alter basal homeostatic CB1R signaling in the CNS and elicit a neg. efficacy response.  Alternatively, peripherally biased CB1R inverse agonists with limited CNS permeability and putative CB1R neutral antagonists expressing modest (if any) inverse-agonist efficacy are garnering attention for treating obesity and related cardiometabolic complications with a potentially enhanced benefit-to-risk profile.Areas covered: This mini-review calls attention to the proposition that CB1R neutral antagonists offer attractive opportunities for pharmacotherapeutic exploitation in the substance abuse/drug addiction space, whereas the restricted CNS accessibility of peripherally biased CB1R inverse agonists circumscribes their therapeutic utility for this indication.Expert opinion: The unique preclin. pharmacol., efficacy profiles, and reduced adverse-event risk of CB1R neutral antagonists make them worthy of translational study for their potential therapeutic application beyond obesity/cardiometabolic disease to include substance-abuse/drug-addiction disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4VSyiuwP_nLVg90H21EOLACvtfcHk0lhrEX2bScTykA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksVOktr4%253D&md5=0af61a6a755b9b527934346cc4e860ba</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1517%2F14728214.2012.660916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728214.2012.660916%26sid%3Dliteratum%253Aachs%26aulast%3DJanero%26aufirst%3DD.%2BR.%26atitle%3DCannabinoid-1%2520receptor%2520%2528CB1R%2529%2520blockers%2520as%2520medicines%253A%2520beyond%2520obesity%2520and%2520cardiometabolic%2520disorders%2520to%2520substance%2520abuse%252Fdrug%2520addiction%2520with%2520CB1R%2520neutral%2520antagonists%26jtitle%3DExpert%2520Opin.%2520Emerging%2520Drugs%26date%3D2012%26volume%3D17%26spage%3D17%26epage%3D29%26doi%3D10.1517%2F14728214.2012.660916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, H. D.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid signaling in health and disease</span>. <i>Can. J. Physiol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">327</span>, <span class="refDoi"> DOI: 10.1139/cjpp-2016-0346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1139%2Fcjpp-2016-0346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=28263083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsl2gtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2017&pages=311-327&author=Y.+Luauthor=H.+D.+Anderson&title=Cannabinoid+signaling+in+health+and+disease&doi=10.1139%2Fcjpp-2016-0346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid signaling in health and disease</span></div><div class="casAuthors">Lu, Yan; Anderson, Hope D.</div><div class="citationInfo"><span class="NLM_cas:title">Canadian Journal of Physiology and Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">311-327</span>CODEN:
                <span class="NLM_cas:coden">CJPPA3</span>;
        ISSN:<span class="NLM_cas:issn">0008-4212</span>.
    
            (<span class="NLM_cas:orgname">Canadian Science Publishing</span>)
        </div><div class="casAbstract">Cannabis sativa has long been used for medicinal purposes.  To improve safety and efficacy, compds. from C.sativa were purified or synthesized and named under an umbrella group as cannabinoids.  Currently, several cannabinoids may be prescribed in Canada for a variety of indications such as nausea and pain.  More recently, an increasing no. of reports suggest other salutary effects assocd. with endogenous cannabinoid signaling including cardioprotection.  The therapeutic potential of cannabinoids is therefore extended; however, evidence is limited and mechanisms remain unclear.  In addn., the use of cannabinoids clin. has been hindered due to pronounced psychoactive side effects.  This review provides an overview on the endocannabinoid system, including known physiol. roles, and conditions in which cannabinoid receptor signaling has been implicated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsd9MesiR56LVg90H21EOLACvtfcHk0lhrEX2bScTykA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsl2gtb8%253D&md5=e3e1c0f219bd9e0d44c0c063dd61626d</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1139%2Fcjpp-2016-0346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1139%252Fcjpp-2016-0346%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DY.%26aulast%3DAnderson%26aufirst%3DH.%2BD.%26atitle%3DCannabinoid%2520signaling%2520in%2520health%2520and%2520disease%26jtitle%3DCan.%2520J.%2520Physiol.%2520Pharmacol.%26date%3D2017%26volume%3D95%26spage%3D311%26epage%3D327%26doi%3D10.1139%2Fcjpp-2016-0346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifulco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Petrocellis, L.</span></span> <span> </span><span class="NLM_article-title">The endocannabinoid system and its therapeutic exploitation</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">771</span>– <span class="NLM_lpage">784</span>, <span class="refDoi"> DOI: 10.1038/nrd1495</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1038%2Fnrd1495" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=15340387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntFCns7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=771-784&author=V.+Di%0AMarzoauthor=M.+Bifulcoauthor=L.+De+Petrocellis&title=The+endocannabinoid+system+and+its+therapeutic+exploitation&doi=10.1038%2Fnrd1495"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The endocannabinoid system and its therapeutic exploitation</span></div><div class="casAuthors">Di Marzo, Vincenzo; Bifulco, Maurizio; De Petrocellis, Luciano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">771-784</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with refs.  The term 'endocannabinoid' - originally coined in the mid-1990s after the discovery of membrane receptors for the psychoactive principle in Cannabis, Δ9-tetrahydrocannabinol and their endogenous ligands - now indicates a whole signalling system that comprises cannabinoid receptors, endogenous ligands and enzymes for ligand biosynthesis and inactivation.  This system seems to be involved in an ever-increasing no. of pathol. conditions.  With novel products already being aimed at the pharmaceutical market little more than a decade since the discovery of cannabinoid receptors, the endocannabinoid system seems to hold even more promise for the future development of therapeutic drugs.  We explore the conditions under which the potential of targeting the endocannabinoid system might be realized in the years to come.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-VBJpBWVazLVg90H21EOLACvtfcHk0lhrEX2bScTykA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntFCns7s%253D&md5=3a1b37143c5f6c8164228a7617d3f412</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnrd1495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1495%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DBifulco%26aufirst%3DM.%26aulast%3DDe%2BPetrocellis%26aufirst%3DL.%26atitle%3DThe%2520endocannabinoid%2520system%2520and%2520its%2520therapeutic%2520exploitation%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D771%26epage%3D784%26doi%3D10.1038%2Fnrd1495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pacher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bátkai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunos, G.</span></span> <span> </span><span class="NLM_article-title">The endocannabinoid system as an emerging target of pharmacotherapy</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">389</span>– <span class="NLM_lpage">462</span>, <span class="refDoi"> DOI: 10.1124/pr.58.3.2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1124%2Fpr.58.3.2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=16968947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVOhtLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2006&pages=389-462&author=P.+Pacherauthor=S.+B%C3%A1tkaiauthor=G.+Kunos&title=The+endocannabinoid+system+as+an+emerging+target+of+pharmacotherapy&doi=10.1124%2Fpr.58.3.2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The endocannabinoid system as an emerging target of pharmacotherapy</span></div><div class="casAuthors">Pacher, Pal; Batkai, Sandor; Kunos, George</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">389-462</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  The recent identification of cannabinoid receptors and their endogenous lipid ligands has triggered an exponential growth of studies exploring the endocannabinoid system and its regulatory functions in health and disease.  Such studies have been greatly facilitated by the introduction of selective cannabinoid receptor antagonists and inhibitors of endocannabinoid metab. and transport, as well as mice deficient in cannabinoid receptors or the endocannabinoid-degrading enzyme fatty acid amidohydrolase.  In the past decade, the endocannabinoid system has been implicated in a growing no. of physiol. functions, both in the central and peripheral nervous systems and in peripheral organs.  More importantly, modulating the activity of the endocannabinoid system turned out to hold therapeutic promise in a wide range of disparate diseases and pathol. conditions, ranging from mood and anxiety disorders, movement disorders such as Parkinson's and Huntington's disease, neuropathic pain, multiple sclerosis and spinal cord injury, to cancer, atherosclerosis, myocardial infarction, stroke, hypertension, glaucoma, obesity/metabolic syndrome, and osteoporosis, to name just a few.  An impediment to the development of cannabinoid medications has been the socially unacceptable psychoactive properties of plant-derived or synthetic agonists, mediated by CB1 receptors.  However, this problem does not arise when the therapeutic aim is achieved by treatment with a CB1 receptor antagonist, such as in obesity, and may also be absent when the action of endocannabinoids is enhanced indirectly through blocking their metab. or transport.  The use of selective CB2 receptor agonists, which lack psychoactive properties, could represent another promising avenue for certain conditions.  The abuse potential of plant-derived cannabinoids may also be limited through the use of prepns. with controlled compn. and the careful selection of does and route of administration.  The growing no. of preclin. studies and clin. trials with compds. that modulate the endocannabinoid system will probably result in novel therapeutic approaches in a no. of diseases for which current treatments do not fully address the patients' need.  Here, we provide a comprehensive overview on the current state of knowledge of the endocannabinoid system as a target of pharmacotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN_yobbKbuLbVg90H21EOLACvtfcHk0ljSUok9vtqRfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVOhtLfO&md5=f54e6d1303645a1c63809879ef2813f3</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1124%2Fpr.58.3.2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.58.3.2%26sid%3Dliteratum%253Aachs%26aulast%3DPacher%26aufirst%3DP.%26aulast%3DB%25C3%25A1tkai%26aufirst%3DS.%26aulast%3DKunos%26aufirst%3DG.%26atitle%3DThe%2520endocannabinoid%2520system%2520as%2520an%2520emerging%2520target%2520of%2520pharmacotherapy%26jtitle%3DPharmacol.%2520Rev.%26date%3D2006%26volume%3D58%26spage%3D389%26epage%3D462%26doi%3D10.1124%2Fpr.58.3.2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luján, M. Á.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheer, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melis, M.</span></span> <span> </span><span class="NLM_article-title">Choosing the right drug: status and future of endocannabinoid research for the prevention of drug-seeking reinstatement</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2020.08.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1016%2Fj.coph.2020.08.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=33068883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A280%3ADC%252BB3s7islSktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2020&pages=29-38&author=M.+%C3%81.+Luj%C3%A1nauthor=J.+F.+Cheerauthor=M.+Melis&title=Choosing+the+right+drug%3A+status+and+future+of+endocannabinoid+research+for+the+prevention+of+drug-seeking+reinstatement&doi=10.1016%2Fj.coph.2020.08.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Choosing the right drug: status and future of endocannabinoid research for the prevention of drug-seeking reinstatement</span></div><div class="casAuthors">Lujan Miguel A; Cheer Joseph F; Melis Miriam</div><div class="citationInfo"><span class="NLM_cas:title">Current opinion in pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">29-38</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Prolonged exposure to drugs of abuse leads to severe alterations in mesocorticolimbic dopamine circuitry deeply implicated in substance use disorders.  Despite considerable efforts, few medications to reduce relapse rates are currently available.  To solve this issue, researchers are uncovering therapeutic opportunities offered by the endocannabinoid system.  The cannabinoid receptor type 1 (CB1R), and its endogenous ligands, participate in orchestration of cue-triggered and stress-triggered responses leading to obtain natural and drug rewards.  Here, we review the evidence supporting the use of CB1R neutral antagonists, allosteric modulators, indirect agonists, as well as multi-target compounds, as improved alternatives compared to classical CB1R antagonists.  The promising therapeutic value of other substrates participating in endocannabinoid signaling, like peroxisome proliferator-activated receptors, is also covered.  Overall, a wide body of pre-clinical evidence avails novel pharmacological strategies interacting with the endocannabinoid system as clinically amenable candidates able to counteract drug-induced dopamine maladaptations contributing to increased risk of relapse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTn0x6l2FqpppVVjGoY74BafW6udTcc2eZfEtMX_LHQ8Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3s7islSktA%253D%253D&md5=54fae570c29dab96d9c4224813f05900</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2020.08.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2020.08.014%26sid%3Dliteratum%253Aachs%26aulast%3DLuj%25C3%25A1n%26aufirst%3DM.%2B%25C3%2581.%26aulast%3DCheer%26aufirst%3DJ.%2BF.%26aulast%3DMelis%26aufirst%3DM.%26atitle%3DChoosing%2520the%2520right%2520drug%253A%2520status%2520and%2520future%2520of%2520endocannabinoid%2520research%2520for%2520the%2520prevention%2520of%2520drug-seeking%2520reinstatement%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2020%26volume%3D56%26spage%3D29%26epage%3D38%26doi%3D10.1016%2Fj.coph.2020.08.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sholler, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huestis, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amendolara, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandrey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, Z. D.</span></span> <span> </span><span class="NLM_article-title">Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids</span>. <i>Pharmacol., Biochem. Behav.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>199</i></span>, <span class="NLM_elocation-id">173059</span> <span class="refDoi"> DOI: 10.1016/j.pbb.2020.173059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1016%2Fj.pbb.2020.173059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=33086126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit12ktr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=199&publication_year=2020&author=D.+J.+Shollerauthor=M.+A.+Huestisauthor=B.+Amendolaraauthor=R.+Vandreyauthor=Z.+D.+Cooper&title=Therapeutic+potential+and+safety+considerations+for+the+clinical+use+of+synthetic+cannabinoids&doi=10.1016%2Fj.pbb.2020.173059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids</span></div><div class="casAuthors">Sholler, Dennis J.; Huestis, Marilyn A.; Amendolara, Benjamin; Vandrey, Ryan; Cooper, Ziva D.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology, Biochemistry and Behavior</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">199</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">173059</span>CODEN:
                <span class="NLM_cas:coden">PBBHAU</span>;
        ISSN:<span class="NLM_cas:issn">0091-3057</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The phytocannabinoid Δ9-tetrahydrocannabinol (THC) was isolated and synthesized in the 1960s.  Two synthetic cannabinoids (SCBs) targeting the cannabinoid 1 (CB1R) and 2 (CB2R) receptors were approved for medical use based on clin. safety and efficacy data: dronabinol (synthetic THC) and nabilone (synthetic THC analog).  To probe the function of the endocannabinoid system further, hundreds of investigational compds. were developed; in particular, agonists with (1) greater CB1/2R affinity relative to THC and (2) full CB1/2R agonist activity.  This pharmacol. profile may pose greater risks for misuse and adverse effects relative to THC, and these SCBs proliferated in retail markets as legal alternatives to cannabis (e.g., novel psychoactive substances [NPS], "Spice," "K2").  This highlights the potential therapeutic efficacy and safety considerations for unique SCBs, including CB1R partial and full agonists, peripherally-restricted CB1R agonists, selective CB2R agonists, selective CB1R antagonists/inverse agonists, CB1R allosteric modulators, endocannabinoid-degrading enzyme inhibitors, and cannabidiol.  We propose promising directions for SCB research that may optimize therapeutic efficacy and diminish potential for adverse events, for example, peripherally-restricted CB1R antagonists/inverse agonists and biased CB1/2R agonists.  Together, these strategies could lead to the discovery of new, therapeutically useful SCBs with reduced neg. public health impact.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8pw8MbqqjCLVg90H21EOLACvtfcHk0ljSUok9vtqRfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit12ktr%252FM&md5=acad53a99a0bd4ea220d9a5903d33e51</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.pbb.2020.173059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pbb.2020.173059%26sid%3Dliteratum%253Aachs%26aulast%3DSholler%26aufirst%3DD.%2BJ.%26aulast%3DHuestis%26aufirst%3DM.%2BA.%26aulast%3DAmendolara%26aufirst%3DB.%26aulast%3DVandrey%26aufirst%3DR.%26aulast%3DCooper%26aufirst%3DZ.%2BD.%26atitle%3DTherapeutic%2520potential%2520and%2520safety%2520considerations%2520for%2520the%2520clinical%2520use%2520of%2520synthetic%2520cannabinoids%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2020%26volume%3D199%26doi%3D10.1016%2Fj.pbb.2020.173059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ross, R. A.</span></span> <span> </span><span class="NLM_article-title">Allosterism and cannabinoid CB(1) receptors: the shape of things to come</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">567</span>– <span class="NLM_lpage">572</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2007.10.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1016%2Fj.tips.2007.10.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=18029031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1KgsLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2007&pages=567-572&author=R.+A.+Ross&title=Allosterism+and+cannabinoid+CB%281%29+receptors%3A+the+shape+of+things+to+come&doi=10.1016%2Fj.tips.2007.10.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Allosterism and cannabinoid CB1 receptors: the shape of things to come</span></div><div class="casAuthors">Ross, Ruth A.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">567-572</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  In 2005, the first evidence was obtained that the cannabinoid CB1 receptor contains an allosteric binding site.  The site can be recognized by synthetic small mols., which display a markedly divergent effect on orthosteric ligand affinity vs. efficacy; these small mols. are allosteric enhancers of agonist binding affinity and allosteric inhibitors of agonist signaling efficacy.  Allosteric modulation heralds a new approach to the manipulation of the endocannabinoid system for therapeutic benefit; it promises to augment the existing portfolio of selective direct agonists, competitive antagonists and enzyme inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQCoxt-Z5_J7Vg90H21EOLACvtfcHk0ljSUok9vtqRfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1KgsLrM&md5=4d2d1dd40f0d4d468f3b597c33f51ee8</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2007.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2007.10.006%26sid%3Dliteratum%253Aachs%26aulast%3DRoss%26aufirst%3DR.%2BA.%26atitle%3DAllosterism%2520and%2520cannabinoid%2520CB%25281%2529%2520receptors%253A%2520the%2520shape%2520of%2520things%2520to%2520come%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2007%26volume%3D28%26spage%3D567%26epage%3D572%26doi%3D10.1016%2Fj.tips.2007.10.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hryhorowicz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaczmarek-Ryś, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrzejewska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staszak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hryhorowicz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korcz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Słomski, R.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulation of cannabinoid receptor 1-current challenges and future opportunities</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>, <span class="NLM_elocation-id">5874</span> <span class="refDoi"> DOI: 10.3390/ijms20235874</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.3390%2Fijms20235874" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtV2ltb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&author=S.+Hryhorowiczauthor=M.+Kaczmarek-Ry%C5%9Bauthor=A.+Andrzejewskaauthor=K.+Staszakauthor=M.+Hryhorowiczauthor=A.+Korczauthor=R.+S%C5%82omski&title=Allosteric+modulation+of+cannabinoid+receptor+1-current+challenges+and+future+opportunities&doi=10.3390%2Fijms20235874"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric modulation of cannabinoid receptor 1-current challenges and future opportunities</span></div><div class="casAuthors">Hryhorowicz, Szymon; Kaczmarek-Rys, Marta; Andrzejewska, Angelika; Staszak, Klaudia; Hryhorowicz, Magdalena; Korcz, Aleksandra; Slomski, Ryszard</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5874</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The cannabinoid receptor type 1 (CB1R), a G protein-coupled receptor (GPCR), plays an essential role in the control of many physiol. processes such as hunger, memory loss, gastrointestinal activity, catalepsy, fear, depression, and chronic pain.  Therefore, it is an attractive target for drug discovery to manage pain, neurodegenerative disorders, obesity, and substance abuse.  However, the psychoactive adverse effects, generated by CB1R activation in the brain, limit the use of the orthosteric CB1R ligands as drugs.  The discovery of CB1R allosteric modulators during the last decade provided new tools to target the CB1R.  Moreover, application of the site-directed mutagenesis in combination with advanced phys. methods, esp. X-ray crystallog. and computational modeling, has opened new horizons for understanding the complexity of the structure, function, and activity of cannabinoid receptors.  In this paper, we present the latest advances in research on the CB1R, its allosteric modulation and allosteric ligands, and their translational potential.  We focused on structural essentials of the cannabinoid 1 receptor- ligand (drug) interactions, as well as modes of CB1R signaling regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6F5JsG7qjmrVg90H21EOLACvtfcHk0li-1I0z8fKhKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtV2ltb3O&md5=a2f28aadb588481a33180246d0b9f992</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.3390%2Fijms20235874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20235874%26sid%3Dliteratum%253Aachs%26aulast%3DHryhorowicz%26aufirst%3DS.%26aulast%3DKaczmarek-Ry%25C5%259B%26aufirst%3DM.%26aulast%3DAndrzejewska%26aufirst%3DA.%26aulast%3DStaszak%26aufirst%3DK.%26aulast%3DHryhorowicz%26aufirst%3DM.%26aulast%3DKorcz%26aufirst%3DA.%26aulast%3DS%25C5%2582omski%26aufirst%3DR.%26atitle%3DAllosteric%2520modulation%2520of%2520cannabinoid%2520receptor%25201-current%2520challenges%2520and%2520future%2520opportunities%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26doi%3D10.3390%2Fijms20235874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Immadi, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kendall, D. A.</span></span> <span> </span><span class="NLM_article-title">Translational potential of allosteric modulators targeting the cannabinoid CB1 receptor</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">324</span>– <span class="NLM_lpage">335</span>, <span class="refDoi"> DOI: 10.1038/s41401-018-0164-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1038%2Fs41401-018-0164-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=30333554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFKjtL%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2019&pages=324-335&author=D.+Luauthor=S.+S.+Immadiauthor=Z.+Wuauthor=D.+A.+Kendall&title=Translational+potential+of+allosteric+modulators+targeting+the+cannabinoid+CB1+receptor&doi=10.1038%2Fs41401-018-0164-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Translational potential of allosteric modulators targeting the cannabinoid CB1 receptor</span></div><div class="casAuthors">Lu, Dai; Immadi, Sri Sujana; Wu, Zhixing; Kendall, Debra A.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">324-335</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The cannabinoid type-1 (CB1) receptor, a G-protein-coupled receptor, is an attractive target for drug discovery due to its involvement in many physiol. processes.  Historically, drug discovery efforts targeting the CB1 receptor have focused on the development of orthosteric ligands that interact with the active site to which endogenous cannabinoids bind.  Research performed over the last several decades has revealed substantial difficulties in translating CB1 orthosteric ligands into druggable candidates.  The difficulty is mainly due to the adverse effects assocd. with orthosteric CB1 ligands.  Recent discoveries of allosteric CB1 modulators provide tremendous opportunities to develop CB1 ligands with novel mechanisms of action; these ligands may potentially improve the pharmacol. effects and enhance drug safety in treating the disorders by regulating the functions of the CB1 receptor.  In this paper, we review and summarize the complex pharmacol. profiles of each class of CB1 allosteric modulators, the development of new classes of CB1 allosteric modulators and the results from in vivo assessments of their therapeutic value.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNjvusPibM57Vg90H21EOLACvtfcHk0li-1I0z8fKhKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFKjtL%252FL&md5=ebef475598356a12bee6d272783ef756</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fs41401-018-0164-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41401-018-0164-x%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DD.%26aulast%3DImmadi%26aufirst%3DS.%2BS.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DKendall%26aufirst%3DD.%2BA.%26atitle%3DTranslational%2520potential%2520of%2520allosteric%2520modulators%2520targeting%2520the%2520cannabinoid%2520CB1%2520receptor%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2019%26volume%3D40%26spage%3D324%26epage%3D335%26doi%3D10.1038%2Fs41401-018-0164-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dopart, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kendall, D. A.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulators of cannabinoid receptor 1: developing compounds for improved specificity</span>. <i>Drug Metab. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1080/03602532.2018.1428342</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1080%2F03602532.2018.1428342" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=29355030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2hsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2018&pages=3-13&author=R.+Dopartauthor=D.+Luauthor=A.+H.+Lichtmanauthor=D.+A.+Kendall&title=Allosteric+modulators+of+cannabinoid+receptor+1%3A+developing+compounds+for+improved+specificity&doi=10.1080%2F03602532.2018.1428342"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric modulators of cannabinoid receptor 1: developing compounds for improved specificity</span></div><div class="casAuthors">Dopart, Rachel; Lu, Dai; Lichtman, Aron H.; Kendall, Debra A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism Reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-13</span>CODEN:
                <span class="NLM_cas:coden">DMTRAR</span>;
        ISSN:<span class="NLM_cas:issn">0360-2532</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The cannabinoid receptor 1 (CB1) is a G protein-coupled receptor (GPCR) that is located primarily in the central nervous system.  CB1 is a therapeutic target which may impact pathways to mediate pain, neurodegenerative disorders, hunger, and drug-seeking behavior.  Despite these benefits, development of orthosteric therapeutic compds., which target the endogenous ligand-binding site of CB1, has been challenging due to detrimental side effects including psychoactivity, depression, and suicidal thoughts.  However, CB1 also has an allosteric binding site(s), which is topog. distinct from the orthosteric site.  Allosteric modulation of CB1 has a no. of potential advantages including providing a mechanism for more precise control of downstream pathways and circumventing these side effects.  In this review, we summarize the concept of allosteric modulation and focus on the structure-activity relationship studies of the well-characterized allosteric modulators, ORG27569 and PSNCBAM-1 and their derivs., and a few other recent modulators.  We review studies on the properties of these modulators on CB1 signaling in cells and their effects in vivo.  While many current allosteric modulators also produce complex outcomes, they provide new advances for the design of CB1 centered therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQsmmRpD5OA7Vg90H21EOLACvtfcHk0li-1I0z8fKhKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2hsrw%253D&md5=4e999878b6dde69103305048cb4e7674</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1080%2F03602532.2018.1428342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F03602532.2018.1428342%26sid%3Dliteratum%253Aachs%26aulast%3DDopart%26aufirst%3DR.%26aulast%3DLu%26aufirst%3DD.%26aulast%3DLichtman%26aufirst%3DA.%2BH.%26aulast%3DKendall%26aufirst%3DD.%2BA.%26atitle%3DAllosteric%2520modulators%2520of%2520cannabinoid%2520receptor%25201%253A%2520developing%2520compounds%2520for%2520improved%2520specificity%26jtitle%3DDrug%2520Metab.%2520Rev.%26date%3D2018%26volume%3D50%26spage%3D3%26epage%3D13%26doi%3D10.1080%2F03602532.2018.1428342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiley, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenakin, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulation: an alternate approach targeting the cannabinoid cb1 receptor</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">474</span>, <span class="refDoi"> DOI: 10.1002/med.21418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1002%2Fmed.21418" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=27879006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmt1als70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=441-474&author=T.+Nguyenauthor=J.+X.+Liauthor=B.+F.+Thomasauthor=J.+L.+Wileyauthor=T.+P.+Kenakinauthor=Y.+Zhang&title=Allosteric+modulation%3A+an+alternate+approach+targeting+the+cannabinoid+cb1+receptor&doi=10.1002%2Fmed.21418"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor</span></div><div class="casAuthors">Nguyen, Thuy; Li, Jun-Xu; Thomas, Brian F.; Wiley, Jenny L.; Kenakin, Terry P.; Zhang, Yanan</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">441-474</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The cannabinoid CB1 receptor is a G protein coupled receptor and plays an important role in many biol. processes and physiol. functions.  A variety of CB1 receptor agonists and antagonists, including endocannabinoids, phytocannabinoids, and synthetic cannabinoids, have been discovered or developed over the past 20 years.  In 2005, it was discovered that the CB1 receptor contains allosteric site(s) that can be recognized by small mols. or allosteric modulators.  A no. of CB1 receptor allosteric modulators, both pos. and neg., have since been reported and importantly, they display pharmacol. characteristics that are distinct from those of orthosteric agonists and antagonists.  Given the psychoactive effects commonly assocd. with CB1 receptor agonists and antagonists/inverse agonists, allosteric modulation may offer an alternate approach to attain potential therapeutic benefits while avoiding inherent side effects of orthosteric ligands.  This review details the complex pharmacol. profiles of these allosteric modulators, their structure-activity relationships, and efforts in elucidating binding modes and mechanisms of actions of reported CB1 allosteric modulators.  The ultimate development of CB1 receptor allosteric ligands could potentially lead to improved therapies for CB1-mediated neurol. disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn_UmNHz3IfrVg90H21EOLACvtfcHk0lgoFXuKk0r_wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmt1als70%253D&md5=3440e86c28aa07132de55c2c66640c2d</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fmed.21418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21418%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DJ.%2BX.%26aulast%3DThomas%26aufirst%3DB.%2BF.%26aulast%3DWiley%26aufirst%3DJ.%2BL.%26aulast%3DKenakin%26aufirst%3DT.%2BP.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DAllosteric%2520modulation%253A%2520an%2520alternate%2520approach%2520targeting%2520the%2520cannabinoid%2520cb1%2520receptor%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2017%26volume%3D37%26spage%3D441%26epage%3D474%26doi%3D10.1002%2Fmed.21418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janero, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, G. A.</span></span> <span> </span><span class="NLM_article-title">Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1223</span>– <span class="NLM_lpage">1237</span>, <span class="refDoi"> DOI: 10.1080/17460441.2016.1245289</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1080%2F17460441.2016.1245289" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=27712124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKltLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1223-1237&author=D.+R.+Janeroauthor=G.+A.+Thakur&title=Leveraging+allostery+to+improve+G+protein-coupled+receptor+%28GPCR%29-directed+therapeutics%3A+cannabinoid+receptor+1+as+discovery+target&doi=10.1080%2F17460441.2016.1245289"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target</span></div><div class="casAuthors">Janero, David R.; Thakur, Ganesh A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1223-1237</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Allosteric modulators of G-protein coupled receptors (GPCRs) hold the promise of improved pharmacol. and safety over typical orthosteric GPCR ligands.  These features are particularly relevant to the cannabinoid receptor 1 (CB1R) GPCR, since typical orthosteric CB1R ligands are assocd. with adverse events that limit their translational potential.  The contextual basis for applying allostery to CB1R is considered from pharmacol., drug-discovery, and medicinal standpoints.  Rational design of small-mol. CB1R allosteric modulators as potential pharmacotherapeutics would be greatly facilitated by direct exptl. characterization of structure-function correlates underlying the biol. activity of chem.-diverse CB1R allosteric modulators, CB1R allosteric ligand-binding binding pockets, and amino acid contact residues crit. to allosteric ligand engagement and activity.  In these regards, designer covalent probes exhibiting well-characterized mol. pharmacol. as CB1R allosteric modulators are emerging as valuable mol. reporters enabling exptl. interrogation of CB1R allosteric site(s) and informing the design of new CB1R agents as drugs.  Synthesis and pharmacol. profiling of CB1R allosteric ligands will continue to provide valuable insights into CB1R structure-function correlates.  The resulting data should expand the repertoire of novel agents capable of exerting therapeutic benefit by modulating CB1R-dependent signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooiQ3WE4T8X7Vg90H21EOLACvtfcHk0lgoFXuKk0r_wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKltLbE&md5=d8cafb1a1f911a4ae292e029c4307609</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1080%2F17460441.2016.1245289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2016.1245289%26sid%3Dliteratum%253Aachs%26aulast%3DJanero%26aufirst%3DD.%2BR.%26aulast%3DThakur%26aufirst%3DG.%2BA.%26atitle%3DLeveraging%2520allostery%2520to%2520improve%2520G%2520protein-coupled%2520receptor%2520%2528GPCR%2529-directed%2520therapeutics%253A%2520cannabinoid%2520receptor%25201%2520as%2520discovery%2520target%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2016%26volume%3D11%26spage%3D1223%26epage%3D1237%26doi%3D10.1080%2F17460441.2016.1245289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janero, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, G. A.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of cannabinoid 1 receptor (cb1r) allosteric modulators: drug discovery applications</span>. <i>Methods Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>593</i></span>,  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1016/bs.mie.2017.06.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1016%2Fbs.mie.2017.06.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=28750808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmvVemtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=593&publication_year=2017&pages=281-315&author=A.+R.+Kulkarniauthor=S.+Garaiauthor=D.+R.+Janeroauthor=G.+A.+Thakur&title=Design+and+synthesis+of+cannabinoid+1+receptor+%28cb1r%29+allosteric+modulators%3A+drug+discovery+applications&doi=10.1016%2Fbs.mie.2017.06.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of cannabinoid 1 receptor (CB1R) allosteric modulators: drug discovery applications</span></div><div class="casAuthors">Kulkarni, Abhijit R.; Garai, Sumanta; Janero, David R.; Thakur, Ganesh A.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">593</span>
        (<span class="NLM_cas:issue">Cannabinoids and Their Receptors</span>),
    <span class="NLM_cas:pages">281-315</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Also expressed in various peripheral tissues, the type-1 cannabinoid receptor (CB1R) is the predominant G protein-coupled receptor (GPCR) in brain, where it is responsible for retrograde control of neurotransmitter release.  Cellular signaling mediated by CB1R is involved in numerous physiol. processes, and pharmacol. CB1R modulation is considered a tenable therapeutic approach for diseases ranging from substance-use disorders and glaucoma to metabolic syndrome.  Despite the design and synthesis of a variety of bioactive small mols. targeted to the CB1R orthosteric ligand-binding site, the potential of CB1R as a therapeutic GPCR has been largely unrealized due to adverse events assocd. with typical orthosteric CB1R agonists and antagonists/inverse agonists.  Modulation of CB1R-mediated signal transmission by targeting alternative allosteric ligand-binding site(s) on the receptor has garnered interest as a potentially safer and more effective therapeutic modality.  This chapter highlights the design and synthesis of novel, pharmacol. active CB1R allosteric modulators and emphasizes how their mol. properties and the pos. and neg. allosteric control they exert can lead to improved CB1R-targeted pharmacotherapeutics, as well as designer covalent probes that can be used to map CB1R allosteric binding domains and inform structure-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEArBHnXvjSLVg90H21EOLACvtfcHk0lgoFXuKk0r_wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmvVemtbo%253D&md5=3054ad925dbee3174764b2bef86a37f7</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fbs.mie.2017.06.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.mie.2017.06.018%26sid%3Dliteratum%253Aachs%26aulast%3DKulkarni%26aufirst%3DA.%2BR.%26aulast%3DGarai%26aufirst%3DS.%26aulast%3DJanero%26aufirst%3DD.%2BR.%26aulast%3DThakur%26aufirst%3DG.%2BA.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520cannabinoid%25201%2520receptor%2520%2528cb1r%2529%2520allosteric%2520modulators%253A%2520drug%2520discovery%2520applications%26jtitle%3DMethods%2520Enzymol.%26date%3D2017%26volume%3D593%26spage%3D281%26epage%3D315%26doi%3D10.1016%2Fbs.mie.2017.06.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shonberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuano, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, J. R.</span></span> <span> </span><span class="NLM_article-title">Biased agonism at G protein-coupled receptors: the promise and the challenges--a medicinal chemistry perspective</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1286</span>– <span class="NLM_lpage">1330</span>, <span class="refDoi"> DOI: 10.1002/med.21318</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1002%2Fmed.21318" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=24796277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslalu7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=1286-1330&author=J.+Shonbergauthor=L.+Lopezauthor=P.+J.+Scammellsauthor=A.+Christopoulosauthor=B.+Capuanoauthor=J.+R.+Lane&title=Biased+agonism+at+G+protein-coupled+receptors%3A+the+promise+and+the+challenges%2D%2Da+medicinal+chemistry+perspective&doi=10.1002%2Fmed.21318"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Biased Agonism at G Protein-Coupled Receptors: The Promise and the Challenges-A Medicinal Chemistry Perspective</span></div><div class="casAuthors">Shonberg, Jeremy; Lopez, Laura; Scammells, Peter J.; Christopoulos, Arthur; Capuano, Ben; Lane, J. Robert</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1286-1330</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Historically, detn. of G protein-coupled receptor (GPCR) ligand efficacy has often been restricted to identifying the ligand as an agonist or antagonist at a given signaling pathway.  This classification was deemed sufficient to predict compd. efficacy at all signaling endpoints, including the therapeutically relevant one(s).  However, it is now apparent that ligands acting at the same GPCR can stabilize multiple, distinct, receptor conformations linked to different functional outcomes.  This phenomenon, known as biased agonism, stimulus bias, or functional selectivity offers the opportunity to sep. on-target therapeutic effects from side effects through the design of drugs that show pathway selectivity.  However, the medicinal chemist faces numerous challenges to develop biased ligands, including the detection and quantification of biased agonism.  This review summarizes the current state of the field of research into biased agonism at GPCRs, with a particular focus on efforts to relate biased agonism to ligand structure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg-egFZpSKvbVg90H21EOLACvtfcHk0lgv6eahjZpU0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslalu7rJ&md5=85a5b385750d21856ae044391c46ee75</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2Fmed.21318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21318%26sid%3Dliteratum%253Aachs%26aulast%3DShonberg%26aufirst%3DJ.%26aulast%3DLopez%26aufirst%3DL.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DCapuano%26aufirst%3DB.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26atitle%3DBiased%2520agonism%2520at%2520G%2520protein-coupled%2520receptors%253A%2520the%2520promise%2520and%2520the%2520challenges--a%2520medicinal%2520chemistry%2520perspective%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2014%26volume%3D34%26spage%3D1286%26epage%3D1330%26doi%3D10.1002%2Fmed.21318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bologna, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teoh, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayoumi, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I. M.</span></span> <span> </span><span class="NLM_article-title">Biased G protein-coupled receptor signaling: new player in modulating physiology and pathology</span>. <i>Biomol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.4062/biomolther.2016.165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.4062%2Fbiomolther.2016.165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A280%3ADC%252BC1c7gsFWhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=12-25&author=Z.+Bolognaauthor=J.+P.+Teohauthor=A.+S.+Bayoumiauthor=Y.+Tangauthor=I.+M.+Kim&title=Biased+G+protein-coupled+receptor+signaling%3A+new+player+in+modulating+physiology+and+pathology&doi=10.4062%2Fbiomolther.2016.165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Biased G Protein-Coupled Receptor Signaling: New Player in Modulating Physiology and Pathology</span></div><div class="casAuthors">Bologna Zuzana; Teoh Jian-Peng; Bayoumi Ahmed S; Tang Yaoliang; Kim Il-Man; Kim Il-Man</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecules & therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-25</span>
        ISSN:<span class="NLM_cas:issn">1976-9148</span>.
    </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are a family of cell-surface proteins that play critical roles in regulating a variety of pathophysiological processes and thus are targeted by almost a third of currently available therapeutics.  It was originally thought that GPCRs convert extracellular stimuli into intracellular signals through activating G proteins, whereas β-arrestins have important roles in internalization and desensitization of the receptor.  Over the past decade, several novel functional aspects of β-arrestins in regulating GPCR signaling have been discovered.  These previously unanticipated roles of β-arrestins to act as signal transducers and mediators of G protein-independent signaling have led to the concept of biased agonism.  Biased GPCR ligands are able to engage with their target receptors in a manner that preferentially activates only G protein- or β-arrestin-mediated downstream signaling.  This offers the potential for next generation drugs with high selectivity to therapeutically relevant GPCR signaling pathways.  In this review, we provide a summary of the recent studies highlighting G protein- or β-arrestin-biased GPCR signaling and the effects of biased ligands on disease pathogenesis and regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRshPzvVvIEzJVVjGoY74BafW6udTcc2eaEbO-Py4I-fbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7gsFWhtg%253D%253D&md5=7cfe8440b5d4e23b6c94d450662e8e54</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.4062%2Fbiomolther.2016.165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4062%252Fbiomolther.2016.165%26sid%3Dliteratum%253Aachs%26aulast%3DBologna%26aufirst%3DZ.%26aulast%3DTeoh%26aufirst%3DJ.%2BP.%26aulast%3DBayoumi%26aufirst%3DA.%2BS.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DI.%2BM.%26atitle%3DBiased%2520G%2520protein-coupled%2520receptor%2520signaling%253A%2520new%2520player%2520in%2520modulating%2520physiology%2520and%2520pathology%26jtitle%3DBiomol.%2520Ther.%26date%3D2017%26volume%3D25%26spage%3D12%26epage%3D25%26doi%3D10.4062%2Fbiomolther.2016.165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeWire, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span> <span> </span><span class="NLM_article-title">, Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology</span>. <i>Circ. Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">216</span>, <span class="refDoi"> DOI: 10.1161/CIRCRESAHA.110.231308</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1161%2FCIRCRESAHA.110.231308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=21737816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFaisL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2011&pages=205-216&author=S.+M.+DeWireauthor=J.+D.+Violin&title=%2C+Biased+ligands+for+better+cardiovascular+drugs%3A+dissecting+G-protein-coupled+receptor+pharmacology&doi=10.1161%2FCIRCRESAHA.110.231308"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Biased Ligands for Better Cardiovascular Drugs: Dissecting G-Protein-Coupled Receptor Pharmacology</span></div><div class="casAuthors">DeWire, Scott M.; Violin, Jonathan D.</div><div class="citationInfo"><span class="NLM_cas:title">Circulation Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">205-216</span>CODEN:
                <span class="NLM_cas:coden">CIRUAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-7330</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Drug discovery efforts targeting G-protein-coupled receptors (GPCR) were immensely successful in creating new cardiovascular medicines.  Currently marketed GPCR drugs are broadly classified as either agonists that activate receptors or antagonists that prevent receptor activation by endogenous stimuli.  However, GPCR couple to a multitude of intracellular signaling pathways beyond classical G-protein signals, and these signals can be independently activated by biased ligands to vastly expand the potential for new drugs at these classic targets.  By selectively engaging only a subset of a receptor's potential intracellular partners, biased ligands may deliver more precise therapeutic benefit with fewer side effects than current GPCR-targeted drugs.  In this review, we discuss the history of biased ligand research, the current understanding of how biased ligands exert their unique pharmacol., and how research into GPCR signaling has uncovered previously unappreciated capabilities of receptor pharmacol.  We focus on several receptors to illustrate the approaches taken and discoveries made, and how these are steadily illuminating the intricacies of GPCR pharmacol.  Discoveries of biased ligands targeting the angiotensin II type 1 receptor and of separable pharmacol. suggesting the potential value of biased ligands targeting the β-adrenergic receptors and nicotinic acid receptor GPR109a highlight the powerful clin. promise of this new category of potential therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpULKUYGC9HqrVg90H21EOLACvtfcHk0lgv6eahjZpU0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFaisL8%253D&md5=5e3ba6c6b9e015cf52759f87dcdd62ed</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1161%2FCIRCRESAHA.110.231308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCRESAHA.110.231308%26sid%3Dliteratum%253Aachs%26aulast%3DDeWire%26aufirst%3DS.%2BM.%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26atitle%3D%252C%2520Biased%2520ligands%2520for%2520better%2520cardiovascular%2520drugs%253A%2520dissecting%2520G-protein-coupled%2520receptor%2520pharmacology%26jtitle%3DCirc.%2520Res.%26date%3D2011%26volume%3D109%26spage%3D205%26epage%3D216%26doi%3D10.1161%2FCIRCRESAHA.110.231308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCorvy, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span> <span> </span><span class="NLM_article-title">Biased ligands of g protein-coupled receptors (GPCRs): structure-functional selectivity relationships (SFSRs) and therapeutic potential</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9841</span>– <span class="NLM_lpage">9878</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00435</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00435" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Snu73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9841-9878&author=L.+Tanauthor=W.+Yanauthor=J.+D.+McCorvyauthor=J.+Cheng&title=Biased+ligands+of+g+protein-coupled+receptors+%28GPCRs%29%3A+structure-functional+selectivity+relationships+%28SFSRs%29+and+therapeutic+potential&doi=10.1021%2Facs.jmedchem.8b00435"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential</span></div><div class="casAuthors">Tan, Liang; Yan, Wenzhong; McCorvy, John D.; Cheng, Jianjun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9841-9878</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  G protein-coupled receptors (GPCRs) signal through both G-protein-dependent and G-protein-independent pathways, and β-arrestin recruitment is the most recognized one of the latter.  Biased ligands selective for either pathway are expected to regulate biol. functions of GPCRs in a more precise way, therefore providing new drug mols. with superior efficacy and/or reduced side effects.  During the past decade, biased ligands have been discovered and developed for many GPCRs, such as the μ opioid receptor, the angiotensin II receptor type 1, the dopamine D2 receptor, and many others.  In this Perspective, recent advances in this field are reviewed by discussing the structure-functional selectivity relationships (SFSRs) of GPCR biased ligands and the therapeutic potential of these mols.  Further understanding of the biol. functions assocd. with each signaling pathway and structural basis for biased signaling will facilitate future drug design in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNFjkAvar29LVg90H21EOLACvtfcHk0liwtoZ0IvFq_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Snu73N&md5=a7bd605b82666357f5a0a209002225e5</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00435%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DL.%26aulast%3DYan%26aufirst%3DW.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DCheng%26aufirst%3DJ.%26atitle%3DBiased%2520ligands%2520of%2520g%2520protein-coupled%2520receptors%2520%2528GPCRs%2529%253A%2520structure-functional%2520selectivity%2520relationships%2520%2528SFSRs%2529%2520and%2520therapeutic%2520potential%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9841%26epage%3D9878%26doi%3D10.1021%2Facs.jmedchem.8b00435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunyady, L.</span></span> <span> </span><span class="NLM_article-title">Signal transduction of the CB1 cannabinoid receptor</span>. <i>J. Mol. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.1677/JME-08-0190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1677%2FJME-08-0190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=19620237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvFSitr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2010&pages=75-85&author=G.+Turuauthor=L.+Hunyady&title=Signal+transduction+of+the+CB1+cannabinoid+receptor&doi=10.1677%2FJME-08-0190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Signal transduction of the CB1 cannabinoid receptor</span></div><div class="casAuthors">Turu, Gabor; Hunyady, Laszlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Endocrinology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1,2</span>),
    <span class="NLM_cas:pages">75-85</span>CODEN:
                <span class="NLM_cas:coden">JMLEEI</span>;
        ISSN:<span class="NLM_cas:issn">0952-5041</span>.
    
            (<span class="NLM_cas:orgname">Society for Endocrinology</span>)
        </div><div class="casAbstract">A review.  The CB1 cannabinoid receptor (CB1R) is the major cannabinoid receptor in neuronal cells and the brain, but it also occurs in endocrine cells and other peripheral tissues.  CB1R is a member of the superfamily of G-protein-coupled receptors (GPCRs), which are characterized by 7 transmembrane helixes.  The major mediators of CB1R are the G proteins of the Gi/o family, which inhibit adenylyl cyclases in most tissues and cells, and regulate ion channels, including calcium and potassium ion channels.  Regulation of ion channels is an important component of neurotransmission modulation by endogenous cannabinoid compds. released in response to depolarization and Ca2+-mobilizing hormones.  However, evidence exists that CB1Rs can also stimulate adenylyl cyclase via Gs, induce receptor-mediated Ca2+ fluxes and stimulate phospholipases in some exptl. models.  Stimulation of CB1R also leads to phosphorylation and activation of mitogen-activated protein kinases (MAPK), such as p42/p44 MAPK, p38 MAPK, and c-Jun N-terminal kinase, which can regulate nuclear transcription factors.  Activated and phosphorylated CB1Rs also assoc. with β-arrestin mols., which can induce the formation of signaling complexes and participate in the regulation of GPCR signaling.  Recent data also suggest that CB1Rs can form homo- and heterodimers/oligomers, and the altered pharmacol. properties of these receptor complexes may explain the pharmacol. differences obsd. in various tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrG11cTBkJabrVg90H21EOLACvtfcHk0liwtoZ0IvFq_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvFSitr0%253D&md5=cc2688221938d5e7908b254ce8116340</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1677%2FJME-08-0190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1677%252FJME-08-0190%26sid%3Dliteratum%253Aachs%26aulast%3DTuru%26aufirst%3DG.%26aulast%3DHunyady%26aufirst%3DL.%26atitle%3DSignal%2520transduction%2520of%2520the%2520CB1%2520cannabinoid%2520receptor%26jtitle%3DJ.%2520Mol.%2520Endocrinol.%26date%3D2010%26volume%3D44%26spage%3D75%26epage%3D85%26doi%3D10.1677%2FJME-08-0190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laprairie, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span> <span> </span><span class="NLM_article-title">Approaches to assess biased signaling at the CB1R receptor</span>. <i>Methods Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>593</i></span>,  <span class="NLM_fpage">259</span>– <span class="NLM_lpage">279</span>, <span class="refDoi"> DOI: 10.1016/bs.mie.2017.06.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1016%2Fbs.mie.2017.06.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=28750807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmvVemtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=593&publication_year=2017&pages=259-279&author=R.+B.+Laprairieauthor=E.+L.+Stahlauthor=L.+M.+Bohn&title=Approaches+to+assess+biased+signaling+at+the+CB1R+receptor&doi=10.1016%2Fbs.mie.2017.06.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Approaches to assess biased signaling at the CB1R receptor</span></div><div class="casAuthors">Laprairie, Robert B.; Stahl, Edward L.; Bohn, Laura M.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">593</span>
        (<span class="NLM_cas:issue">Cannabinoids and Their Receptors</span>),
    <span class="NLM_cas:pages">259-279</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">G protein-coupled receptors, such as the cannabinoid type 1 receptor (CB1R), have been shown to interact with multiple binding partners to transmit signals.  In both transfected cell systems and in endogenously expressing cell lines, CB1R signaling has been described as multifaceted.  The question remains as to how this highly widely expressed receptor signals in a given cell at a given time in vivo.  The concept of functional selectivity, or biased agonism, describes the ability of an agonist to engage the receptor in a manner that preferentially engages certain signaling interactions (e.g., G proteins) over others (e.g., β-arrestins), presumably by stabilizing certain receptor conformations.  There is growing interest in using such properties of ligands to direct signaling downstream of CB1R toward desirable therapeutic outcomes and to avoid adverse side effects.  While it is not currently clear what pathways should be engaged and which should be avoided, the development of biased agonist tool compds. will aid in answering these questions.  In this chapter, we discuss the approaches and caveats to assessing biased agonism at the CB1R.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGEt-ToYWUh7Vg90H21EOLACvtfcHk0lgphEQzOCkN5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmvVemtb0%253D&md5=2c02853c478dbe994bc0a97694d2f9b7</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fbs.mie.2017.06.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.mie.2017.06.031%26sid%3Dliteratum%253Aachs%26aulast%3DLaprairie%26aufirst%3DR.%2BB.%26aulast%3DStahl%26aufirst%3DE.%2BL.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26atitle%3DApproaches%2520to%2520assess%2520biased%2520signaling%2520at%2520the%2520CB1R%2520receptor%26jtitle%3DMethods%2520Enzymol.%26date%3D2017%26volume%3D593%26spage%3D259%26epage%3D279%26doi%3D10.1016%2Fbs.mie.2017.06.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mallipeddi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janero, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvonok, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makriyannis, A.</span></span> <span> </span><span class="NLM_article-title">Functional selectivity at G-protein coupled receptors: advancing cannabinoid receptors as drug targets</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">11</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2016.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1016%2Fj.bcp.2016.11.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=27890725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCnsL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2017&pages=1-11&author=S.+Mallipeddiauthor=D.+R.+Janeroauthor=N.+Zvonokauthor=A.+Makriyannis&title=Functional+selectivity+at+G-protein+coupled+receptors%3A+advancing+cannabinoid+receptors+as+drug+targets&doi=10.1016%2Fj.bcp.2016.11.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Functional selectivity at G-protein coupled receptors: Advancing cannabinoid receptors as drug targets</span></div><div class="casAuthors">Mallipeddi, Srikrishnan; Janero, David R.; Zvonok, Nikolai; Makriyannis, Alexandros</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-11</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The phenomenon of functional selectivity, whereby a ligand preferentially directs the information output of a G-protein coupled receptor (GPCR) along (a) particular effector pathway(s) and away from others, has redefined traditional GPCR signaling paradigms to provide a new approach to structure-based drug design.  The two principal cannabinoid receptors (CBRs) 1 and 2 belong to the class-A GPCR subfamily and are considered tenable therapeutic targets for several indications.  Yet conventional orthosteric ligands (agonists, antagonists/inverse agonists) for these receptors have had very limited clin. utility due to their propensity to incite on-target adverse events.  Chem. distinct classes of cannabinergic ligands exhibit signaling bias at CBRs towards individual subsets of signal transduction pathways.  In this review, we discuss the known signaling pathways regulated by CBRs and examine the current evidence for functional selectivity at CBRs in response to endogenous and exogenous cannabinergic ligands as biased agonists.  We further discuss the receptor and ligand structural features allowing for selective activation of CBR-dependent functional responses.  The design and development of biased ligands may offer a pathway to therapeutic success for novel CBR-targeted drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeBMv00pJezbVg90H21EOLACvtfcHk0lgphEQzOCkN5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCnsL3K&md5=a447353e190125cdd3d7e363eab0e137</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2016.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2016.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DMallipeddi%26aufirst%3DS.%26aulast%3DJanero%26aufirst%3DD.%2BR.%26aulast%3DZvonok%26aufirst%3DN.%26aulast%3DMakriyannis%26aufirst%3DA.%26atitle%3DFunctional%2520selectivity%2520at%2520G-protein%2520coupled%2520receptors%253A%2520advancing%2520cannabinoid%2520receptors%2520as%2520drug%2520targets%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2017%26volume%3D128%26spage%3D1%26epage%3D11%26doi%3D10.1016%2Fj.bcp.2016.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ibsen, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glass, M.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid CB(1) and CB(2) receptor signaling and bias</span>. <i>Cannabis Cannabinoid Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1089/can.2016.0037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1089%2Fcan.2016.0037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=28861504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkslGmtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2017&pages=48-60&author=M.+S.+Ibsenauthor=M.+Connorauthor=M.+Glass&title=Cannabinoid+CB%281%29+and+CB%282%29+receptor+signaling+and+bias&doi=10.1089%2Fcan.2016.0037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid CB1 and CB2 receptor signaling and bias</span></div><div class="casAuthors">Ibsen, Mikkel Soes; Connor, Mark; Glass, Michelle</div><div class="citationInfo"><span class="NLM_cas:title">Cannabis and Cannabinoid Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-60</span>CODEN:
                <span class="NLM_cas:coden">CCRAEP</span>;
        ISSN:<span class="NLM_cas:issn">2378-8763</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">A review.  An agonist that acts through a single receptor can activate numerous signaling pathways.  Recent studies have suggested that different ligands can differentially activate these pathways by stabilizing a limited range of receptor conformations, which in turn preferentially drive different downstream signaling cascades.  This concept, termed "biased signaling" represents an exciting therapeutic opportunity to target specific pathways that elicit only desired effects, while avoiding undesired effects mediated by different signaling cascades.  The cannabinoid receptors CB1 and CB2 each activate multiple pathways, and evidence is emerging for bias within these pathways.  This review will summarize the current evidence for biased signaling through cannabinoid receptor subtypes CB1 and CB2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUIt-yOeNWv7Vg90H21EOLACvtfcHk0lgphEQzOCkN5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkslGmtbg%253D&md5=17eb23b3331bdb8ca7050d2307180702</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1089%2Fcan.2016.0037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fcan.2016.0037%26sid%3Dliteratum%253Aachs%26aulast%3DIbsen%26aufirst%3DM.%2BS.%26aulast%3DConnor%26aufirst%3DM.%26aulast%3DGlass%26aufirst%3DM.%26atitle%3DCannabinoid%2520CB%25281%2529%2520and%2520CB%25282%2529%2520receptor%2520signaling%2520and%2520bias%26jtitle%3DCannabis%2520Cannabinoid%2520Res.%26date%3D2017%26volume%3D2%26spage%3D48%26epage%3D60%26doi%3D10.1089%2Fcan.2016.0037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laprairie, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagher, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denovan-Wright, E. M.</span></span> <span> </span><span class="NLM_article-title">Biased type 1 cannabinoid receptor signaling influences neuronal viability in a cell culture model of Huntington disease</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">364</span>– <span class="NLM_lpage">375</span>, <span class="refDoi"> DOI: 10.1124/mol.115.101980</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1124%2Fmol.115.101980" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=26700564" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFeltLnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2016&pages=364-375&author=R.+B.+Laprairieauthor=A.+M.+Bagherauthor=M.+E.+Kellyauthor=E.+M.+Denovan-Wright&title=Biased+type+1+cannabinoid+receptor+signaling+influences+neuronal+viability+in+a+cell+culture+model+of+Huntington+disease&doi=10.1124%2Fmol.115.101980"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Biased type 1 cannabinoid receptor signaling influences neuronal viability in a cell culture model of Huntington disease</span></div><div class="casAuthors">Laprairie, Robert B.; Bagher, Amina M.; Kelly, Melanie E. M.; Denovan-Wright, Eileen M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">364-375</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Huntington disease (HD) is an inherited, autosomal dominant, neurodegenerative disorder with limited treatment options.  Prior to motor symptom onset or neuronal cell loss in HD, levels of the type 1 cannabinoid receptor (CB1) decrease in the basal ganglia.  Decreasing CB1 levels are strongly correlated with chorea and cognitive deficit.  CB1 agonists are functionally selective (biased) for divergent signaling pathways.  In this study, six cannabinoids were tested for signaling bias in in vitro models of medium spiny projection neurons expressing wild-type (STHdhQ7/Q7) or mutant huntingtin protein (STHdhQ111/Q111).  Signaling bias was assessed using the Black and Leff operational model.  Relative activity [ΔlogR (τ/KA)] and system bias (ΔΔlogR) were calcd. relative to the ref. compd. WIN55,212-2 for Gαi/o, Gas, Gαq, Gβγ, and β-arrestin1 signaling following treatment with 2-arachidonoylglycerol (2-AG), anandamide (AEA), CP55,940, Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and THC+CBD (1:1), and compared between wild-type and HD cells.  The Emax of Gαi/o-dependent extracellular signal-regulated kinase (ERK) signaling was 50% lower in HD cells compared with wild-type cells.  2-AG and AEA displayed Gαi/o/Gβγ bias and normalized CB1 protein levels and improved cell viability, whereas CP55,940 and THC displayed β-arrestin1 bias and reduced CB1 protein levels and cell viability in HD cells.  CBD was not a CB1 agonist but inhibited THC-dependent signaling (THC+CBD).  Therefore, enhancing Gαi/o-biased endocannabinoid signaling may be therapeutically beneficial in HD.  In contrast, cannabinoids that are β-arrestin-biased-such as THC found at high levels in modern varieties of marijuana-may be detrimental to CB1 signaling, particularly in HD where CB1 levels are already reduced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdgxoxZrX1ObVg90H21EOLACvtfcHk0ljXji7PlvseAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFeltLnP&md5=fe544fe3afc0ab0ca739ab887be7c971</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1124%2Fmol.115.101980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.115.101980%26sid%3Dliteratum%253Aachs%26aulast%3DLaprairie%26aufirst%3DR.%2BB.%26aulast%3DBagher%26aufirst%3DA.%2BM.%26aulast%3DKelly%26aufirst%3DM.%2BE.%26aulast%3DDenovan-Wright%26aufirst%3DE.%2BM.%26atitle%3DBiased%2520type%25201%2520cannabinoid%2520receptor%2520signaling%2520influences%2520neuronal%2520viability%2520in%2520a%2520cell%2520culture%2520model%2520of%2520Huntington%2520disease%26jtitle%3DMol.%2520Pharmacol.%26date%3D2016%26volume%3D89%26spage%3D364%26epage%3D375%26doi%3D10.1124%2Fmol.115.101980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Zoubi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reggio, P. H.</span></span> <span> </span><span class="NLM_article-title">Structural insights into CB1 receptor biased signaling</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>, <span class="NLM_elocation-id">1837</span> <span class="refDoi"> DOI: 10.3390/ijms20081837</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.3390%2Fijms20081837" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFGlt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&author=R.+Al-Zoubiauthor=P.+Moralesauthor=P.+H.+Reggio&title=Structural+insights+into+CB1+receptor+biased+signaling&doi=10.3390%2Fijms20081837"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into CB1 receptor biased signaling</span></div><div class="casAuthors">Al-Zoubi, Rufaa; Morales, Paula; Reggio, Patricia H.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1837</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The endocannabinoid system has emerged as a promising target for the treatment of numerous diseases, including cancer, neurodegenerative disorders, and metabolic syndromes.  Thus far, two cannabinoid receptors, CB1 and CB2, have been discovered, which are found predominantly in the central nervous system (CB1) or the immune system (CB2), among other organs and tissues.  CB1 receptor ligands have been shown to induce a complex pattern of intracellular effects.  The binding of a ligand induces distinct conformational changes in the receptor, which will eventually translate into distinct intracellular signaling pathways through coupling to specific intracellular effector proteins.  These proteins can mediate receptor desensitization, trafficking, or signaling.  Ligand specificity and selectivity, complex cellular components, and the concomitant expression of other proteins (which either regulate the CB1 receptor or are regulated by the CB1 receptor) will affect the therapeutic outcome of its targeting.  With an increased interest in G protein-coupled receptors (GPCR) research, in-depth studies using mutations, biol. assays, and spectroscopic techniques (such as NMR, EPR, MS, FRET, and X-ray crystallog.), as well as computational modeling, have begun to reveal a set of concerted structural features in Class A GPCRs which relate to signaling pathways and the mechanisms of ligand-induced activation, deactivation, or activity modulation.  This review will focus on the structural features of the CB1 receptor, mutations known to bias its signaling, and reported studies of CB1 receptor ligands to control its specific signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhpn5qpenLKrVg90H21EOLACvtfcHk0ljXji7PlvseAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFGlt7w%253D&md5=2ef4a63e0feebbffa453cb5d17600247</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.3390%2Fijms20081837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20081837%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Zoubi%26aufirst%3DR.%26aulast%3DMorales%26aufirst%3DP.%26aulast%3DReggio%26aufirst%3DP.%2BH.%26atitle%3DStructural%2520insights%2520into%2520CB1%2520receptor%2520biased%2520signaling%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26doi%3D10.3390%2Fijms20081837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Vallée, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitiello, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellocchio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hébert-Chatelain, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monlezun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Garcia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasanetz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cathala, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roullot-Lacarrière, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shore, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deroche-Gamonet, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spampinato, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Revest, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maldonado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reggio, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsicano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piazza, P. V.</span></span> <span> </span><span class="NLM_article-title">Pregnenolone can protect the brain from cannabis intoxication</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>343</i></span>,  <span class="NLM_fpage">94</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1126/science.1243985</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1126%2Fscience.1243985" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=24385629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkslyn" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2014&pages=94-98&author=M.+Vall%C3%A9eauthor=S.+Vitielloauthor=L.+Bellocchioauthor=E.+H%C3%A9bert-Chatelainauthor=S.+Monlezunauthor=E.+Martin-Garciaauthor=F.+Kasanetzauthor=G.+L.+Baillieauthor=F.+Paninauthor=A.+Cathalaauthor=V.+Roullot-Lacarri%C3%A8reauthor=S.+Fabreauthor=D.+P.+Hurstauthor=D.+L.+Lynchauthor=D.+M.+Shoreauthor=V.+Deroche-Gamonetauthor=U.+Spampinatoauthor=J.+M.+Revestauthor=R.+Maldonadoauthor=P.+H.+Reggioauthor=R.+A.+Rossauthor=G.+Marsicanoauthor=P.+V.+Piazza&title=Pregnenolone+can+protect+the+brain+from+cannabis+intoxication&doi=10.1126%2Fscience.1243985"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27aR"><div class="casContent"><span class="casTitleNuber">27a</span><div class="casTitle"><span class="NLM_cas:atitle">Pregnenolone Can Protect the Brain from Cannabis Intoxication</span></div><div class="casAuthors">Vallee, Monique; Vitiello, Sergio; Bellocchio, Luigi; Hebert-Chatelain, Etienne; Monlezun, Stephanie; Martin-Garcia, Elena; Kasanetz, Fernando; Baillie, Gemma L.; Panin, Francesca; Cathala, Adeline; Roullot-Lacarriere, Valerie; Fabre, Sandy; Hurst, Dow P.; Lynch, Diane L.; Shore, Derek M.; Deroche-Gamonet, Veronique; Spampinato, Umberto; Revest, Jean-Michel; Maldonado, Rafael; Reggio, Patricia H.; Ross, Ruth A.; Marsicano, Giovanni; Piazza, Pier Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">6166</span>),
    <span class="NLM_cas:pages">94-98</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Pregnenolone is considered the inactive precursor of all steroid hormones, and its potential functional effects have been largely uninvestigated.  The administration of the main active principle of Cannabis sativa (marijuana), [Δ]9-tetrahydrocannabinol (THC), substantially increases the synthesis of pregnenolone in the brain via activation of the type-1 cannabinoid (CB1) receptor.  Pregnenolone then, acting as a signaling-specific inhibitor of the CB1 receptor, reduces several effects of THC.  This neg. feedback mediated by pregnenolone reveals a previously unknown paracrine/autocrine loop protecting the brain from CB1 receptor overactivation that could open an unforeseen approach for the treatment of cannabis intoxication and addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxyr3EtybQNbVg90H21EOLACvtfcHk0ljXji7PlvseAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkslyn&md5=b3e34c241de1f660c134329045966865</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.1126%2Fscience.1243985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1243985%26sid%3Dliteratum%253Aachs%26aulast%3DVall%25C3%25A9e%26aufirst%3DM.%26aulast%3DVitiello%26aufirst%3DS.%26aulast%3DBellocchio%26aufirst%3DL.%26aulast%3DH%25C3%25A9bert-Chatelain%26aufirst%3DE.%26aulast%3DMonlezun%26aufirst%3DS.%26aulast%3DMartin-Garcia%26aufirst%3DE.%26aulast%3DKasanetz%26aufirst%3DF.%26aulast%3DBaillie%26aufirst%3DG.%2BL.%26aulast%3DPanin%26aufirst%3DF.%26aulast%3DCathala%26aufirst%3DA.%26aulast%3DRoullot-Lacarri%25C3%25A8re%26aufirst%3DV.%26aulast%3DFabre%26aufirst%3DS.%26aulast%3DHurst%26aufirst%3DD.%2BP.%26aulast%3DLynch%26aufirst%3DD.%2BL.%26aulast%3DShore%26aufirst%3DD.%2BM.%26aulast%3DDeroche-Gamonet%26aufirst%3DV.%26aulast%3DSpampinato%26aufirst%3DU.%26aulast%3DRevest%26aufirst%3DJ.%2BM.%26aulast%3DMaldonado%26aufirst%3DR.%26aulast%3DReggio%26aufirst%3DP.%2BH.%26aulast%3DRoss%26aufirst%3DR.%2BA.%26aulast%3DMarsicano%26aufirst%3DG.%26aulast%3DPiazza%26aufirst%3DP.%2BV.%26atitle%3DPregnenolone%2520can%2520protect%2520the%2520brain%2520from%2520cannabis%2520intoxication%26jtitle%3DScience%26date%3D2014%26volume%3D343%26spage%3D94%26epage%3D98%26doi%3D10.1126%2Fscience.1243985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit27b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Laprairie, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohamed, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zagzoog, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, M. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denovan-Wright, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, G. A.</span></span> <span> </span><span class="NLM_article-title">Indomethacin enhances type 1 cannabinoid receptor signaling</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">12070</span> <span class="refDoi"> DOI: 10.3389/fnmol.2019.00257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.3389%2Ffnmol.2019.00257" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&author=R.+B.+Laprairieauthor=K.+A.+Mohamedauthor=A.+Zagzoogauthor=M.+E.+M.+Kellyauthor=L.+A.+Stevensonauthor=R.+Pertweeauthor=E.+M.+Denovan-Wrightauthor=G.+A.+Thakur&title=Indomethacin+enhances+type+1+cannabinoid+receptor+signaling&doi=10.3389%2Ffnmol.2019.00257"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2019.00257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2019.00257%26sid%3Dliteratum%253Aachs%26aulast%3DLaprairie%26aufirst%3DR.%2BB.%26aulast%3DMohamed%26aufirst%3DK.%2BA.%26aulast%3DZagzoog%26aufirst%3DA.%26aulast%3DKelly%26aufirst%3DM.%2BE.%2BM.%26aulast%3DStevenson%26aufirst%3DL.%2BA.%26aulast%3DPertwee%26aufirst%3DR.%26aulast%3DDenovan-Wright%26aufirst%3DE.%2BM.%26aulast%3DThakur%26aufirst%3DG.%2BA.%26atitle%3DIndomethacin%2520enhances%2520type%25201%2520cannabinoid%2520receptor%2520signaling%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2019%26volume%3D12%26doi%3D10.3389%2Ffnmol.2019.00257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit27c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pamplona, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes de Lima, O.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duarte, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bento, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villarinho, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellocchio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wotjak, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monory, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canetti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matias, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calixto, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsicano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guimarães, M. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, R. N.</span></span> <span> </span><span class="NLM_article-title">Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">21134</span>– <span class="NLM_lpage">21139</span>, <span class="refDoi"> DOI: 10.1073/pnas.1202906109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1073%2Fpnas.1202906109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=23150578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnt1eksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2012&pages=21134-21139&author=F.+A.+Pamplonaauthor=J.+Ferreiraauthor=O.+Menezes+de+Limaauthor=F.+S.+Duarteauthor=A.+F.+Bentoauthor=S.+Fornerauthor=J.+G.+Villarinhoauthor=L.+Bellocchioauthor=C.+T.+Wotjakauthor=R.+Lernerauthor=K.+Monoryauthor=B.+Lutzauthor=C.+Canettiauthor=I.+Matiasauthor=J.+B.+Calixtoauthor=G.+Marsicanoauthor=M.+Z.+Guimar%C3%A3esauthor=R.+N.+Takahashi&title=Anti-inflammatory+lipoxin+A4+is+an+endogenous+allosteric+enhancer+of+CB1+cannabinoid+receptor&doi=10.1073%2Fpnas.1202906109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27cR"><div class="casContent"><span class="casTitleNuber">27c</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor</span></div><div class="casAuthors">Pamplona, Fabricio A.; Ferreira, Juliano; Menezes de Lima, Octavio, Jr.; Duarte, Filipe Silveira; Bento, Allisson Freire; Forner, Stefania; Villarinho, Jardel G.; Bellocchio, Luigi; Wotjak, Carsten T.; Lerner, Raissa; Monory, Krisztina; Lutz, Beat; Canetti, Claudio; Matias, Isabelle; Calixto, Joao Batista; Marsicano, Giovanni; Guimaraes, Marilia Z. P.; Takahashi, Reinaldo N.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">21134-21139, S21134/1-S21134/6</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Allosteric modulation of G-protein-coupled receptors represents a key goal of current pharmacol.  In particular, endogenous allosteric modulators might represent important targets of interventions aimed at maximizing therapeutic efficacy and reducing side effects of drugs.  The anti-inflammatory lipid lipoxin A4 is an endogenous allosteric enhancer of the CB1 cannabinoid receptor.  Lipoxin A4 was detected in brain tissues, did not compete for the orthosteric binding site of the CB1 receptor (vs. 3H-SR141716A), and did not alter endocannabinoid metab. (as opposed to URB597 and MAFP), but it enhanced affinity of anandamide at the CB1 receptor, thereby potentiating the effects of this endocannabinoid both in vitro and in vivo.  In addn., lipoxin A4 displayed a CB1 receptor-dependent protective effect against β-amyloid (1-40)-induced spatial memory impairment in mice.  The discovery of lipoxins as a class of endogenous allosteric modulators of CB1 receptors may foster the therapeutic exploitation of the endocannabinoid system, in particular for the treatment of neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtolBezEx077Vg90H21EOLACvtfcHk0ljrRYQAJMW0TQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnt1eksw%253D%253D&md5=594b68271d19309dcdc26f1c59738bdc</span></div><a href="/servlet/linkout?suffix=cit27c&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1202906109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1202906109%26sid%3Dliteratum%253Aachs%26aulast%3DPamplona%26aufirst%3DF.%2BA.%26aulast%3DFerreira%26aufirst%3DJ.%26aulast%3DMenezes%2Bde%2BLima%26aufirst%3DO.%26aulast%3DDuarte%26aufirst%3DF.%2BS.%26aulast%3DBento%26aufirst%3DA.%2BF.%26aulast%3DForner%26aufirst%3DS.%26aulast%3DVillarinho%26aufirst%3DJ.%2BG.%26aulast%3DBellocchio%26aufirst%3DL.%26aulast%3DWotjak%26aufirst%3DC.%2BT.%26aulast%3DLerner%26aufirst%3DR.%26aulast%3DMonory%26aufirst%3DK.%26aulast%3DLutz%26aufirst%3DB.%26aulast%3DCanetti%26aufirst%3DC.%26aulast%3DMatias%26aufirst%3DI.%26aulast%3DCalixto%26aufirst%3DJ.%2BB.%26aulast%3DMarsicano%26aufirst%3DG.%26aulast%3DGuimar%25C3%25A3es%26aufirst%3DM.%2BZ.%26aulast%3DTakahashi%26aufirst%3DR.%2BN.%26atitle%3DAnti-inflammatory%2520lipoxin%2520A4%2520is%2520an%2520endogenous%2520allosteric%2520enhancer%2520of%2520CB1%2520cannabinoid%2520receptor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2012%26volume%3D109%26spage%3D21134%26epage%3D21139%26doi%3D10.1073%2Fpnas.1202906109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singla, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skobieranda, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soergel, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salamea, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burt, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demitrack, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viscusi, E. R.</span></span> <span> </span><span class="NLM_article-title">APOLLO-2: a randomized, placebo and active-controlled phase iii study investigating oliceridine (TRV130), a G protein-biased ligand at the μ-opioid receptor, for management of moderate to severe acute pain following abdominoplasty</span>. <i>Pain pract.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">715</span>– <span class="NLM_lpage">731</span>, <span class="refDoi"> DOI: 10.1111/papr.12801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1111%2Fpapr.12801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=31162798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A280%3ADC%252BB3M3jtFClsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=715-731&author=N.+K.+Singlaauthor=F.+Skobierandaauthor=D.+G.+Soergelauthor=M.+Salameaauthor=D.+A.+Burtauthor=M.+A.+Demitrackauthor=E.+R.+Viscusi&title=APOLLO-2%3A+a+randomized%2C+placebo+and+active-controlled+phase+iii+study+investigating+oliceridine+%28TRV130%29%2C+a+G+protein-biased+ligand+at+the+%CE%BC-opioid+receptor%2C+for+management+of+moderate+to+severe+acute+pain+following+abdominoplasty&doi=10.1111%2Fpapr.12801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">APOLLO-2: A Randomized, Placebo and Active-Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein-Biased Ligand at the μ-Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty</span></div><div class="casAuthors">Singla Neil K; Skobieranda Franck; Soergel David G; Salamea Monica; Burt David A; Demitrack Mark A; Viscusi Eugene R</div><div class="citationInfo"><span class="NLM_cas:title">Pain practice : the official journal of World Institute of Pain</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">715-731</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  The clinical utility of conventional IV opioids is limited by the occurrence of opioid-related adverse events.  Oliceridine is a novel G protein-biased μ-opioid receptor agonist designed to provide analgesia with an improved safety and tolerability profile.  This phase III, double-blind, randomized trial (APOLLO-2 [NCT02820324]) evaluated the efficacy and safety of oliceridine for acute pain following abdominoplasty.  METHODS:  Patients received a loading dose of either placebo, oliceridine (1.5 mg), or morphine (4 mg), followed by demand doses via patient-controlled analgesia (0.1, 0.35, or 0.5 mg oliceridine; 1 mg morphine; or placebo) with a 6-minute lockout interval.  The primary endpoint was the proportion of treatment responders over 24 hours for oliceridine regimens compared to placebo.  Secondary outcomes included a predefined composite measure of respiratory safety burden (RSB, representing the cumulative duration of respiratory safety events) and the proportion of treatment responders vs. morphine.  RESULTS:  A total of 401 patients were treated with study medication.  Effective analgesia was observed for all oliceridine regimens, with responder rates of 61.0%, 76.3%, and 70.0% for the 0.1-, 0.35-, and 0.5-mg regimens, respectively, compared with 45.7% for placebo (all P < 0.05) and 78.3% for morphine.  Oliceridine 0.35- and 0.5-mg demand dose regimens were equi-analgesic to morphine using a noninferiority analysis.  RSB showed a dose-dependent increase across oliceridine regimens (mean hours [standard deviation], 0.1 mg: 0.43 [1.56]; 0.35 mg: 1.48 [3.83]; 0.5 mg: 1.59 [4.26]; all comparisons not significant at P > 0.05 vs. placebo: 0.60 [2.82]).  The RSB measure for morphine was 1.72 (3.86) (P < 0.05 vs. placebo).  Gastrointestinal adverse events increased in a dose-dependent manner across oliceridine demand dose regimens (0.1 mg: 49.4%; 0.35 mg: 65.8%; 0.5 mg: 78.8%; vs. placebo: 47.0%; and morphine: 79.3%).  In comparison to morphine, the proportion of patients experiencing nausea or vomiting was lower with the 2 equi-analgesic dose regimens of 0.35 and 0.5 mg oliceridine.  CONCLUSIONS:  Oliceridine is a safe and effective IV analgesic for the relief of moderate to severe acute postoperative pain in patients undergoing abdominoplasty.  Since the low-dose regimen of 0.1 mg oliceridine was superior to placebo but not as effective as the morphine regimen, safety comparisons to morphine are relevant only to the 2 equi-analgesic dose groups of 0.35 and 0.5 mg, which showed a favorable safety and tolerability profile regarding respiratory and gastrointestinal adverse effects compared to morphine.  These findings support that oliceridine may provide a new treatment option for patients with moderate to severe acute pain where an IV opioid is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSpVn3NtI2fPmZyxfu64m4ffW6udTcc2eYxifyJAutblbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3jtFClsQ%253D%253D&md5=7654216d8ca422cdd285f73d7774c87b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1111%2Fpapr.12801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fpapr.12801%26sid%3Dliteratum%253Aachs%26aulast%3DSingla%26aufirst%3DN.%2BK.%26aulast%3DSkobieranda%26aufirst%3DF.%26aulast%3DSoergel%26aufirst%3DD.%2BG.%26aulast%3DSalamea%26aufirst%3DM.%26aulast%3DBurt%26aufirst%3DD.%2BA.%26aulast%3DDemitrack%26aufirst%3DM.%2BA.%26aulast%3DViscusi%26aufirst%3DE.%2BR.%26atitle%3DAPOLLO-2%253A%2520a%2520randomized%252C%2520placebo%2520and%2520active-controlled%2520phase%2520iii%2520study%2520investigating%2520oliceridine%2520%2528TRV130%2529%252C%2520a%2520G%2520protein-biased%2520ligand%2520at%2520the%2520%25CE%25BC-opioid%2520receptor%252C%2520for%2520management%2520of%2520moderate%2520to%2520severe%2520acute%2520pain%2520following%2520abdominoplasty%26jtitle%3DPain%2520pract.%26date%3D2019%26volume%3D19%26spage%3D715%26epage%3D731%26doi%3D10.1111%2Fpapr.12801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotchev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rominger, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koblish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewire, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crombie, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, D. S.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships and discovery of a G protein biased μ opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8019</span>– <span class="NLM_lpage">8031</span>, <span class="refDoi"> DOI: 10.1021/jm4010829</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4010829" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFSmsrjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8019-8031&author=X.+T.+Chenauthor=P.+Pitisauthor=G.+Liuauthor=C.+Yuanauthor=D.+Gotchevauthor=C.+L.+Cowanauthor=D.+H.+Romingerauthor=M.+Koblishauthor=S.+M.+Dewireauthor=A.+L.+Crombieauthor=J.+D.+Violinauthor=D.+S.+Yamashita&title=Structure-activity+relationships+and+discovery+of+a+G+protein+biased+%CE%BC+opioid+receptor+ligand%2C+%5B%283-methoxythiophen-2-yl%29methyl%5D%28%7B2-%5B%289R%29-9-%28pyridin-2-yl%29-6-oxaspiro-%5B4.5%5Ddecan-9-yl%5Dethyl%7D%29amine+%28TRV130%29%2C+for+the+treatment+of+acute+severe+pain&doi=10.1021%2Fjm4010829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationships and Discovery of a G Protein Biased μ Opioid Receptor Ligand, [(3-Methoxythiophen-2-yl)methyl]({2-[(9R)9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the Treatment of Acute Severe Pain</span></div><div class="casAuthors">Chen, Xiao-Tao; Pitis, Philip; Liu, Guodong; Yuan, Catherine; Gotchev, Dimitar; Cowan, Conrad L.; Rominger, David H.; Koblish, Michael; DeWire, Scott M.; Crombie, Aimee L.; Violin, Jonathan D.; Yamashita, Dennis S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8019-8031</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The concept of ligand bias at G protein coupled receptors has been introduced to describe ligands which preferentially stimulate one intracellular signaling pathway over another.  There is growing interest in developing biased G protein coupled receptor ligands to yield safer, better tolerated, and more efficacious drugs.  The classical μ opioid morphine elicited increased efficacy and duration of analgesic response with reduced side effects in β-arrestin-2 knockout mice compared to wild-type mice, suggesting that G protein biased μ opioid receptor agonists would be more efficacious with reduced adverse events.  Here we describe our efforts to identify a potent, selective, and G protein biased μ opioid receptor agonist, TRV130 (I).  This novel mol. demonstrated an improved therapeutic index (analgesia vs adverse effects) in rodent models and characteristics appropriate for clin. development.  It is currently being evaluated in human clin. trials for the treatment of acute severe pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-rI0Et_vFqrVg90H21EOLACvtfcHk0li8BRDSoivg2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFSmsrjK&md5=c80bd62062f31418f18392f97c880bea</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm4010829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4010829%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%2BT.%26aulast%3DPitis%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DGotchev%26aufirst%3DD.%26aulast%3DCowan%26aufirst%3DC.%2BL.%26aulast%3DRominger%26aufirst%3DD.%2BH.%26aulast%3DKoblish%26aufirst%3DM.%26aulast%3DDewire%26aufirst%3DS.%2BM.%26aulast%3DCrombie%26aufirst%3DA.%2BL.%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26aulast%3DYamashita%26aufirst%3DD.%2BS.%26atitle%3DStructure-activity%2520relationships%2520and%2520discovery%2520of%2520a%2520G%2520protein%2520biased%2520%25CE%25BC%2520opioid%2520receptor%2520ligand%252C%2520%255B%25283-methoxythiophen-2-yl%2529methyl%255D%2528%257B2-%255B%25289R%2529-9-%2528pyridin-2-yl%2529-6-oxaspiro-%255B4.5%255Ddecan-9-yl%255Dethyl%257D%2529amine%2520%2528TRV130%2529%252C%2520for%2520the%2520treatment%2520of%2520acute%2520severe%2520pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8019%26epage%3D8031%26doi%3D10.1021%2Fjm4010829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeWire, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rominger, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graczyk, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitis, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotchev, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koblish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lark, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Violin, J. D.</span></span> <span> </span><span class="NLM_article-title">A G protein-biased ligand at the μ–opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>344</i></span>,  <span class="NLM_fpage">708</span>– <span class="NLM_lpage">717</span>, <span class="refDoi"> DOI: 10.1124/jpet.112.201616</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1124%2Fjpet.112.201616" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=23300227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvVaisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2013&pages=708-717&author=S.+M.+DeWireauthor=D.+S.+Yamashitaauthor=D.+H.+Romingerauthor=G.+Liuauthor=C.+L.+Cowanauthor=T.+M.+Graczykauthor=X.-T.+Chenauthor=P.+M.+Pitisauthor=D.+Gotchevauthor=C.+Yuanauthor=M.+Koblishauthor=M.+W.+Larkauthor=J.+D.+Violin&title=A+G+protein-biased+ligand+at+the+%CE%BC%E2%80%93opioid+receptor+is+potently+analgesic+with+reduced+gastrointestinal+and+respiratory+dysfunction+compared+with+morphine&doi=10.1124%2Fjpet.112.201616"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine</span></div><div class="casAuthors">DeWire, Scott M.; Yamashita, Dennis S.; Rominger, David H.; Liu, Guodong; Cowan, Conrad L.; Graczyk, Thomas M.; Chen, Xiao-Tao; Pitis, Philip M.; Gotchev, Dimitar; Yuan, Catherine; Koblish, Michael; Lark, Michael W.; Violin, Jonathan D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">708-717</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The concept of ligand bias at G protein-coupled receptors broadens the possibilities for agonist activities and provides the opportunity to develop safer, more selective therapeutics.  Morphine pharmacol. in β-arrestin-2 knockout mice suggested that a ligand that promotes coupling of the μ-opioid receptor (MOR) to G proteins, but not β-arrestins, would result in higher analgesic efficacy, less gastrointestinal dysfunction, and less respiratory suppression than morphine.  Here we report the discovery of TRV130 ([(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl]ethyl})amine), a novel MOR G protein-biased ligand.  In cell-based assays, TRV130 elicits robust G protein signaling, with potency and efficacy similar to morphine, but with far less β-arrestin recruitment and receptor internalization.  In mice and rats, TRV130 is potently analgesic while causing less gastrointestinal dysfunction and respiratory suppression than morphine at equianalgesic doses.  TRV130 successfully translates evidence that analgesic and adverse MOR signaling pathways are distinct into a biased ligand with differentiated pharmacol.  These preclin. data suggest that TRV130 may be a safer and more tolerable therapeutic for treating severe pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps3tTP2BOOKrVg90H21EOLACvtfcHk0li8BRDSoivg2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvVaisro%253D&md5=33a685cd1952dd9cb1fb82afe78452af</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.201616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.201616%26sid%3Dliteratum%253Aachs%26aulast%3DDeWire%26aufirst%3DS.%2BM.%26aulast%3DYamashita%26aufirst%3DD.%2BS.%26aulast%3DRominger%26aufirst%3DD.%2BH.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DCowan%26aufirst%3DC.%2BL.%26aulast%3DGraczyk%26aufirst%3DT.%2BM.%26aulast%3DChen%26aufirst%3DX.-T.%26aulast%3DPitis%26aufirst%3DP.%2BM.%26aulast%3DGotchev%26aufirst%3DD.%26aulast%3DYuan%26aufirst%3DC.%26aulast%3DKoblish%26aufirst%3DM.%26aulast%3DLark%26aufirst%3DM.%2BW.%26aulast%3DViolin%26aufirst%3DJ.%2BD.%26atitle%3DA%2520G%2520protein-biased%2520ligand%2520at%2520the%2520%25CE%25BC%25E2%2580%2593opioid%2520receptor%2520is%2520potently%2520analgesic%2520with%2520reduced%2520gastrointestinal%2520and%2520respiratory%2520dysfunction%2520compared%2520with%2520morphine%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D344%26spage%3D708%26epage%3D717%26doi%3D10.1124%2Fjpet.112.201616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tae, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choo, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of β-arrestin biased ligands of 5-HT(7)R</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7218</span>– <span class="NLM_lpage">7233</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00642</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00642" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlGit7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7218-7233&author=Y.+Kimauthor=H.+Kimauthor=J.+Leeauthor=J.+K.+Leeauthor=S.+J.+Minauthor=J.+Seongauthor=H.+Rhimauthor=J.+Taeauthor=H.+J.+Leeauthor=H.+Choo&title=Discovery+of+%CE%B2-arrestin+biased+ligands+of+5-HT%287%29R&doi=10.1021%2Facs.jmedchem.8b00642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of β-Arrestin Biased Ligands of 5-HT7R</span></div><div class="casAuthors">Kim, Youngjae; Kim, Hyunguk; Lee, Jieon; Lee, Jae Kyun; Min, Sun-Joon; Seong, Jihye; Rhim, Hyewhon; Tae, Jinsung; Lee, Hyunjoo Jenny; Choo, Hyunah</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7218-7233</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Though many studies have been published about therapeutic potentials of selective 5-HT7R ligands, there have been few biased ligands of 5-HT7R.  The development of potent and selective biased ligands of 5-HT7R would be of great help in understanding the relationship between pharmacol. effects and G protein/β-arrestin signaling pathways of 5-HT7R.  To identify 5-HT7R ligands with biased agonism, the authors designed and synthesized a series of tetrahydroazepine derivs. 1 and 2 with arylpyrazolo moiety or arylisoxazolo moiety.  Through several biol. evaluations such as binding affinity, selectivity profile, and functions in G protein and β-arrestin signaling pathways, 3-(4-chlorophenyl)-1,4,5,6,7,8-hexahydropyrazolo[3,4-d]azepine 1g was discovered as the β-arrestin biased ligand of 5-HT7R.  In an EEG test, 1g increased total non-rapid eye movement (NREM) sleep time and decreased total rapid eye movement (REM) sleep time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiLWYVPSvmwbVg90H21EOLACvtfcHk0ljYYWPCcMAtLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlGit7jK&md5=07149c8e43780d20812d7f5dd835ed7e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00642%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%2BK.%26aulast%3DMin%26aufirst%3DS.%2BJ.%26aulast%3DSeong%26aufirst%3DJ.%26aulast%3DRhim%26aufirst%3DH.%26aulast%3DTae%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DChoo%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520%25CE%25B2-arrestin%2520biased%2520ligands%2520of%25205-HT%25287%2529R%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7218%26epage%3D7233%26doi%3D10.1021%2Facs.jmedchem.8b00642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cook, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mistry, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furness, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scammells, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conigrave, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, K.</span></span> <span> </span><span class="NLM_article-title">Biased allosteric modulation at the CaS receptor engendered by structurally diverse calcimimetics</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">200</span>, <span class="refDoi"> DOI: 10.1111/bph.12937</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1111%2Fbph.12937" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=25220431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWlsL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=185-200&author=A.+E.+Cookauthor=S.+N.+Mistryauthor=K.+J.+Gregoryauthor=S.+G.+Furnessauthor=P.+M.+Sextonauthor=P.+J.+Scammellsauthor=A.+D.+Conigraveauthor=A.+Christopoulosauthor=K.+Leach&title=Biased+allosteric+modulation+at+the+CaS+receptor+engendered+by+structurally+diverse+calcimimetics&doi=10.1111%2Fbph.12937"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Biased allosteric modulation at the CaS receptor engendered by structurally diverse calcimimetics</span></div><div class="casAuthors">Cook, A. E.; Mistry, S. N.; Gregory, K. J.; Furness, S. G. B.; Sexton, P. M.; Scammells, P. J.; Conigrave, A. D.; Christopoulos, A.; Leach, K.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">185-200</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Clin. use of cinacalcet in hyperparathyroidism is complicated by its tendency to induce hypocalcemia, arising partly from activation of calcium-sensing receptors (CaS receptors) in the thyroid and stimulation of calcitonin release.  CaS receptor allosteric modulators that selectively bias signalling towards pathways that mediate desired effects [e.g. parathyroid hormone (PTH) suppression] rather than those mediating undesirable effects (e.g. elevated serum calcitonin), may offer better therapies.  Exptl. Approach : We characterized the ligand-biased profile of novel calcimimetics in HEK293 cells stably expressing human CaS receptors, by monitoring intracellular calcium (Ca2+i) mobilization, inositol phosphate (IP)1 accumulation, ERK1/2 phosphorylation (pERK1/2) and receptor expression.  Key Results : Phenylalkylamine calcimimetics were biased towards allosteric modulation of Ca2+i mobilization and IP1 accumulation.  S,R-calcimimetic B was biased only towards IP1 accumulation.  R,R-calcimimetic B and AC-265347 were biased towards IP1 accumulation and pERK1/2.  Nor-calcimimetic B was unbiased.  In contrast to phenylalkylamines and calcimimetic B analogs, AC-265347 did not promote trafficking of a loss-of-expression, naturally occurring, CaS receptor mutation (G670E).  Conclusions and Implications : The ability of R,R-calcimimetic B and AC-265347 to bias signalling towards pERK1/2 and IP1 accumulation may explain their suppression of PTH levels in vivo at concns. that have no effect on serum calcitonin levels.  The demonstration that AC-265347 promotes CaS receptor receptor signalling, but not trafficking reveals a novel profile of ligand-biased modulation at CaS receptors The identification of allosteric modulators that bias CaS receptor signalling towards distinct intracellular pathways provides an opportunity to develop desirable biased signalling profiles in vivo for mediating selective physiol. responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOAjm2vqgRE7Vg90H21EOLACvtfcHk0liqWWDdQLVufg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWlsL3P&md5=238f469a40ace3cf598dc49584bf0497</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1111%2Fbph.12937&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12937%26sid%3Dliteratum%253Aachs%26aulast%3DCook%26aufirst%3DA.%2BE.%26aulast%3DMistry%26aufirst%3DS.%2BN.%26aulast%3DGregory%26aufirst%3DK.%2BJ.%26aulast%3DFurness%26aufirst%3DS.%2BG.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DConigrave%26aufirst%3DA.%2BD.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DLeach%26aufirst%3DK.%26atitle%3DBiased%2520allosteric%2520modulation%2520at%2520the%2520CaS%2520receptor%2520engendered%2520by%2520structurally%2520diverse%2520calcimimetics%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D185%26epage%3D200%26doi%3D10.1111%2Fbph.12937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rook, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghoshal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerson, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregory, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vinson, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byun, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bubser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nedelcovych, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gould, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niswender, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavreysen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conde-Ceide, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcazar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolomé-Nebreda, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talpos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steckler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, P. J.</span></span> <span> </span><span class="NLM_article-title">Biased mGlu5-positive allosteric modulators provide in vivo efficacy without potentiating mGlu5 modulation of NMDAR currents</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">1029</span>– <span class="NLM_lpage">1040</span>, <span class="refDoi"> DOI: 10.1016/j.neuron.2015.03.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1016%2Fj.neuron.2015.03.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=25937172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnslOisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2015&pages=1029-1040&author=J.+M.+Rookauthor=Z.+Xiangauthor=X.+Lvauthor=A.+Ghoshalauthor=J.+W.+Dickersonauthor=T.+M.+Bridgesauthor=K.+A.+Johnsonauthor=D.+J.+Fosterauthor=K.+J.+Gregoryauthor=P.+N.+Vinsonauthor=A.+D.+Thompsonauthor=N.+Byunauthor=R.+L.+Collierauthor=M.+Bubserauthor=M.+T.+Nedelcovychauthor=R.+W.+Gouldauthor=S.+R.+Staufferauthor=J.+S.+Danielsauthor=C.+M.+Niswenderauthor=H.+Lavreysenauthor=C.+Mackieauthor=S.+Conde-Ceideauthor=J.+Alcazarauthor=J.+M.+Bartolom%C3%A9-Nebredaauthor=G.+J.+Macdonaldauthor=J.+C.+Talposauthor=T.+Stecklerauthor=C.+K.+Jonesauthor=C.+W.+Lindsleyauthor=P.+J.+Conn&title=Biased+mGlu5-positive+allosteric+modulators+provide+in+vivo+efficacy+without+potentiating+mGlu5+modulation+of+NMDAR+currents&doi=10.1016%2Fj.neuron.2015.03.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents</span></div><div class="casAuthors">Rook, Jerri M.; Xiang, Zixiu; Lv, Xiaohui; Ghoshal, Ayan; Dickerson, Jonathan W.; Bridges, Thomas M.; Johnson, Kari A.; Foster, Daniel J.; Gregory, Karen J.; Vinson, Paige N.; Thompson, Analisa D.; Byun, Nellie; Collier, Rebekah L.; Bubser, Michael; Nedelcovych, Michael T.; Gould, Robert W.; Stauffer, Shaun R.; Daniels, J. Scott; Niswender, Colleen M.; Lavreysen, Hilde; Mackie, Claire; Conde-Ceide, Susana; Alcazar, Jesus; Bartolome-Nebreda, Jose M.; MacDonald, Gregor J.; Talpos, John C.; Steckler, Thomas; Jones, Carrie K.; Lindsley, Craig W.; Conn, P. Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1029-1040</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Schizophrenia is assocd. with disruptions in N-methyl-D-aspartate glutamate receptor subtype (NMDAR)-mediated excitatory synaptic signaling.  The metabotropic glutamate receptor subtype 5 (mGlu5) is a closely assocd. signaling partner with NMDARs and regulates NMDAR function in forebrain regions implicated in the pathol. of schizophrenia.  Efficacy of mGlu5 pos. allosteric modulators (PAMs) in animal models of psychosis and cognition was previously attributed to potentiation of NMDAR function.  To directly test this hypothesis, we identified VU0409551 as a novel mGlu5 PAM that exhibits distinct stimulus bias and selectively potentiates mGlu5 coupling to Gαq-mediated signaling but not mGlu5 modulation of NMDAR currents or NMDAR-dependent synaptic plasticity in the rat hippocampus.  Interestingly, VU0409551 produced robust antipsychotic-like and cognition-enhancing activity in animal models.  These data provide surprising new mechanistic insights into the actions of mGlu5 PAMs and suggest that modulation of NMDAR currents is not crit. for in vivo efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouKRBBcza96rVg90H21EOLACvtfcHk0liNaSUvwICNkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnslOisLc%253D&md5=c5f0a8cf83e1b2d8e0d3541a39cd0529</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.neuron.2015.03.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuron.2015.03.063%26sid%3Dliteratum%253Aachs%26aulast%3DRook%26aufirst%3DJ.%2BM.%26aulast%3DXiang%26aufirst%3DZ.%26aulast%3DLv%26aufirst%3DX.%26aulast%3DGhoshal%26aufirst%3DA.%26aulast%3DDickerson%26aufirst%3DJ.%2BW.%26aulast%3DBridges%26aufirst%3DT.%2BM.%26aulast%3DJohnson%26aufirst%3DK.%2BA.%26aulast%3DFoster%26aufirst%3DD.%2BJ.%26aulast%3DGregory%26aufirst%3DK.%2BJ.%26aulast%3DVinson%26aufirst%3DP.%2BN.%26aulast%3DThompson%26aufirst%3DA.%2BD.%26aulast%3DByun%26aufirst%3DN.%26aulast%3DCollier%26aufirst%3DR.%2BL.%26aulast%3DBubser%26aufirst%3DM.%26aulast%3DNedelcovych%26aufirst%3DM.%2BT.%26aulast%3DGould%26aufirst%3DR.%2BW.%26aulast%3DStauffer%26aufirst%3DS.%2BR.%26aulast%3DDaniels%26aufirst%3DJ.%2BS.%26aulast%3DNiswender%26aufirst%3DC.%2BM.%26aulast%3DLavreysen%26aufirst%3DH.%26aulast%3DMackie%26aufirst%3DC.%26aulast%3DConde-Ceide%26aufirst%3DS.%26aulast%3DAlcazar%26aufirst%3DJ.%26aulast%3DBartolom%25C3%25A9-Nebreda%26aufirst%3DJ.%2BM.%26aulast%3DMacdonald%26aufirst%3DG.%2BJ.%26aulast%3DTalpos%26aufirst%3DJ.%2BC.%26aulast%3DSteckler%26aufirst%3DT.%26aulast%3DJones%26aufirst%3DC.%2BK.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DConn%26aufirst%3DP.%2BJ.%26atitle%3DBiased%2520mGlu5-positive%2520allosteric%2520modulators%2520provide%2520in%2520vivo%2520efficacy%2520without%2520potentiating%2520mGlu5%2520modulation%2520of%2520NMDAR%2520currents%26jtitle%3DNeuron%26date%3D2015%26volume%3D86%26spage%3D1029%26epage%3D1040%26doi%3D10.1016%2Fj.neuron.2015.03.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khoury, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clément, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laporte, S. A.</span></span> <span> </span><span class="NLM_article-title">Allosteric and biased g protein-coupled receptor signaling regulation: potentials for new therapeutics</span>. <i>Front. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">339</span> <span class="refDoi"> DOI: 10.3389/fendo.2014.00068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.3389%2Ffendo.2014.00068" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&author=E.+Khouryauthor=S.+Cl%C3%A9mentauthor=S.+A.+Laporte&title=Allosteric+and+biased+g+protein-coupled+receptor+signaling+regulation%3A+potentials+for+new+therapeutics&doi=10.3389%2Ffendo.2014.00068"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.3389%2Ffendo.2014.00068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffendo.2014.00068%26sid%3Dliteratum%253Aachs%26aulast%3DKhoury%26aufirst%3DE.%26aulast%3DCl%25C3%25A9ment%26aufirst%3DS.%26aulast%3DLaporte%26aufirst%3DS.%2BA.%26atitle%3DAllosteric%2520and%2520biased%2520g%2520protein-coupled%2520receptor%2520signaling%2520regulation%253A%2520potentials%2520for%2520new%2520therapeutics%26jtitle%3DFront.%2520Endocrinol.%26date%3D2014%26volume%3D5%26doi%3D10.3389%2Ffendo.2014.00068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laprairie, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deschamps, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, M. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janero, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascio, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenakin, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denovan-Wright, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, G. A.</span></span> <span> </span><span class="NLM_article-title">Enantiospecific allosteric modulation of cannabinoid 1 receptor</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1188</span>– <span class="NLM_lpage">1203</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.6b00310</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.6b00310" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1ehsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1188-1203&author=R.+B.+Laprairieauthor=P.+M.+Kulkarniauthor=J.+R.+Deschampsauthor=M.+E.+M.+Kellyauthor=D.+R.+Janeroauthor=M.+G.+Cascioauthor=L.+A.+Stevensonauthor=R.+G.+Pertweeauthor=T.+P.+Kenakinauthor=E.+M.+Denovan-Wrightauthor=G.+A.+Thakur&title=Enantiospecific+allosteric+modulation+of+cannabinoid+1+receptor&doi=10.1021%2Facschemneuro.6b00310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor</span></div><div class="casAuthors">Laprairie, Robert B.; Kulkarni, Pushkar M.; Deschamps, Jeffrey R.; Kelly, Melanie E. M.; Janero, David R.; Cascio, Maria G.; Stevenson, Lesley A.; Pertwee, Roger G.; Kenakin, Terrence P.; Denovan-Wright, Eileen M.; Thakur, Ganesh A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1188-1203</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The cannabinoid 1 receptor (CB1R) is one of the most widely expressed metabotropic G protein-coupled receptors in brain, and its participation in various (patho)physiol. processes has made CB1R activation a viable therapeutic modality.  Adverse psychotropic effects limit the clin. utility of CB1R orthosteric agonists and have promoted the search for CB1R pos. allosteric modulators (PAMs) with the promise of improved drug-like pharmacol. and enhanced safety over typical CB1R agonists.  In this study, the authors describe the synthesis and in vitro and ex vivo pharmacol. of the novel allosteric CB1R modulator GAT211 (racemic) and its resolved enantiomers, GAT228 (R) and GAT229 (S).  GAT211 engages CB1R allosteric site(s), enhances the binding of the orthosteric full agonist [3H]CP55,490 and reduces the binding of the orthosteric antagonist/inverse agonist [3H]SR141716A.  GAT211 displayed both PAM and agonist activity in HEK293A and Neuro2a cells expressing human recombinant CB1R (hCB1R) and, in mouse-brain membranes rich in native CB1R.  GAT211 also exhibited a strong PAM effect in isolated vas deferens endogenously expressing CB1R.  Each resolved and crystd. GAT211 enantiomer showed a markedly distinctive pharmacol. as a CB1R allosteric modulator.  In all biol. systems examd., GAT211's allosteric agonist activity resided with the R-(+)-enantiomer (GAT228), whereas its PAM activity resided with the S-(-)-enantiomer (GAT229), which lacked intrinsic activity.  These results constitute the first demonstration of enantiomer-selective CB1R pos. allosteric modulation and set a precedent whereby enantiomeric resoln. can decisively define the mol. pharmacol. of a CB1R allosteric ligand.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooxvSjynl3_LVg90H21EOLACvtfcHk0liNaSUvwICNkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1ehsrY%253D&md5=3b8735a91bd9026c10dea58687d339de</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.6b00310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.6b00310%26sid%3Dliteratum%253Aachs%26aulast%3DLaprairie%26aufirst%3DR.%2BB.%26aulast%3DKulkarni%26aufirst%3DP.%2BM.%26aulast%3DDeschamps%26aufirst%3DJ.%2BR.%26aulast%3DKelly%26aufirst%3DM.%2BE.%2BM.%26aulast%3DJanero%26aufirst%3DD.%2BR.%26aulast%3DCascio%26aufirst%3DM.%2BG.%26aulast%3DStevenson%26aufirst%3DL.%2BA.%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26aulast%3DKenakin%26aufirst%3DT.%2BP.%26aulast%3DDenovan-Wright%26aufirst%3DE.%2BM.%26aulast%3DThakur%26aufirst%3DG.%2BA.%26atitle%3DEnantiospecific%2520allosteric%2520modulation%2520of%2520cannabinoid%25201%2520receptor%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2017%26volume%3D8%26spage%3D1188%26epage%3D1203%26doi%3D10.1021%2Facschemneuro.6b00310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffer, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reggio, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, G. A.</span></span> <span> </span><span class="NLM_article-title">Identification of CB1 receptor allosteric sites using force-biased MMC simulated annealing and validation by structure-activity relationship studies</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1216</span>– <span class="NLM_lpage">1221</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00256</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00256" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlGjs7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1216-1221&author=D.+P.+Hurstauthor=S.+Garaiauthor=P.+M.+Kulkarniauthor=P.+C.+Schafferauthor=P.+H.+Reggioauthor=G.+A.+Thakur&title=Identification+of+CB1+receptor+allosteric+sites+using+force-biased+MMC+simulated+annealing+and+validation+by+structure-activity+relationship+studies&doi=10.1021%2Facsmedchemlett.9b00256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of CB1 Receptor Allosteric Sites Using Force-Biased MMC Simulated Annealing and Validation by Structure-Activity Relationship Studies</span></div><div class="casAuthors">Hurst, Dow P.; Garai, Sumanta; Kulkarni, Pushkar M.; Schaffer, Peter C.; Reggio, Patricia H.; Thakur, Ganesh A.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1216-1221</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pos. allosteric modulation of the cannabinoid 1 receptor (CB1R) has demonstrated distinct therapeutic advantages that address several limitations assocd. with orthosteric agonism and has opened a promising therapeutic avenue for further drug development.  To advance the development of CB1R pos. allosteric modulators, it is important to understand the mol. architecture of CB1R allosteric site(s).  The goal of this work was to use Force-Biased MMC Simulated Annealing to identify binding sites for GAT228 (R), a partial allosteric agonist, and GAT229 (S), a pos. allosteric modulator (PAM) at the CB1R.  Our studies suggest that GAT228 binds in an intracellular (IC) TMH1-2-4 exosite that would allow this compd. to act as a CB1 allosteric agonist as well as a CB1 PAM.  In contrast, GAT229 binds at the extracellular (EC) ends of TMH2/3, just beneath the EC1 loop.  At this site, this compd. can act as CB1 PAM only.  Finally, these results were successfully validated through the synthesis and biochem. evaluation of a focused library of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovBTh9777IpLVg90H21EOLACvtfcHk0liwcXtbdbAJiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlGjs7rK&md5=b031138e216be74d13caf799fc5f151c</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00256%26sid%3Dliteratum%253Aachs%26aulast%3DHurst%26aufirst%3DD.%2BP.%26aulast%3DGarai%26aufirst%3DS.%26aulast%3DKulkarni%26aufirst%3DP.%2BM.%26aulast%3DSchaffer%26aufirst%3DP.%2BC.%26aulast%3DReggio%26aufirst%3DP.%2BH.%26aulast%3DThakur%26aufirst%3DG.%2BA.%26atitle%3DIdentification%2520of%2520CB1%2520receptor%2520allosteric%2520sites%2520using%2520force-biased%2520MMC%2520simulated%2520annealing%2520and%2520validation%2520by%2520structure-activity%2520relationship%2520studies%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D1216%26epage%3D1221%26doi%3D10.1021%2Facsmedchemlett.9b00256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffer, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leo, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zagzoog, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janero, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abood, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmowitch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straiker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szczesniak, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denovan-Wright, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohmann, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reggio, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laprairie, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, G. A.</span></span> <span> </span><span class="NLM_article-title">Application of fluorine- and nitrogen-walk approaches: defining the structural and functional diversity of 2-phenylindole class of cannabinoid 1 receptor positive allosteric modulators</span>. <i>J. Med. Chem</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">542</span>– <span class="NLM_lpage">568</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01142</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01142" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1WktrbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=542-568&author=S.+Garaiauthor=P.+M.+Kulkarniauthor=P.+C.+Schafferauthor=L.+M.+Leoauthor=A.+L.+Brandtauthor=A.+Zagzoogauthor=T.+Blackauthor=X.+Linauthor=D.+P.+Hurstauthor=D.+R.+Janeroauthor=M.+E.+Aboodauthor=A.+Zimmowitchauthor=A.+Straikerauthor=R.+G.+Pertweeauthor=M.+Kellyauthor=A.+M.+Szczesniakauthor=E.+M.+Denovan-Wrightauthor=K.+Mackieauthor=A.+G.+Hohmannauthor=P.+H.+Reggioauthor=R.+B.+Laprairieauthor=G.+A.+Thakur&title=Application+of+fluorine-+and+nitrogen-walk+approaches%3A+defining+the+structural+and+functional+diversity+of+2-phenylindole+class+of+cannabinoid+1+receptor+positive+allosteric+modulators&doi=10.1021%2Facs.jmedchem.9b01142"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Application of Fluorine- and Nitrogen-Walk Approaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of Cannabinoid 1 Receptor Positive Allosteric Modulators</span></div><div class="casAuthors">Garai, Sumanta; Kulkarni, Pushkar M.; Schaffer, Peter C.; Leo, Luciana M.; Brandt, Asher L.; Zagzoog, Ayat; Black, Tallan; Lin, Xiaoyan; Hurst, Dow P.; Janero, David R.; Abood, Mary E.; Zimmowitch, Anaelle; Straiker, Alex; Pertwee, Roger G.; Kelly, Melanie; Szczesniak, Anna-Maria; Denovan-Wright, Eileen M.; Mackie, Ken; Hohmann, Andrea G.; Reggio, Patricia H.; Laprairie, Robert B.; Thakur, Ganesh A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">542-568</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cannabinoid 1 receptor (CB1R) allosteric ligands hold far-reaching therapeutic promise.  We report application of fluoro- and nitrogen-walk approaches to enhance the drug-like properties of GAT211, a prototype CB1R allosteric agonist-pos. allosteric modulator (ago-PAM).  Several analogs exhibited improved functional potency (cAMP, arrestin2), metabolic stability, and aq. soly.  Two key analogs, GAT591 (6r) and GAT593 (6s), exhibited augmented allosteric-agonist and PAM activities in neuronal cultures, improved metabolic stability, and enhanced orthosteric agonist binding (CP55,940).  Both also exhibited good analgesic potency in the CFA inflammatory-pain model with longer duration of action over GAT211 while devoid of adverse cannabimimetic effects.  Another analog, GAT592 (9j), exhibited moderate ago-PAM potency and improved aq. soly. with therapeutic redn. of intraocular pressure in murine glaucoma models.  The SAR findings and the enhanced allosteric activity in this class of allosteric modulators were accounted for in our recently developed computational model for CB1R allosteric activation and pos. allosteric modulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOfHY8Dr6ugbVg90H21EOLACvtfcHk0liwcXtbdbAJiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1WktrbF&md5=42e8edb208751b040c3f6d7481381834</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01142%26sid%3Dliteratum%253Aachs%26aulast%3DGarai%26aufirst%3DS.%26aulast%3DKulkarni%26aufirst%3DP.%2BM.%26aulast%3DSchaffer%26aufirst%3DP.%2BC.%26aulast%3DLeo%26aufirst%3DL.%2BM.%26aulast%3DBrandt%26aufirst%3DA.%2BL.%26aulast%3DZagzoog%26aufirst%3DA.%26aulast%3DBlack%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DHurst%26aufirst%3DD.%2BP.%26aulast%3DJanero%26aufirst%3DD.%2BR.%26aulast%3DAbood%26aufirst%3DM.%2BE.%26aulast%3DZimmowitch%26aufirst%3DA.%26aulast%3DStraiker%26aufirst%3DA.%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26aulast%3DKelly%26aufirst%3DM.%26aulast%3DSzczesniak%26aufirst%3DA.%2BM.%26aulast%3DDenovan-Wright%26aufirst%3DE.%2BM.%26aulast%3DMackie%26aufirst%3DK.%26aulast%3DHohmann%26aufirst%3DA.%2BG.%26aulast%3DReggio%26aufirst%3DP.%2BH.%26aulast%3DLaprairie%26aufirst%3DR.%2BB.%26aulast%3DThakur%26aufirst%3DG.%2BA.%26atitle%3DApplication%2520of%2520fluorine-%2520and%2520nitrogen-walk%2520approaches%253A%2520defining%2520the%2520structural%2520and%2520functional%2520diversity%2520of%25202-phenylindole%2520class%2520of%2520cannabinoid%25201%2520receptor%2520positive%2520allosteric%2520modulators%26jtitle%3DJ.%2520Med.%2520Chem%26date%3D2020%26volume%3D63%26spage%3D542%26epage%3D568%26doi%3D10.1021%2Facs.jmedchem.9b01142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cairns, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szczesniak, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straiker, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldridge, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, M. E. M.</span></span> <span> </span><span class="NLM_article-title">The in vivo effects of the CB(1)-positive allosteric modulator GAT229 on intraocular pressure in ocular normotensive and hypertensive mice</span>. <i>J. Ocul. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">582</span>– <span class="NLM_lpage">590</span>, <span class="refDoi"> DOI: 10.1089/jop.2017.0037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1089%2Fjop.2017.0037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=28719234" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFygsb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2017&pages=582-590&author=E.+A.+Cairnsauthor=A.+M.+Szczesniakauthor=A.+J.+Straikerauthor=P.+M.+Kulkarniauthor=R.+G.+Pertweeauthor=G.+A.+Thakurauthor=W.+H.+Baldridgeauthor=M.+E.+M.+Kelly&title=The+in+vivo+effects+of+the+CB%281%29-positive+allosteric+modulator+GAT229+on+intraocular+pressure+in+ocular+normotensive+and+hypertensive+mice&doi=10.1089%2Fjop.2017.0037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The In Vivo Effects of the CB1-Positive Allosteric Modulator GAT229 on Intraocular Pressure in Ocular Normotensive and Hypertensive Mice</span></div><div class="casAuthors">Cairns, Elizabeth A.; Szczesniak, Anna-Maria; Straiker, Alex J.; Kulkarni, Pushkar M.; Pertwee, Roger G.; Thakur, Ganesh A.; Baldridge, William H.; Kelly, Melanie E. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Ocular Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">582-590</span>CODEN:
                <span class="NLM_cas:coden">JOPTFU</span>;
        ISSN:<span class="NLM_cas:issn">1080-7683</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Purpose: Orthosteric cannabinoid receptor 1 (CB1) activation leads to decreases in intraocular pressure (IOP).  However, use of orthosteric CB1 agonists chronically has several disadvantages, limiting their usefulness as clin. relevant drugs.  Allosteric modulators interact with topog. distinct sites to orthosteric ligands and may be useful to circumvent some of these disadvantages.  The purpose of this study was to investigate the effects of the novel CB1-pos. allosteric modulator (PAM) GAT229 on IOP.  Methods: IOP was measured using rebound tonometry in anesthetized normotensive C57Bl/6 mice and in a genetic model of ocular hypertension [nose, eyes, ears (nee) mice] before drug administration, and at 1, 6, and 12 h thereafter.  Results: In normotensive mice, topical administration of 5 μL GAT229 alone at either 0.2% or 2% did not reduce IOP.  However, a subthreshold dose (0.25%) of the nonselective orthosteric CB1 agonist WIN 55,212-2, when combined with 0.2% GAT229, significantly reduced IOP compared with vehicle at 6 and 12 h.  Similarly, combination of subthreshold Δ9-tetrahydrocannabinol (a nonselective orthosteric CB1 agonist; 1 mg/kg) with topical 0.2% GAT229 produced IOP lowering at 6 h.  In nee mice, administration of topical 0.2% GAT229 or 10 mg/kg GAT229 alone was sufficient to lower IOP at 6 and 12 h, and 12 h, resp.  Conclusions: The CB1 PAM GAT229 reduces IOP in ocular hypertensive mice and enhanced CB1-mediated IOP redn. when combined with subthreshold CB1 orthosteric ligands in normotensive mice.  Administration of CB1 PAMs may provide a novel approach to reduce IOP with fewer of the disadvantages assocd. with orthosteric CB1 activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg-prZqx6SbLVg90H21EOLACvtfcHk0liwcXtbdbAJiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFygsb%252FN&md5=e371ae4c2384fe7ad9080b14f55a114d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1089%2Fjop.2017.0037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fjop.2017.0037%26sid%3Dliteratum%253Aachs%26aulast%3DCairns%26aufirst%3DE.%2BA.%26aulast%3DSzczesniak%26aufirst%3DA.%2BM.%26aulast%3DStraiker%26aufirst%3DA.%2BJ.%26aulast%3DKulkarni%26aufirst%3DP.%2BM.%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26aulast%3DThakur%26aufirst%3DG.%2BA.%26aulast%3DBaldridge%26aufirst%3DW.%2BH.%26aulast%3DKelly%26aufirst%3DM.%2BE.%2BM.%26atitle%3DThe%2520in%2520vivo%2520effects%2520of%2520the%2520CB%25281%2529-positive%2520allosteric%2520modulator%2520GAT229%2520on%2520intraocular%2520pressure%2520in%2520ocular%2520normotensive%2520and%2520hypertensive%2520mice%26jtitle%3DJ.%2520Ocul.%2520Pharmacol.%2520Ther.%26date%3D2017%26volume%3D33%26spage%3D582%26epage%3D590%26doi%3D10.1089%2Fjop.2017.0037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slivicki, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohmann, A. G.</span></span> <span> </span><span class="NLM_article-title">Positive allosteric modulation of cannabinoid receptor type 1 suppresses pathological pain without producing tolerance or dependence</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">722</span>– <span class="NLM_lpage">733</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2017.06.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1016%2Fj.biopsych.2017.06.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=28823711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlKnu7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2018&pages=722-733&author=R.+A.+Slivickiauthor=Z.+Xuauthor=P.+M.+Kulkarniauthor=R.+G.+Pertweeauthor=K.+Mackieauthor=G.+A.+Thakurauthor=A.+G.+Hohmann&title=Positive+allosteric+modulation+of+cannabinoid+receptor+type+1+suppresses+pathological+pain+without+producing+tolerance+or+dependence&doi=10.1016%2Fj.biopsych.2017.06.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence</span></div><div class="casAuthors">Slivicki, Richard A.; Xu, Zhili; Kulkarni, Pushkar M.; Pertwee, Roger G.; Mackie, Ken; Thakur, Ganesh A.; Hohmann, Andrea G.</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">722-733</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Activation of cannabinoid CB1 receptors suppresses pathol. pain but also produces unwanted central side effects.  We hypothesized that a pos. allosteric modulator of CB1 signaling would suppress inflammatory and neuropathic pain without producing cannabimimetic effects or phys. dependence.  We also asked whether a CB1 pos. allosteric modulator would synergize with inhibitors of endocannabinoid deactivation and/or an orthosteric cannabinoid agonist.  GAT211, a novel CB1 pos. allosteric modulator, was evaluated for antinociceptive efficacy and tolerance in models of neuropathic and/or inflammatory pain.  Cardinal signs of direct CB1-receptor activation were evaluated together with the propensity to induce reward or aversion and phys. dependence.  Comparisons were made with inhibitors of endocannabinoid deactivation (JZL184, URB597) or an orthosteric cannabinoid agonist (WIN55,212-2).  All studies used 4 to 11 subjects per group.  GAT211 suppressed allodynia induced by complete Freund's adjuvant and the chemotherapeutic agent paclitaxel in wild-type but not CB1 knockout mice.  GAT211 did not impede paclitaxel-induced tumor cell line toxicity.  GAT211 did not produce cardinal signs of direct CB1-receptor activation in the presence or absence of pathol. pain.  GAT211 produced synergistic antiallodynic effects with fatty acid amide hydrolase and monoacylglycerol lipase inhibitors in paclitaxel-treated mice.  Therapeutic efficacy was preserved over 19 days of chronic dosing with GAT211, but it was not preserved with the monoacylglycerol lipase inhibitor JZL184.  The CB1 antagonist rimonabant pptd. withdrawal in mice treated chronically with WIN55,212-2 but not in mice treated with GAT211.  GAT211 did not induce conditioned place preference or aversion.  Pos. allosteric modulation of CB1-receptor signaling shows promise as a safe and effective analgesic strategy that lacks tolerance, dependence, and abuse liability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGywGwzs6XErVg90H21EOLACvtfcHk0lhwNzBWRNtLMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlKnu7fF&md5=836de2b8e00dc1db269a2bf9247b26bc</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2017.06.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2017.06.032%26sid%3Dliteratum%253Aachs%26aulast%3DSlivicki%26aufirst%3DR.%2BA.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DKulkarni%26aufirst%3DP.%2BM.%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26aulast%3DMackie%26aufirst%3DK.%26aulast%3DThakur%26aufirst%3DG.%2BA.%26aulast%3DHohmann%26aufirst%3DA.%2BG.%26atitle%3DPositive%2520allosteric%2520modulation%2520of%2520cannabinoid%2520receptor%2520type%25201%2520suppresses%2520pathological%2520pain%2520without%2520producing%2520tolerance%2520or%2520dependence%26jtitle%3DBiol.%2520Psychiatry%26date%3D2018%26volume%3D84%26spage%3D722%26epage%3D733%26doi%3D10.1016%2Fj.biopsych.2017.06.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitjavila, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanato, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greig, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straiker, A.</span></span> <span> </span><span class="NLM_article-title">Enantiomer-specific positive allosteric modulation of CB(1) signaling in autaptic hippocampal neurons</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">475</span>– <span class="NLM_lpage">481</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2017.11.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1016%2Fj.phrs.2017.11.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=29158048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFaht73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2018&pages=475-481&author=J.+Mitjavilaauthor=D.+Yinauthor=P.+M.+Kulkarniauthor=C.+Zanatoauthor=G.+A.+Thakurauthor=R.+Rossauthor=I.+Greigauthor=K.+Mackieauthor=A.+Straiker&title=Enantiomer-specific+positive+allosteric+modulation+of+CB%281%29+signaling+in+autaptic+hippocampal+neurons&doi=10.1016%2Fj.phrs.2017.11.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Enantiomer-specific positive allosteric modulation of CB1 signaling in autaptic hippocampal neurons</span></div><div class="casAuthors">Mitjavila, Jose; Yin, Danielle; Kulkarni, Pushkar M.; Zanato, Chiara; Thakur, Ganesh A.; Ross, Ruth; Greig, Iain; Mackie, Ken; Straiker, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">475-481</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The cannabinoid signaling system is found throughout the CNS and its involvement in several pathol. processes makes it an attractive therapeutic target.  Because orthosteric CB1 cannabinoid receptor ligands have undesirable adverse effects there has been great interest in the development of allosteric modulators - both neg. (NAMs) and pos. (PAMs) - of these receptors.  NAMs of CB1 appeared first on the scene, followed more recently by PAMs.  Because allosteric modulation can vary depending on the orthosteric ligand it is important to study their function in a system that employs endogenous cannabinoids.  We have recently surveyed first generation NAMs using cultured autaptic hippocampal neurons.  These neurons express depolarization induced suppression of excitation (DSE), a form of synaptic plasticity that is mediated by CB1 and 2-arachidonoyl glycerol (2-AG); they are therefore an excellent neuronal model of endogenous cannabinoid signaling in which to test CB1 modulators.  In this study we find that while two related compds., GAT211 and ZCZ011, each show PAM-like responses in autaptic hippocampal neurons, they also exhibit complex pharmacol.  Notably we were able to sep. the PAM- and agonist-like responses of GAT211 by examg. the enantiomers of this racemic compd.: GAT228 and GAT229.  We find that GAT229 exhibits PAM-like behavior while GAT228 appears to directly activate the CB1 receptor.  Both GAT229 and ZCZ011 represent the first PAMs that we have found to be effective in using this 2-AG utilizing neuronal model system.  Because these compds. may exhibit both probe selectivity and biased signaling it will be important to test them with anandamide as well as other signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqP6o0WGEOh57Vg90H21EOLACvtfcHk0lhwNzBWRNtLMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFaht73K&md5=ddf0047d224cadbd6f5449f325dfee6e</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2017.11.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2017.11.019%26sid%3Dliteratum%253Aachs%26aulast%3DMitjavila%26aufirst%3DJ.%26aulast%3DYin%26aufirst%3DD.%26aulast%3DKulkarni%26aufirst%3DP.%2BM.%26aulast%3DZanato%26aufirst%3DC.%26aulast%3DThakur%26aufirst%3DG.%2BA.%26aulast%3DRoss%26aufirst%3DR.%26aulast%3DGreig%26aufirst%3DI.%26aulast%3DMackie%26aufirst%3DK.%26aulast%3DStraiker%26aufirst%3DA.%26atitle%3DEnantiomer-specific%2520positive%2520allosteric%2520modulation%2520of%2520CB%25281%2529%2520signaling%2520in%2520autaptic%2520hippocampal%2520neurons%26jtitle%3DPharmacol.%2520Res.%26date%3D2018%26volume%3D129%26spage%3D475%26epage%3D481%26doi%3D10.1016%2Fj.phrs.2017.11.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laprairie, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagher, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rourke, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zrein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cairns, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, M. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinal, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denovan-Wright, E. M.</span></span> <span> </span><span class="NLM_article-title">Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington’s disease in the R6/2 mouse model</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2019.03.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1016%2Fj.neuropharm.2019.03.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=30940536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmvFSntLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2019&pages=1-12&author=R.+B.+Laprairieauthor=A.+M.+Bagherauthor=J.+L.+Rourkeauthor=A.+Zreinauthor=E.+A.+Cairnsauthor=M.+E.+M.+Kellyauthor=C.+J.+Sinalauthor=P.+M.+Kulkarniauthor=G.+A.+Thakurauthor=E.+M.+Denovan-Wright&title=Positive+allosteric+modulation+of+the+type+1+cannabinoid+receptor+reduces+the+signs+and+symptoms+of+Huntington%E2%80%99s+disease+in+the+R6%2F2+mouse+model&doi=10.1016%2Fj.neuropharm.2019.03.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model</span></div><div class="casAuthors">Laprairie, Robert B.; Bagher, Amina M.; Rourke, Jillian L.; Zrein, Adel; Cairns, Elizabeth A.; Kelly, Melanie E. M.; Sinal, Christopher J.; Kulkarni, Pushkar M.; Thakur, Ganesh A.; Denovan-Wright, Eileen M.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Huntington's disease (HD) is an inherited progressive neurodegenerative disease characterized by motor, cognitive, and behavioral changes.  One of the earliest changes to occur in HD is a redn. in cannabinoid 1 receptor (CB1) levels in the striatum, which is strongly correlated with HD pathogenesis.  CB1 pos. allosteric modulators (PAM) enhance receptor affinity for, and efficacy of activation by, orthosteric ligands, including the endocannabinoids anandamide and 2-arachidonoylglycerol.  The goal of this study was to det. whether the recently characterized CB1 allosteric modulators GAT211 (racemic), GAT228 (R-enantiomer), and GAT229 (S-enantiomer), affected the signs and symptoms of HD.  GAT211, GAT228, and GAT229 were evaluated in normal and HD cell models, and in a transgenic mouse model of HD (7-wk-old male R6/2 mice, 10 mg/kg/d, 21 d, i.p.).  GAT229 was a CB1 PAM that improved cell viability in HD cells and improved motor coordination, delayed symptom onset, and normalized gene expression in R6/2 HD mice.  GAT228 was an allosteric agonist that did not enhance endocannabinoid signaling or change symptom progression in R6/2 mice.  GAT211 displayed intermediate effects between its enantiomers.  Changes in gene expression, and not protein, were quantified in R6/2 HD mice because HD pathogenesis is assocd. with dysregulation of mRNA levels.  The data presented here provide the first proof of principle for the use of CB1 PAMs to treat the signs and symptoms of HD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSECuO-Cj0_7Vg90H21EOLACvtfcHk0lhwNzBWRNtLMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmvFSntLc%253D&md5=87a0af0b3a176875c6859e95d65f4fa4</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2019.03.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2019.03.033%26sid%3Dliteratum%253Aachs%26aulast%3DLaprairie%26aufirst%3DR.%2BB.%26aulast%3DBagher%26aufirst%3DA.%2BM.%26aulast%3DRourke%26aufirst%3DJ.%2BL.%26aulast%3DZrein%26aufirst%3DA.%26aulast%3DCairns%26aufirst%3DE.%2BA.%26aulast%3DKelly%26aufirst%3DM.%2BE.%2BM.%26aulast%3DSinal%26aufirst%3DC.%2BJ.%26aulast%3DKulkarni%26aufirst%3DP.%2BM.%26aulast%3DThakur%26aufirst%3DG.%2BA.%26aulast%3DDenovan-Wright%26aufirst%3DE.%2BM.%26atitle%3DPositive%2520allosteric%2520modulation%2520of%2520the%2520type%25201%2520cannabinoid%2520receptor%2520reduces%2520the%2520signs%2520and%2520symptoms%2520of%2520Huntington%25E2%2580%2599s%2520disease%2520in%2520the%2520R6%252F2%2520mouse%2520model%26jtitle%3DNeuropharmacology%26date%3D2019%26volume%3D151%26spage%3D1%26epage%3D12%26doi%3D10.1016%2Fj.neuropharm.2019.03.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neuhofer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chioma, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beloate, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalivas, P. W.</span></span> <span> </span><span class="NLM_article-title">The loss of NMDAR-dependent LTD following cannabinoid self-administration is restored by positive allosteric modulation of CB1 receptors</span>. <i>Addict. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span>, <span class="NLM_elocation-id">e12843</span> <span class="refDoi"> DOI: 10.1111/adb.12843</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1111%2Fadb.12843" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=31733097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit1elurnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&author=D.+Neuhoferauthor=S.+M.+Spencerauthor=V.+C.+Chiomaauthor=L.+N.+Beloateauthor=D.+Schwartzauthor=P.+W.+Kalivas&title=The+loss+of+NMDAR-dependent+LTD+following+cannabinoid+self-administration+is+restored+by+positive+allosteric+modulation+of+CB1+receptors&doi=10.1111%2Fadb.12843"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">The loss of NMDAR-dependent LTD following cannabinoid self-administration is restored by positive allosteric modulation of CB1 receptors</span></div><div class="casAuthors">Neuhofer, Daniela; Spencer, Sade M.; Chioma, Vivian C.; Beloate, Lauren N.; Schwartz, Danielle; Kalivas, Peter W.</div><div class="citationInfo"><span class="NLM_cas:title">Addiction Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e12843</span>CODEN:
                <span class="NLM_cas:coden">ADBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1369-1600</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Glutamatergic plasticity in the nucleus accumbens core (NAcore) is a key neuronal process in appetitive learning and contributes to pathologies such as drug addiction.  Understanding how this plasticity factors into cannabis addiction and relapse has been hampered by the lack of a rodent model of cannabis self-administration.  We used i.v. self-administration of two constituents of cannabis, Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) to examine how contingent cannabis use and cue-induced cannabinoid-seeking alters glutamatergic neurotransmission and synaptic plasticity in NAcore.  NMDA receptor (NMDAR)-dependent long-term depression (LTD) in the NAcore was lost after cannabinoid, but not sucrose self-administration.  Surprisingly, when rats underwent cue-induced cannabinoid seeking, LTD was restored.  Loss of LTD was accompanied by desensitization of cannabinoid receptor 1 (CB1R).  CB1R are positioned to regulate synaptic plasticity by being expressed on glutamatergic terminals and neg. regulating presynaptic excitability and glutamate release.  Supporting this possibility, LTD was restored by promoting CB1R signaling with the CB1 pos. allosteric modulator GAT211.  These data implicate NAcore CB1R as crit. regulators of metaplasticity induced by cannabis self-administration and the cues predicting cannabis availability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEDquDs9RsC7Vg90H21EOLACvtfcHk0lhGNzMj_0rxnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit1elurnL&md5=6af1e44992e78cb475f6f07fb5362ae3</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1111%2Fadb.12843&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fadb.12843%26sid%3Dliteratum%253Aachs%26aulast%3DNeuhofer%26aufirst%3DD.%26aulast%3DSpencer%26aufirst%3DS.%2BM.%26aulast%3DChioma%26aufirst%3DV.%2BC.%26aulast%3DBeloate%26aufirst%3DL.%2BN.%26aulast%3DSchwartz%26aufirst%3DD.%26aulast%3DKalivas%26aufirst%3DP.%2BW.%26atitle%3DThe%2520loss%2520of%2520NMDAR-dependent%2520LTD%2520following%2520cannabinoid%2520self-administration%2520is%2520restored%2520by%2520positive%2520allosteric%2520modulation%2520of%2520CB1%2520receptors%26jtitle%3DAddict.%2520Biol.%26date%3D2020%26volume%3D25%26doi%3D10.1111%2Fadb.12843" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thapa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cairns, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szczesniak, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straiker, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, M. E. M.</span></span> <span> </span><span class="NLM_article-title">Allosteric cannabinoid receptor 1 (CB1) ligands reduce ocular pain and inflammation</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span>, <span class="NLM_elocation-id">417</span> <span class="refDoi"> DOI: 10.3390/molecules25020417</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.3390%2Fmolecules25020417" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktVSjtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&author=D.+Thapaauthor=E.+A.+Cairnsauthor=A.+M.+Szczesniakauthor=P.+M.+Kulkarniauthor=A.+J.+Straikerauthor=G.+A.+Thakurauthor=M.+E.+M.+Kelly&title=Allosteric+cannabinoid+receptor+1+%28CB1%29+ligands+reduce+ocular+pain+and+inflammation&doi=10.3390%2Fmolecules25020417"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric cannabinoid receptor 1 (CB1) ligands reduce ocular pain and inflammation</span></div><div class="casAuthors">Thapa, Dinesh; Cairns, Elizabeth A.; Szczesniak, Anna-Maria; Kulkarni, Pushkar M.; Straiker, Alex J.; Thakur, Ganesh A.; Kelly, Melanie E. M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">417</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Cannabinoid receptor 1 (CB1) activation has been reported to reduce transient receptor potential cation channel subfamily V member 1 (TRPV1)-induced inflammatory responses and is anti-nociceptive and anti-inflammatory in corneal injury.  We examd. whether allosteric ligands, can modulate CB1 signaling to reduce pain and inflammation in corneal hyperalgesia.  Corneal hyperalgesia was generated by chem. cauterization of cornea in wildtype and CB2 knockout (CB2-/-) mice.  The novel racemic CB1 allosteric ligand GAT211 and its enantiomers GAT228 and GAT229 were examd. alone or in combination with the orthosteric CB1 agonist delta8 -tetrahydrocannabinol (delta8 -THC).  Pain responses were assessed following capsaicin (1 microM) stimulation of injured corneas at 6 h post-cauterization.  Corneal neutrophil infiltration was also analyzed.  GAT228, but not GAT229 or GAT211, reduced pain scores in response to capsaicin stimulation.  Combination treatments of 0.5% GAT229 or 1% GAT211 with subthreshold delta8 -THC (0.4%) significantly reduced pain scores following capsaicin stimulation.  The anti-nociceptive effects of both GAT229 and GAT228 were blocked with CB1 antagonist AM251, but remained unaffected in CB2-/- mice.  Two percent GAT228, or the combination of 0.2% delta8 -THC with 0.5% GAT229 also significantly reduced corneal inflammation.  CB1 allosteric ligands could offer a novel approach for treating corneal pain and inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_doQTvEiJSbVg90H21EOLACvtfcHk0lhGNzMj_0rxnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktVSjtbs%253D&md5=3e5bf9cc7c7a43bcb10fece203eacf55</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.3390%2Fmolecules25020417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules25020417%26sid%3Dliteratum%253Aachs%26aulast%3DThapa%26aufirst%3DD.%26aulast%3DCairns%26aufirst%3DE.%2BA.%26aulast%3DSzczesniak%26aufirst%3DA.%2BM.%26aulast%3DKulkarni%26aufirst%3DP.%2BM.%26aulast%3DStraiker%26aufirst%3DA.%2BJ.%26aulast%3DThakur%26aufirst%3DG.%2BA.%26aulast%3DKelly%26aufirst%3DM.%2BE.%2BM.%26atitle%3DAllosteric%2520cannabinoid%2520receptor%25201%2520%2528CB1%2529%2520ligands%2520reduce%2520ocular%2520pain%2520and%2520inflammation%26jtitle%3DMolecules%26date%3D2020%26volume%3D25%26doi%3D10.3390%2Fmolecules25020417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slivicki, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mali, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crystal, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohmann, A. G.</span></span> <span> </span><span class="NLM_article-title">Positive allosteric modulation of CB(1) cannabinoid receptor signaling enhances morphine antinociception and attenuates morphine tolerance without enhancing morphine- induced dependence or reward</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">54</span> <span class="refDoi"> DOI: 10.3389/fnmol.2020.00054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.3389%2Ffnmol.2020.00054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=32410959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlCiurnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2020&author=R.+A.+Slivickiauthor=V.+Iyerauthor=S.+S.+Maliauthor=S.+Garaiauthor=G.+A.+Thakurauthor=J.+D.+Crystalauthor=A.+G.+Hohmann&title=Positive+allosteric+modulation+of+CB%281%29+cannabinoid+receptor+signaling+enhances+morphine+antinociception+and+attenuates+morphine+tolerance+without+enhancing+morphine-+induced+dependence+or+reward&doi=10.3389%2Ffnmol.2020.00054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Positive allosteric modulation of CB1 cannabinoid receptor signaling enhances morphine antinociception and attenuates morphine tolerance without enhancing morphine- induced dependence or reward</span></div><div class="casAuthors">Slivicki, Richard A.; Iyer, Vishakh; Mali, Sonali S.; Garai, Sumanta; Thakur, Ganesh A.; Crystal, Jonathon D.; Hohmann, Andrea G.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Molecular Neuroscience</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">54</span>CODEN:
                <span class="NLM_cas:coden">FMNRAJ</span>;
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Opioid analgesics represent a crit. treatment for chronic pain in the analgesic ladder of the World Health Organization.  However, their use can result in a no. of unwanted side-effects including incomplete efficacy, constipation, phys. dependence, and overdose liability.  Cannabinoids enhance the pain-relieving effects of opioids in preclin. studies and dampen unwanted side-effects resulting from excessive opioid intake.  We recently reported that a CB1 pos. allosteric modulator (PAM) exhibits antinociceptive efficacy in models of pathol. pain and lacks the adverse side effects of direct CB1 receptor activation.  In the present study, we evaluated whether a CB1 PAM would enhance morphine's therapeutic efficacy in an animal model of chemotherapyinduced neuropathic pain and characterized its impact on unwanted side-effects assocd. with chronic opioid administration.  In paclitaxel-treated mice, both the CB1 PAM GAT211 and the opioid analgesic morphine reduced paclitaxel-induced behavioral hypersensitivities to mech. and cold stimulation in a dose-dependent manner.  Isobolog. anal. revealed that combinations of GAT211 and morphine resulted in anti-allodynic synergism.  In paclitaxel-treated mice, a sub-threshold dose of GAT211 prevented the development of tolerance to the anti-allodynic effects of morphine over 20 days of once daily dosing.  However, GAT211 did not reliably alter somatic withdrawal signs (i.e., jumps, paw tremors) in morphine-dependent neuropathic mice challenged with naloxone.  In otherwise na.ovrddot.ive mice, GAT211 also prolonged antinociceptive efficacy of morphine in the tail-flick test and reduced the overall right-ward shift in the ED50 for morphine to produce antinociception in the tail-flick test, consistent with attenuation of morphine tolerance.  Pretreatment with GAT211 did not alter somatic signs of μ opioid receptor dependence in mice rendered dependent upon morphine via s.c. implantation of a morphine pellet.  Moreover, GAT211 did not reliably alter μ-opioid receptor-mediated reward as measured by conditioned place preference to morphine.  Our results suggest that a CB1 PAM may be beneficial in enhancing and prolonging the therapeutic properties of opioids while potentially sparing unwanted side-effects (e.g., tolerance) that occur with repeated opioid treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf78yT9Yo5I7Vg90H21EOLACvtfcHk0lhGNzMj_0rxnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlCiurnI&md5=faabe8b5ba0f5fba03d10fba5a9eaaab</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2020.00054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2020.00054%26sid%3Dliteratum%253Aachs%26aulast%3DSlivicki%26aufirst%3DR.%2BA.%26aulast%3DIyer%26aufirst%3DV.%26aulast%3DMali%26aufirst%3DS.%2BS.%26aulast%3DGarai%26aufirst%3DS.%26aulast%3DThakur%26aufirst%3DG.%2BA.%26aulast%3DCrystal%26aufirst%3DJ.%2BD.%26aulast%3DHohmann%26aufirst%3DA.%2BG.%26atitle%3DPositive%2520allosteric%2520modulation%2520of%2520CB%25281%2529%2520cannabinoid%2520receptor%2520signaling%2520enhances%2520morphine%2520antinociception%2520and%2520attenuates%2520morphine%2520tolerance%2520without%2520enhancing%2520morphine-%2520induced%2520dependence%2520or%2520reward%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2020%26volume%3D13%26doi%3D10.3389%2Ffnmol.2020.00054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Datta, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilpin, N. W.</span></span> <span> </span><span class="NLM_article-title">Positive allosteric modulation of the cannabinoid type-1 receptor (CB1R) in periaqueductal gray (PAG) antagonizes anti-nociceptive and cellular effects of a mu-opioid receptor agonist in morphine-withdrawn rats</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>237</i></span>,  <span class="NLM_fpage">3729</span>– <span class="NLM_lpage">3739</span>, <span class="refDoi"> DOI: 10.1007/s00213-020-05650-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1007%2Fs00213-020-05650-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=32857187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A280%3ADC%252BB38bhs1WisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=237&publication_year=2020&pages=3729-3739&author=U.+Dattaauthor=L.+K.+Kelleyauthor=J.+W.+Middletonauthor=N.+W.+Gilpin&title=Positive+allosteric+modulation+of+the+cannabinoid+type-1+receptor+%28CB1R%29+in+periaqueductal+gray+%28PAG%29+antagonizes+anti-nociceptive+and+cellular+effects+of+a+mu-opioid+receptor+agonist+in+morphine-withdrawn+rats&doi=10.1007%2Fs00213-020-05650-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Positive allosteric modulation of the cannabinoid type-1 receptor (CB1R) in periaqueductal gray (PAG) antagonizes anti-nociceptive and cellular effects of a mu-opioid receptor agonist in morphine-withdrawn rats</span></div><div class="casAuthors">Datta Udita; Kelley Leslie K; Gilpin Nicholas W; Datta Udita; Middleton Jason W; Middleton Jason W; Gilpin Nicholas W; Middleton Jason W; Gilpin Nicholas W; Gilpin Nicholas W</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">237</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3729-3739</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Opioid drugs are a first-line treatment for severe acute pain and other chronic pain conditions, but long-term opioid drug use produces opioid-induced hyperalgesia (OIH).  Co-administration of cannabinoids with opioid receptor agonists produce anti-nociceptive synergy, but cannabinoid receptor agonists may also produce undesirable side effects.  Therefore, positive allosteric modulators (PAM) of cannabinoid type-1 receptors (CB1R) may provide an option reducing pain and/or enhancing the anti-hyperalgesic effects of opioids without the side effects, tolerance, and dependence observed with the use of ligands that target the orthosteric binding sites.  This study tested GAT211, a PAM of cannabinoid type-1 receptors (CB1R), for its ability to enhance the anti-hyperalgesic effects of the mu-opioid receptor (MOR) agonist DAMGO in rats treated chronically with morphine (or saline) and tested during withdrawal.  We tested the effects of intra-periaqueductal gray (PAG) injections of (1) DAMGO, (2) GAT211, or (3) DAMGO + GAT211 on thermal nociception in chronic morphine-treated rats that were hyperalgesic and also in saline-treated control rats.  We used slice electrophysiology to test the effects of DAMGO/GAT211 bath application on synaptic transmission in the vlPAG.  Intra-PAG DAMGO infusions dose-dependently reversed chronic morphine-induced hyperalgesia, but intra-PAG GAT211 did not alter nociception at the doses we tested.  When co-administered into the PAG, GAT211 antagonized the anti-nociceptive effects of DAMGO in morphine-withdrawn rats.  DAMGO suppressed synaptic inhibition in the vlPAG of brain slices taken from saline- and morphine-treated rats, and GAT211 attenuated DAMGO-induced suppression of synaptic inhibition in vlPAG neurons via actions at CB1R.  These findings show that positive allosteric modulation of CB1R antagonizes the behavioral and cellular effects of a MOR agonist in the PAG of rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRmNuShziTDJQHqQV89nF-2fW6udTcc2eZ-LP7KK3L89rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38bhs1WisA%253D%253D&md5=68c3282a5ab5a1a7da020a1f1c651791</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1007%2Fs00213-020-05650-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00213-020-05650-5%26sid%3Dliteratum%253Aachs%26aulast%3DDatta%26aufirst%3DU.%26aulast%3DKelley%26aufirst%3DL.%2BK.%26aulast%3DMiddleton%26aufirst%3DJ.%2BW.%26aulast%3DGilpin%26aufirst%3DN.%2BW.%26atitle%3DPositive%2520allosteric%2520modulation%2520of%2520the%2520cannabinoid%2520type-1%2520receptor%2520%2528CB1R%2529%2520in%2520periaqueductal%2520gray%2520%2528PAG%2529%2520antagonizes%2520anti-nociceptive%2520and%2520cellular%2520effects%2520of%2520a%2520mu-opioid%2520receptor%2520agonist%2520in%2520morphine-withdrawn%2520rats%26jtitle%3DPsychopharmacology%26date%3D2020%26volume%3D237%26spage%3D3729%26epage%3D3739%26doi%3D10.1007%2Fs00213-020-05650-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schaffer, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janero, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, G. A.</span></span> <span> </span><span class="NLM_article-title">Focused structure-activity relationship profiling around the 2-phenylindole scaffold of a cannabinoid type-1 receptor agonist-positive allosteric modulator: site-III aromatic-ring congeners with enhanced activity and solubility</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>28</i></span>, <span class="NLM_elocation-id">115727</span> <span class="refDoi"> DOI: 10.1016/j.bmc.2020.115727</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1016%2Fj.bmc.2020.115727" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2020&author=P.+C.+Schafferauthor=P.+M.+Kulkarniauthor=D.+R.+Janeroauthor=G.+A.+Thakur&title=Focused+structure-activity+relationship+profiling+around+the+2-phenylindole+scaffold+of+a+cannabinoid+type-1+receptor+agonist-positive+allosteric+modulator%3A+site-III+aromatic-ring+congeners+with+enhanced+activity+and+solubility&doi=10.1016%2Fj.bmc.2020.115727"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2020.115727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2020.115727%26sid%3Dliteratum%253Aachs%26aulast%3DSchaffer%26aufirst%3DP.%2BC.%26aulast%3DKulkarni%26aufirst%3DP.%2BM.%26aulast%3DJanero%26aufirst%3DD.%2BR.%26aulast%3DThakur%26aufirst%3DG.%2BA.%26atitle%3DFocused%2520structure-activity%2520relationship%2520profiling%2520around%2520the%25202-phenylindole%2520scaffold%2520of%2520a%2520cannabinoid%2520type-1%2520receptor%2520agonist-positive%2520allosteric%2520modulator%253A%2520site-III%2520aromatic-ring%2520congeners%2520with%2520enhanced%2520activity%2520and%2520solubility%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D28%26doi%3D10.1016%2Fj.bmc.2020.115727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schönherr, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cernak, T.</span></span> <span> </span><span class="NLM_article-title">Profound methyl effects in drug discovery and a call for new C-H methylation reactions</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">12256</span>– <span class="NLM_lpage">12267</span>, <span class="refDoi"> DOI: 10.1002/anie.201303207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1002%2Fanie.201303207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252FptVahuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=12256-12267&author=H.+Sch%C3%B6nherrauthor=T.+Cernak&title=Profound+methyl+effects+in+drug+discovery+and+a+call+for+new+C-H+methylation+reactions&doi=10.1002%2Fanie.201303207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Profound methyl effects in drug discovery and a call for new C-H methylation reactions</span></div><div class="casAuthors">Schonherr Heike; Cernak Tim</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie (International ed. in English)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">12256-67</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The methyl group is one of the most commonly occurring carbon fragments in small-molecule drugs.  This simplest alkyl fragment appears in more than 67 % of the top-selling drugs of 2011 and can modulate both the biological and physical properties of a molecule.  This Review focuses on so-called magic methyl effects on binding potency, where the seemingly mundane change of C H to C Me improves the IC50  value of a drug candidate more than 100-fold.  This discussion is followed by a survey of recent advances in synthetic chemistry that allow the direct methylation of C(sp(2) ) H and C(sp(3) ) H bonds.  It is our hope that the relevance of the meager methyl group to drug discovery as presented herein will inspire reports on new C H methylation reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTyoLZDDgvsMh0LsK7uFuY7fW6udTcc2eZ-LP7KK3L89rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252FptVahuw%253D%253D&md5=ef08f80e55b2c530b49e4306da024902</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fanie.201303207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201303207%26sid%3Dliteratum%253Aachs%26aulast%3DSch%25C3%25B6nherr%26aufirst%3DH.%26aulast%3DCernak%26aufirst%3DT.%26atitle%3DProfound%2520methyl%2520effects%2520in%2520drug%2520discovery%2520and%2520a%2520call%2520for%2520new%2520C-H%2520methylation%2520reactions%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D12256%26epage%3D12267%26doi%3D10.1002%2Fanie.201303207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barreiro, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kümmerle, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraga, C. A.</span></span> <span> </span><span class="NLM_article-title">The methylation effect in medicinal chemistry</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">5215</span>– <span class="NLM_lpage">5246</span>, <span class="refDoi"> DOI: 10.1021/cr200060g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr200060g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFChsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2011&pages=5215-5246&author=E.+J.+Barreiroauthor=A.+E.+K%C3%BCmmerleauthor=C.+A.+Fraga&title=The+methylation+effect+in+medicinal+chemistry&doi=10.1021%2Fcr200060g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">The Methylation Effect in Medicinal Chemistry</span></div><div class="casAuthors">Barreiro, Eliezer J.; Kummerle, Arthur E.; Fraga, Carlos A. M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5215-5246</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this review, we aimed to highlight the importance of the simple Me group as a very useful structural modification in the rational design of bioactive compds. and drugs.  We selected different examples from distinct classes of org. compds. with several pharmacol. properties in order to illustrate that an apparent subtle mol. modification can strongly alter the biol. profile of a drug.  The Me effect alter both biol. phases of a drug, represented by its pharmacodynamic and pharmacokinetc profile, due to the modifications introduced in the stereoeletronic properties.  In fact, it was illustrated that distinct metabolic behavior or receptor affinity could be modified by the Me effect.  Among the examples included many other important ones could be used, such as the importance of the Me in modified the bioprofile of Ph ethanolamines with differentiation in the mol. recognition pattern among different adrenergic receptor subtypes.  The introduction of an simple extra Me connected to the N-alkylpiperidine moiety present in PDE5 inhibitor raisng the discovery of me-too drug vardenafil for erectile dysfunction.  In fact, the correct use of this strategy for mol. modification and design of drugs or drug-candidate compds. may be useful from both a pharmacokinetic and a pharmacodynamic point of view, representing an important tool for the medicinal chemist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx5w0XiOyJ7bVg90H21EOLACvtfcHk0lgx-UovNpWVXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFChsrk%253D&md5=1cfdacf68ea53408c0f671a1dffb6d3a</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fcr200060g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr200060g%26sid%3Dliteratum%253Aachs%26aulast%3DBarreiro%26aufirst%3DE.%2BJ.%26aulast%3DK%25C3%25BCmmerle%26aufirst%3DA.%2BE.%26aulast%3DFraga%26aufirst%3DC.%2BA.%26atitle%3DThe%2520methylation%2520effect%2520in%2520medicinal%2520chemistry%26jtitle%3DChem.%2520Rev.%26date%3D2011%26volume%3D111%26spage%3D5215%26epage%3D5246%26doi%3D10.1021%2Fcr200060g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirado-Rives, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span> <span> </span><span class="NLM_article-title">Methyl effects on protein-ligand binding</span>. <i>J. Med. Chem</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4489</span>– <span class="NLM_lpage">5000</span>, <span class="refDoi"> DOI: 10.1021/jm3003697</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003697" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsV2iu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4489-5000&author=C.+S.+Leungauthor=S.+S.+Leungauthor=J.+Tirado-Rivesauthor=W.+L.+Jorgensen&title=Methyl+effects+on+protein-ligand+binding&doi=10.1021%2Fjm3003697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Methyl Effects on Protein-Ligand Binding</span></div><div class="casAuthors">Leung, Cheryl S.; Leung, Siegfried S. F.; Tirado-Rives, Julian; Jorgensen, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4489-4500</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The effects of addn. of a Me group to a lead compd. on biol. activity are examd.  A literature anal. of >2000 cases reveals that an activity boost of a factor of 10 or more is found with an 8% frequency, and a 100-fold boost is a 1 in 200 event.  Four cases in the latter category are analyzed in depth to elucidate any unusual aspects of the protein-ligand binding, distribution of water mols., and changes in conformational energetics.  The analyses include Monte Carlo/free-energy perturbation (MC/FEP) calcns. for Me replacements in inhibitor series for p38α MAP kinase, ACK1, PTP1B, and thrombin.  Me substitutions ortho to an aryl ring can be particularly effective at improving activity by inducing a propitious conformational change.  The greatest improvements in activity arise from coupling the conformational gain with the burial of the Me group in a hydrophobic region of the protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX0Czyhgy6KbVg90H21EOLACvtfcHk0lgx-UovNpWVXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsV2iu7Y%253D&md5=0ea58d9c1bf845d383931b6a017f9b37</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm3003697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003697%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DC.%2BS.%26aulast%3DLeung%26aufirst%3DS.%2BS.%26aulast%3DTirado-Rives%26aufirst%3DJ.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26atitle%3DMethyl%2520effects%2520on%2520protein-ligand%2520binding%26jtitle%3DJ.%2520Med.%2520Chem%26date%3D2012%26volume%3D55%26spage%3D4489%26epage%3D5000%26doi%3D10.1021%2Fjm3003697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharbanda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakkaniga, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frett, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.-Y.</span></span> <span> </span><span class="NLM_article-title">The Exploration of Chirality for Improved Druggability within the Human Kinome</span>. <i>J. Med. Chem</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">469</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00640</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00640" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVCntLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=441-469&author=D.+Sahaauthor=A.+Kharbandaauthor=W.+Yanauthor=N.+R.+Lakkanigaauthor=B.+Frettauthor=H.-Y.+Li&title=The+Exploration+of+Chirality+for+Improved+Druggability+within+the+Human+Kinome&doi=10.1021%2Facs.jmedchem.9b00640"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">The Exploration of Chirality for Improved Druggability within the Human Kinome</span></div><div class="casAuthors">Saha, Debasmita; Kharbanda, Anupreet; Yan, Wei; Lakkaniga, Naga Rajiv; Frett, Brendan; Li, Hong-Yu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">441-469</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Chirality is important in drug discovery because stereoselective drugs can ameliorate therapeutic difficulties including adverse toxicity and poor pharmacokinetic profiles.  The human kinome, a major druggable enzyme class has been exploited to treat a wide range of diseases.  However, many kinase inhibitors are planar and overlap in chem. space, which leads to selectivity and toxicity issues.  By exploring chirality within the kinome, a new iteration of kinase inhibitors is being developed to better utilize the three-dimensional nature of the kinase active site.  Exploration into novel chem. space, in turn, will also improve drug soly. and pharmacokinetic profiles.  This perspective explores the role of chirality to improve kinome druggability and will serve as a resource for pioneering kinase inhibitor development to address current therapeutic needs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-wP_4kQzQNrVg90H21EOLACvtfcHk0lgx-UovNpWVXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVCntLzE&md5=5feba0b73e6ab003971feb705ad2d7ac</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00640%26sid%3Dliteratum%253Aachs%26aulast%3DSaha%26aufirst%3DD.%26aulast%3DKharbanda%26aufirst%3DA.%26aulast%3DYan%26aufirst%3DW.%26aulast%3DLakkaniga%26aufirst%3DN.%2BR.%26aulast%3DFrett%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DH.-Y.%26atitle%3DThe%2520Exploration%2520of%2520Chirality%2520for%2520Improved%2520Druggability%2520within%2520the%2520Human%2520Kinome%26jtitle%3DJ.%2520Med.%2520Chem%26date%3D2020%26volume%3D63%26spage%3D441%26epage%3D469%26doi%3D10.1021%2Facs.jmedchem.9b00640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guida, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, K. G.</span></span> <span> </span><span class="NLM_article-title">The significance of chirality in drug design and development</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">760</span>– <span class="NLM_lpage">770</span>, <span class="refDoi"> DOI: 10.2174/156802611795165098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.2174%2F156802611795165098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=21291399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1Ojsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=760-770&author=W.+H.+Brooksauthor=W.+C.+Guidaauthor=K.+G.+Daniel&title=The+significance+of+chirality+in+drug+design+and+development&doi=10.2174%2F156802611795165098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">The significance of chirality in drug design and development</span></div><div class="casAuthors">Brooks, W. H.; Guida, W. C.; Daniel, K. G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">760-770</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Proteins are often enantioselective towards their binding partners.  When designing small mols. to interact with these targets, one should consider stereoselectivity.  As considerations for exploring structure space evolve, chirality is increasingly important.  Binding affinity for a chiral drug can differ for diastereomers and between enantiomers.  For the virtual screening and computational design stage of drug development, this problem can be compounded by incomplete stereochem. information in structure libraries leading to a "coin toss" as to whether or not the "ideal" chiral structure is present.  Creating every stereoisomer for each chiral compd. in a structure library leads to an exponential increase in the no. of structures resulting in potentially unmanageable file sizes and screening times.  Therefore, only key chiral structures, enantiomeric pairs based on relative stereochem. need be included, and lead to a compromise between exploration of chem. space and maintaining manageable libraries.  In clin. environments, enantiomers of chiral drugs can have reduced, no, or even deleterious effects.  This underscores the need to avoid mixts. of compds. and focus on chiral synthesis.  Governmental regulations emphasizing the need to monitor chirality in drug development have increased.  The United States Food and Drug Administration issued guidelines and policies in 1992 concerning the development of chiral compds.  These guidelines require that abs. stereochem. be known for compds. with chiral centers and that this information should be established early in drug development in order that the anal. can be considered valid.  From exploration of structure space to governmental regulations it is clear that the question of chirality in drug design is of vital importance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4TgZ0W1QUdrVg90H21EOLACvtfcHk0lhZPi3-qwKaPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1Ojsrw%253D&md5=eb78aca17518a7fd04d8cfc3c5d0ec78</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.2174%2F156802611795165098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611795165098%26sid%3Dliteratum%253Aachs%26aulast%3DBrooks%26aufirst%3DW.%2BH.%26aulast%3DGuida%26aufirst%3DW.%2BC.%26aulast%3DDaniel%26aufirst%3DK.%2BG.%26atitle%3DThe%2520significance%2520of%2520chirality%2520in%2520drug%2520design%2520and%2520development%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D760%26epage%3D770%26doi%3D10.2174%2F156802611795165098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranade, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, G. A.</span></span> <span> </span><span class="NLM_article-title">Microwave-accelerated conjugate addition of 2-arylindoles to substituted β-nitrostyrenes in the presence of ammonium trifluoroacetate: an efficient approach for the synthesis of a novel class of CB1 cannabinoid receptor allosteric modulators</span>. <i>J. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2079</span>– <span class="NLM_lpage">2084</span>, <span class="refDoi"> DOI: 10.1002/jhet.2861</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1002%2Fjhet.2861" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs1Oru78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2017&pages=2079-2084&author=P.+M.+Kulkarniauthor=A.+Ranadeauthor=S.+Garaiauthor=G.+A.+Thakur&title=Microwave-accelerated+conjugate+addition+of+2-arylindoles+to+substituted+%CE%B2-nitrostyrenes+in+the+presence+of+ammonium+trifluoroacetate%3A+an+efficient+approach+for+the+synthesis+of+a+novel+class+of+CB1+cannabinoid+receptor+allosteric+modulators&doi=10.1002%2Fjhet.2861"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Microwave-accelerated Conjugate Addition of 2-Arylindoles to Substituted β-Nitrostyrenes in the Presence of Ammonium Trifluoroacetate: An Efficient Approach for the Synthesis of a Novel Class of CB1 Cannabinoid Receptor Allosteric Modulators</span></div><div class="casAuthors">Kulkarni, Pushkar M.; Ranade, Ameya; Garai, Sumanta; Thakur, Ganesh A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Heterocyclic Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">2079-2084</span>CODEN:
                <span class="NLM_cas:coden">JHTCAD</span>;
        ISSN:<span class="NLM_cas:issn">1943-5193</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">2-Arylindoles, in general, exhibit reduced reactivity towards the conjugate addn. to substituted nitrostyrenes, when compared with indoles.  An efficient, expeditious, and high-yielding conjugate addn. of 2-arylindoles to substituted β-nitrostyrenes in the presence of ammonium trifluoroacetate under microwave irradn is reported here.  This method is mild with high and reproducible yields and is selective for addn. of β-nitrostyrenes when compared with other electrophiles.  The results obtained from the optimized microwave method consistently provided improved yields of the title compds., e.g., I, in a shorter time compared with those of the conventional heating synthetic route.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHYh9vHbyRDLVg90H21EOLACvtfcHk0lhZPi3-qwKaPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs1Oru78%253D&md5=523324377e4551828ea3c8b22905b307</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1002%2Fjhet.2861&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.2861%26sid%3Dliteratum%253Aachs%26aulast%3DKulkarni%26aufirst%3DP.%2BM.%26aulast%3DRanade%26aufirst%3DA.%26aulast%3DGarai%26aufirst%3DS.%26aulast%3DThakur%26aufirst%3DG.%2BA.%26atitle%3DMicrowave-accelerated%2520conjugate%2520addition%2520of%25202-arylindoles%2520to%2520substituted%2520%25CE%25B2-nitrostyrenes%2520in%2520the%2520presence%2520of%2520ammonium%2520trifluoroacetate%253A%2520an%2520efficient%2520approach%2520for%2520the%2520synthesis%2520of%2520a%2520novel%2520class%2520of%2520CB1%2520cannabinoid%2520receptor%2520allosteric%2520modulators%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D2017%26volume%3D54%26spage%3D2079%26epage%3D2084%26doi%3D10.1002%2Fjhet.2861" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, J. R.</span></span> <span> </span><span class="NLM_article-title">The [<sup>35</sup>S]GTPgammaS binding assay: approaches and applications in pharmacology</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">489</span>– <span class="NLM_lpage">508</span>, <span class="refDoi"> DOI: 10.1016/j.lfs.2003.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1016%2Fj.lfs.2003.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=14609727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovVGgur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2003&pages=489-508&author=C.+Harrisonauthor=J.+R.+Traynor&title=The+%5B35S%5DGTPgammaS+binding+assay%3A+approaches+and+applications+in+pharmacology&doi=10.1016%2Fj.lfs.2003.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">The [35S]GTPγS binding assay: approaches and applications in pharmacology</span></div><div class="casAuthors">Harrison, C.; Traynor, J. R.</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">489-508</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review.  Receptors of the of seven transmembrane spanning, heterotrimeric G protein coupled family (GPCR) play crucial roles in regulating physiol. functions and consequently are targets for the action of many classes of drugs.  Activation of receptor by agonist leads to the dissocn. of GDP from Gα of the Gαβγ heterotrimer, followed by the binding of GTP to Gα and subsequent modulation of downstream effectors.  The G protein heterotrimer is reformed by GTPase activity of the Gα subunit, forming Gα-GDP and so allowing Gα and Gβγ to recombine.  The [35S]GTPγS assay measures the level of G protein activation following agonist occupation of a GPCR, by detg. the binding of the non-hydrolyzable analog [35S]GTPγS to Gα subunits.  Thus, the assay measures a functional consequence of receptor occupancy at one of the earliest receptor-mediated events.  The assay allows for traditional pharmacol. parameters of potency, efficacy and antagonist affinity, with the advantage that agonist measures are not subjected to amplification or other modulation that may occur when analyzing parameters further downstream of the receptor.  In general the assay is exptl. more feasible for receptors coupled to the abundant Gi/o proteins.  Nevertheless, [35S]GTPγS binding assays are used with GPCRs that couple to the Gs and Gq families of G proteins, esp. in artificial expression systems, or using receptor-Gα constructs or immunopptn. of [35S]GTPγS-labeled Gα.  The relative simplicity of the assay has made it very popular and its use is providing insights into contemporary pharmacol. topics including the roles of accessory proteins in signaling, constitutive activity of receptors and agonist specific signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxfMRPq_yzZLVg90H21EOLACvtfcHk0lhZPi3-qwKaPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovVGgur8%253D&md5=e7f4c739fd78cda7029439c9ff48e570</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2003.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2003.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DHarrison%26aufirst%3DC.%26aulast%3DTraynor%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520%255B35S%255DGTPgammaS%2520binding%2520assay%253A%2520approaches%2520and%2520applications%2520in%2520pharmacology%26jtitle%3DLife%2520Sci.%26date%3D2003%26volume%3D74%26spage%3D489%26epage%3D508%26doi%3D10.1016%2Fj.lfs.2003.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasanetz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friemel, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lassalle, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steindel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monory, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäfer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miederer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leweke, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreckenberger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reggio, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manzoni, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spanagel, R.</span></span> <span> </span><span class="NLM_article-title">Enhanced functional activity of the cannabinoid type-1 receptor mediates adolescent behavior</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">13975</span>– <span class="NLM_lpage">13988</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.1937-15.2015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1523%2FJNEUROSCI.1937-15.2015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=26468198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvFyru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=13975-13988&author=M.+Schneiderauthor=F.+Kasanetzauthor=D.+L.+Lynchauthor=C.+M.+Friemelauthor=O.+Lassalleauthor=D.+P.+Hurstauthor=F.+Steindelauthor=K.+Monoryauthor=C.+Sch%C3%A4ferauthor=I.+Miedererauthor=F.+M.+Lewekeauthor=M.+Schreckenbergerauthor=B.+Lutzauthor=P.+H.+Reggioauthor=O.+J.+Manzoniauthor=R.+Spanagel&title=Enhanced+functional+activity+of+the+cannabinoid+type-1+receptor+mediates+adolescent+behavior&doi=10.1523%2FJNEUROSCI.1937-15.2015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54aR"><div class="casContent"><span class="casTitleNuber">54a</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced functional activity of the cannabinoid type-1 receptor mediates adolescent behavior</span></div><div class="casAuthors">Schneider, Miriam; Kasanetz, Fernando; Lynch, Diane L.; Friemel, Chris M.; Lassalle, Olivier; Hurst, Dow P.; Steindel, Frauke; Monory, Krisztina; Schaefer, Carola; Miederer, Isabelle; Leweke, F. Markus; Schreckenberger, Mathias; Lutz, Beat; Reggio, Patricia H.; Manzoni, Olivier J.; Spanagel, Rainer</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">13975-13988</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Adolescence is characterized by drastic behavioral adaptations and comprises a particularly vulnerable period for the emergence of various psychiatric disorders.  Growing evidence reveals that the pathophysiol. of these disorders might derive from aberrations of normal neurodevelopmental changes in the adolescent brain.  Understanding the mol. underpinnings of adolescent behavior is therefore crit. for understanding the origin of psychopathol., but the mol. mechanisms that trigger adolescent behavior are unknown.  Here, we hypothesize that the cannabinoid type-1 receptor (CB1R) may play a crit. role in mediating adolescent behavior because enhanced endocannabinoid (eCB) signaling has been suggested to occur transiently during adolescence.  To study enhanced CB1R signaling, we introduced a missense mutation (F238L) into the rat Cnr1 gene that encodes for the CB1R.  According to our hypothesis, rats with the F238L mutation (Cnr1F238L) should sustain features of adolescent behavior into adulthood.  Gain of function of the mutated receptor was demonstrated by in silico modeling and was verified functionally in a series of biochem. and electrophysiol. expts.  Mutant rats exhibit an adolescent-like phenotype during adulthood compared with wild-type littermates, with typical high risk/novelty seeking, increased peer interaction, enhanced impulsivity, and augmented reward sensitivity for drug and nondrug reward.  Partial inhibition of CB1R activity in Cnr1F238L mutant rats normalized behavior and led to a wild-type phenotype.  We conclude that the activity state and functionality of the CB1R is crit. for mediating adolescent behavior.  These findings implicate the eCB system as an important research target for the neuropathol. of adolescent-onset mental health disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRQPO9k5w-hrVg90H21EOLACvtfcHk0lj8t5h6rQ8qew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvFyru70%253D&md5=a4b96441d101d2816c3148e7bfe3fed4</span></div><a href="/servlet/linkout?suffix=cit54a&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.1937-15.2015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.1937-15.2015%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DM.%26aulast%3DKasanetz%26aufirst%3DF.%26aulast%3DLynch%26aufirst%3DD.%2BL.%26aulast%3DFriemel%26aufirst%3DC.%2BM.%26aulast%3DLassalle%26aufirst%3DO.%26aulast%3DHurst%26aufirst%3DD.%2BP.%26aulast%3DSteindel%26aufirst%3DF.%26aulast%3DMonory%26aufirst%3DK.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DC.%26aulast%3DMiederer%26aufirst%3DI.%26aulast%3DLeweke%26aufirst%3DF.%2BM.%26aulast%3DSchreckenberger%26aufirst%3DM.%26aulast%3DLutz%26aufirst%3DB.%26aulast%3DReggio%26aufirst%3DP.%2BH.%26aulast%3DManzoni%26aufirst%3DO.%2BJ.%26aulast%3DSpanagel%26aufirst%3DR.%26atitle%3DEnhanced%2520functional%2520activity%2520of%2520the%2520cannabinoid%2520type-1%2520receptor%2520mediates%2520adolescent%2520behavior%26jtitle%3DJ.%2520Neurosci.%26date%3D2015%26volume%3D35%26spage%3D13975%26epage%3D13988%26doi%3D10.1523%2FJNEUROSCI.1937-15.2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit54b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramesh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrell, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenbaum, D. M.</span></span> <span> </span><span class="NLM_article-title">Structure of an allosteric modulator bound to the CB1 cannabinoid receptor</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1199</span>– <span class="NLM_lpage">1205</span>, <span class="refDoi"> DOI: 10.1038/s41589-019-0387-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1038%2Fs41589-019-0387-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=31659318" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVCksLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=1199-1205&author=Z.+Shaoauthor=W.+Yanauthor=K.+Chapmanauthor=K.+Rameshauthor=A.+J.+Ferrellauthor=J.+Yinauthor=X.+Wangauthor=Q.+Xuauthor=D.+M.+Rosenbaum&title=Structure+of+an+allosteric+modulator+bound+to+the+CB1+cannabinoid+receptor&doi=10.1038%2Fs41589-019-0387-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54bR"><div class="casContent"><span class="casTitleNuber">54b</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of an allosteric modulator bound to the CB1 cannabinoid receptor</span></div><div class="casAuthors">Shao, Zhenhua; Yan, Wei; Chapman, Karen; Ramesh, Karthik; Ferrell, Aaron J.; Yin, Jie; Wang, Xuehui; Xu, Qingping; Rosenbaum, Daniel M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1199-1205</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The CB1 receptor mediates the central nervous system response to cannabinoids, and is a drug target for pain, anxiety and seizures.  CB1 also responds to allosteric modulators, which influence cannabinoid binding and efficacy.  To understand the mechanism of these compds., we solved the crystal structure of CB1 with the neg. allosteric modulator (NAM) ORG27569 and the agonist CP55940.  The structure reveals that the NAM binds to an extrahelical site within the inner leaflet of the membrane, which overlaps with a conserved site of cholesterol interaction in many G protein-coupled receptors (GPCRs).  The ternary structure with ORG27569 and CP55940 captures an intermediate state of the receptor, in which arom. residues at the base of the agonist-binding pocket adopt an inactive conformation despite the large contraction of the orthosteric pocket.  The structure illustrates a potential strategy for drug modulation of CB1 and other class A GPCRs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqz52KMEDfkTbVg90H21EOLACvtfcHk0lixeiaLgi5Krw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVCksLnM&md5=58150bc1805c874c5dce7ed13fcf7c68</span></div><a href="/servlet/linkout?suffix=cit54b&amp;dbid=16384&amp;doi=10.1038%2Fs41589-019-0387-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41589-019-0387-2%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DZ.%26aulast%3DYan%26aufirst%3DW.%26aulast%3DChapman%26aufirst%3DK.%26aulast%3DRamesh%26aufirst%3DK.%26aulast%3DFerrell%26aufirst%3DA.%2BJ.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DRosenbaum%26aufirst%3DD.%2BM.%26atitle%3DStructure%2520of%2520an%2520allosteric%2520modulator%2520bound%2520to%2520the%2520CB1%2520cannabinoid%2520receptor%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2019%26volume%3D15%26spage%3D1199%26epage%3D1205%26doi%3D10.1038%2Fs41589-019-0387-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Straiker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, K.</span></span> <span> </span><span class="NLM_article-title">Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones</span>. <i>J. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>569</i></span>,  <span class="NLM_fpage">501</span>– <span class="NLM_lpage">517</span>, <span class="refDoi"> DOI: 10.1113/jphysiol.2005.091918</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1113%2Fjphysiol.2005.091918" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=16179366" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsVagug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=569&publication_year=2005&pages=501-517&author=A.+Straikerauthor=K.+Mackie&title=Depolarization-induced+suppression+of+excitation+in+murine+autaptic+hippocampal+neurones&doi=10.1113%2Fjphysiol.2005.091918"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones</span></div><div class="casAuthors">Straiker, Alex; Mackie, Ken</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physiology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">569</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">501-517</span>CODEN:
                <span class="NLM_cas:coden">JPHYA7</span>;
        ISSN:<span class="NLM_cas:issn">0022-3751</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Depolarization-induced suppression of excitation and inhibition (DSE and DSI) appear to be important forms of short-term retrograde neuronal plasticity involving endocannabinoids (eCB) and the activation of presynaptic cannabinoid CB1 receptors.  We report here that CB1-dependent DSE can be elicited from autaptic cultures of excitatory mouse hippocampal neurons.  DSE in autaptic cultures is both more robust and elicited with a more physiol. relevant stimulus than has been thus far reported for conventional hippocampal cultures.  An addnl. requirement for autaptic DSE is filled internal calcium stores.  Pharmacol. expts. favor a role for 2-arachidonyl glycerol (2-AG) rather than arachidonyl ethanolamide (AEA) or Noladin ether as the relevant endocannabinoid to elicit DSE.  In particular, the latter two compds. fail to reversibly inhibit EPSCs, a quality inconsistent with the role of bona fide eCB mediating DSE.  Δ9-Tetrahydrocannabinol (Δ9-THC) fails to inhibit EPSCs, yet readily occludes both DSE and EPSC inhibition by a synthetic CB1 agonist, WIN 55212-2.  With long-term exposure (∼18 h), Δ9-THC also desensitizes CB1 receptors.  Lastly, a functional endocannabinoid transporter is necessary for the expression of DSE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhFvlhyemQq7Vg90H21EOLACvtfcHk0lixeiaLgi5Krw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsVagug%253D%253D&md5=40ce0ec2c297af8d70bcd84db3736e64</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1113%2Fjphysiol.2005.091918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1113%252Fjphysiol.2005.091918%26sid%3Dliteratum%253Aachs%26aulast%3DStraiker%26aufirst%3DA.%26aulast%3DMackie%26aufirst%3DK.%26atitle%3DDepolarization-induced%2520suppression%2520of%2520excitation%2520in%2520murine%2520autaptic%2520hippocampal%2520neurones%26jtitle%3DJ.%2520Physiol.%26date%3D2005%26volume%3D569%26spage%3D501%26epage%3D517%26doi%3D10.1113%2Fjphysiol.2005.091918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cvenkel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolko, M.</span></span> <span> </span><span class="NLM_article-title">Current medical therapy and future trends in the management of glaucoma treatment</span>. <i>J. Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>2020</i></span>, <span class="NLM_elocation-id">6138132</span> <span class="refDoi"> DOI: 10.1155/2020/6138132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1155%2F2020%2F6138132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=32774906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A280%3ADC%252BB38fjsVCkuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2020&publication_year=2020&author=B.+Cvenkelauthor=M.+Kolko&title=Current+medical+therapy+and+future+trends+in+the+management+of+glaucoma+treatment&doi=10.1155%2F2020%2F6138132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Current Medical Therapy and Future Trends in the Management of Glaucoma Treatment</span></div><div class="casAuthors">Cvenkel Barbara; Cvenkel Barbara; Kolko Miriam; Kolko Miriam</div><div class="citationInfo"><span class="NLM_cas:title">Journal of ophthalmology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">2020</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6138132</span>
        ISSN:<span class="NLM_cas:issn">2090-004X</span>.
    </div><div class="casAbstract">Glaucoma is a neurodegenerative disease characterized by progressive loss of retinal ganglion cells and their axons.  Lowering of intraocular pressure (IOP) is currently the only proven treatment strategy for glaucoma.  However, some patients show progressive loss of visual field and quality of life despite controlled IOP which indicates that other factors are implicated in glaucoma.  Therefore, approaches that could prevent or decrease the rate of progression and do not rely on IOP lowering have gained much attention.  Effective neuroprotection has been reported in animal models of glaucoma, but till now, no neuroprotective agents have been clinically approved.  The present update provides an overview of currently available IOP-lowering medications.  Moreover, potential new treatment targets for IOP-lowering and neuroprotective therapy are discussed.  Finally, future trends in glaucoma therapy are addressed, including sustained drug delivery systems and progress toward personalized medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSMFibbL4rTiMuCWE5mhx1RfW6udTcc2eZdgMXPFPoiI7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38fjsVCkuw%253D%253D&md5=36f6ca225337e170e92fbdfe9e9735be</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1155%2F2020%2F6138132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2020%252F6138132%26sid%3Dliteratum%253Aachs%26aulast%3DCvenkel%26aufirst%3DB.%26aulast%3DKolko%26aufirst%3DM.%26atitle%3DCurrent%2520medical%2520therapy%2520and%2520future%2520trends%2520in%2520the%2520management%2520of%2520glaucoma%2520treatment%26jtitle%3DJ.%2520Ophthalmol.%26date%3D2020%26volume%3D2020%26doi%3D10.1155%2F2020%2F6138132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, F. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittag, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podos, S. M.</span></span> <span> </span><span class="NLM_article-title">Effect of WIN 55212-2, a cannabinoid receptor agonist, on aqueous humor dynamics in monkeys</span>. <i>Arch. Ophthalmol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1001/archopht.121.1.87</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1001%2Farchopht.121.1.87" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=12523891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BD3sXps1Kqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2003&pages=87-90&author=F.+Y.+Chienauthor=R.+F.+Wangauthor=T.+W.+Mittagauthor=S.+M.+Podos&title=Effect+of+WIN+55212-2%2C+a+cannabinoid+receptor+agonist%2C+on+aqueous+humor+dynamics+in+monkeys&doi=10.1001%2Farchopht.121.1.87"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57aR"><div class="casContent"><span class="casTitleNuber">57a</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of WIN 55212-2, a cannabinoid receptor agonist, on aqueous humor dynamics in monkeys</span></div><div class="casAuthors">Chien, Fred Y.; Wang, Rong-Fang; Mittag, Thomas W.; Podos, Steven M.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Ophthalmology (Chicago, IL, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-90</span>CODEN:
                <span class="NLM_cas:coden">AROPAW</span>;
        ISSN:<span class="NLM_cas:issn">0003-9950</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">The aim of this study was to evaluate the effects of WIN 55212-2, a cannabinoid receptor agonist, on intraocular pressure and aq. humor dynamics in normal monkeys and monkeys with glaucoma.  Intraocular pressure was measured prior to and up to 6 h after the topical administration of WIN 55212-2 to 1 eye of 5 normal monkeys and to the glaucomatous eye of 8 monkeys with unilateral laser-induced glaucoma.  Tonog. outflow facility and fluorophotometric flow rates of aq. humor were measured in 6 normal monkeys before and after treatment.  In normal monkeys, a single dose of WIN 55212-2 reduced intraocular pressure for 4, 5, or 6 h, with a max. redn. of 1.4±0.4 (mean±SEM) mm Hg, 2.9±0.4 mm Hg, and 3.4±0.6 mm Hg following the 0.07%, 0.2%, and 0.5% concns., resp. (P=.08).  In 8 glaucomatous monkey eyes, the ocular hypotensive effect was maintained for 5 days with twice-daily administration of 0.5% WIN 55212-2.  Outflow facility was unchanged (P=.34) and aq. humor flow was decreased by 18% (P=.04) in the treated eyes compared with vehicle-treated contralateral control eyes in normal monkeys.  WIN 55212-2, a cannabinoid agonist at the CB1 receptor, reduces intraocular pressure in both normal and glaucomatous monkey eyes.  A decrease of aq. flow appears to account for the intraocular pressure redn. in normal monkey eyes.  Cannabinoid agonists at the CB1 receptor, a new class of antiglaucoma agents that is different from currently used clin. drugs, may have clin. potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJOplBIeXYnbVg90H21EOLACvtfcHk0ljAB6nORUQSqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXps1Kqtw%253D%253D&md5=9ef2302217f126972c45800eb190d760</span></div><a href="/servlet/linkout?suffix=cit57a&amp;dbid=16384&amp;doi=10.1001%2Farchopht.121.1.87&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchopht.121.1.87%26sid%3Dliteratum%253Aachs%26aulast%3DChien%26aufirst%3DF.%2BY.%26aulast%3DWang%26aufirst%3DR.%2BF.%26aulast%3DMittag%26aufirst%3DT.%2BW.%26aulast%3DPodos%26aufirst%3DS.%2BM.%26atitle%3DEffect%2520of%2520WIN%252055212-2%252C%2520a%2520cannabinoid%2520receptor%2520agonist%252C%2520on%2520aqueous%2520humor%2520dynamics%2520in%2520monkeys%26jtitle%3DArch.%2520Ophthalmol.%26date%3D2003%26volume%3D121%26spage%3D87%26epage%3D90%26doi%3D10.1001%2Farchopht.121.1.87" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit57b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hodges, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reggio, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, K.</span></span> <span> </span><span class="NLM_article-title">Evidence against cannabinoid receptor involvement in intraocular pressure effects of cannabinoids in rabbits</span>. <i>Ophthalmic Res.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">5</span>, <span class="refDoi"> DOI: 10.1159/000267984</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1159%2F000267984" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=9112260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADyaK2sXis1Kktrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1997&pages=1-5&author=L.+C.+Hodgesauthor=P.+H.+Reggioauthor=K.+Green&title=Evidence+against+cannabinoid+receptor+involvement+in+intraocular+pressure+effects+of+cannabinoids+in+rabbits&doi=10.1159%2F000267984"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57bR"><div class="casContent"><span class="casTitleNuber">57b</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence against cannabinoid receptor involvement in intraocular pressure effects of cannabinoids in rabbits</span></div><div class="casAuthors">Hodges, Linda C.; Reggio, Patricia H.; Green, Keith</div><div class="citationInfo"><span class="NLM_cas:title">Ophthalmic Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-5</span>CODEN:
                <span class="NLM_cas:coden">OPRSAQ</span>;
        ISSN:<span class="NLM_cas:issn">0030-3747</span>.
    
            (<span class="NLM_cas:orgname">Karger</span>)
        </div><div class="casAbstract">A possible cannabinoid receptor involvement of cannabinoids was investigated in the intraocular-pressure (IOP)-lowering effect.  The IOP effect in normotensive rabbits after systemic administration of an aminoalkylindole, WIN-55,212-2, and of (R)-(+)-methanandamide, a hydrolysis-resistant endogenous ligand deriv., was examd.  The decrease in IOP for animals treated with WIN-55,212-2 was marginal and for animals treated with (R)-(+)-methanandamide was negligible.  The IOP-lowering effect of cannabinoids cannot be mediated by a cannabinoid receptor in rabbits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEAHm_NCO19rVg90H21EOLACvtfcHk0ljAB6nORUQSqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXis1Kktrs%253D&md5=90c952537426634a3e04ebe4fead1d3c</span></div><a href="/servlet/linkout?suffix=cit57b&amp;dbid=16384&amp;doi=10.1159%2F000267984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000267984%26sid%3Dliteratum%253Aachs%26aulast%3DHodges%26aufirst%3DL.%2BC.%26aulast%3DReggio%26aufirst%3DP.%2BH.%26aulast%3DGreen%26aufirst%3DK.%26atitle%3DEvidence%2520against%2520cannabinoid%2520receptor%2520involvement%2520in%2520intraocular%2520pressure%2520effects%2520of%2520cannabinoids%2520in%2520rabbits%26jtitle%3DOphthalmic%2520Res.%26date%3D1997%26volume%3D29%26spage%3D1%26epage%3D5%26doi%3D10.1159%2F000267984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beazley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szczesniak, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straiker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, M. E.</span></span> <span> </span><span class="NLM_article-title">Indirect sympatholytic actions at β-adrenoceptors account for the ocular hypotensive actions of cannabinoid receptor agonists</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>339</i></span>,  <span class="NLM_fpage">757</span>– <span class="NLM_lpage">767</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.185769</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1124%2Fjpet.111.185769" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=21885619" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtVSks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=2011&pages=757-767&author=B.+D.+Hudsonauthor=M.+Beazleyauthor=A.+M.+Szczesniakauthor=A.+Straikerauthor=M.+E.+Kelly&title=Indirect+sympatholytic+actions+at+%CE%B2-adrenoceptors+account+for+the+ocular+hypotensive+actions+of+cannabinoid+receptor+agonists&doi=10.1124%2Fjpet.111.185769"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Indirect sympatholytic actions at β-adrenoceptors account for the ocular hypotensive actions of cannabinoid receptor agonists</span></div><div class="casAuthors">Hudson, Brian D.; Beazley, Meggie; Szczesniak, Anna-Maria; Straiker, Alex; Kelly, Melanie E. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">339</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">757-767</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Intraocular pressure (IOP) is the primary risk factor for glaucoma, a blinding eye disease.  Cannabinoid agonists have long been known to decrease IOP, suggesting they may be useful in glaucoma treatment.  However, the specific mechanism by which cannabinoids generate this ocular hypotensive effect remains unknown.  The current evidence suggests the cannabinoids reduce IOP through actions at cannabinoid 1 (CB1) receptors within the eye, and adrenergic receptors (ARs) may also contribute to this action of cannabinoids.  Considering this, the present study aimed to elucidate the mechanism behind the ocular hypotensive properties of cannabinoids through the use of mice genetically lacking either cannabinoid receptors or βARs.  Cannabinoid agonists, βAR antagonists, and βAR agonists decreased IOP in wild-type mice and CB2(-/-) mice.  In contrast, none of these compds. were found to reduce IOP in βAR(-/-) or CB1(-/-) mice.  Desensitization of the βARs and depletion of catecholamines in wild-type mice also eliminated the ability of the cannabinoid agonist (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone mesylate (WIN 55,212-2) to reduce IOP, strongly implicating a role for both βARs and catecholamines in the ocular hypotensive properties of cannabinoids.  Finally, CB1 receptors were shown to colocalize with tyrosine hydroxylase, a marker for adrenergic neurons.  Taken together, these findings suggest that βARs are required for the ocular hypotensive properties of cannabinoids, and cannabinoids reduce IOP by acting as indirect sympatholytics and inhibiting norepinephrine release within the eye.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrz4eDDne9ip7Vg90H21EOLACvtfcHk0lhqL02i-4-9Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtVSks7Y%253D&md5=6a96e5b99beecaa26be1c49e78358d11</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.185769&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.185769%26sid%3Dliteratum%253Aachs%26aulast%3DHudson%26aufirst%3DB.%2BD.%26aulast%3DBeazley%26aufirst%3DM.%26aulast%3DSzczesniak%26aufirst%3DA.%2BM.%26aulast%3DStraiker%26aufirst%3DA.%26aulast%3DKelly%26aufirst%3DM.%2BE.%26atitle%3DIndirect%2520sympatholytic%2520actions%2520at%2520%25CE%25B2-adrenoceptors%2520account%2520for%2520the%2520ocular%2520hypotensive%2520actions%2520of%2520cannabinoid%2520receptor%2520agonists%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D339%26spage%3D757%26epage%3D767%26doi%3D10.1124%2Fjpet.111.185769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laine, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Järvinen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mechoulam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breuer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Järvinen, T.</span></span> <span> </span><span class="NLM_article-title">Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">3216</span>– <span class="NLM_lpage">3222</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=12356827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A280%3ADC%252BD38vpsFCktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2002&pages=3216-3222&author=K.+Laineauthor=K.+J%C3%A4rvinenauthor=R.+Mechoulamauthor=A.+Breuerauthor=T.+J%C3%A4rvinen&title=Comparison+of+the+enzymatic+stability+and+intraocular+pressure+effects+of+2-arachidonylglycerol+and+noladin+ether%2C+a+novel+putative+endocannabinoid"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid</span></div><div class="casAuthors">Laine Krista; Jarvinen Kristiina; Mechoulam Raphael; Breuer Aviva; Jarvinen Tomi</div><div class="citationInfo"><span class="NLM_cas:title">Investigative ophthalmology & visual science</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3216-22</span>
        ISSN:<span class="NLM_cas:issn">0146-0404</span>.
    </div><div class="casAbstract">PURPOSE:  The endogenous cannabinoids N-arachidonylethanolamide (AEA) and 2-arachidonylglycerol (2-AG) are known to decrease intraocular pressure (IOP).  Recently, a novel putative endogenous cannabinoid, noladin ether, was isolated in porcine and rat brains.  In the present study, both the degradation of endogenous cannabinoids in ocular tissues and the effect on IOP of 2-AG and noladin ether were compared.  METHODS:  The rates of enzymatic degradation for AEA, 2-AG, and noladin ether were determined in bovine cornea and iris-ciliary body homogenates. 2-AG and noladin ether were dissolved in either hydroxypropyl-beta-cyclodextrin (HP-beta-CD) or propylene glycol and administered unilaterally to the rabbit eye.  IOPs were measured in the treated and untreated eyes.  The CB1 receptor antagonist AM251 was administered topically 15 minutes before the cannabinoids to investigate whether CB1 receptors mediate the effect on IOP produced by 2-AG and noladin ether.  RESULTS:  Noladin ether degraded more slowly than either 2-AG or AEA in the iris-ciliary body and cornea homogenates.  The effect on IOP of 2-AG was biphasic (i.e., an initial increase in IOP followed by a reduction in the treated eye).  Noladin ether decreased IOP immediately after topical administration, and no initial IOP increase was observed in the treated eye.  The CB1 receptor antagonist AM251 (25 micro g) blocked the effect on IOP of noladin ether but did not affect the action of 2-AG.  CONCLUSIONS:  Topical administration of the novel putative endogenous cannabinoid noladin ether decreased IOP in rabbits.  This IOP reduction was most probably mediated through the CB1 receptor.  The effect on IOP of noladin ether differed from those of the known endogenous cannabinoids AEA and 2-AG, probably because of its more stable chemical structure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAdY8KXZB9SB0LsK7uFuY7fW6udTcc2eYFhkSn6-6FBrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38vpsFCktQ%253D%253D&md5=46611db5d2af4d4fb66c4593d1f32a4a</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLaine%26aufirst%3DK.%26aulast%3DJ%25C3%25A4rvinen%26aufirst%3DK.%26aulast%3DMechoulam%26aufirst%3DR.%26aulast%3DBreuer%26aufirst%3DA.%26aulast%3DJ%25C3%25A4rvinen%26aufirst%3DT.%26atitle%3DComparison%2520of%2520the%2520enzymatic%2520stability%2520and%2520intraocular%2520pressure%2520effects%2520of%25202-arachidonylglycerol%2520and%2520noladin%2520ether%252C%2520a%2520novel%2520putative%2520endocannabinoid%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2002%26volume%3D43%26spage%3D3216%26epage%3D3222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedberg-Buenz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M. G.</span></span> <span> </span><span class="NLM_article-title">Anterior segment dysgenesis and early-onset glaucoma in nee mice with mutation of Sh3pxd2b</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">2679</span>– <span class="NLM_lpage">2688</span>, <span class="refDoi"> DOI: 10.1167/iovs.10-5993</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1167%2Fiovs.10-5993" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=21282566" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmslSqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2011&pages=2679-2688&author=M.+Maoauthor=A.+Hedberg-Buenzauthor=D.+Koehnauthor=S.+W.+Johnauthor=M.+G.+Anderson&title=Anterior+segment+dysgenesis+and+early-onset+glaucoma+in+nee+mice+with+mutation+of+Sh3pxd2b&doi=10.1167%2Fiovs.10-5993"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Anterior segment dysgenesis and early-onset glaucoma in nee mice with mutation of Sh3pxd2b</span></div><div class="casAuthors">Mao, Mao; Hedberg-Buenz, Adam; Koehn, Demelza; John, Simon W. M.; Anderson, Michael G.</div><div class="citationInfo"><span class="NLM_cas:title">Investigative Ophthalmology & Visual Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2679-2688</span>CODEN:
                <span class="NLM_cas:coden">IOVSDA</span>;
        ISSN:<span class="NLM_cas:issn">1552-5783</span>.
    
            (<span class="NLM_cas:orgname">Association for Research in Vision and Ophthalmology</span>)
        </div><div class="casAbstract">PURPOSE: Mutations in SH3PXD2B cause Frank-Ter Haar syndrome, a rare condition characterized by congenital glaucoma, as well as craniofacial, skeletal, and cardiac anomalies.  The nee strain of mice carries a spontaneously arising mutation in Sh3pxd2b.  The purpose of this study was to test whether nee mice develop glaucoma.  METHODS: Eyes of nee mutants and strain-matched controls were comparatively analyzed at multiple ages by slit lamp examn., intraocular pressure recording, and histol. anal.  Cross sections of the optic nerve were analyzed to confirm glaucomatous progression.  RESULTS: Slit lamp examn. showed that, from an early age, nee mice uniformly exhibited severe iridocorneal adhesions around the entire circumference of the eye.  Presumably as a consequence of aq. humor outflow blockage, they rapidly developed multiple indexes of glaucoma.  By 3 to 4 mo of age, they exhibited high intraocular pressure (30.8 ± 12.5 mmHg; mean ± SD), corneal opacity, and enlarged anterior chambers.  Although histol. analyses at P17 did not reveal any indexes of damage, similar anal. at 3 to 4 mo of age revealed a course of progressive retinal ganglion cell loss, optic nerve head excavation, and axon loss.  CONCLUSIONS: Eyes of nee mice exhibit anterior segment dysgenesis and early-onset glaucoma.  Because SH3PXD2B is predicted to be a podosome adaptor protein, these findings implicate podosomes in normal development of the iridocorneal angle and the genes influencing podosomes as candidates in glaucoma.  Because of the early-onset, high-penetrance glaucoma, nee mice offer many potential advantages as a new mouse model of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgj1Mi_HwQyrVg90H21EOLACvtfcHk0lhqL02i-4-9Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmslSqt70%253D&md5=a996b8713e0987b89b2abc3e18b3118a</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1167%2Fiovs.10-5993&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.10-5993%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DM.%26aulast%3DHedberg-Buenz%26aufirst%3DA.%26aulast%3DKoehn%26aufirst%3DD.%26aulast%3DJohn%26aufirst%3DS.%2BW.%26aulast%3DAnderson%26aufirst%3DM.%2BG.%26atitle%3DAnterior%2520segment%2520dysgenesis%2520and%2520early-onset%2520glaucoma%2520in%2520nee%2520mice%2520with%2520mutation%2520of%2520Sh3pxd2b%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2011%26volume%3D52%26spage%3D2679%26epage%3D2688%26doi%3D10.1167%2Fiovs.10-5993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Järvinen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pate, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laine, K.</span></span> <span> </span><span class="NLM_article-title">Cannabinoids in the treatment of glaucoma</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1016/S0163-7258(02)00259-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1016%2FS0163-7258%2802%2900259-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=12182967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BD38XmtlKjsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2002&pages=203-220&author=T.+J%C3%A4rvinenauthor=D.+W.+Pateauthor=K.+Laine&title=Cannabinoids+in+the+treatment+of+glaucoma&doi=10.1016%2FS0163-7258%2802%2900259-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoids in the treatment of glaucoma</span></div><div class="casAuthors">Jarvinen, Tomi; Pate, David W.; Laine, Krista</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">203-220</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review.  The leading cause of irreversible blindness is glaucoma, a disease normally characterized by the development of ocular hypertension and consequent damage to the optic nerve at its point of retinal attachment.  This results in a narrowing of the visual field, and eventually results in blindness.  A no. of drugs are available to lower intraocular pressure (IOP), but, occasionally, they are ineffective or have intolerable side-effects for some patients and can lose efficacy with chronic administration.  The smoking of marijuana has decreased IOP in glaucoma patients.  Cannabinoid drugs, therefore, are thought to have significant potential for pharmaceutical development.  However, as the mechanism surrounding their effect on IOP initially was thought to involve the CNS, issues of psychoactivity hindered progress.  The discovery of ocular cannabinoid receptors implied an explanation for the induction of hypotension by topical cannabinoid applications, and has stimulated a new phase of ophthalmic cannabinoid research.  Featured within these investigations is the possibility that at least some cannabinoids may ameliorate optic neuronal damage through suppression of N-methyl-D-aspartate receptor hyperexcitability, stimulation of neural microcirculation, and the suppression of both apoptosis and damaging free radical reactions, among other mechanisms.  Sepn. of therapeutic actions from side-effects now seems possible through a diverse array of novel chem., pharmacol., and formulation strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZPQjQHx9cVrVg90H21EOLACvtfcHk0ljSP_fe9Sc3aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmtlKjsrs%253D&md5=6237e2d43288e40e6257757283116d02</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2802%2900259-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252802%252900259-0%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25A4rvinen%26aufirst%3DT.%26aulast%3DPate%26aufirst%3DD.%2BW.%26aulast%3DLaine%26aufirst%3DK.%26atitle%3DCannabinoids%2520in%2520the%2520treatment%2520of%2520glaucoma%26jtitle%3DPharmacol.%2520Ther.%26date%3D2002%26volume%3D95%26spage%3D203%26epage%3D220%26doi%3D10.1016%2FS0163-7258%2802%2900259-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cairns, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldridge, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, M. E.</span></span> <span> </span><span class="NLM_article-title">The endocannabinoid system as a therapeutic target in glaucoma</span>. <i>Neural Plast.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2016</i></span>, <span class="NLM_elocation-id">9364091</span> <span class="refDoi"> DOI: 10.1155/2016/9364091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1155%2F2016%2F9364091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=26881140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A280%3ADC%252BC28jhtVymuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2016&publication_year=2016&author=E.+A.+Cairnsauthor=W.+H.+Baldridgeauthor=M.+E.+Kelly&title=The+endocannabinoid+system+as+a+therapeutic+target+in+glaucoma&doi=10.1155%2F2016%2F9364091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">The Endocannabinoid System as a Therapeutic Target in Glaucoma</span></div><div class="casAuthors">Cairns Elizabeth A; Baldridge William H; Kelly Melanie E M</div><div class="citationInfo"><span class="NLM_cas:title">Neural plasticity</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2016</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9364091</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Glaucoma is an irreversible blinding eye disease which produces progressive retinal ganglion cell (RGC) loss.  Intraocular pressure (IOP) is currently the only modifiable risk factor, and lowering IOP results in reduced risk of progression of the disorder.  The endocannabinoid system (ECS) has attracted considerable attention as a potential target for the treatment of glaucoma, largely due to the observed IOP lowering effects seen after administration of exogenous cannabinoids.  However, recent evidence has suggested that modulation of the ECS may also be neuroprotective.  This paper will review the use of cannabinoids in glaucoma, presenting pertinent information regarding the pathophysiology of glaucoma and how alterations in cannabinoid signalling may contribute to glaucoma pathology.  Additionally, the mechanisms and potential for the use of cannabinoids and other novel agents that target the endocannabinoid system in the treatment of glaucoma will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRRFS7HBs9MUmLFM_lbR1VmfW6udTcc2eZYbIYSR4myNrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jhtVymuw%253D%253D&md5=ee545657c1713957eee166b3ebcf8fdb</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1155%2F2016%2F9364091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2016%252F9364091%26sid%3Dliteratum%253Aachs%26aulast%3DCairns%26aufirst%3DE.%2BA.%26aulast%3DBaldridge%26aufirst%3DW.%2BH.%26aulast%3DKelly%26aufirst%3DM.%2BE.%26atitle%3DThe%2520endocannabinoid%2520system%2520as%2520a%2520therapeutic%2520target%2520in%2520glaucoma%26jtitle%3DNeural%2520Plast.%26date%3D2016%26volume%3D2016%26doi%3D10.1155%2F2016%2F9364091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gamage, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abood, M. E.</span></span> <span> </span><span class="NLM_article-title">CB(1) allosteric modulator Org27569 is an antagonist/inverse agonist of ERK1/2 signaling</span>. <i>Cannabis Cannabinoid Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">272</span>– <span class="NLM_lpage">280</span>, <span class="refDoi"> DOI: 10.1089/can.2016.0028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1089%2Fcan.2016.0028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=28660254" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC1MXkslGntLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2016&pages=272-280&author=T.+F.+Gamageauthor=J.+C.+Andersonauthor=M.+E.+Abood&title=CB%281%29+allosteric+modulator+Org27569+is+an+antagonist%2Finverse+agonist+of+ERK1%2F2+signaling&doi=10.1089%2Fcan.2016.0028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">CB1 allosteric modulator Org27569 is an antagonist/inverse agonist of ERK1/2 signaling</span></div><div class="casAuthors">Gamage, Thomas F.; Anderson, Johnathon C.; Abood, Mary E.</div><div class="citationInfo"><span class="NLM_cas:title">Cannabis and Cannabinoid Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">272-280</span>CODEN:
                <span class="NLM_cas:coden">CCRAEP</span>;
        ISSN:<span class="NLM_cas:issn">2378-8763</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Allosteric modulation of cannabinoid type-1 receptors (CB1) is a novel means through which signaling bias may be exerted.  Org27569 remains the most-characterized CB1 allosteric modulator, yet there are conflicting reports regarding its effects on extracellular signal-regulated kinase (ERK) signaling.  We conducted a systematic evaluation of Org27569's effects on cannabinoid agonists and ERK signaling.  HEK293 cells transfected with the human cannabinoid type-1 receptor (hCB1) were treated with Org27569 alone or in combination with the endocannabinoid 2-arachidonoylglycerol (2-AG), the synthetic cannabinoid CP55,940, or the phytocannabinoid delta-9-tetrahydrocannabinol (THC) and ERK activation was measured by western blot.  Overnight treatment with pertussis toxin (PTX) was used to det. the role of Gi/o in Org27569's inverse agonist effects.  HEK293 cells transfected with green fluorescent protein tagged hCB1 receptor were used to assess effects of Org27569 on CP55,940-induced receptor internalization.  Subcellular fractionation was used to det. effects of Org27569 on ERK phosphorylation in both nuclear and cytosolic compartments.  We found that Org27569 is an antagonist of hCB1-mediated ERK signaling in HEK293 cells where it fully blocks CP55,940-but does not completely inhibit THC- and 2-AG-stimulated ERK1/2 activation following 5 min treatment.  In hCB1 HEK293 cells, CP55,940 (1 μM) treatment produced a significant increase in puncta at 20, 40, 60, and 120 min, consistent with receptor internalization.  Org27569 (10 μM) co-treatment prevented internalization at each time point and alone had no effect.  Org27569 reduced basal ERK phosphorylation in hCB1 HEK293 cells but not in untransfected cells following 20 min treatment.  Overnight treatment with PTX abated this response.  Following subcellular fractionation, Org27569 produced a significant decrease in ERK phosphorylation in the nuclear-enriched and cytosolic fractions.  These data are consistent with previous studies demonstrating that CB1-mediated ERK1/2 activation is Gi/o-dependent and that Org27569 is an inverse agonist of CB1 receptors.  Abrogation of Org27569's ability to reduce basal ERK phosphorylation following treatment with PTX and lack of inverse agonist effects in untransfected HEK293 cells demonstrates that Org27569 acts via CB1-Gi/o to produce this effect.  To our knowledge, this is the first reported demonstration of inverse agonism of ERK signaling by Org27569.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqBloG3aPcHrVg90H21EOLACvtfcHk0ljSP_fe9Sc3aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXkslGntLo%253D&md5=36afa6bf4fe1821e54a5dc662d20891b</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1089%2Fcan.2016.0028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fcan.2016.0028%26sid%3Dliteratum%253Aachs%26aulast%3DGamage%26aufirst%3DT.%2BF.%26aulast%3DAnderson%26aufirst%3DJ.%2BC.%26aulast%3DAbood%26aufirst%3DM.%2BE.%26atitle%3DCB%25281%2529%2520allosteric%2520modulator%2520Org27569%2520is%2520an%2520antagonist%252Finverse%2520agonist%2520of%2520ERK1%252F2%2520signaling%26jtitle%3DCannabis%2520Cannabinoid%2520Res.%26date%3D2016%26volume%3D1%26spage%3D272%26epage%3D280%26doi%3D10.1089%2Fcan.2016.0028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abood, M. E.</span></span> <span> </span><span class="NLM_article-title">Mutation of a highly conserved aspartate residue in the second transmembrane domain of the cannabinoid receptors, CB1 and CB2, disrupts G-protein coupling</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">651</span>– <span class="NLM_lpage">658</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=9580609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADyaK1cXjtF2gu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=1998&pages=651-658&author=Q.+Taoauthor=M.+E.+Abood&title=Mutation+of+a+highly+conserved+aspartate+residue+in+the+second+transmembrane+domain+of+the+cannabinoid+receptors%2C+CB1+and+CB2%2C+disrupts+G-protein+coupling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Mutation of a highly conserved aspartate residue in the second transmembrane domain of the cannabinoid receptors, CB1 and CB2, disrupts G-protein coupling</span></div><div class="casAuthors">Tao, Qing; Abood, Mary E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">651-658</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The cannabinoid receptors, CB1 and CB2, are members of the G-protein coupled receptor family and share many of this family's structural features.  A highly conserved aspartic acid residue in the second transmembrane domain of G-protein coupled receptors has been shown for many of these receptors to be functionally important for agonist binding and/or G-protein coupling.  To det. whether this residue is involved in cannabinoid receptor function, we used site-directed mutagenesis of receptor cDNA followed by expression of the mutant receptor in HEK 293 cells.  Aspartate 163 (in CB1) and aspartate 80 (in CB2) were substituted with either asparagine or glutamate.  Stably transfected cell lines were tested for radioligand binding and inhibition of cAMP accumulation.  Binding of the cannabinoid receptor agonist [3H]CP-55,940 was not affected by either mutation in either the CB1 or CB2 receptor, nor were the affinities of anandamide or (-)-Δ9-tetrahydrocannabinol.  Binding of the CB1-selective receptor antagonist SR141716A also was unaltered.  However, the affinity of WIN 55,212-2 was attenuated significantly in the CB1, but not the CB2, mutant receptors.  Studies examg. inhibition of cAMP accumulation showed reduced effects of cannabinoid agonists in the mutated receptors.  Our data suggest that this aspartate residue is not generally important for ligand recognition in the cannabinoid receptors; however, it is required for communication with G proteins and signal transduction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIV5bwm7yRiLVg90H21EOLACvtfcHk0ljziyEkMbFg7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjtF2gu7w%253D&md5=4a99aa57ccb002fc02e301400d439da8</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTao%26aufirst%3DQ.%26aulast%3DAbood%26aufirst%3DM.%2BE.%26atitle%3DMutation%2520of%2520a%2520highly%2520conserved%2520aspartate%2520residue%2520in%2520the%2520second%2520transmembrane%2520domain%2520of%2520the%2520cannabinoid%2520receptors%252C%2520CB1%2520and%2520CB2%252C%2520disrupts%2520G-protein%2520coupling%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1998%26volume%3D285%26spage%3D651%26epage%3D658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miess, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gondin, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yousuf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinborn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mösslein, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Göldner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruland, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bünemann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krasel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halls, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canals, M.</span></span> <span> </span><span class="NLM_article-title">Multisite phosphorylation is required for sustained interaction with GRKs and arrestins during rapid μ-opioid receptor desensitization</span>. <i>Sci. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">eaas9609</span> <span class="refDoi"> DOI: 10.1126/scisignal.aas9609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1126%2Fscisignal.aas9609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=30018083" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&author=E.+Miessauthor=A.+B.+Gondinauthor=A.+Yousufauthor=R.+Steinbornauthor=N.+M%C3%B6ssleinauthor=Y.+Yangauthor=M.+G%C3%B6ldnerauthor=J.+G.+Rulandauthor=M.+B%C3%BCnemannauthor=C.+Kraselauthor=M.+J.+Christieauthor=M.+L.+Hallsauthor=S.+Schulzauthor=M.+Canals&title=Multisite+phosphorylation+is+required+for+sustained+interaction+with+GRKs+and+arrestins+during+rapid+%CE%BC-opioid+receptor+desensitization&doi=10.1126%2Fscisignal.aas9609"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.aas9609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.aas9609%26sid%3Dliteratum%253Aachs%26aulast%3DMiess%26aufirst%3DE.%26aulast%3DGondin%26aufirst%3DA.%2BB.%26aulast%3DYousuf%26aufirst%3DA.%26aulast%3DSteinborn%26aufirst%3DR.%26aulast%3DM%25C3%25B6sslein%26aufirst%3DN.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DG%25C3%25B6ldner%26aufirst%3DM.%26aulast%3DRuland%26aufirst%3DJ.%2BG.%26aulast%3DB%25C3%25BCnemann%26aufirst%3DM.%26aulast%3DKrasel%26aufirst%3DC.%26aulast%3DChristie%26aufirst%3DM.%2BJ.%26aulast%3DHalls%26aufirst%3DM.%2BL.%26aulast%3DSchulz%26aufirst%3DS.%26aulast%3DCanals%26aufirst%3DM.%26atitle%3DMultisite%2520phosphorylation%2520is%2520required%2520for%2520sustained%2520interaction%2520with%2520GRKs%2520and%2520arrestins%2520during%2520rapid%2520%25CE%25BC-opioid%2520receptor%2520desensitization%26jtitle%3DSci.%2520Signaling%26date%3D2018%26volume%3D11%26doi%3D10.1126%2Fscisignal.aas9609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R. G.</span></span> <span> </span><span class="NLM_article-title">The ring test: a quantitative method for assessing the ‘cataleptic’ effect of cannabis in mice</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1972</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">753</span>– <span class="NLM_lpage">763</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.1972.tb06900.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1111%2Fj.1476-5381.1972.tb06900.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=4655271" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADyaE3sXms1Oltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=1972&pages=753-763&author=R.+G.+Pertwee&title=The+ring+test%3A+a+quantitative+method+for+assessing+the+%E2%80%98cataleptic%E2%80%99+effect+of+cannabis+in+mice&doi=10.1111%2Fj.1476-5381.1972.tb06900.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Ring test.  Quantitative method for assessing the cataleptic effect of cannabis in mice</span></div><div class="casAuthors">Pertwee, R. G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1972</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">753-63</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    </div><div class="casAbstract">The length of time a mouse remained completely immobile when placed in a prone position across a horizontally suspended wire ring 5.5 cm in diam. could be used to assess the cataleptic effect of cannabis.  The effect of cannabis on motility was a dose-related, graded response.  Threshold doses of cannabis ext. were 12.5 mg per kg when injected i.v. and 100 mg per kg when injected i.p. or s.c.  Characteristic changes in behavior on the ring induced by cannabis ext. were also produced by chlorpromazine-HCl, but not by Na barbitone.  Δ1-Tetrahydrocannabinol (THC) [1972-08-3] was largely responsible for the effect of cannabis ext. on motility; the potency ratio of THC to cannabis ext. was between 10 and 20.  Δ1-Tetrahydrocannabidivarol [31262-37-0] also affected mobility but was less active than THC.  Cannabidiol [13956-29-1] had no effect, even at doses up to 100 mg per kg, i.p.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2Lm_ZL8Wp5rVg90H21EOLACvtfcHk0ljziyEkMbFg7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE3sXms1Oltg%253D%253D&md5=e3ed3a63360b54de7f394e1afb399328</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1972.tb06900.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1972.tb06900.x%26sid%3Dliteratum%253Aachs%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26atitle%3DThe%2520ring%2520test%253A%2520a%2520quantitative%2520method%2520for%2520assessing%2520the%2520%25E2%2580%2598cataleptic%25E2%2580%2599%2520effect%2520of%2520cannabis%2520in%2520mice%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1972%26volume%3D46%26spage%3D753%26epage%3D763%26doi%3D10.1111%2Fj.1476-5381.1972.tb06900.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ignatowska-Jankowska, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinsey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damaj, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poklis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiley, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanato, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greig, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtman, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, R. A.</span></span> <span> </span><span class="NLM_article-title">A cannabinoid cb1 receptor-positive allosteric modulator reduces neuropathic pain in the mouse with no psychoactive effects</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2948</span>– <span class="NLM_lpage">2959</span>, <span class="refDoi"> DOI: 10.1038/npp.2015.148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1038%2Fnpp.2015.148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=26052038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Chu7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2015&pages=2948-2959&author=B.+M.+Ignatowska-Jankowskaauthor=G.+L.+Baillieauthor=S.+Kinseyauthor=M.+Croweauthor=S.+Ghoshauthor=R.+A.+Owensauthor=I.+M.+Damajauthor=J.+Poklisauthor=J.+L.+Wileyauthor=M.+Zandaauthor=C.+Zanatoauthor=I.+R.+Greigauthor=A.+H.+Lichtmanauthor=R.+A.+Ross&title=A+cannabinoid+cb1+receptor-positive+allosteric+modulator+reduces+neuropathic+pain+in+the+mouse+with+no+psychoactive+effects&doi=10.1038%2Fnpp.2015.148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">A Cannabinoid CB1 Receptor-Positive Allosteric Modulator Reduces Neuropathic Pain in the Mouse with No Psychoactive Effects</span></div><div class="casAuthors">Ignatowska-Jankowska, Bogna M.; Baillie, Gemma L.; Kinsey, Steven; Crowe, Molly; Ghosh, Sudeshna; Owens, Robert A.; Damaj, Imad M.; Poklis, Justin; Wiley, Jenny L.; Zanda, Matteo; Zanato, Chiara; Greig, Iain R.; Lichtman, Aron H.; Ross, Ruth A.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2948-2959</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The CB1 receptor represents a promising target for the treatment of several disorders including pain-related disease states.  However, therapeutic applications of Δ9-tetrahydrocannabinol and other CB1 orthosteric receptor agonists remain limited because of psychoactive side effects.  Pos. allosteric modulators (PAMs) offer an alternative approach to enhance CB1 receptor function for therapeutic gain with the promise of reduced side effects.  Here we describe the development of the novel synthetic CB1 PAM, 6-methyl-3-(2-nitro-1-(thiophen-2-yl)ethyl)-2-phenyl-1H-indole (ZCZ011), which augments the in vitro and in vivo pharmacol. actions of the CB1 orthosteric agonists CP55,940 and N-arachidonoylethanolamine (AEA).  ZCZ011 potentiated binding of [3H]CP55,940 to the CB1 receptor as well as enhancing AEA-stimulated [35S]GTPγS binding in mouse brain membranes and β-arrestin recruitment and ERK phosphorylation in hCB1 cells.  In the whole animal, ZCZ011 is brain penetrant, increased the potency of these orthosteric agonists in mouse behavioral assays indicative of cannabimimetic activity, including antinociception, hypothermia, catalepsy, locomotor activity, and in the drug discrimination paradigm.  Administration of ZCZ011 alone was devoid of activity in these assays and did not produce a conditioned place preference or aversion, but elicited CB1 receptor-mediated antinociceptive effects in the chronic constriction nerve injury model of neuropathic pain and carrageenan model of inflammatory pain.  These data suggest that ZCZ011 acts as a CB1 PAM and provide the first proof of principle that CB1 PAMs offer a promising strategy to treat neuropathic and inflammatory pain with minimal or no cannabimimetic side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGrwc1SxmigLVg90H21EOLACvtfcHk0ljziyEkMbFg7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Chu7jI&md5=353f294dc5044468997e98fb49711abf</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2015.148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2015.148%26sid%3Dliteratum%253Aachs%26aulast%3DIgnatowska-Jankowska%26aufirst%3DB.%2BM.%26aulast%3DBaillie%26aufirst%3DG.%2BL.%26aulast%3DKinsey%26aufirst%3DS.%26aulast%3DCrowe%26aufirst%3DM.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DOwens%26aufirst%3DR.%2BA.%26aulast%3DDamaj%26aufirst%3DI.%2BM.%26aulast%3DPoklis%26aufirst%3DJ.%26aulast%3DWiley%26aufirst%3DJ.%2BL.%26aulast%3DZanda%26aufirst%3DM.%26aulast%3DZanato%26aufirst%3DC.%26aulast%3DGreig%26aufirst%3DI.%2BR.%26aulast%3DLichtman%26aufirst%3DA.%2BH.%26aulast%3DRoss%26aufirst%3DR.%2BA.%26atitle%3DA%2520cannabinoid%2520cb1%2520receptor-positive%2520allosteric%2520modulator%2520reduces%2520neuropathic%2520pain%2520in%2520the%2520mouse%2520with%2520no%2520psychoactive%2520effects%26jtitle%3DNeuropsychopharmacology%26date%3D2015%26volume%3D40%26spage%3D2948%26epage%3D2959%26doi%3D10.1038%2Fnpp.2015.148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grim, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiley, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endres, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negus, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtman, A. H.</span></span> <span> </span><span class="NLM_article-title">Apparent CB(1) receptor rimonabant affinity estimates: combination with thc and synthetic cannabinoids in the mouse in vivo triad model</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>362</i></span>,  <span class="NLM_fpage">210</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.1124/jpet.117.240192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1124%2Fjpet.117.240192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=28442584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFOqsb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2017&pages=210-218&author=T.+W.+Grimauthor=A.+J.+Moralesauthor=B.+F.+Thomasauthor=J.+L.+Wileyauthor=G.+W.+Endresauthor=S.+S.+Negusauthor=A.+H.+Lichtman&title=Apparent+CB%281%29+receptor+rimonabant+affinity+estimates%3A+combination+with+thc+and+synthetic+cannabinoids+in+the+mouse+in+vivo+triad+model&doi=10.1124%2Fjpet.117.240192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Apparent CB1 Receptor rimonabant affinity estimates: combination with THC and synthetic cannabinoids in the mouse in vivo triad model</span></div><div class="casAuthors">Grim, T. W.; Morales, A. J.; Thomas, B. F.; Wiley, J. L.; Endres, G. W.; Negus, S. S.; Lichtman, A. H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">362</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">210-218</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Synthetic cannabinoids (SCs) represent an emerging class of abused drugs assocd. with psychiatric complications and other substantial health risks.  These ligands are largely sold over the internet for human consumption, presumably because of their high cannabinoid 1 receptor (CB1R) affinity and their potency in eliciting pharmacol. effects similar to Δ9-tetrahydrocannabinol (THC), as well as circumventing laws illegalizing this plant.  Factors potentially contributing to the increased prevalence of SC abuse and related hospitalizations, such as increased CB1R efficacy and non-CB1R targets, highlight the need for quant. pharmacol. analyses to det. receptor mediation of the pharmacol. effects of cannabinoids.  Accordingly, the present study used pA2 and pKB analyses for quant. detn. of CB1R mediation in which we utilized the CB1R-selective inverse agonist/antagonist rimonabant to elicit rightward shifts in the dose-response curves of five SCs (i.e., A-834,735D; WIN55,212-2; CP55,950; JWH-073; and CP47,497) and THC in producing common cannabimimetic effects (i.e., catalepsy, antinociception, and hypothermia).  The results revealed overall similarity of pA2 and pKB values for these compds. and suggest that CB1Rs, and not other pharmacol. targets, largely mediated the central pharmacol. effects of SCs.  More generally, affinity estn. offers a powerful pharmacol. approach to assess potential receptor heterogeneity subserving in vivo pharmacol. effects of SCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVV1fny3iBx7Vg90H21EOLACvtfcHk0lh_KN5ouBtevA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFOqsb3L&md5=3d8f408cdc6911b513e1f303b799fe95</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1124%2Fjpet.117.240192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.117.240192%26sid%3Dliteratum%253Aachs%26aulast%3DGrim%26aufirst%3DT.%2BW.%26aulast%3DMorales%26aufirst%3DA.%2BJ.%26aulast%3DThomas%26aufirst%3DB.%2BF.%26aulast%3DWiley%26aufirst%3DJ.%2BL.%26aulast%3DEndres%26aufirst%3DG.%2BW.%26aulast%3DNegus%26aufirst%3DS.%2BS.%26aulast%3DLichtman%26aufirst%3DA.%2BH.%26atitle%3DApparent%2520CB%25281%2529%2520receptor%2520rimonabant%2520affinity%2520estimates%253A%2520combination%2520with%2520thc%2520and%2520synthetic%2520cannabinoids%2520in%2520the%2520mouse%2520in%2520vivo%2520triad%2520model%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D362%26spage%3D210%26epage%3D218%26doi%3D10.1124%2Fjpet.117.240192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bekkers, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, C. F.</span></span> <span> </span><span class="NLM_article-title">Excitatory and inhibitory autaptic currents in isolated hippocampal neurons maintained in cell culture</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">7834</span>– <span class="NLM_lpage">7838</span>, <span class="refDoi"> DOI: 10.1073/pnas.88.17.7834</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1073%2Fpnas.88.17.7834" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1679238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A280%3ADyaK3Mzlt1Srtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=1991&pages=7834-7838&author=J.+M.+Bekkersauthor=C.+F.+Stevens&title=Excitatory+and+inhibitory+autaptic+currents+in+isolated+hippocampal+neurons+maintained+in+cell+culture&doi=10.1073%2Fpnas.88.17.7834"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Excitatory and inhibitory autaptic currents in isolated hippocampal neurons maintained in cell culture</span></div><div class="casAuthors">Bekkers J M; Stevens C F</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7834-8</span>
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Individual rat hippocampal neurons, grown in isolation from other neurons on small spots of permissive substrate, were studied in order to characterize the electrical properties of the synapses that such cells formed with themselves (autapses).  Excitatory (probably glutamatergic) or inhibitory (probably type A gamma-aminobutyratergic) autapses were frequently found.  Excitatory autaptic currents reversed near the potential expected for monovalent cations were blocked by the glutamatergic antagonist kynurenic acid, and possessed a slow component with the pharmacological profile of N-methyl-D-aspartate-type channels.  These currents also exhibited trial-to-trial statistical fluctuations in their amplitudes, this being well-described by quantal analysis.  Inhibitory autaptic currents reversed at hyperpolarized potentials, as expected for chloride-permeable pores and were blocked by picrotoxin, a type A gamma-aminobutyric receptor antagonist.  It is concluded that autaptic currents in culture are identical to those found at synapses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQhZyx5UjrkLNTiMd2aNQVUfW6udTcc2ebwud0NisoHdrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3Mzlt1Srtw%253D%253D&md5=27a067146b950d6a65dc4038a97da464</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1073%2Fpnas.88.17.7834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.88.17.7834%26sid%3Dliteratum%253Aachs%26aulast%3DBekkers%26aufirst%3DJ.%2BM.%26aulast%3DStevens%26aufirst%3DC.%2BF.%26atitle%3DExcitatory%2520and%2520inhibitory%2520autaptic%2520currents%2520in%2520isolated%2520hippocampal%2520neurons%2520maintained%2520in%2520cell%2520culture%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1991%26volume%3D88%26spage%3D7834%26epage%3D7838%26doi%3D10.1073%2Fpnas.88.17.7834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furshpan, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLeish, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Lague, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, D. D.</span></span> <span> </span><span class="NLM_article-title">Chemical transmission between rat sympathetic neurons and cardiac myocytes developing in microcultures: evidence for cholinergic, adrenergic, and dual-function neurons</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">4225</span>– <span class="NLM_lpage">4229</span>, <span class="refDoi"> DOI: 10.1073/pnas.73.11.4225</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1073%2Fpnas.73.11.4225" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=186792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADyaE2sXktV2ntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1976&pages=4225-4229&author=E.+J.+Furshpanauthor=P.+R.+MacLeishauthor=P.+H.+O%E2%80%99Lagueauthor=D.+D.+Potter&title=Chemical+transmission+between+rat+sympathetic+neurons+and+cardiac+myocytes+developing+in+microcultures%3A+evidence+for+cholinergic%2C+adrenergic%2C+and+dual-function+neurons&doi=10.1073%2Fpnas.73.11.4225"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical transmission between rat sympathetic neurons and cardiac myocytes developing in microcultures:  Evidence for cholinergic, adrenergic, and dual-function neurons</span></div><div class="casAuthors">Furshpan, E. J.; MacLeish, P. R.; O'Lague, P. H.; Potter, D. D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4225-9</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Electrophysiol. studies were made on microcultures (300-500 μm in diameter) in which solitary sympathetic principal neurons from newborn rats grew on previously dissocd. rat heart cells.  Some neurons inhibited, some excited, and others 1st inhibited and then excited the cardiac myocytes.  Application of drugs provided evidence for the secretion of acetylcholine by the 1st group, catecholamines by the 2nd, and both acetylcholine and catecholamines by the 3rd.  Solitary neurons which inhibited the myocytes usually excited themselves at nicotinic synapses (autapses).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgFtcbbCa32bVg90H21EOLACvtfcHk0lhmAjwzYZlzgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXktV2ntg%253D%253D&md5=627484d1d91c7ec1168d90d7d48ef507</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1073%2Fpnas.73.11.4225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.73.11.4225%26sid%3Dliteratum%253Aachs%26aulast%3DFurshpan%26aufirst%3DE.%2BJ.%26aulast%3DMacLeish%26aufirst%3DP.%2BR.%26aulast%3DO%25E2%2580%2599Lague%26aufirst%3DP.%2BH.%26aulast%3DPotter%26aufirst%3DD.%2BD.%26atitle%3DChemical%2520transmission%2520between%2520rat%2520sympathetic%2520neurons%2520and%2520cardiac%2520myocytes%2520developing%2520in%2520microcultures%253A%2520evidence%2520for%2520cholinergic%252C%2520adrenergic%252C%2520and%2520dual-function%2520neurons%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1976%26volume%3D73%26spage%3D4225%26epage%3D4229%26doi%3D10.1073%2Fpnas.73.11.4225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levison, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, K. D.</span></span> <span> </span><span class="NLM_article-title">Characterization and partial purification of AIM: a plasma protein that induces rat cerebral type 2 astroglia from bipotential glial progenitors</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">782</span>– <span class="NLM_lpage">794</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.1991.tb08220.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1111%2Fj.1471-4159.1991.tb08220.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1861150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADyaK3MXlt1ynu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1991&pages=782-794&author=S.+W.+Levisonauthor=K.+D.+McCarthy&title=Characterization+and+partial+purification+of+AIM%3A+a+plasma+protein+that+induces+rat+cerebral+type+2+astroglia+from+bipotential+glial+progenitors&doi=10.1111%2Fj.1471-4159.1991.tb08220.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization and partial purification of AIM:  a plasma protein that induces rat cerebral type 2 astroglia from bipotential glial progenitors</span></div><div class="casAuthors">Levison, Steven W.; McCarthy, Ken D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">782-94</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    </div><div class="casAbstract">Studies on glial cultures have demonstrated that fetal bovine serum contains a factor that induces bipotential glial precursors known as oligodendrocyte-type 2 astrocyte (O-2A) progenitors to become type 2 astroglia rather than oligodendroglia.  The goal of this research was to characterize and purify this factor, termed the astroglia-inducing mol. (AIM).  The use of cultures enriched in O-2A progenitors indicated that AIM is present in human and bovine sera and that fetal bovine serum qualified as the best serum for purifying AIM.  AIM is heat and trypsin labile and may be a plasma glycoprotein.  A 240-fold enriched AIM prepn. was produced by applying an (NH4)2SO4 ppt. of fetal bovine serum to heparin and then lentil lectin-agarose, followed by gel filtration chromatog.  In crude prepns., AIM activity migrated at 50 kDa by gel filtration.  With enrichment, activity was seen at several mol. masses, all of which were approx. multiples of 50 kDa.  Treatment with 6 M guanidine-HCl generated an AIM with a mol. mass between 12 and 18 kDa, a result suggesting that AIM aggregates.  On a preparative isoelec. focusing gel, AIM activity most frequently migrated between pH values of 3 and 4; however, proteins with isoelec. points of >9 or at 6 also had activity in several expts.  These data suggest that either multiple AIMs exist or a single AIM exists that assocs. with other proteins.  Immunofluorescence for ganglioside GD3 and glial fibrillary acidic protein confirmed that AIM prepns. induce type 2 astroglia from O-2A progenitors and suggests that AIM has little effect on type 1 astroglia.  None of the known growth factors that have been tested to date mimics its effects, so AIM may be a novel differentiation factor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRq9szkAlHpLVg90H21EOLACvtfcHk0lhmAjwzYZlzgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXlt1ynu7g%253D&md5=2cd50a1094f8e42552919e9987518ebc</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.1991.tb08220.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.1991.tb08220.x%26sid%3Dliteratum%253Aachs%26aulast%3DLevison%26aufirst%3DS.%2BW.%26aulast%3DMcCarthy%26aufirst%3DK.%2BD.%26atitle%3DCharacterization%2520and%2520partial%2520purification%2520of%2520AIM%253A%2520a%2520plasma%2520protein%2520that%2520induces%2520rat%2520cerebral%2520type%25202%2520astroglia%2520from%2520bipotential%2520glial%2520progenitors%26jtitle%3DJ.%2520Neurochem.%26date%3D1991%26volume%3D57%26spage%3D782%26epage%3D794%26doi%3D10.1111%2Fj.1471-4159.1991.tb08220.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bochevarov, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwood, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braden, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philipp, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinaldo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halls, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friesner, R. A.</span></span> <span> </span><span class="NLM_article-title">Jaguar: A high-performance quantum chemistry software program with strengths in life and materials sciences</span>. <i>Int. J. Quantum Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">2110</span>– <span class="NLM_lpage">2142</span>, <span class="refDoi"> DOI: 10.1002/qua.24481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1002%2Fqua.24481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVCqs7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2013&pages=2110-2142&author=A.+D.+Bochevarovauthor=E.+Harderauthor=T.+F.+Hughesauthor=J.+R.+Greenwoodauthor=D.+A.+Bradenauthor=D.+M.+Philippauthor=D.+Rinaldoauthor=M.+D.+Hallsauthor=J.+Zhangauthor=R.+A.+Friesner&title=Jaguar%3A+A+high-performance+quantum+chemistry+software+program+with+strengths+in+life+and+materials+sciences&doi=10.1002%2Fqua.24481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Jaguar: A high-performance quantum chemistry software program with strengths in life and materials sciences</span></div><div class="casAuthors">Bochevarov, Art D.; Harder, Edward; Hughes, Thomas F.; Greenwood, Jeremy R.; Braden, Dale A.; Philipp, Dean M.; Rinaldo, David; Halls, Mathew D.; Zhang, Jing; Friesner, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Quantum Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2110-2142</span>CODEN:
                <span class="NLM_cas:coden">IJQCB2</span>;
        ISSN:<span class="NLM_cas:issn">0020-7608</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Jaguar is an ab initio quantum chem. program that specializes in fast electronic structure predictions for mol. systems of medium and large size.  Jaguar focuses on computational methods with reasonable computational scaling with the size of the system, such as d. functional theory (DFT) and local second-order Moller-Plesset perturbation theory.  The favorable scaling of the methods and the high efficiency of the program make it possible to conduct routine computations involving several thousand MOs.  This performance is achieved through a utilization of the pseudospectral approxn. and several levels of parallelization.  The speed advantages are beneficial for applying Jaguar in biomol. computational modeling.  Addnl., owing to its superior wave function guess for transition-metal-contg. systems, Jaguar finds applications in inorg. and bioinorg. chem.  The emphasis on larger systems and transition metal elements paves the way toward developing Jaguar for its use in materials science modeling.  The article describes the historical and new features of Jaguar, such as improved parallelization of many modules, innovations in ab initio pKa prediction, and new semiempirical corrections for nondynamic correlation errors in DFT.  Jaguar applications in drug discovery, materials science, force field parameterization, and other areas of computational research are reviewed.  Timing benchmarks and other results obtained from the most recent Jaguar code are provided.  The article concludes with a discussion of challenges and directions for future development of the program. © 2013 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt_0dnCf0Yq7Vg90H21EOLACvtfcHk0lhmAjwzYZlzgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVCqs7%252FP&md5=2fc119bb9e0501e55d7292f7735c24ea</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1002%2Fqua.24481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fqua.24481%26sid%3Dliteratum%253Aachs%26aulast%3DBochevarov%26aufirst%3DA.%2BD.%26aulast%3DHarder%26aufirst%3DE.%26aulast%3DHughes%26aufirst%3DT.%2BF.%26aulast%3DGreenwood%26aufirst%3DJ.%2BR.%26aulast%3DBraden%26aufirst%3DD.%2BA.%26aulast%3DPhilipp%26aufirst%3DD.%2BM.%26aulast%3DRinaldo%26aufirst%3DD.%26aulast%3DHalls%26aufirst%3DM.%2BD.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26atitle%3DJaguar%253A%2520A%2520high-performance%2520quantum%2520chemistry%2520software%2520program%2520with%2520strengths%2520in%2520life%2520and%2520materials%2520sciences%26jtitle%3DInt.%2520J.%2520Quantum%2520Chem.%26date%3D2013%26volume%3D113%26spage%3D2110%26epage%3D2142%26doi%3D10.1002%2Fqua.24481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ballesteros, J. A.</span>; <span class="NLM_string-name">Weinstein, H.</span></span> <span> </span><span class="NLM_article-title">[19] Integrated Methods for the Construction of Three-dimensional Models and Computational Probing of Structure-function Relations in G Protein-coupled Receptors</span>. In  <i>Methods in Neuroscience</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sealfon, S. C.</span></span>, Ed.; <span class="NLM_publisher-name">Academic Press</span>, <span class="NLM_year">1995</span>; Vol.  <span class="NLM_volume">25</span>, pp  <span class="NLM_fpage">366</span>– <span class="NLM_lpage">428</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1016%2FS1043-9471%2805%2980049-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1995&pages=366-428&author=J.+A.+Ballesteros&author=H.+Weinsteinauthor=S.+C.+Sealfon&title=Methods+in+Neuroscience"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2FS1043-9471%2805%2980049-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FS1043-9471%252805%252980049-7%26sid%3Dliteratum%253Aachs%26aulast%3DBallesteros%26aufirst%3DJ.%2BA.%26atitle%3D%255B19%255D%2520Integrated%2520Methods%2520for%2520the%2520Construction%2520of%2520Three-dimensional%2520Models%2520and%2520Computational%2520Probing%2520of%2520Structure-function%2520Relations%2520in%2520G%2520Protein-coupled%2520Receptors%26btitle%3DMethods%2520in%2520Neuroscience%26aulast%3DSealfon%26aufirst%3DS.%2BC.%26pub%3DAcademic%2520Press%26date%3D1995%26volume%3D25%26spage%3D366%26epage%3D428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mayne, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saam, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tajkhorshid, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gumbart, J. C.</span></span> <span> </span><span class="NLM_article-title">Rapid parameterization of small molecules using the Force Field Toolkit</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">2757</span>– <span class="NLM_lpage">2770</span>, <span class="refDoi"> DOI: 10.1002/jcc.23422</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1002%2Fjcc.23422" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=24000174" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlyrt73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=2757-2770&author=C.+G.+Mayneauthor=J.+Saamauthor=K.+Schultenauthor=E.+Tajkhorshidauthor=J.+C.+Gumbart&title=Rapid+parameterization+of+small+molecules+using+the+Force+Field+Toolkit&doi=10.1002%2Fjcc.23422"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid parameterization of small molecules using the force field toolkit</span></div><div class="casAuthors">Mayne, Christopher G.; Saam, Jan; Schulten, Klaus; Tajkhorshid, Emad; Gumbart, James C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">2757-2770</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The inability to rapidly generate accurate and robust parameters for novel chem. matter continues to severely limit the application of mol. dynamics simulations to many biol. systems of interest, esp. in fields such as drug discovery.  Although the release of generalized versions of common classical force fields, for example, General Amber Force Field and CHARMM General Force Field, have posited guidelines for parameterization of small mols., many tech. challenges remain that have hampered their wide-scale extension.  The Force Field Toolkit (ffTK), described herein, minimizes common barriers to ligand parameterization through algorithm and method development, automation of tedious and error-prone tasks, and graphical user interface design.  Distributed as a VMD plugin, ffTK facilitates the traversal of a clear and organized workflow resulting in a complete set of CHARMM-compatible parameters.  A variety of tools are provided to generate quantum mech. target data, setup multidimensional optimization routines, and analyze parameter performance.  Parameters developed for a small test set of mols. using ffTK were comparable to existing CGenFF parameters in their ability to reproduce exptl. measured values for pure-solvent properties (<15% error from expt.) and free energy of solvation (±0.5 kcal/mol from expt.). © 2013 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBvn6UpP2II7Vg90H21EOLACvtfcHk0lihgWd1tPPIcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlyrt73J&md5=73e241b77bcc903ab94acb2f187be578</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1002%2Fjcc.23422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.23422%26sid%3Dliteratum%253Aachs%26aulast%3DMayne%26aufirst%3DC.%2BG.%26aulast%3DSaam%26aufirst%3DJ.%26aulast%3DSchulten%26aufirst%3DK.%26aulast%3DTajkhorshid%26aufirst%3DE.%26aulast%3DGumbart%26aufirst%3DJ.%2BC.%26atitle%3DRapid%2520parameterization%2520of%2520small%2520molecules%2520using%2520the%2520Force%2520Field%2520Toolkit%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2013%26volume%3D34%26spage%3D2757%26epage%3D2770%26doi%3D10.1002%2Fjcc.23422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vanommeslaeghe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatcher, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acharya, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darian, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guvench, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vorobyov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackerell, A. D.,  Jr.</span></span> <span> </span><span class="NLM_article-title">CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">671</span>– <span class="NLM_lpage">690</span>, <span class="refDoi"> DOI: 10.1002/jcc.21367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1002%2Fjcc.21367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=19575467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlentbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=671-690&author=K.+Vanommeslaegheauthor=E.+Hatcherauthor=C.+Acharyaauthor=S.+Kunduauthor=S.+Zhongauthor=J.+Shimauthor=E.+Darianauthor=O.+Guvenchauthor=P.+Lopesauthor=I.+Vorobyovauthor=A.+D.+Mackerell&title=CHARMM+general+force+field%3A+A+force+field+for+drug-like+molecules+compatible+with+the+CHARMM+all-atom+additive+biological+force+fields&doi=10.1002%2Fjcc.21367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields</span></div><div class="casAuthors">Vanommeslaeghe, K.; Hatcher, E.; Acharya, C.; Kundu, S.; Zhong, S.; Shim, J.; Darian, E.; Guvench, O.; Lopes, P.; Vorobyov, I.; Mackerell, A. D., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">671-690</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The widely used CHARMM additive all-atom force field includes parameters for proteins, nucleic acids, lipids, and carbohydrates.  In the present article, an extension of the CHARMM force field to drug-like mols. is presented.  The resulting CHARMM General Force Field (CGenFF) covers a wide range of chem. groups present in biomols. and drug-like mols., including a large no. of heterocyclic scaffolds.  The parametrization philosophy behind the force field focuses on quality at the expense of transferability, with the implementation concg. on an extensible force field.  Statistics related to the quality of the parametrization with a focus on exptl. validation are presented.  Addnl., the parametrization procedure, described fully in the present article in the context of the model systems, pyrrolidine, and 3-phenoxymethyl-pyrrolidine will allow users to readily extend the force field to chem. groups that are not explicitly covered in the force field as well as add functional groups to and link together mols. already available in the force field.  CGenFF thus makes it possible to perform "all-CHARMM" simulations on drug-target interactions thereby extending the utility of CHARMM force fields to medicinally relevant systems. © 2009 Wiley Periodicals, Inc.J Comput Chem, 2010.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCuh0CLdmxN7Vg90H21EOLACvtfcHk0lihgWd1tPPIcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlentbc%253D&md5=26212e0e4f73bded0c89d4b411cd3833</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21367%26sid%3Dliteratum%253Aachs%26aulast%3DVanommeslaeghe%26aufirst%3DK.%26aulast%3DHatcher%26aufirst%3DE.%26aulast%3DAcharya%26aufirst%3DC.%26aulast%3DKundu%26aufirst%3DS.%26aulast%3DZhong%26aufirst%3DS.%26aulast%3DShim%26aufirst%3DJ.%26aulast%3DDarian%26aufirst%3DE.%26aulast%3DGuvench%26aufirst%3DO.%26aulast%3DLopes%26aufirst%3DP.%26aulast%3DVorobyov%26aufirst%3DI.%26aulast%3DMackerell%26aufirst%3DA.%2BD.%26atitle%3DCHARMM%2520general%2520force%2520field%253A%2520A%2520force%2520field%2520for%2520drug-like%2520molecules%2520compatible%2520with%2520the%2520CHARMM%2520all-atom%2520additive%2520biological%2520force%2520fields%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2010%26volume%3D31%26spage%3D671%26epage%3D690%26doi%3D10.1002%2Fjcc.21367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vanommeslaeghe, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raman, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKerell, A. D.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Automation of the CHARMM General Force Field (CGenFF) II: assignment of bonded parameters and partial atomic charges</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">3155</span>– <span class="NLM_lpage">3168</span>, <span class="refDoi"> DOI: 10.1021/ci3003649</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci3003649" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Gns7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=3155-3168&author=K.+Vanommeslaegheauthor=E.+P.+Ramanauthor=A.+D.+MacKerell&title=Automation+of+the+CHARMM+General+Force+Field+%28CGenFF%29+II%3A+assignment+of+bonded+parameters+and+partial+atomic+charges&doi=10.1021%2Fci3003649"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Automation of the CHARMM General Force Field (CGenFF) II: Assignment of Bonded Parameters and Partial Atomic Charges</span></div><div class="casAuthors">Vanommeslaeghe, K.; Raman, E. Prabhu; MacKerell, A. D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3155-3168</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mol. mechanics force fields are widely used in computer-aided drug design for the study of drug candidates interacting with biol. systems.  In these simulations, the biol. part is typically represented by a specialized biomol. force field, while the drug is represented by a matching general (org.) force field.  In order to apply these general force fields to an arbitrary drug-like mol., functionality for assignment of atom types, parameters, and partial at. charges is required.  In the present article, algorithms for the assignment of parameters and charges for the CHARMM General Force Field (CGenFF) are presented.  These algorithms rely on the existing parameters and charges that were detd. as part of the parametrization of the force field.  Bonded parameters are assigned based on the similarity between the atom types that define said parameters, while charges are detd. using an extended bond-charge increment scheme.  Charge increments were optimized to reproduce the charges on model compds. that were part of the parametrization of the force field.  Case studies are presented to clarify the functioning of the algorithms and the significance of their output data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0zgm66CLdn7Vg90H21EOLACvtfcHk0lihgWd1tPPIcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Gns7fF&md5=e676ad1f42cb1e98dd353d4d285e8d13</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Fci3003649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci3003649%26sid%3Dliteratum%253Aachs%26aulast%3DVanommeslaeghe%26aufirst%3DK.%26aulast%3DRaman%26aufirst%3DE.%2BP.%26aulast%3DMacKerell%26aufirst%3DA.%2BD.%26atitle%3DAutomation%2520of%2520the%2520CHARMM%2520General%2520Force%2520Field%2520%2528CGenFF%2529%2520II%253A%2520assignment%2520of%2520bonded%2520parameters%2520and%2520partial%2520atomic%2520charges%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2012%26volume%3D52%26spage%3D3155%26epage%3D3168%26doi%3D10.1021%2Fci3003649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frisch, M. J.</span>; <span class="NLM_string-name">Trucks, G. W.</span>; <span class="NLM_string-name">Schlegel, H. B.</span>; <span class="NLM_string-name">Scuseria, G. E.</span>; <span class="NLM_string-name">Robb, M. A.</span>; <span class="NLM_string-name">Cheeseman, J. R.</span>; <span class="NLM_string-name">Scalmani, G.</span>; <span class="NLM_string-name">Barone, V.</span>; <span class="NLM_string-name">Petersson, G. A.</span>; <span class="NLM_string-name">Nakatsuji, H.</span>; <span class="NLM_string-name">Li, X.</span>; <span class="NLM_string-name">Caricato, M.</span>; <span class="NLM_string-name">Marenich, A. V.</span>; <span class="NLM_string-name">Bloino, J.</span>; <span class="NLM_string-name">Janesko, B. G.</span>; <span class="NLM_string-name">Gomperts, R.</span>; <span class="NLM_string-name">Mennucci, B.</span>; <span class="NLM_string-name">Hratchian, H. P.</span>; <span class="NLM_string-name">Ortiz, J. V.</span>; <span class="NLM_string-name">Izmaylov, A. F.</span>; <span class="NLM_string-name">Sonnenberg, J. L.</span>; <span class="NLM_string-name">Williams-Young, D.</span>; <span class="NLM_string-name">Ding, F.</span>; <span class="NLM_string-name">Lipparini, F.</span>; <span class="NLM_string-name">Egidi, F.</span>; <span class="NLM_string-name">Goings, J.</span>; <span class="NLM_string-name">Peng, B.</span>; <span class="NLM_string-name">Petrone, A.</span>; <span class="NLM_string-name">Henderson, T.</span>; <span class="NLM_string-name">Ranasinghe, D.</span>; <span class="NLM_string-name">Zakrzewski, V. G.</span>; <span class="NLM_string-name">Gao, J.</span>; <span class="NLM_string-name">Rega, N.</span>; <span class="NLM_string-name">Zheng, G.</span>; <span class="NLM_string-name">Liang, W.</span>; <span class="NLM_string-name">Hada, M.</span>; <span class="NLM_string-name">Ehara, M.</span>; <span class="NLM_string-name">Toyota, K.</span>; <span class="NLM_string-name">Fukuda, R.</span>; <span class="NLM_string-name">Hasegawa, J.</span>; <span class="NLM_string-name">Ishida, M.</span>; <span class="NLM_string-name">Nakajima, T.</span>; <span class="NLM_string-name">Honda, Y.</span>; <span class="NLM_string-name">Kitao, O.</span>; <span class="NLM_string-name">Nakai, H.</span>; <span class="NLM_string-name">Vreven, T.</span>; <span class="NLM_string-name">Throssell, K.,  Jr.</span>; <span class="NLM_string-name">Montgomery, J. A.</span>; <span class="NLM_string-name">Peralta, J. E.</span>; <span class="NLM_string-name">Ogliaro, F.</span>; <span class="NLM_string-name">Bearpark, M. J.</span>; <span class="NLM_string-name">Heyd, J. J.</span>; <span class="NLM_string-name">Brothers, E. N.</span>; <span class="NLM_string-name">Kudin, K. N.</span>; <span class="NLM_string-name">Staroverov, V. N.</span>; <span class="NLM_string-name">Keith, T. A.</span>; <span class="NLM_string-name">Kobayashi, R.</span>; <span class="NLM_string-name">Normand, J.</span>; <span class="NLM_string-name">Raghavachari, K.</span>; <span class="NLM_string-name">Rendell, A. P.</span>; <span class="NLM_string-name">Burant, J. C.</span>; <span class="NLM_string-name">Iyengar, S. S.</span>; <span class="NLM_string-name">Tomasi, J.</span>; <span class="NLM_string-name">Cossi, M.</span>; <span class="NLM_string-name">Millam, J. M.</span>; <span class="NLM_string-name">Klene, M.</span>; <span class="NLM_string-name">Adamo, C.</span>; <span class="NLM_string-name">Cammi, R.</span>; <span class="NLM_string-name">Ochterski, J. W.</span>; <span class="NLM_string-name">Martin, R. L.</span>; <span class="NLM_string-name">Morokuma, K.</span>; <span class="NLM_string-name">Farkas, O.</span>; <span class="NLM_string-name">Foresman, J. B.</span>; <span class="NLM_string-name">Fox, D. J.</span></span> <i>Gaussian 16</i>, revision C.01; <span class="NLM_publisher-name">Gaussian Inc.</span>: <span class="NLM_publisher-loc">Wallingford, CT</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.17265%2F2159-5313%2F2016.09.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=M.+J.+Frisch&author=G.+W.+Trucks&author=H.+B.+Schlegel&author=G.+E.+Scuseria&author=M.+A.+Robb&author=J.+R.+Cheeseman&author=G.+Scalmani&author=V.+Barone&author=G.+A.+Petersson&author=H.+Nakatsuji&author=X.+Li&author=M.+Caricato&author=A.+V.+Marenich&author=J.+Bloino&author=B.+G.+Janesko&author=R.+Gomperts&author=B.+Mennucci&author=H.+P.+Hratchian&author=J.+V.+Ortiz&author=A.+F.+Izmaylov&author=J.+L.+Sonnenberg&author=D.+Williams-Young&author=F.+Ding&author=F.+Lipparini&author=F.+Egidi&author=J.+Goings&author=B.+Peng&author=A.+Petrone&author=T.+Henderson&author=D.+Ranasinghe&author=V.+G.+Zakrzewski&author=J.+Gao&author=N.+Rega&author=G.+Zheng&author=W.+Liang&author=M.+Hada&author=M.+Ehara&author=K.+Toyota&author=R.+Fukuda&author=J.+Hasegawa&author=M.+Ishida&author=T.+Nakajima&author=Y.+Honda&author=O.+Kitao&author=H.+Nakai&author=T.+Vreven&author=K.+Throssell&author=J.+A.+Montgomery&author=J.+E.+Peralta&author=F.+Ogliaro&author=M.+J.+Bearpark&author=J.+J.+Heyd&author=E.+N.+Brothers&author=K.+N.+Kudin&author=V.+N.+Staroverov&author=T.+A.+Keith&author=R.+Kobayashi&author=J.+Normand&author=K.+Raghavachari&author=A.+P.+Rendell&author=J.+C.+Burant&author=S.+S.+Iyengar&author=J.+Tomasi&author=M.+Cossi&author=J.+M.+Millam&author=M.+Klene&author=C.+Adamo&author=R.+Cammi&author=J.+W.+Ochterski&author=R.+L.+Martin&author=K.+Morokuma&author=O.+Farkas&author=J.+B.+Foresman&author=D.+J.+Fox&title=Gaussian+16"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.17265%2F2159-5313%2F2016.09.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26id%3Ddoi%3A10.17265%252F2159-5313%252F2016.09.003%26sid%3Dliteratum%253Aachs%26aulast%3DFrisch%26aufirst%3DM.%2BJ.%26jtitle%3DGaussian%252016%26pub%3DGaussian%2520Inc%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lomize, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pogozheva, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosberg, H. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lomize, A. L.</span></span> <span> </span><span class="NLM_article-title">OPM database and PPM web server: resources for positioning of proteins in membranes</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">D370</span>– <span class="NLM_lpage">D376</span>, <span class="refDoi"> DOI: 10.1093/nar/gkr703</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1093%2Fnar%2Fgkr703" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=21890895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs12hurzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=D370-D376&author=M.+A.+Lomizeauthor=I.+D.+Pogozhevaauthor=H.+Jooauthor=H.+I.+Mosbergauthor=A.+L.+Lomize&title=OPM+database+and+PPM+web+server%3A+resources+for+positioning+of+proteins+in+membranes&doi=10.1093%2Fnar%2Fgkr703"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">OPM database and PPM web server: resources for positioning of proteins in membranes</span></div><div class="casAuthors">Lomize, Mikhail A.; Pogozheva, Irina D.; Joo, Hyeon; Mosberg, Henry I.; Lomize, Andrei L.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">D1</span>),
    <span class="NLM_cas:pages">D370-D376</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The Orientations of Proteins in Membranes (OPM) database is a curated web resource that provides spatial positions of membrane-bound peptides and proteins of known three-dimensional structure in the lipid bilayer, together with their structural classification, topol. and intracellular localization.  OPM currently contains more than 1200 transmembrane and peripheral proteins and peptides from approx. 350 organisms that represent approx. 3800 Protein Data Bank entries.  Proteins are classified into classes, superfamilies and families and assigned to 21 distinct membrane types.  Spatial positions of proteins with respect to the lipid bilayer are optimized by the PPM 2.0 method that accounts for the hydrophobic, hydrogen bonding and electrostatic interactions of the proteins with the anisotropic water-lipid environment described by the dielec. const. and hydrogen-bonding profiles.  The OPM database is freely accessible at http://opm.phar.umich.edu.  Data can be sorted, searched or retrieved using the hierarchical classification, source organism, localization in different types of membranes.  The database offers downloadable coordinates of proteins and peptides with membrane boundaries.  A gallery of protein images and several visualization tools are provided.  The database is supplemented by the PPM server (http://opm.phar.umich.edu/server.php) which can be used for calcg. spatial positions in membranes of newly detd. proteins structures or theor. models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo76Y6X6BHLRbVg90H21EOLACvtfcHk0linpLidpJH52A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs12hurzJ&md5=b931126c56d227ab0eb6c5762c1dae6b</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkr703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkr703%26sid%3Dliteratum%253Aachs%26aulast%3DLomize%26aufirst%3DM.%2BA.%26aulast%3DPogozheva%26aufirst%3DI.%2BD.%26aulast%3DJoo%26aufirst%3DH.%26aulast%3DMosberg%26aufirst%3DH.%2BI.%26aulast%3DLomize%26aufirst%3DA.%2BL.%26atitle%3DOPM%2520database%2520and%2520PPM%2520web%2520server%253A%2520resources%2520for%2520positioning%2520of%2520proteins%2520in%2520membranes%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2012%26volume%3D40%26spage%3DD370%26epage%3DD376%26doi%3D10.1093%2Fnar%2Fgkr703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, W.</span></span> <span> </span><span class="NLM_article-title">Automated builder and database of protein/membrane complexes for molecular dynamics simulations</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">e880</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0000880</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1371%2Fjournal.pone.0000880" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=17849009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A280%3ADC%252BD2srjsFyjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&author=S.+Joauthor=T.+Kimauthor=W.+Im&title=Automated+builder+and+database+of+protein%2Fmembrane+complexes+for+molecular+dynamics+simulations&doi=10.1371%2Fjournal.pone.0000880"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Automated builder and database of protein/membrane complexes for molecular dynamics simulations</span></div><div class="casAuthors">Jo Sunhwan; Kim Taehoon; Im Wonpil</div><div class="citationInfo"><span class="NLM_cas:title">PloS one</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e880</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Molecular dynamics simulations of membrane proteins have provided deeper insights into their functions and interactions with surrounding environments at the atomic level.  However, compared to solvation of globular proteins, building a realistic protein/membrane complex is still challenging and requires considerable experience with simulation software.  Membrane Builder in the CHARMM-GUI website (http://www.charmm-gui.org) helps users to build such a complex system using a web browser with a graphical user interface.  Through a generalized and automated building process including system size determination as well as generation of lipid bilayer, pore water, bulk water, and ions, a realistic membrane system with virtually any kinds and shapes of membrane proteins can be generated in 5 minutes to 2 hours depending on the system size.  Default values that were elaborated and tested extensively are given in each step to provide reasonable options and starting points for both non-expert and expert users.  The efficacy of Membrane Builder is illustrated by its applications to 12 transmembrane and 3 interfacial membrane proteins, whose fully equilibrated systems with three different types of lipid molecules (DMPC, DPPC, and POPC) and two types of system shapes (rectangular and hexagonal) are freely available on the CHARMM-GUI website.  One of the most significant advantages of using the web environment is that, if a problem is found, users can go back and re-generate the whole system again before quitting the browser.  Therefore, Membrane Builder provides the intuitive and easy way to build and simulate the biologically important membrane system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAsncNNJLqIBfKb6ELK8t0fW6udTcc2eZzk82dAzrODrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2srjsFyjsQ%253D%253D&md5=d2384741fc1d18b33cff16b254fc006b</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0000880&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0000880%26sid%3Dliteratum%253Aachs%26aulast%3DJo%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DT.%26aulast%3DIm%26aufirst%3DW.%26atitle%3DAutomated%2520builder%2520and%2520database%2520of%2520protein%252Fmembrane%2520complexes%2520for%2520molecular%2520dynamics%2520simulations%26jtitle%3DPLoS%2520One%26date%3D2007%26volume%3D2%26doi%3D10.1371%2Fjournal.pone.0000880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swails, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeom, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastman, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemkul, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pande, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Case, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, C. L.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKerell, A. D.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klauda, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Im, W.</span></span> <span> </span><span class="NLM_article-title">CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM simulations using the CHARMM36 additive force field</span>. <i>J. Chem. Theory Comput.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">405</span>– <span class="NLM_lpage">413</span>, <span class="refDoi"> DOI: 10.1021/acs.jctc.5b00935</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jctc.5b00935" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVWru7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=405-413&author=J.+Leeauthor=X.+Chengauthor=J.+M.+Swailsauthor=M.+S.+Yeomauthor=P.+K.+Eastmanauthor=J.+A.+Lemkulauthor=S.+Weiauthor=J.+Bucknerauthor=J.+C.+Jeongauthor=Y.+Qiauthor=S.+Joauthor=V.+S.+Pandeauthor=D.+A.+Caseauthor=C.+L.+Brooksauthor=A.+D.+MacKerellauthor=J.+B.+Klaudaauthor=W.+Im&title=CHARMM-GUI+input+generator+for+NAMD%2C+GROMACS%2C+AMBER%2C+OpenMM%2C+and+CHARMM%2FOpenMM+simulations+using+the+CHARMM36+additive+force+field&doi=10.1021%2Facs.jctc.5b00935"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM Simulations Using the CHARMM36 Additive Force Field</span></div><div class="casAuthors">Lee, Jumin; Cheng, Xi; Swails, Jason M.; Yeom, Min Sun; Eastman, Peter K.; Lemkul, Justin A.; Wei, Shuai; Buckner, Joshua; Jeong, Jong Cheol; Qi, Yifei; Jo, Sunhwan; Pande, Vijay S.; Case, David A.; Brooks, Charles L.; MacKerell, Alexander D.; Klauda, Jeffery B.; Im, Wonpil</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Theory and Computation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">405-413</span>CODEN:
                <span class="NLM_cas:coden">JCTCCE</span>;
        ISSN:<span class="NLM_cas:issn">1549-9618</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Proper treatment of nonbonded interactions is essential for the accuracy of mol. dynamics (MD) simulations, esp. in studies of lipid bilayers.  The use of the CHARMM36 force field (C36 FF) in different MD simulation programs can result in disagreements with published simulations performed with CHARMM due to differences in the protocols used to treat the long-range and 1-4 nonbonded interactions.  In this study, we systematically test the use of the C36 lipid FF in NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM.  A wide range of Lennard-Jones (LJ) cutoff schemes and integrator algorithms were tested to find the optimal simulation protocol to best match bilayer properties of six lipids with varying acyl chain satn. and head groups.  MD simulations of a 1,2-dipalmitoyl-sn-phosphatidylcholine (DPPC) bilayer were used to obtain the optimal protocol for each program.  MD simulations with all programs were found to reasonably match the DPPC bilayer properties (surface area per lipid, chain order parameters, and area compressibility modulus) obtained using the std. protocol used in CHARMM as well as from expts.  The optimal simulation protocol was then applied to the other five lipid simulations and resulted in excellent agreement between results from most simulation programs as well as with exptl. data.  AMBER compared least favorably with the expected membrane properties, which appears to be due to its use of the hard-truncation in the LJ potential vs. a force-based switching function used to smooth the LJ potential as it approaches the cutoff distance.  The optimal simulation protocol for each program has been implemented in CHARMM-GUI.  This protocol is expected to be applicable to the remainder of the additive C36 FF including the proteins, nucleic acids, carbohydrates, and small mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrioKQ5MoVZkrVg90H21EOLACvtfcHk0lh_KqJ40Jk1Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVWru7nI&md5=1e986f2c205aca8fb80442bc9c95b229</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Facs.jctc.5b00935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jctc.5b00935%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DX.%26aulast%3DSwails%26aufirst%3DJ.%2BM.%26aulast%3DYeom%26aufirst%3DM.%2BS.%26aulast%3DEastman%26aufirst%3DP.%2BK.%26aulast%3DLemkul%26aufirst%3DJ.%2BA.%26aulast%3DWei%26aufirst%3DS.%26aulast%3DBuckner%26aufirst%3DJ.%26aulast%3DJeong%26aufirst%3DJ.%2BC.%26aulast%3DQi%26aufirst%3DY.%26aulast%3DJo%26aufirst%3DS.%26aulast%3DPande%26aufirst%3DV.%2BS.%26aulast%3DCase%26aufirst%3DD.%2BA.%26aulast%3DBrooks%26aufirst%3DC.%2BL.%26aulast%3DMacKerell%26aufirst%3DA.%2BD.%26aulast%3DKlauda%26aufirst%3DJ.%2BB.%26aulast%3DIm%26aufirst%3DW.%26atitle%3DCHARMM-GUI%2520input%2520generator%2520for%2520NAMD%252C%2520GROMACS%252C%2520AMBER%252C%2520OpenMM%252C%2520and%2520CHARMM%252FOpenMM%2520simulations%2520using%2520the%2520CHARMM36%2520additive%2520force%2520field%26jtitle%3DJ.%2520Chem.%2520Theory%2520Comput.%26date%3D2016%26volume%3D12%26spage%3D405%26epage%3D413%26doi%3D10.1021%2Facs.jctc.5b00935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauscher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nawrocki, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feig, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Groot, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grubmüller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKerell, A. D.,  Jr.</span></span> <span> </span><span class="NLM_article-title">CHARMM36m: an improved force field for folded and intrinsically disordered proteins</span>. <i>Nat. Methods</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">71</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1038/nmeth.4067</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1038%2Fnmeth.4067" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=27819658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVSiu77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=71-73&author=J.+Huangauthor=S.+Rauscherauthor=G.+Nawrockiauthor=T.+Ranauthor=M.+Feigauthor=B.+L.+de+Grootauthor=H.+Grubm%C3%BCllerauthor=A.+D.+MacKerell&title=CHARMM36m%3A+an+improved+force+field+for+folded+and+intrinsically+disordered+proteins&doi=10.1038%2Fnmeth.4067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">CHARMM36m: an improved force field for folded and intrinsically disordered proteins</span></div><div class="casAuthors">Huang, Jing; Rauscher, Sarah; Nawrocki, Grzegorz; Ran, Ting; Feig, Michael; de Groot, Bert L.; Grubmuller, Helmut; MacKerell, Alexander D. Jr</div><div class="citationInfo"><span class="NLM_cas:title">Nature Methods</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">71-73</span>CODEN:
                <span class="NLM_cas:coden">NMAEA3</span>;
        ISSN:<span class="NLM_cas:issn">1548-7091</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The all-atom additive CHARMM36 protein force field is widely used in mol. modeling and simulations.  We present its refinement, CHARMM36m (http://mackerell.umaryland.edu/charmm_ff.shtml), with improved accuracy in generating polypeptide backbone conformational ensembles for intrinsically disordered peptides and proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2_cEd6RiZUbVg90H21EOLACvtfcHk0lh_KqJ40Jk1Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVSiu77I&md5=0aa151fbef2ee0b5e2cfb593c54330c2</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1038%2Fnmeth.4067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnmeth.4067%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DRauscher%26aufirst%3DS.%26aulast%3DNawrocki%26aufirst%3DG.%26aulast%3DRan%26aufirst%3DT.%26aulast%3DFeig%26aufirst%3DM.%26aulast%3Dde%2BGroot%26aufirst%3DB.%2BL.%26aulast%3DGrubm%25C3%25BCller%26aufirst%3DH.%26aulast%3DMacKerell%26aufirst%3DA.%2BD.%26atitle%3DCHARMM36m%253A%2520an%2520improved%2520force%2520field%2520for%2520folded%2520and%2520intrinsically%2520disordered%2520proteins%26jtitle%3DNat.%2520Methods%26date%3D2017%26volume%3D14%26spage%3D71%26epage%3D73%26doi%3D10.1038%2Fnmeth.4067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klauda, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venable, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freites, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tobias, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mondragon-Ramirez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vorobyov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKerell, A. D.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastor, R. W.</span></span> <span> </span><span class="NLM_article-title">Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types</span>. <i>J. Phys. Chem. B</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">7830</span>– <span class="NLM_lpage">7843</span>, <span class="refDoi"> DOI: 10.1021/jp101759q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jp101759q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmsVGjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2010&pages=7830-7843&author=J.+B.+Klaudaauthor=R.+M.+Venableauthor=J.+A.+Freitesauthor=J.+W.+O%E2%80%99Connorauthor=D.+J.+Tobiasauthor=C.+Mondragon-Ramirezauthor=I.+Vorobyovauthor=A.+D.+MacKerellauthor=R.+W.+Pastor&title=Update+of+the+CHARMM+all-atom+additive+force+field+for+lipids%3A+validation+on+six+lipid+types&doi=10.1021%2Fjp101759q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Update of the CHARMM All-Atom Additive Force Field for Lipids: Validation on Six Lipid Types</span></div><div class="casAuthors">Klauda, Jeffery B.; Venable, Richard M.; Freites, J. Alfredo; O'Connor, Joseph W.; Tobias, Douglas J.; Mondragon-Ramirez, Carlos; Vorobyov, Igor; MacKerell, Alexander D., Jr.; Pastor, Richard W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry B</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7830-7843</span>CODEN:
                <span class="NLM_cas:coden">JPCBFK</span>;
        ISSN:<span class="NLM_cas:issn">1520-6106</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A significant modification to the additive all-atom CHARMM lipid force field (FF) is developed and applied to phospholipid bilayers with both choline and ethanolamine contg. head groups and with both satd. and unsatd. aliph. chains.  Motivated by the current CHARMM lipid FF (C27 and C27r) systematically yielding values of the surface area per lipid that are smaller than exptl. ests. and gel-like structures of bilayers well above the gel transition temp., selected torsional, Lennard-Jones and partial at. charge parameters were modified by targeting both quantum mech. (QM) and exptl. data.  QM calcns. ranging from high-level ab initio calcns. on small mols. to semiempirical QM studies on a 1,2-dipalmitoyl-sn-phosphatidylcholine (DPPC) bilayer in combination with exptl. thermodn. data were used as target data for parameter optimization.  These changes were tested with simulations of pure bilayers at high hydration of the following six lipids: DPPC, 1,2-dimyristoyl-sn-phosphatidylcholine (DMPC), 1,2-dilauroyl-sn-phosphatidylcholine (DLPC), 1-palmitoyl-2-oleoyl-sn-phosphatidylcholine (POPC), 1,2-dioleoyl-sn-phosphatidylcholine (DOPC), and 1-palmitoyl-2-oleoyl-sn-phosphatidylethanolamine (POPE); simulations of a low hydration DOPC bilayer were also performed.  Agreement with exptl. surface area is on av. within 2%, and the d. profiles agree well with neutron and x-ray diffraction expts.  NMR deuterium order parameters (SCD) are well predicted with the new FF, including proper splitting of the SCD for the aliph. carbon adjacent to the carbonyl for DPPC, POPE, and POPC bilayers.  The area compressibility modulus and frequency dependence of 13C NMR relaxation rates of DPPC and the water distribution of low hydration DOPC bilayers also agree well with expt.  Accordingly, the presented lipid FF, referred to as C36, allows for mol. dynamics simulations to be run in the tensionless ensemble (NPT), and is anticipated to be of utility for simulations of pure lipid systems as well as heterogeneous systems including membrane proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhTVhlLR7mEbVg90H21EOLACvtfcHk0lh7YYgGgHS2pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmsVGjtrk%253D&md5=04c4d3aa1a59740190994d7df80cbb71</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1021%2Fjp101759q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp101759q%26sid%3Dliteratum%253Aachs%26aulast%3DKlauda%26aufirst%3DJ.%2BB.%26aulast%3DVenable%26aufirst%3DR.%2BM.%26aulast%3DFreites%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DJ.%2BW.%26aulast%3DTobias%26aufirst%3DD.%2BJ.%26aulast%3DMondragon-Ramirez%26aufirst%3DC.%26aulast%3DVorobyov%26aufirst%3DI.%26aulast%3DMacKerell%26aufirst%3DA.%2BD.%26aulast%3DPastor%26aufirst%3DR.%2BW.%26atitle%3DUpdate%2520of%2520the%2520CHARMM%2520all-atom%2520additive%2520force%2520field%2520for%2520lipids%253A%2520validation%2520on%2520six%2520lipid%2520types%26jtitle%3DJ.%2520Phys.%2520Chem.%2520B%26date%3D2010%26volume%3D114%26spage%3D7830%26epage%3D7843%26doi%3D10.1021%2Fjp101759q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Case, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheatham, T. E.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darden, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gohlke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merz, K. M.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onufriev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmerling, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, R. J.</span></span> <span> </span><span class="NLM_article-title">The Amber biomolecular simulation programs</span>. <i>J. Comput. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1668</span>– <span class="NLM_lpage">1688</span>, <span class="refDoi"> DOI: 10.1002/jcc.20290</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1002%2Fjcc.20290" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=16200636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1SlsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2005&pages=1668-1688&author=D.+A.+Caseauthor=T.+E.+Cheathamauthor=T.+Dardenauthor=H.+Gohlkeauthor=R.+Luoauthor=K.+M.+Merzauthor=A.+Onufrievauthor=C.+Simmerlingauthor=B.+Wangauthor=R.+J.+Woods&title=The+Amber+biomolecular+simulation+programs&doi=10.1002%2Fjcc.20290"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">The amber biomolecular simulation programs</span></div><div class="casAuthors">Case, David A.; Cheatham, Thomas E., III; Darden, Tom; Gohlke, Holger; Luo, Ray; Merz, Kenneth M., Jr.; Onufriev, Alexey; Simmerling, Carlos; Wang, Bing; Woods, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1668-1688</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The authors describe the development, current features, and some directions for future development of the Amber package of computer programs.  This package evolved from a program that was constructed in the late 1970s to do Assisted Model Building with Energy Refinement, and now contains a group of programs embodying a no. of powerful tools of modern computational chem., focused on mol. dynamics and free energy calcns. of proteins, nucleic acids, and carbohydrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGre0tZP_Umb7rVg90H21EOLACvtfcHk0lh7YYgGgHS2pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1SlsbbM&md5=93be29ff894bab96c783d24e9886c7d0</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1002%2Fjcc.20290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.20290%26sid%3Dliteratum%253Aachs%26aulast%3DCase%26aufirst%3DD.%2BA.%26aulast%3DCheatham%26aufirst%3DT.%2BE.%26aulast%3DDarden%26aufirst%3DT.%26aulast%3DGohlke%26aufirst%3DH.%26aulast%3DLuo%26aufirst%3DR.%26aulast%3DMerz%26aufirst%3DK.%2BM.%26aulast%3DOnufriev%26aufirst%3DA.%26aulast%3DSimmerling%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWoods%26aufirst%3DR.%2BJ.%26atitle%3DThe%2520Amber%2520biomolecular%2520simulation%2520programs%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2005%26volume%3D26%26spage%3D1668%26epage%3D1688%26doi%3D10.1002%2Fjcc.20290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salomon-Ferrer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Götz, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poole, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Grand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, R. C.</span></span> <span> </span><span class="NLM_article-title">Routine microsecond molecular dynamics simulations with AMBER on GPUs. 2. explicit solvent particle mesh ewald</span>. <i>J. Chem. Theory Comput.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">3878</span>– <span class="NLM_lpage">3888</span>, <span class="refDoi"> DOI: 10.1021/ct400314y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ct400314y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1arsrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=3878-3888&author=R.+Salomon-Ferrerauthor=A.+W.+G%C3%B6tzauthor=D.+Pooleauthor=S.+Le+Grandauthor=R.+C.+Walker&title=Routine+microsecond+molecular+dynamics+simulations+with+AMBER+on+GPUs.+2.+explicit+solvent+particle+mesh+ewald&doi=10.1021%2Fct400314y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 2. Explicit Solvent Particle Mesh Ewald</span></div><div class="casAuthors">Salomon-Ferrer, Romelia; Gotz, Andreas W.; Poole, Duncan; Le Grand, Scott; Walker, Ross C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Theory and Computation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3878-3888</span>CODEN:
                <span class="NLM_cas:coden">JCTCCE</span>;
        ISSN:<span class="NLM_cas:issn">1549-9618</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We present an implementation of explicit solvent all atom classical mol. dynamics (MD) within the AMBER program package that runs entirely on CUDA-enabled GPUs.  First released publicly in Apr. 2010 as part of version 11 of the AMBER MD package and further improved and optimized over the last two years, this implementation supports the three most widely used statistical mech. ensembles (NVE, NVT, and NPT), uses particle mesh Ewald (PME) for the long-range electrostatics, and runs entirely on CUDA-enabled NVIDIA graphics processing units (GPUs), providing results that are statistically indistinguishable from the traditional CPU version of the software and with performance that exceeds that achievable by the CPU version of AMBER software running on all conventional CPU-based clusters and supercomputers.  We briefly discuss three different precision models developed specifically for this work (SPDP, SPFP, and DPDP) and highlight the tech. details of the approach as it extends beyond previously reported work [Goetz et al., J.  Chem.  Theory Comput.2012, DOI: 10.1021/ct200909j; Le Grand et al., Comp.  Phys.  Comm.2013, DOI: 10.1016/j.cpc.2012.09.022].We highlight the substantial improvements in performance that are seen over traditional CPU-only machines and provide validation of our implementation and precision models.  We also provide evidence supporting our decision to deprecate the previously described fully single precision (SPSP) model from the latest release of the AMBER software package.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY-M2E_jgUmLVg90H21EOLACvtfcHk0lh7YYgGgHS2pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1arsrzP&md5=57e18d35e8b81e9a79788ef5af17d19f</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1021%2Fct400314y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fct400314y%26sid%3Dliteratum%253Aachs%26aulast%3DSalomon-Ferrer%26aufirst%3DR.%26aulast%3DG%25C3%25B6tz%26aufirst%3DA.%2BW.%26aulast%3DPoole%26aufirst%3DD.%26aulast%3DLe%2BGrand%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DR.%2BC.%26atitle%3DRoutine%2520microsecond%2520molecular%2520dynamics%2520simulations%2520with%2520AMBER%2520on%2520GPUs.%25202.%2520explicit%2520solvent%2520particle%2520mesh%2520ewald%26jtitle%3DJ.%2520Chem.%2520Theory%2520Comput.%26date%3D2013%26volume%3D9%26spage%3D3878%26epage%3D3888%26doi%3D10.1021%2Fct400314y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehlert, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span> <span> </span><span class="NLM_article-title">A novel method for analyzing extremely biased agonism at G protein-coupled receptors</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">866</span>– <span class="NLM_lpage">877</span>, <span class="refDoi"> DOI: 10.1124/mol.114.096503</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1124%2Fmol.114.096503" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=25680753" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFOntb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2015&pages=866-877&author=E.+L.+Stahlauthor=L.+Zhouauthor=F.+J.+Ehlertauthor=L.+M.+Bohn&title=A+novel+method+for+analyzing+extremely+biased+agonism+at+G+protein-coupled+receptors&doi=10.1124%2Fmol.114.096503"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">A novel method for analyzing extremely biased agonism at G protein-coupled receptors</span></div><div class="casAuthors">Stahl, Edward L.; Zhou, Lei; Ehlert, Frederick J.; Bohn, Laura M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">866-877</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Seven transmembrane receptors were originally named and characterized based on their ability to couple to heterotrimeric G proteins.  The assortment of coupling partners for G protein-coupled receptors has subsequently expanded to include other effectors (most notably the βarrestins).  This diversity of partners available to the receptor has prompted the pursuit of ligands that selectively activate only a subset of the available partners.  A biased or functionally selective ligand may be able to distinguish between different active states of the receptor, and this would result in the preferential activation of one signaling cascade more than another.  Although application of the "std." operational model for analyzing ligand bias is useful and suitable in most cases, there are limitations that arise when the biased agonist fails to induce a significant response in one of the assays being compared.  In this article, we describe a quant. method for measuring ligand bias that is particularly useful for such cases of extreme bias.  Using simulations and exptl. evidence from several κ opioid receptor agonists, we illustrate a "competitive" model for quantitating the degree and direction of bias.  By comparing the results obtained from the competitive model with the std. model, we demonstrate that the competitive model expands the potential for evaluating the bias of very partial agonists.  We conclude the competitive model provides a useful mechanism for analyzing the bias of partial agonists that exhibit extreme bias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmxvwRDHZE07Vg90H21EOLACvtfcHk0ljFsVFCPJP4Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFOntb4%253D&md5=213952bf90b981cc66dc31bab8afe8df</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1124%2Fmol.114.096503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.114.096503%26sid%3Dliteratum%253Aachs%26aulast%3DStahl%26aufirst%3DE.%2BL.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DEhlert%26aufirst%3DF.%2BJ.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26atitle%3DA%2520novel%2520method%2520for%2520analyzing%2520extremely%2520biased%2520agonism%2520at%2520G%2520protein-coupled%2520receptors%26jtitle%3DMol.%2520Pharmacol.%26date%3D2015%26volume%3D87%26spage%3D866%26epage%3D877%26doi%3D10.1124%2Fmol.114.096503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Black, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leff, P.</span></span> <span> </span><span class="NLM_article-title">Operational models of pharmacological agonism</span>. <i>Proc. R. Soc. B</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>220</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1098/rspb.1983.0093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1098%2Frspb.1983.0093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=6141562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADyaL2cXmtFaqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=220&publication_year=1983&pages=141-162&author=J.+W.+Blackauthor=P.+Leff&title=Operational+models+of+pharmacological+agonism&doi=10.1098%2Frspb.1983.0093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Operational models of pharmacological agonism</span></div><div class="casAuthors">Black, J. W.; Leff, P.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the Royal Society of London, Series B:  Biological Sciences</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">220</span>
        (<span class="NLM_cas:issue">1219</span>),
    <span class="NLM_cas:pages">141-62</span>CODEN:
                <span class="NLM_cas:coden">PRLBA4</span>;
        ISSN:<span class="NLM_cas:issn">0080-4649</span>.
    </div><div class="casAbstract">A general, operational model is presented which explicitly describes pharmacol. agonism in terms of 3 parameters: an agonist-receptor dissocn. const., the total receptor concn. [Ro], and a parameter (KE) which defines the transduction of the agonist-receptor complex into pharmacol. effect.  The ratio RO/KE, the transducer ratio (τ), is a logical definition for the efficacy of an agonist in a system.  The model provides a chem. definition of intrinsic efficacy, making this parameter exptl. accessible in principle.  Alternate models are compared and contrasted with regard to their practical and conceptual utilities in exptl. pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonpXVldFQ_nbVg90H21EOLACvtfcHk0ljFsVFCPJP4Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXmtFaqtA%253D%253D&md5=a0421df9c56495d48d076010acf44b65</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1098%2Frspb.1983.0093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frspb.1983.0093%26sid%3Dliteratum%253Aachs%26aulast%3DBlack%26aufirst%3DJ.%2BW.%26aulast%3DLeff%26aufirst%3DP.%26atitle%3DOperational%2520models%2520of%2520pharmacological%2520agonism%26jtitle%3DProc.%2520R.%2520Soc.%2520B%26date%3D1983%26volume%3D220%26spage%3D141%26epage%3D162%26doi%3D10.1098%2Frspb.1983.0093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kenakin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muniz-Medina, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novick, S.</span></span> <span> </span><span class="NLM_article-title">A simple method for quantifying functional selectivity and agonist bias</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1021/cn200111m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn200111m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ChtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=193-203&author=T.+Kenakinauthor=C.+Watsonauthor=V.+Muniz-Medinaauthor=A.+Christopoulosauthor=S.+Novick&title=A+simple+method+for+quantifying+functional+selectivity+and+agonist+bias&doi=10.1021%2Fcn200111m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">A Simple Method for Quantifying Functional Selectivity and Agonist Bias</span></div><div class="casAuthors">Kenakin, Terry; Watson, Christian; Muniz-Medina, Vanessa; Christopoulos, Arthur; Novick, Steven</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">193-203</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Activation of seven-transmembrane (7TM) receptors by agonists does not always lead to uniform activation of all signaling pathways mediated by a given receptor.  Relative to other ligands, many agonists are "biased" toward producing subsets of receptor behaviors.  A hallmark of such "functional selectivity" is cell type dependence; this poses a particular problem for the profiling of agonists in whole cell test systems removed from the therapeutic one(s).  Such response-specific cell-based variability makes it difficult to guide medicinal chem. efforts aimed at identifying and optimizing therapeutically meaningful agonist bias.  For this reason, we present a scale, based on the Black and Leff operational model, that contains the key elements required to describe 7TM agonism, namely, affinity (KA-1) for the receptor and efficacy (τ) in activating a particular signaling pathway.  Utilizing a "transduction coeff." term, log(τ/KA), this scale can statistically evaluate selective agonist effects in a manner that can theor. inform structure-activity studies and/or drug candidate selection matrixes.  The bias of four chemokines for CCR5-mediated inositol phosphate prodn. vs. internalization is quantified to illustrate the practical application of this method.  The independence of this method with respect to receptor d. and the calcn. of statistical ests. of confidence of differences are specifically discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxSkELs1bHQLVg90H21EOLACvtfcHk0ljFsVFCPJP4Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ChtLvN&md5=270841d11f9720caaf3e59a6fe0aee74</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Fcn200111m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn200111m%26sid%3Dliteratum%253Aachs%26aulast%3DKenakin%26aufirst%3DT.%26aulast%3DWatson%26aufirst%3DC.%26aulast%3DMuniz-Medina%26aufirst%3DV.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DNovick%26aufirst%3DS.%26atitle%3DA%2520simple%2520method%2520for%2520quantifying%2520functional%2520selectivity%2520and%2520agonist%2520bias%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2012%26volume%3D3%26spage%3D193%26epage%3D203%26doi%3D10.1021%2Fcn200111m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ehlert, F. J.</span></span> <span> </span><span class="NLM_article-title">Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">194</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=2828914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADyaL1cXhsValurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1988&pages=187-194&author=F.+J.+Ehlert&title=Estimation+of+the+affinities+of+allosteric+ligands+using+radioligand+binding+and+pharmacological+null+methods"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods</span></div><div class="casAuthors">Ehlert, Frederick J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">187-94</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">The theor. basis for using radioligand binding and pharmacol. techniques to est. the dissocn. consts. of drugs which interact allosterically with receptors is described.  This theory predicts that an allosteric ligand changes the affinity of another ligand which binds at the primary recognition site on the receptor complex without affecting the binding capacity of the primary ligand.  The magnitude of this effect depends on the amt. of cooperativity (pos. or neg.) between the binding of ligands at the allosteric and primary recognition sites.  It is possible to est. the dissocn. const. of an allosteric ligand by measuring its effect on the binding of a radioligand at a fixed concn.  In this situation, the dissocn. const. of the allosteric ligand can be calcd. from the concn. of ligand which causes half of its maximal effect on radioligand binding.  The effects of an allosteric ligand on the pharmacol. responses to an agonist can be attributed to changes in affinity and intrinsic efficacy of the agonist-receptor complex.  If the agonist used in the pharmacol. expts. has a large receptor reserve, or if, the allosteric ligand only influences the affinity of the agonist, then the dissocn. const. of the allosteric ligand can be calcd. from the results of expts. in which the concn. of agonist required for half-maximal response (EC50) is measured in the presence of various concns. of the allosteric ligand.  If the agonist used in the pharmacol. expts. is a partial agonist with little receptor reserve, then the shift in the EC50 of the agonist caused by the allosteric ligand may be dependent on the affinity of the agonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjQE02Mx2NPLVg90H21EOLACvtfcHk0ljFsVFCPJP4Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXhsValurs%253D&md5=f987788cd58fb05902ff94e390917c18</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEhlert%26aufirst%3DF.%2BJ.%26atitle%3DEstimation%2520of%2520the%2520affinities%2520of%2520allosteric%2520ligands%2520using%2520radioligand%2520binding%2520and%2520pharmacological%2520null%2520methods%26jtitle%3DMol.%2520Pharmacol.%26date%3D1988%26volume%3D33%26spage%3D187%26epage%3D194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stockton, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birdsall, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgen, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulme, E. C.</span></span> <span> </span><span class="NLM_article-title">Modification of the binding properties of muscarinic receptors by gallamine</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">551</span>– <span class="NLM_lpage">557</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=6865905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADyaL3sXktFKntrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1983&pages=551-557&author=J.+M.+Stocktonauthor=N.+J.+Birdsallauthor=A.+S.+Burgenauthor=E.+C.+Hulme&title=Modification+of+the+binding+properties+of+muscarinic+receptors+by+gallamine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Modification of the binding properties of muscarinic receptors by gallamine</span></div><div class="casAuthors">Stockton, J. M.; Birdsall, N. J. M.; Burgen, A. S. V.; Hulme, E. C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">551-7</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    </div><div class="casAbstract">The interaction of gallamine (I)  [153-76-4] with muscarinic receptors from different tissues was investigated.  Gallamine binds to a site distinct from the conventional muscarinic ligand binding site and modulates the binding of agonists and antagonists to the conventional binding site.  In agreement with reported pharmacol. studies, the effects of gallamine on the binding of muscarinic ligands are much greater in heart than in other tissues.  These findings suggest the possibility of developing novel and selective muscarinic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcmXxiIuzlm7Vg90H21EOLACvtfcHk0ljNS5AbIg7uAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXktFKntrs%253D&md5=4087dbe9e26b089b2ff1e251ca66fca3</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStockton%26aufirst%3DJ.%2BM.%26aulast%3DBirdsall%26aufirst%3DN.%2BJ.%26aulast%3DBurgen%26aufirst%3DA.%2BS.%26aulast%3DHulme%26aufirst%3DE.%2BC.%26atitle%3DModification%2520of%2520the%2520binding%2520properties%2520of%2520muscarinic%2520receptors%2520by%2520gallamine%26jtitle%3DMol.%2520Pharmacol.%26date%3D1983%26volume%3D23%26spage%3D551%26epage%3D557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Price, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntosh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westwood, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, R. A.</span></span> <span> </span><span class="NLM_article-title">Allosteric modulation of the cannabinoid CB1 receptor</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">1484</span>– <span class="NLM_lpage">1495</span>, <span class="refDoi"> DOI: 10.1124/mol.105.016162</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=10.1124%2Fmol.105.016162" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=16113085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtF2it7nM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2005&pages=1484-1495&author=M.+R.+Priceauthor=G.+L.+Baillieauthor=A.+Thomasauthor=L.+A.+Stevensonauthor=M.+Eassonauthor=R.+Goodwinauthor=A.+McLeanauthor=L.+McIntoshauthor=G.+Goodwinauthor=G.+Walkerauthor=P.+Westwoodauthor=J.+Marrsauthor=F.+Thomsonauthor=P.+Cowleyauthor=A.+Christopoulosauthor=R.+G.+Pertweeauthor=R.+A.+Ross&title=Allosteric+modulation+of+the+cannabinoid+CB1+receptor&doi=10.1124%2Fmol.105.016162"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric modulation of the cannabinoid CB1 receptor</span></div><div class="casAuthors">Price, Martin R.; Baillie, Gemma L.; Thomas, Adele; Stevenson, Lesley A.; Easson, Morag; Goodwin, Richard; McLean, Adele; McIntosh, Lorraine; Goodwin, Gillian; Walker, Glenn; Westwood, Paul; Marrs, Julia; Thomson, Fiona; Cowley, Phillip; Christopoulos, Arthur; Pertwee, Roger G.; Ross, Ruth A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1484-1495</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The authors investigated the pharmacol. of three novel compds., Org 27569, Org 27759 and Org 29647 at the cannabinoid CB1 receptor.  In equil. binding assays, the Org compds. significantly increased the binding of the CB1 receptor agonist [3H]CP 55,940 [(1R,3R,4R)-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-4-(3-hydroxypropyl) cyclohexan-1-ol], indicative of a pos. cooperative allosteric effect.  The same compds. caused a significant, but incomplete, decrease in the specific binding of the CB1 receptor inverse agonist [3H]SR 141716A [N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H -pyrazole-3-carboximide hydrochloride], indicative of a limited neg. binding cooperativity.  Anal. of the data according to an allosteric ternary complex model revealed that the estd. affinity of each Org compd. was not significantly different when the radioligand was [3H]CP 55,940 or [3H]SR 141716A.  However, the estd. cooperatively factor for the interaction between modulator and radioligand was greater than 1 when detd. against [3H]CP 55,940 and less than 1 when detd. against [3H]SR 141716A.  [3H]CP 55,940 dissocn. kinetic studies also validated the allosteric nature of the Org compds., because they all significantly decreased radioligand dissocn.  These data suggest that the Org compds. bind allosterically to the CB1 receptor and elicit a conformational change that increases agonist affinity for the orthosteric binding site.  In contrast to the binding assays, however, the Org compds. behaved as insurmountable antagonists of receptor function; in the reporter gene assay, the guanosine 5'-O-(3-[35S]thio)triphosphate binding assay and the mouse vas deferens assay they elicited a significant redn. in the Emax value for CB1 receptor agonists.  The data presented clearly demonstrate, for the first time, that the cannabinoid CB1 receptor contains an allosteric binding site that can be recognized by synthetic small mol. ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq98nUa2ffQ7bVg90H21EOLACvtfcHk0ljNS5AbIg7uAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtF2it7nM&md5=a342d304a8157b1e7b962755a775154d</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1124%2Fmol.105.016162&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.105.016162%26sid%3Dliteratum%253Aachs%26aulast%3DPrice%26aufirst%3DM.%2BR.%26aulast%3DBaillie%26aufirst%3DG.%2BL.%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DStevenson%26aufirst%3DL.%2BA.%26aulast%3DEasson%26aufirst%3DM.%26aulast%3DGoodwin%26aufirst%3DR.%26aulast%3DMcLean%26aufirst%3DA.%26aulast%3DMcIntosh%26aufirst%3DL.%26aulast%3DGoodwin%26aufirst%3DG.%26aulast%3DWalker%26aufirst%3DG.%26aulast%3DWestwood%26aufirst%3DP.%26aulast%3DMarrs%26aufirst%3DJ.%26aulast%3DThomson%26aufirst%3DF.%26aulast%3DCowley%26aufirst%3DP.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26aulast%3DRoss%26aufirst%3DR.%2BA.%26atitle%3DAllosteric%2520modulation%2520of%2520the%2520cannabinoid%2520CB1%2520receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2005%26volume%3D68%26spage%3D1484%26epage%3D1495%26doi%3D10.1124%2Fmol.105.016162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6KQI" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6KQI','PDB','6KQI'); return false;">PDB: 6KQI</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6N4B" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6N4B','PDB','6N4B'); return false;">PDB: 6N4B</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i59"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00040">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_34534"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00040?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00040</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline"><sup>1</sup>H NMR spectra, HPLC chromatogram, XRD data, figures for preliminary cAMP and β-arrestin2 data, and additional computational figures (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00040/suppl_file/jm1c00040_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00040/suppl_file/jm1c00040_si_002.csv">CSV</a>)</p></li><li><p class="inline">6n4b_CB1-Gi_2019 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00040/suppl_file/jm1c00040_si_003.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00040/suppl_file/jm1c00040_si_001.pdf">jm1c00040_si_001.pdf (2.17 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00040/suppl_file/jm1c00040_si_002.csv">jm1c00040_si_002.csv (0.97 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00040/suppl_file/jm1c00040_si_003.pdb">jm1c00040_si_003.pdb (759.85 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00040&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00040%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-12%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00040" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799b4cc58dc32cd","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
